

Shandong Weigao Group Medical Polymer Company Limited* 山東威高集團醫用高分子製品股份有限公司

(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(在中華人民共和國註冊成立的股份有限公司)
(Stock Code 股票號碼：1066)

* For identification purposes only
僅供識別

Annual Report 2021 年報

WEGO 威高

CORPORATE INFORMATION	公司資料	2
CORPORATE PROFILE	公司簡介	4
CHAIRMAN'S STATEMENT	主席報告書	8
MANAGEMENT DISCUSSION AND ANALYSIS	管理層討論與分析	11
REPORT OF THE SUPERVISORY COMMITTEE	監事會報告書	24
REPORT OF THE DIRECTORS	董事會報告	26
CORPORATE GOVERNANCE REPORT	企業管治報告	55
DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT	董事、監事及高級管理人員	77
INDEPENDENT AUDITOR'S REPORT	獨立核數師報告書	85
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME	綜合損益及其他全面收入報表	91
CONSOLIDATED STATEMENT OF FINANCIAL POSITION	綜合財務狀況表	93
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY	綜合權益變動報表	95
CONSOLIDATED STATEMENT OF CASH FLOWS	綜合現金流量報表	97
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS	綜合財務報表附註	100
FINANCIAL SUMMARY	財務概要	312

CORPORATE INFORMATION 公司資料

DIRECTORS AND SUPERVISORS

Executive Directors

Mr. LONG Jing (*Chairman*)
Mr. CONG Rinan

Non-executive Director

Mr. TANG Zhengpeng
Mr. CHEN Lin
Mr. LIAN Xiaoming

Independent non-executive Directors

Mr. LO Wai Hung
Ms. FU Mingzhong
Ms. WANG Jinxia

Supervisors

Mr. HU Yunyong
Ms. GU Meijun
Mr. YUE Chunliang

CORPORATE INFORMATION

Registered office and principal place of business in the People's Republic of China (the "PRC")

18 Xingshan Road
Torch Hi-tech Science Park
Weihai
Shandong Province
PRC

Principal place of business in Hong Kong

29/F Two Chinachem Central
26 Des Voeux Road Central
Hong Kong

Company secretary

Ms. WONG Miu Ling, Phillis, *FCG and HKFCG*

Compliance officer

Mr. LONG Jing

董事及監事

執行董事

龍經先生 (*主席*)
叢日楠先生

非執行董事

湯正鵬先生
陳林先生
連小明先生

獨立非執行董事

盧偉雄先生
付明仲女士
王錦霞女士

監事

胡雲涌先生
谷美君女士
岳春良先生

公司資料

中華人民共和國(「中國」)註冊辦事處及 主要營業地點

中國
山東省
威海市
火炬高新技術產業開發區
興山路18號

香港主要營業地點

香港
德輔道中26號
華懋中心II期29樓

公司秘書

黃妙玲女士 *FCG及HKFCG*

監察主任

龍經先生

Audit Committee

Mr. LO Wai Hung (*Chairman*)
Ms. FU Mingzhong
Ms. WANG Jinxia

Remuneration Committee

Mr. LO Wai Hung (*Chairman*)
Ms. FU Mingzhong
Ms. WANG Jinxia

Corporate Governance Committee

Mr. LONG Jing (*Chairman*)
Mr. LO Wai Hung
Ms. FU Mingzhong
Ms. WANG Jinxia

Nomination Committee

Mr. LO Wai Hung (*Chairman*)
Ms. FU Mingzhong
Ms. WANG Jinxia

Authorised representatives

Mr. LONG Jing
Ms. WONG Miu Ling, Phillis

Auditors

Deloitte Touche Tohmatsu
Certified Public Accountants

Hong Kong share registrars and transfer office

Tricor Standard Limited
Level 54, Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

Principal bankers

1. Agriculture Bank of China, Weihai Branch
2. Bank of China, Weihai Branch

Website of the Company

www.weigaogroup.com

Stock Code

1066

審核委員會

盧偉雄先生 (*主席*)
付明仲女士
王錦霞女士

薪酬委員會

盧偉雄先生 (*主席*)
付明仲女士
王錦霞女士

企業管治委員會

龍經先生 (*主席*)
盧偉雄先生
付明仲女士
王錦霞女士

提名委員會

盧偉雄先生 (*主席*)
付明仲女士
王錦霞女士

授權代表

龍經先生
黃妙玲女士

核數師

德勤·關黃陳方會計師行
執業會計師

香港股份過戶登記處

卓佳標準有限公司
香港
灣仔
皇后大道東183號
合和中心54樓

主要往來銀行

1. 中國農業銀行－威海市分行
2. 中國銀行－威海市分行

本公司網址

www.weigaogroup.com

股份代號

1066


**SHANDONG WEIGAO GROUP MEDICAL
POLYMER COMPANY LIMITED**

**山東威高集團醫用高分子製品股份
有限公司**

Shandong Weigao Group Medical Polymer Company Limited (the “Company”) and its subsidiaries (together the “Group”) is principally engaged in the research and development, production and sale of medical device products, orthopaedic products, interventional products, pharma packaging products, blood management products and operates financing business. For the year ended 31 December 2021 (the “Year”), the revenue of the Company was approximately RMB13,151,719,000 (2020: approximately RMB11,622,337,000), representing an increase of 13.2% over the previous year. Net profit attributable to the owners of the Company was approximately RMB2,244,778,000 (2020: approximately RMB2,086,783,000), representing an increase of 7.6% over last year. As at the date of this report, the Group added 461 hospitals, 116 other medical institutions and 731 distributors to its PRC customer base. The Group has a PRC customer base of 7,982 in total (including 3,115 hospitals, 414 blood stations, 1,101 medical units and 3,352 distributors) and an overseas customer base of 7,092 in aggregate (including 3,540 hospitals, 1,631 other medical units and 1,921 distributors).

山東威高集團醫用高分子製品股份有限公司（「本公司」）及其附屬公司（統稱「本集團」）主要從事研發、生產及銷售醫療器械產品、骨科產品、介入產品、藥品包裝產品、血液管理產品及經營融資業務。截至二零二一年十二月三十一日止年度（「本年度」），本公司收入約人民幣13,151,719,000元（二零二零年：約人民幣11,622,337,000元），較上一年度增長13.2%。本公司擁有人應佔純利約人民幣2,244,778,000元（二零二零年：約人民幣2,086,783,000元），較上一年度增長7.6%。於本報告日期，本集團國內客戶增加461家醫院，116家其他醫療機構以及731家經銷商。本集團的國內客戶總數為7,982家（包括醫院3,115家、血站414家、醫療單位1,101家和經銷商3,352家），海外客戶總數為7,092家（包括醫院3,540家、其他醫療單位1,631家和經銷商1,921家）。


Revenue Breakdown



收入明細

	% of sales 銷售佔比
● Clinical Care 臨床護理	34.8%
● Wound Management 創傷管理	3.1%
● Anesthesia and Surgery 麻醉及手術	1.9%
● Medical Testing 醫學檢驗	2.2%
● Other Consumables 其他耗材	5.4%
● Orthopaedic Products 骨科產品	16.2%
● Pharma Packaging 藥品包裝	15.5%
● Interventional Products 介入產品	13.5%
● Blood Management 血液管理	7.4%

Segment Profit Breakdown



分部溢利明細

	% of segment profit 分部溢利佔比
● Medical Device 醫療器械	31.5%
● Pharma Packaging 藥品包裝	29.1%
● Orthopaedic Products 骨科產品	25.9%
● Blood Management 血液管理	5.8%
● Interventional Product 介入產品	5.1%
● Others 其他	2.6%


Segmental revenues (RMBmn) 分部收入 (人民幣百萬元)

% of revenues 收入佔比

		2021	2020	% Change 變動百分比	2021	2020
		二零二一年	二零二零年		二零二一年	二零二零年
Medical Device Products	醫療器械產品	6,235	5,748	8.4%	47.4%	49.4%
Clinical Care	臨床護理	4,575	4,266	7.2%	34.8%	36.6%
Wound Management	創傷管理	412	347	19.0%	3.1%	3.0%
Anesthesia and Surgery	麻醉及手術	248	193	28.3%	1.9%	1.7%
Medical Testing	醫學檢驗	295	276	6.9%	2.2%	2.4%
Other Consumables	其他耗材	705	666	6.0%	5.4%	5.7%
Orthopaedic Products	骨科產品	2,127	1,748	21.7%	16.2%	15.0%
Pharma Packaging	藥品包裝	2,040	1,694	20.4%	15.5%	14.6%
Interventional Products	介入產品	1,773	1,611	10.0%	13.5%	13.9%
Blood Management	血液管理	977	821	19.0%	7.4%	7.1%
Total	總計	13,152	11,622	13.2%	100.0%	100.0%

Geographic breakdown

地區明細



	% of sales 銷售佔比
● PRC 中國	79.8%
● United States 美國	8.7%
● Asia 亞洲	5.3%
● EMEA 歐洲、中東及非洲	3.8%
● Others 其他	2.4%

		Segmental revenues (RMBmn) 分部收入 (人民幣百萬元)			% of revenues 收入佔比	
		2021 二零二一年	2020 二零二零年	% Change 變動百分比	2021 二零二一年	2020 二零二零年
PRC	中國	10,495	9,090	15.5%	79.8%	78.2%
United States	美國	1,146	1,140	0.5%	8.7%	9.8%
Asia	亞洲	701	579	21.1%	5.3%	5.0%
Europe, the Middle East and Africa	歐洲、中東及非洲	502	503	(0.2%)	3.8%	4.3%
RoW	世界其他地區	308	310	(0.6%)	2.4%	2.7%
Total	總計	13,152	11,622	13.2%	100.0%	100.0%

FINANCIAL SUMMARY

財務摘要

		2021	2020	Increase (decrease)
		二零二一年	二零二零年	增長(減少)
		RMB'000	RMB'000	%
		人民幣千元	人民幣千元	
Turnover	營業額	13,151,719	11,622,337	13.2%
Gross profit	毛利	7,269,404	6,499,571	11.8%
Net profit attributable to the owners of the Company	本公司擁有人應佔純利	2,244,778	2,086,783	7.6%
Net profit attributable to the owners of the Company (excluding extraordinary items)	不計特殊項目本公司擁有人應佔純利	2,442,937	2,030,137	20.3%

During the year ended 31 December 2021 (the "Year"), extraordinary items include a post-tax share awards expense of RMB35,084,000 newly granted by the Company and the post-tax provision for expenses of one pending litigation attributable to owners of the Company of RMB163,075,000 (extraordinary items in 2020: nil).

截至二零二一年十二月三十一日止年度（「本年度」），特殊項目為本公司新授出稅後股份獎勵費用人民幣35,084,000元和本公司擁有人應佔一項未決訴訟之稅後預提費用人民幣163,075,000元（二零二零年特殊項目：無）。

**ANNUAL GENERAL MEETING AND CLOSURE
OF REGISTER OF MEMBERS**

Attending and Voting in the Annual General Meeting

In order to determine the shareholders who are entitled to attend and vote at the annual general meeting to be dated 6 June 2022 (the "Annual General Meeting"), the register of members of the Company will be closed from Monday, 30 May 2022 to Monday, 6 June 2022 (both days inclusive), during which period no transfer of H Shares will be effected. In order to qualify for attending and voting in the Annual General Meeting, Shareholders should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company's H Share registrar, Tricor Standard Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong for registration no later than 4:30 p.m. on Friday, 27 May 2022. In order to qualify for attending and voting in the Annual General Meeting:-

Latest time to lodge in transfer instrument accompanied by the share certificates for H Shares 4:30 p.m.,
Friday, 27 May 2022

Closure of register of members of the Company for attending and voting in the Annual General Meeting Monday,
30 May 2022 to
Monday, 6 June 2022
(both days inclusive)

Date of the Annual General Meeting Monday,
6 June 2022

股東週年大會及暫停辦理股份過戶登記手續

出席股東週年大會並於會上投票

為釐定股東出席將於二零二二年六月六日舉行之股東週年大會（「股東週年大會」）並於會上投票的資格，本公司將於二零二二年五月三十日（星期一）至二零二二年六月六日（星期一）（首尾兩日包括在內）暫停過戶登記，於該期間將不會辦理H股的過戶登記手續。為符合資格出席股東週年大會並於會上投票，股東應確保所有過戶文件連同有關股票不遲於二零二二年五月二十七日（星期五）下午四時三十分送交本公司的H股過戶登記處卓佳標準有限公司，地址為香港皇后大道東183號合和中心54樓，以辦理登記手續。為符合資格出席股東週年大會並於會上投票：-

交回過戶文件連同
H股股票之最後時限 二零二二年
五月二十七日
(星期五)
下午四時三十分

本公司暫停股份
過戶登記以出席
股東週年大會並於
會上投票 二零二二年
五月三十日（星期一）至
二零二二年六月六日
(星期一)
(首尾兩日包括在內)

股東週年大會日期 二零二二年
六月六日
(星期一)

Entitlement of Proposed Final dividend

In order to determine entitlement to the proposed final dividend payment, the register of members of the Company for H Shares will be closed from Saturday, 11 June 2022 to Thursday, 16 June 2022 (both days inclusive), during which period no transfer of H Shares will be effected. In order to qualify for entitlement of the proposed final dividend, Shareholders should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company's H Share registrar, Tricor Standard Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration no later than 4:30 p.m. on Friday, 10 June 2022.

In order to qualify to entitle the final dividend for the year ended 31 December 2021:-

Latest time to lodge in transfer instrument accompanied by the share certificates for H Shares 4:30 p.m.,
Friday, 10 June 2022

Closure of register of members of the Company for entitlement of the final dividend for the year ended 31 December 2021 Saturday,
11 June 2022 to Thursday,
16 June 2022
(both days inclusive)

Record date for the entitlement of the final dividend Thursday,
16 June 2022

Expected despatch date of the final dividend Friday,
15 July 2022

The final dividend will be despatched at the risk of those entitled thereto to their respective registered addresses on or before Friday, 15 July 2022.

建議末期股息之權利

為確定股東收取建議末期股息付款之權利，本公司將於二零二二年六月十一日（星期六）至二零二二年六月十六日（星期四）（首尾兩日包括在內）暫停H股的過戶登記，於該期間將不會辦理H股的過戶登記手續。為符合資格收取建議末期股息之權利，股東應確保所有過戶文件連同有關股票不遲於二零二二年六月十日（星期五）下午四時三十分送交本公司之H股過戶登記處卓佳標準有限公司，地址為香港灣仔皇后大道東183號合和中心54樓，以辦理登記手續。

為符合資格獲派截至二零二一年十二月三十一日止年度之末期股息：-

交回過戶文件連同
H股股票之
最後時限 二零二二年
六月十日
(星期五)
下午四時三十分

本公司暫停股份過戶
登記以釐定
截至二零二一年
十二月三十一日
止年度之末期股息之
權利 二零二二年
六月十一日(星期六)至
二零二二年
六月十六日(星期四)
(首尾兩日包括在內)

釐定末期股息
權利之記錄日期 二零二二年
六月十六日(星期四)

預期末期股息
寄發日期 二零二二年
七月十五日(星期五)

末期股息將於二零二二年七月十五日（星期五）或之前按有權獲派末期股息之持有人各自之登記地址寄發予彼等，郵誤風險由彼等自行承擔。

PROPOSED FINAL DIVIDEND

The Board proposed the distribution of a final dividend for the year ended 31 December 2021 of RMB0.065 (2020: RMB0.068) (before considering any tax effect) per share totaling RMB297,091,000 (2020: RMB307,519,000), which will be subject to the approval of shareholders of the Company at the Annual General Meeting. The final dividend will be denominated and declared in Renminbi. Final dividend on non-listed domestic shares of the Company, for full circulation H Shareholders and for investors investing in the H shares of the Company through Shanghai-Hong Kong Stock Connect or Shenzhen-Hong Kong Stock Connect (the "Southbound Trading") will be paid in Renminbi, and the final dividend for other H Shareholders of the Company will be paid in Hong Kong dollars. The exchange rate for the final dividend to be paid in Hong Kong dollars will be the mean of the exchange rates of Renminbi to Hong Kong dollars as announced by the People's Bank of China during the five business days preceding the date of approval of the final dividend at the Annual General Meeting. The Company will appoint a receiving agent in Hong Kong and Mainland China respectively and will pay to such receiving agent the final dividend (after deductions of relevant tax, if applicable) declared for payment to Shareholders. The final dividend will be paid by the receiving agent on or before Friday, 15 July 2022. The cheques will be despatched to H Shareholders by ordinary post at their own risks. The payment of the final dividend is subject to the Shareholders' approval at the AGM.

ACKNOWLEDGEMENTS

The Group's various achievements as mentioned above are attributable to the continued supports of the staff, customers and business partners and shareholders. I would like to take this opportunity to express my most sincere thanks for all your contributions!

On behalf of the Board

LONG Jing

Chairman

14 April 2022

建議末期股息

董事會建議派發截至二零二一年十二月三十一日止年度之末期股息每股人民幣0.065元(二零二零年：人民幣0.068元(未考慮任何稅務影響))，涉及總額為人民幣297,091,000元(二零二零年：人民幣307,519,000元)，須於股東週年大會獲本公司股東批准後，方可作實。末期股息將以人民幣計值和宣派。本公司之非上市內資股末期股息、H股全流通股東末期股息及通過滬港通或深港通(「港股通」)持有本公司H股的投資者的末期股息將以人民幣派付，而本公司其他H股股東末期股息將以港元派付。以港幣發放的末期股息計算的匯率以於股東週年大會批准末期股息當日之前五個工作日中國人民銀行公佈的人民幣兌換港幣平均基準匯率為準。本公司將在香港及中國內地分別委任收款代理人，並會將已宣派的末期股息(經扣除相關稅項後，如適用)支付予收款代理人，以代支付股東。收款代理人將於二零二二年七月十五日(星期五)或之前支付末期股息。支票將以平郵方式寄予H股股東，郵誤風險由H股股東承擔。支付末期股息須待股東於股東週年大會上批准後方可作實。

致謝

本人在上文提及本集團各項成就，均有賴於全體僱員、顧客及業務夥伴和各位股東一貫以來不斷的支持。對於彼等的貢獻，本人謹此致以深切感謝!

代表董事會

龍經

主席

二零二二年四月十四日

OPTIMISATION OF PRODUCT MIX

During the year ended 31 December 2021 (the “Year”), the gross profit margin of the Group decreased from 55.9% of last year to 55.3%, which was mainly attributable to the effect from change of product structure.

The existing major products of the Group under each business line are as follows:

Clinical care business includes vascular and non-vascular access infusion devices include infusion sets, syringes, puncture needles, specialized single-use clinical collection kits, digital products for clinical care, digestive nutrition, primary care products

Wound management includes wound healing dressings, wound suture, wound cleaning and nonvascular catheter supporting extracorporeal devices

Anesthesia and surgery business includes general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, open and minimally invasive surgical equipment

Medical testing business includes blood collection devices and blood glucose testing

Orthopaedic business includes trauma, spinal implant, artificial joints, sports injury, soft tissue repair, reconstruction implant, orthopaedic filling, and orthopaedic related surgical tools

Interventional business includes tumor intervention, vascular intervention and interventional imaging

Pharma packaging business includes prefilled syringes and pre-filled flush syringes

Blood management business includes blood collection, storage, separation and sterilization consumables and equipment

產品結構優化調整

於截至二零二一年十二月三十一日止年度（「年內」），本集團毛利率由去年的55.9%下降到55.3%，主要是產品結構變化產生的影響。

本集團各業務領域現有主要產品如下：

臨床護理業務包括輸液、注射、穿刺等血管輸液器械及非血管輸液器械、臨床特定用途的一次性使用各種套裝、臨床護理數字化產品、消化營養、基礎護理產品

創傷管理業務包括：創面癒合敷料、傷口縫合、傷口清理、與非血管內導管配套用體外器械

麻醉及手術業務包括：全身麻醉耗材、局部麻耗材、麻醉輔助耗材、ICU使用的器械；開放及微創手術器械

醫學檢驗業務包括：採血器具、血糖檢驗

骨科業務：創傷、脊柱植入物，人工關節，運動損傷、軟組織修復及重建植入物、骨填充材料、骨科相關手術工具

介入業務：腫瘤介入、血管介入、影像介入

藥品包裝業務包括：預灌封注射器、沖管注射器

血液管理業務包括：血液採集、貯存、分離、滅菌消毒耗材及設備

OPTIMISATION OF PRODUCT MIX (continued)

1. During the Year, the clinical care business recorded a turnover of approximately RMB4,574,811,000, an increase of 7.2% over last year. With an enhanced product mix, it has compensated for the reduced demand due to the restricted clinical business opening affected by the COVID-19. The Group continued to maintain a dominant position in the market segment.
2. During the Year, the orthopaedic business recorded a turnover of approximately RMB2,126,594,000, representing an increase of 21.7% over last year. Measures such as further consolidating its market position in the spine segment, increased marketing of joint products, further penetration of distribution channels and establishment of a logistic platform have driven sales growth.
3. During the Year, the interventional business recorded a turnover of approximately RMB1,772,944,000, representing an increase of 10.0% over last year. The revenue calculated at a fixed exchange rate increased by 16.8% over last year, which was mainly attributable to the significant growth in the sales of Argon. The sales of Argon products in the PRC market achieved remarkable progress.
4. During the Year, the pharma packaging business recorded a turnover of approximately RMB2,040,355,000, representing an increase of 20.5% over last year. Prefilled syringes recorded a year-on-year increase of 35.2%, further expanded its market influence in the segment of pre-pack bio-pharmaceuticals and built a broad customer base.

產品結構優化調整 (續)

1. 年內，臨床護理業務錄得營業額約為人民幣4,574,811,000元，較去年增長7.2%，憑借豐富產品組合，彌補了新冠疫情臨床開放受限所導致的需求下降；本集團繼續於該領域市場保持優勢地位。
2. 年內，骨科業務營業收入約為人民幣2,126,594,000元，較去年增長21.7%，通過進一步鞏固在脊柱領域的市場地位、加大關節產品市場推廣，以及渠道下沉、搭建物流平台等措施，較好的拉動銷售增長。
3. 年內，介入業務錄得營業額約為人民幣1,772,944,000元，較去年增長10.0%，按固定匯率計算的收入較去年增長16.8%。主要是美國愛琅公司銷售額增長明顯，美國愛琅產品在中國市場的銷售取得顯著進展。
4. 年內，藥品包裝業務錄得營業額約為人民幣2,040,355,000元，較去年增長20.5%。其中預灌封注射器同比增長35.2%，進一步擴大在生物製藥包裝領域的市場影響力，形成廣泛客戶基礎。

RESEARCH AND DEVELOPMENT

For the year ended 31 December 2021, the Group obtained 144 new patents and 161 new patents are under application in the PRC. Product registration certificates for 40 new products were obtained. The research and development for 29 products were completed for which application for product registration certificates are underway. For overseas market, 13 new patents are under application and the research and development for 181 products were completed for which application for product registration certificates are underway.

The strategy of placing strong emphasis on research and development has enhanced the competitiveness and laid a foundation for the Company to fully leverage on its customer resources and provided the Group with new profit growth drivers.

For the year ended 31 December 2021, the Group had over 554 product registration certificates and 652 patents, of which 97 were patents on invention, in the PRC. For overseas market, the Group had over 742 product registration certificates and 193 patents.

In view of the need for the strategic adjustments to product mix, the Group continued to increase efforts on the improvement and subdivision of product layout in existing products series, so as to maintain its leading position in research and development capability in China. For the year ended 31 December 2021, total research and development expenses amounted to approximately RMB492,133,000 (2020: approximately RMB424,422,000), representing 3.7% (2020: 3.7%) of the revenue of the Group.

PRODUCTION

During the Year, in order to constantly expand production capacity, the Group continued to expand its production facilities including workshops of syringe and prefilled syringe to satisfy the sales demand for future market growth. Meanwhile, the Group proactively promoted improvement of production processes and enhanced intellectualization and automation of production equipment. The production costs were reduced through efficiency enhancement and scientific management, maintaining the Company's overall profitability.

研究與開發

截至二零二一年十二月三十一日止年度，本集團中國國內新獲得專利144項，正在申請中的161項，新取得產品註冊證40項，已經研發完成、尚在取證過程中的有29項。海外市場，正在申請中的專利13項，已經研發完成、尚在取證過程中的產品註冊證有181項。

注重研發的策略提升了公司的競爭力，為充分利用客戶資源奠定了基礎，並為集團盈利提供了新的增長點。

截至二零二一年十二月三十一日止年度，本集團國內擁有逾554項產品註冊證，652項專利，其中97項是發明專利。海外，擁有逾742項產品註冊證，193項專利。

基於產品結構戰略性調整的要求，本集團繼續加大在現有產品系列框架內完善細分產品佈局，持續保持本土研發實力的領先地位。截至二零二一年十二月三十一日止年度，研發之總開支約為人民幣492,133,000元（二零二零年：約人民幣424,422,000元），佔本集團收入的3.7%（二零二零年：3.7%）。

生產

年內，本集團為了持續擴大產能，繼續擴建了包括注射器車間、預灌封注射器車間等生產設施，以滿足未來市場增長的銷售需求。同時積極推進生產工藝改進，生產設備智能化、自動化水平，通過效率提升和科學管理降低生產成本，保持公司整體盈利能力。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

SALES AND MARKETING

During the Year, the Group consolidated the marketing management system and further adhered to the strategy of sales channel integration and product mix adjustment and to focus on marketing resources on customer development and maintenance in the core healthcare market. The Group achieved substantial results in key client accounts management. As at the date of this report, the Group newly added 461 hospitals, 116 other medical institutions and 731 distributors to its PRC customer base, and the Group has a PRC customer base of 7,982 in aggregate (including 3,115 hospitals, 414 blood stations, 1,101 other medical units and 3,352 distributors) and an overseas customer base of 7,092 in aggregate (including 3,540 hospitals, 1,631 other medical units and 1,921 distributors).

Sales comparison by geographical regions when compared with the last year is set out as follows:

Turnover by Geographical Information

Regions 地區		2021	2020	Increase or decrease over corresponding period %
		二零二一年 RMB'000 人民幣千元	二零二零年 RMB'000 人民幣千元	較同期 增減% %
The PRC	國內			
- Eastern and Central	- 華東與華中	5,203,106	4,477,690	16.2%
- Northern	- 華北	2,330,107	1,976,735	17.9%
- Southern	- 華南	960,983	836,743	14.8%
- Northeast	- 東北	898,181	795,878	12.9%
- Southwest	- 西南	857,764	755,887	13.5%
- Northwest	- 西北	245,296	247,666	(1.0%)
PRC sub-total	國內小計	10,495,437	9,090,599	15.5%
Overseas	海外			
- USA	- 美國	1,145,923	1,139,575	0.6%
- Asia	- 亞洲	701,240	578,895	21.1%
- Europe, Middle East and Africa	- 歐洲、中東及非洲	501,919	503,502	(0.3%)
- Others	- 其他	307,200	309,766	(0.8%)
Overseas sub-total	海外小計	2,656,282	2,531,738	4.9%
Total	總計	13,151,719	11,622,337	13.2%

銷售及市場推廣

年度內，本集團強化了營銷管理體系，繼續堅持銷售渠道整合與產品結構調整之策略，將營銷資源重點聚焦於核心醫療市場的客戶開發與維護。本集團開展大客戶管理取得顯著成效。於本報告刊發日期，本集團國內客戶新增461家醫院、116家其他醫療機構以及731家經銷商，本集團的國內客戶總數為7,982家（包括醫院3,115家、血站414家、其他醫療單位1,101家和經銷商3,352家），海外客戶總數為7,092家（包括醫院3,540家、其他醫療單位1,631家和經銷商1,921家）。

各種產品在不同地區的銷售與去年對比如下：

營業收入地區資料

SALES AND MARKETING (continued)

Turnover by Geographical Information (continued)

Overseas revenue increased by 10.6% over last year at fixed exchange rates.

The integration of sales channels has strengthened the Group's market penetration and influence over the customers. It enhanced sales contribution per customer and continued to drive up the product penetration to high-end customers and was an important approach in generating revenue growth for the Group.

Adjustment in product mix was another important factor in enhancing the results for the Year. Comparison of revenue of principal products with that in last year is as follows:

Product category 產品類別	For the year ended 31 December 截至十二月三十一日止年度			For the six months ended 31 December 截至十二月三十一日止六個月		
	2021 二零二一年 RMB'000 人民幣千元	2020 二零二零年 RMB'000 人民幣千元	Over corresponding period 較同期 %	2021 二零二一年 RMB'000 人民幣千元	2020 二零二零年 RMB'000 人民幣千元	Over corresponding period 較同期 %
Medical device products 醫療器械產品	6,234,964	5,748,582	8.4%	3,362,761	3,285,702	2.3%
Clinical care 臨床護理	4,574,811	4,267,450	7.2%	2,470,254	2,406,881	2.6%
Wound management 創傷管理	412,385	346,590	19.0%	215,876	213,465	1.1%
Anesthesia and surgery 麻醉及手術	247,631	193,051	28.3%	129,669	127,788	1.5%
Medical testing 醫學檢驗	294,833	275,780	6.9%	168,878	176,589	(4.4%)
Other consumables 其他耗材	705,304	665,711	5.9%	378,084	360,979	4.7%
Orthopaedic products 骨科產品	2,126,594	1,747,774	21.7%	1,042,149	917,170	13.6%
Interventional products 介入產品	1,772,944	1,611,583	10.0%	907,556	828,321	9.6%
Pharma packaging products 藥品包裝	2,040,355	1,693,798	20.5%	1,082,632	929,283	16.5%
Blood management 血液管理	976,862	820,600	19.0%	527,017	446,352	18.1%
Total 總計	13,151,719	11,622,337	13.2%	6,922,115	6,406,828	8.0%

HUMAN RESOURCES

As at 31 December 2021, the Group employed a total of 11,123 employees. The breakdown by departments when compared with last year is as follows:

銷售及市場推廣 (續)

營業收入地區資料 (續)

海外收入按固定匯率計算較去年增長10.6%。

渠道的整合，增強了本集團在客戶群的滲透力、影響力，提高了單客戶的貢獻率，持續推進核心客戶的產品滲透率，是本集團拉動收入增長的一項重要手段。

產品結構的調整為提升年內業績的另一項重要因素，各主導產品收入與上年對比情況如下：

人力資源

於二零二一年十二月三十一日，本集團共聘用11,123名僱員，與去年比較的部門分析如下：

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

DEPARTMENT

部門

		2021 二零二一年	2020 二零二零年
Production	生產	5,589	5,404
Sales and marketing	銷售及市場推廣	2,846	2,616
Research and development	研發	1,229	1,165
Finance and administration	財務及行政	551	538
Quality control	質量控制	519	330
Management	管理	308	228
Purchasing	採購	81	152
Total	總計	11,123	10,433

There are a total of 997 overseas employees who are resided in Hong Kong, USA and Europe. Other employees of the Group are resided in Mainland China. During the Year, the total cost of salaries, welfare and social benefits of the Group amounted to approximately RMB2,031,048,000 (2020: approximately RMB1,887,811,000).

海外僱員997名，分別於香港、美國、歐洲等地居住，本集團的其他僱員均位於中國內地。年內，本集團在員工薪資、福利、社會保障等的成本總額約為人民幣2,031,048,000元（二零二零年：約為人民幣1,887,811,000元）。

REMUNERATION SYSTEM

The Group's remuneration policy has been determined based on its performance, changes in the local consumption power and competition in human resources market. The remuneration policy so determined has become the basis of determining the salary level of employees recruited for different positions. The salary of each employee is determined according to the employee's performance, ability, employment conditions and the salary standards set by the Company. Remuneration of directors is proposed by the Remuneration Committee with reference to the operating results of the Company, personal performance of the directors and market competition. The proposed remuneration of directors is proposed by the Board subject to approval by shareholders at forthcoming annual general meeting.

薪酬訂立制度

本集團的薪酬政策是根據其表現，本地的消費水平變化和人力資源市場競爭狀況釐定。該釐定的薪酬政策作為聘任不同崗位僱員薪資水平的基準。每位僱員的薪資視乎僱員的表現、能力、任職條件及本公司的預定薪資標準而定。董事的酬金是由薪酬委員會經參考本公司的經營業績、董事個人表現及市場競爭情況的基礎上制定薪酬方案，並經股東於股東週年大會上授權董事會釐定。

FINANCIAL REVIEW

For the year ended 31 December 2021, the Group recorded a turnover for the year of approximately RMB13,151,719,000, representing an increase of 13.2% over the previous financial year. Net profit attributable to the owners of the Company was approximately RMB2,244,778,000 (2020: approximately RMB2,086,783,000), representing an increase of approximately 7.6% as compared with the previous year. Net profit attributable to the owners of the Company (excluding extraordinary items) was approximately RMB2,442,937,000 (2020: approximately RMB2,030,137,000 without taking the accounting restatement into account), representing an increase of approximately 20.3% over the previous year.

FINANCIAL SUMMARY

		2021 二零二一年 RMB'000 人民幣千元	2020 二零二零年 RMB'000 人民幣千元	Increase (decrease) 增長(減少) %
Turnover	營業額	13,151,719	11,622,337	13.2%
Gross profit	毛利	7,269,404	6,499,571	11.8%
Net profit attributable to the owners of the Company	本公司擁有人應佔純利	2,244,778	2,086,783	7.6%
Net profit attributable to the owners of the Company (excluding extraordinary items)	不計特殊項目本公司擁有人應佔純利	2,442,937	2,030,137	20.3%

During the Year, extraordinary items include a post-tax share awards expense of RMB35,084,000 newly granted by the Company and the post-tax provision for expenses of one pending litigation attributable to owners of the Company of RMB163,075,000 (extraordinary items in 2020: nil).

LIQUIDITY AND FINANCIAL RESOURCES

The Group has maintained a sound financial position. As at 31 December 2021, the Group's cash and bank balance amounted to approximately RMB6,628,927,000. For the year ended 31 December 2021, net cash flow from operating activities of the Group amounted to approximately RMB3,035,163,000, representing a sound cash flow position.

財務回顧

截至二零二一年十二月三十一日止年度，年度營業額達至約人民幣13,151,719,000元，較上一財政年度增長了13.2%。本公司擁有人應佔純利約人民幣2,244,778,000元（二零二零年：約人民幣2,086,783,000元），較上一年度上升約7.6%。不計特殊項目的本公司擁有人應佔純利約人民幣2,442,937,000元（二零二零年不考慮會計重述：約人民幣2,030,137,000元），較上一年度上升約20.3%。

財務摘要

		2021 二零二一年 RMB'000 人民幣千元	2020 二零二零年 RMB'000 人民幣千元	Increase (decrease) 增長(減少) %
Turnover	營業額	13,151,719	11,622,337	13.2%
Gross profit	毛利	7,269,404	6,499,571	11.8%
Net profit attributable to the owners of the Company	本公司擁有人應佔純利	2,244,778	2,086,783	7.6%
Net profit attributable to the owners of the Company (excluding extraordinary items)	不計特殊項目本公司擁有人應佔純利	2,442,937	2,030,137	20.3%

年內，特殊項目為本公司新授出稅後股份獎勵費用35,084,000元和本公司擁有人應佔一項未決訴訟之稅後預提費用人民幣163,075,000元（二零二零年特殊項目：無）。

流動資金及財務資源

本集團於本年度維持良好的財務狀況。於二零二一年十二月三十一日，本集團現金及銀行結餘約為人民幣6,628,927,000元。截至二零二一年十二月三十一日止年度，本集團經營活動現金流量淨額約為人民幣3,035,163,000元，現金流量狀況良好。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

LIQUIDITY AND FINANCIAL RESOURCES

(continued)

For the year ended 31 December 2021, total interest expenses of the Group amounted to approximately RMB140,396,000 (2020: total interest expenses of approximately RMB178,935,000).

GEARING RATIO

The gearing ratio of the Group as at the end of 2021 reduced to 21.1% (2020: 23.8%).

As at 31 December 2021, total net cash of the Group amounted to approximately RMB2,572,362,000 (2020: net cash of approximately RMB1,375,356,000). The gearing ratio represents total debt as a percentage of total capital. Total debt is calculated as total borrowings. Total capital is calculated as the Group's shareholders' fund.

FOREIGN EXCHANGE RISKS

The Group's purchases and sales are mainly conducted in the PRC and the United States. Assets, liabilities and transactions in the PRC are denominated in RMB, while overseas assets and transactions are mainly denominated in US dollars. Foreign exchange risk mainly arises from outstanding borrowings denominated in foreign currencies. The Group has adopted foreign currency hedging instruments to achieve better foreign exchange risk management. The objective of the hedge is to minimise the volatility of the RMB expenditures expected to be incurred in the future to meet foreign currency liabilities. The Group's risk management policy is to partially hedge the forecasted cash flows in foreign currencies by considering the appropriate hedging instruments and costs of hedging. The Group uses foreign exchange structured derivative financial contracts to hedge its foreign currency risk. For the twelve months ended 31 December 2021, the Group had not encountered any material difficulty due to currency fluctuation nor had it affected its funds for operation purpose.

Due to the fluctuation in exchange rates, the Company realised a foreign exchange loss equivalent to RMB39,357,000 for the year ended 31 December 2021 (2020: foreign exchange loss equivalent to RMB39,977,000).

流動資金及財務資源 (續)

截至二零二一年十二月三十一日止年度，本集團的利息支出總額約為人民幣140,396,000元（二零二零年：利息支出總額約為人民幣178,935,000元）。

資本負債比率

本集團二零二一年年末的資本負債比率下降至21.1%（二零二零年：為23.8%）。

於二零二一年十二月三十一日，本集團淨現金總額約為人民幣2,572,362,000元（二零二零年：淨現金約為人民幣1,375,356,000元）。資本負債比率指債務總額與資本總額之百分比。債務總額乃按借貸總額計算。資本總額乃按本集團之股東資金計算。

匯率風險

本集團的採購和銷售以中國、美國兩地為主。中國境內資產、負債及交易以人民幣計值，海外資產及交易主要以美元計值，外匯風險主要來源於未償還的外幣借貸。本集團已採用了外幣對沖工具來達到更好的外匯風險管理。對沖保值的目標在於使預計未來可能發生的償還外幣負債需要的人民幣支出的波動性最小化。本集團的風險管理政策是在考慮合適的對沖工具以及對沖的成本後，部分對沖外幣預測現金流量。本集團通過外匯結構性衍生金融合同來對沖外匯風險。截至二零二一年十二月三十一日止十二個月，本集團並無因匯率波動而遇到重大困難或自身的營運資金受到影響。

由於匯率變動，本公司於截至二零二一年十二月三十一日止年度，形成匯兌損失折合人民幣39,357,000元（二零二零年：形成匯兌損失折合人民幣39,977,000元）。

CONTINGENT LIABILITIES

A subsidiary of the Group was defendant in a product liability claim. The Group recorded a pre-tax charge of RMB522,650,000 for losses related to product liability litigation. The Group regularly monitors and evaluates the status of product liability, and may, from time-to-time, engages in settlement and medication discussions, taking into consideration of developments in the matters and the inherent risks and uncertainties surrounding the litigation. As of the balance sheet date, the Group has applied judgement and provided for possible expenses related to the litigation.

MATERIAL INVESTMENTS/FUTURE MATERIAL INVESTMENT PLANS

1. During the Year, the Group continued to invest approximately RMB1,070,684,000 in purchase of properties and production facilities and plant construction for the purpose of enhancing the overall construction of the industrial zone for the Group's medical consumables.
2. During the Year, the Group contributed RMB1,115,000,000 to acquire the equity interest held by Weigao Holding Company Limited in Wego Healthcare Fund Holding Corporation, whose major asset is the entire interest in Rad Source Technologies Inc..
3. The Group planned to invest RMB770,000,000 to acquire the 38.5% interest in the Songyuan Healthcare Industry Fund (松源健康醫療產業基金), which focuses on the investments in the medical and healthcare sector mainly covering medical devices, bio-pharmaceuticals, medical services and rehabilitation and elderly care, of which a total of RMB154,000,000 has been contributed.
4. In 2022, the Group planned to invest approximately RMB700,000,000 in the new production lines, which is expected to be successively put in operation by 2024.
5. In 2022, the Group planned to invest approximately RMB150,000,000 in the upgrading and reconfiguration of the single-use consumables production equipment to further enhance the level of production automation.

或有負債

本集團一間附屬公司乃一宗產品責任索賠的被告。本集團就產品責任訴訟的相關損失錄得稅前費用人民幣522,650,000元。本集團定期監察及評估產品責任的狀況，並可能不時參與和解及調解討論（經考慮事件的發展以及圍繞訴訟的固有風險及不確定性）。截至資產負債表日期，本集團已對與訴訟有關的可能費用作出判斷及撥備。

重大投資／未來重大投資計劃

1. 本年度，本集團繼續投資約人民幣1,070,684,000元，用於購買物業、生產設備與建設廠房，為完善本集團醫療耗材工業園整體建設之用。
2. 年內，本集團出資人民幣1,115,000,000元收購威高集團有限公司持有的Wego Healthcare Fund Holding Corporation股權，該公司的主要資產為Rad Source Technologies Inc.的全部權益。
3. 本集團計劃出資人民幣770,000,000元投資松源健康醫療產業基金，佔比38.5%，該基金重點投資於以醫療器械、生物醫藥、醫療服務、康復養老為主的醫療健康領域，已累計出資人民幣154,000,000元。
4. 二零二二年計劃投資約人民幣700,000,000元，購置新生產線，預計二零二四年可陸續投入生產。
5. 二零二二年計劃繼續投入約人民幣150,000,000元，持續用於一次性耗材的設備更新與改造項目，進一步提升生產的自動化水平。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

MATERIAL INVESTMENTS/FUTURE MATERIAL INVESTMENT PLANS (continued)

Save for the above material investments and investment plans, the Group had no future plans involving significant investments or capital assets acquisition as at 31 December 2021.

CAPITAL COMMITMENT

As at 31 December 2021, the capital commitment including acquisition, investment and purchase of property, plant and equipment which the Group and the Company had contracted for but not provided amounted to approximately RMB1,113,104,000 (2020: approximately RMB2,393,246,000). The above amounts will be financed by the internal resources of the Group.

PLEDGE OF THE GROUP'S ASSETS

As at 31 December 2021, the Group had pledged the equity interest in Weihai Jierui Medical Products Company Ltd., Shandong Financial Leasing Company Ltd. and Shanghai Financial Leasing Company Ltd., wholly owned subsidiaries of the Group, and Shandong Weigao Puri Pharmaceutical Packaging Co., Ltd., a wholly-controlled subsidiary of the Group, to secure the long-term borrowings from International Finance Corporation, and pledged bank deposits of RMB760,895,000 (2020: RMB340,129,000) to secure short-term borrowing, bills and letters of credit granted to the Group.

The Group had pledged bills receivable of RMB54,188,000 (2020: RMB128,188,000) to secure bank facilities.

As at 31 December 2021, the loan principal of Argon Medical Devices Holding, Inc. ("Argon") amounted to US\$336,406,000, which was secured by a security package of 100% equity interests in Argon and its subsidiaries as well as the property, plant and equipment, intangible assets, inventories, trade and other receivables, bank deposits and cash of Argon. In the meantime, the Company provided guarantee for Argon.

重大投資／未來重大投資計劃 (續)

除上述重大投資與投資計劃外，於二零二一年十二月三十一日，本集團並無參與重大投資或購入資本資產之未來計劃。

資本承擔

於二零二一年十二月三十一日，本集團及本公司已經簽約但尚未作出撥備收購、投資及購置物業、廠房及設備等的資本承擔約為人民幣1,113,104,000元（二零二零年：約人民幣2,393,246,000元），上述款項將以本集團之內部資源支付。

本集團資產抵押

於二零二一年十二月三十一日，本集團已質押對全資子公司威海潔瑞醫用製品有限公司、山東融資租賃公司有限公司、上海融資租賃公司有限公司、本集團全資控股子公司山東威高普瑞醫藥包裝有限公司的股權以獲取國際金融公司的長期借款，及已抵押銀行存款人民幣760,895,000元（二零二零年：人民幣340,129,000元）以獲取授予本集團的短期借款、票據及信用證額度。

本集團已質押應收票據人民幣54,188,000元（二零二零年：人民幣128,188,000元）以取得銀行信用額度。

於二零二一年十二月三十一日，愛琅醫療器械控股有限公司（「愛琅」）貸款本金336,406,000美元，以愛琅及其子公司的100%股權共同擔保，以愛琅的物業、廠房及設備、無形資產、存款、貿易和其他應收款、銀行存款和現金作為擔保物，同時本公司為愛琅提供擔保。

RESERVES AND DISTRIBUTABLE RESERVES

As at 31 December 2021, total reserves of the Group amounted to RMB18,810,028,000 (2020: RMB17,581,347,000).

Under the PRC laws and regulations, the Company's distributable reserves will be based on the lower of the amount calculated according to the PRC accounting principles and rules and the amount calculated according to the Hong Kong generally accepted accounting principles. As at 31 December 2021, the distributable reserves of the Company were approximately RMB8,220,181,000 (2020: RMB7,168,030,000).

REVIEW AND OUTLOOK

As a result of the intermittent reoccurrence of the COVID-19 across the country in 2021, response measures were actively carried out nationwide. Medical institutions also adopted quarantine visits, care restrictions and other measures. The number of out-patient and in-patient visits across the country increased as compared with that of 2020 but decreased as compared with the level before the outbreak of the COVID-19. The COVID-19 will continue to have significant adverse impacts on the demand for medical services. The Company made continuous efforts, overcame difficulties, assisted and cooperated with medical institutions and downstream customers and actively responded to challenges brought about by the COVID-19.

The national healthcare reform policies entered into full implementation in 2021. The negotiations on medical insurance, the sixth round of centralised procurement, the volume-based procurements of high-value consumables and DRGs/DIP are exerting far-reaching influence on the medical industry. Leveraging its ample product portfolios and extensive market coverage, the Company maintained strong resistance to risks. The Company fully predicted industry policies and carried out layout in advance to respond actively. Through various means such as the upgrading and updating of products, sound cost control and expansion of grass-roots markets, the Company seized opportunities and expanded its market share.

儲備及可供分派儲備

於二零二一年十二月三十一日，本集團儲備總額為人民幣18,810,028,000元（二零二零年：人民幣17,581,347,000元）。

根據中國的法律及條例，本公司可供分派的儲備將以按照中國會計原則及規則所計算金額與按照香港公認會計原則所計算金額中的較低者為基準。於二零二一年十二月三十一日，本公司可供分派的儲備約為人民幣8,220,181,000元（二零二零年：人民幣7,168,030,000元）。

回顧與展望

二零二一年全國仍然有間斷性的出現新冠疫情，全國各地均積極採取應對措施，醫療機構亦進行隔離就診、限制陪護等措施。全國門診人數及住院人數比二零二零年有提升，但比疫情前仍有下滑，疫情對醫療需求仍繼續產生較大不利影響。公司持續努力，克服困難，協助配合醫療機構和下遊客戶，積極應對疫情帶來的挑戰。

二零二一年國家醫改政策進入全面推進，包括醫保談判、第六輪集採、高值耗材帶量採購、DRGs/DIP等，正在對醫療行業產生深遠影響。公司憑借豐富的產品組合和市場覆蓋，有較強的風險應對能力。公司對行業政策進行充分預判，提前佈局，積極應對。通過產品升級換代、良好的成本控制、基層市場開拓等各種措施，抓住機會，提升市場份額。

REVIEW AND OUTLOOK (continued)

The government boosted efforts in encouraging innovation in medical devices. As the R&D and approval of new products sped up, enterprises engaged in innovation in medical devices displayed unprecedented vitality. The Company seized opportunities, increased investment and accelerated in R&D activities. Meanwhile, it strategically conducted communications and cooperation with such innovative startups to accelerate the introduction and market access of new products. The Company sped up the improvement of product portfolios to respond to market changes.

The Company continuously improves and enhances governance and promotes strategies on sustainable development to facilitate long-term and high-quality development. It highlights responsible operation and meets the social demands for medical products with high-quality products. The Company emphasises the green development concept and implements the concept, targets and action measures on energy saving and emission reduction in production and operation.

As a leading domestic platform-based medical devices company, the Company enjoys significant competitiveness on the following aspects:

- 1) Outstanding corporate culture and distinguished market reputation and brand influence.

The Company always practices the corporate culture of conscience, honesty and loyalty to meet clinical demands. With the strong rigid demand in the market, the implementation of volume-based procurements and the efficiency improvement in industrial chains on medical devices and consumables, it will significantly facilitate the Company to rapidly expand its market share.

- 2) Open, inclusive and sharing platform advantages.

The Company promotes the coordination and cooperation of all segments and the sharing of resources to fully stimulate the flexibility and vitality of all segments. Through strategic review, the Company actively cultivates and deploys new business segments with an aim to build them into new growth points.

回顧與展望 (續)

政府加大力度鼓勵醫療器械創新。新產品的研發、獲批速度加快，醫療器械創新企業展現出空前的活力。公司抓住機遇，加大研發投入，加快研發進展。同時，策略性與這些創新型初創企業開展溝通、合作，以加速新產品上市和市場准入。公司加快完善產品組合，應對市場變化。

公司持續完善、提升治理水平，推行可持續發展策略，助力長期高質量發展。公司強調負責任經營，以優質的產品滿足社會對醫療產品的需求。公司強調綠色發展理念，將節能減排的理念、目標和行動措施，貫穿到生產經營中去。

公司是國內領先的醫療器械平台型公司，在以下幾個方面有顯著的競爭力：

- 1) 優秀的企業文化、卓越的市場口碑和品牌影響力。

公司始終踐行良心、誠心、忠心的企業文化，滿足臨床需求。產品的市場剛需強，隨著帶量採購的實施，醫療器械、耗材的產業鏈效率優化，極大有利於公司快速提升市場份額。

- 2) 開放、包容和共享的平台優勢。

公司推動各板塊的協同、合作和資源共享，充分激發各板塊的靈活性和活力。公司通過戰略梳理，積極培育和佈局新的業務板塊，以期成為新的增長點。

REVIEW AND OUTLOOK (continued)

3) Solid manufacturing foundations.

The Company enjoys remarkable advantages on automation, materials science, cost control, capacity layout and quality control and fully meets the requirements of volume-based procurements on price and quality. The Company will continue to improve its digital management on production and manufacturing, actively deploy new materials, new technologies and new processes to maintain and improve the manufacturing competitiveness.

4) Customer resources and channel coverage.

After year of efforts, the Company has developed an outstanding marketing system applicable to the PRC market. It enhanced channel advantages through further integration of sales channels. The Company continuously sped up the improvement of product portfolios through R&D, cooperation on domestic and foreign products and M&As to give full display to channel advantages.

5) The Company formulates development strategies and medium and long-term development plans on a rolling basis.

Based on the changes in industry policies and competition layout, clinical demands and the accumulation of its own resources, the Company proposed three operation strategies on “platform-based”, “international” and “digital” development and two guarantee strategies on “talents” and “innovation”. It will create long-term and stable value through the implementation of such strategies.

Despite various challenges in the future, the management has full confidence on the long-term and sustainable development of the Company. With its strategic layout in extensive business fields and high-quality products, persistent in adapting to market, future operating strategy and motivating employee creativity, the management believes that the Company will continue to maintain its leading position in the PRC market. Meanwhile, the Company will proactively promote global resource sharing to achieve the coordinated development of domestic and foreign markets, thus supporting the stable growth in the operating results of the Group.

回顧與展望 (續)

3) 紮實的製造業基礎。

公司在自動化水平、材料學、成本控制、產能佈局、質量控制等方面都有明顯優勢，充分滿足帶量採購對價格和質量的需求。公司將繼續提升生產製造的數字化管理水平，積極佈局新材料、新技術、新工藝，維持和提升製造業的競爭力優勢。

4) 客戶資源及渠道覆蓋。

通過多年的努力，公司打造了適用中國市場的優秀營銷體系。通過進一步的銷售渠道整合，提升渠道優勢。公司持續通過研發、國內外產品合作、併購等，加速完善產品組合，充分發揮渠道優勢。

5) 公司滾動制定發展戰略和中長期發展規劃。

結合行業政策和競爭格局的變化、臨床需求、自身資源的積累等情況，提出「平台化」、「國際化」、「數字化」三大經營戰略和「人才」、「創新」兩大保障戰略。通過戰略的貫徹和實施創造長期穩健的價值。

雖然未來面臨各種挑戰，但管理層對公司的長期和可持續發展充滿信心。管理層相信，憑借公司廣泛的業務領域戰略佈局及高質量產品，堅持適應市場、面向未來的經營策略，激發員工創造性，公司將繼續保持中國市場領先地位。同時積極推動公司全球資源共享，實現國內外市場協同發展，支持本集團經營業績穩健增長。

REPORT OF THE SUPERVISORY COMMITTEE

監事會報告書

To all shareholders:

The Supervisory Committee (the “Supervisory Committee”) of Shandong Weigao Group Medical Polymer Company Limited, in compliance with the relevant requirements of the Company Law and the Articles of Association of the Company, has conducted its work in accordance with the fiduciary principle, and has taken up an active role to work seriously and with diligence to protect the interests of the Company and its shareholders.

During the Year, the Supervisory Committee had reviewed cautiously the development plans of the Company and provided reasonable suggestions and opinions to the Board. It also strictly and effectively monitored and supervised the Company’s management in making significant policies and decisions to ensure that they are in compliance with the relevant requirements of the Company Law and the Articles of Association of the Company, and in the interests of its shareholders.

We have reviewed and agreed to the report of the Directors, audited financial statements and the dividend to be proposed by the Board for presentation at the forthcoming annual general meeting. We are of the opinion that the Directors, the chief executive officer and other senior management of the Company are able to strictly observe their fiduciary duty, to act diligently, to exercise their authority faithfully in the best interests of the Company and to work in accordance with the Articles of Association of the Company. The transactions between the Company and connected parties are in the interests of the shareholders as a whole and under fair and reasonable price.

As of today, none of the Directors, chief executive officer and senior management staff had been found to have abused their authority, damaged the interests of the Company or infringed upon the interests of its shareholders and employees. None of them was found to be in breach of any laws and regulations or the Articles of Association of the Company.

致各位股東：

山東威高集團醫用高分子製品股份有限公司監事會（「本監事會」）遵照公司法及本公司組織章程細則的有關規定，遵守誠信原則，認真履行職責，保護本公司及其股東利益，勤勉主動地開展工作。

在本年度內，本監事會對本公司的發展計劃進行謹慎審核，並向董事會提出合理的建議和意見，對本公司管理層的重大決策及決定是否符合公司法及本公司組織章程細則的有關規定，是否符合股東利益等，進行了嚴謹及有效的監督。

本監事會已審閱並同意董事會提呈予應屆股東週年大會的董事會報告、經審核財務報表及建議派發的股息。本監事會認為本公司董事、行政總裁及其他高級管理人員能夠嚴格遵守誠信原則，工作勤勉盡職並真誠地以本公司最佳利益為出發點行使職權，並按照本公司組織章程細則開展各項工作。本公司與關連人士進行的交易均符合股東的整體利益，且價格公平合理。

本監事會至今並無發現董事、行政總裁及高級管理人員濫用職權，損害本公司利益或侵犯本公司股東和員工權益的行為，亦未發現上述人員違反任何法律法規或本公司的組織章程細則。

REPORT OF THE SUPERVISORY COMMITTEE
監事會報告書

The Supervisory Committee is satisfied with the achievement and cost-effectiveness of the Company in 2021 and has great confidence in the future prospect of the Company.

本監事會對本公司於二零二一年的各項工作和取得的成本效益表示滿意，並對本公司的未來前景充滿信心。

By Order of the Supervisory Committee
**Shandong Weigao Group Medical Polymer
Company Limited**
HU Yunyong
Chairman of Supervisory Committee
Weihai, Shandong Province, the PRC

承本監事會命
**山東威高集團醫用高分子製品股份
有限公司**
本監事會主席
胡雲涌
中國山東省威海市

14 April 2022

二零二二年四月十四日

REPORT OF THE DIRECTORS 董事會報告

The Directors are pleased to submit their annual report and the audited financial statements of the Group for the year ended 31 December 2021.

The Company was established and registered as a joint stock company with limited liability in the PRC under the Company Law of the PRC on 28 December 2000. The H Shares of the Company were listed on GEM of the Stock Exchange of Hong Kong Limited (the "Stock Exchange") on 27 February 2004 and were transferred to Main Board of the Stock Exchange on 29 July 2010. On 7 August 2018, the Company completed the H share full circulation pilot project to convert and list 2,638,600,000 unlisted or domestic shares into H shares. As at 31 December 2021, there was a total issued share capital of 4,522,332,324 H Shares and 48,300,000 non-listed domestic shares.

PRINCIPAL ACTIVITIES

Based in Shandong province, the Company is principally engaged in the research and development, production and sale of single-use medical device products and operates finance lease and factoring business in the PRC. The Group has a wide range of products, which cover eight principle business lines of clinical care, wound management, medical testing, anesthesia and surgery, orthopaedic products, interventional products, pharma packaging and blood management. The Group's products are sold under its own brand names, including "Jierui", "Wego Ortho", "Yahua", "Bangde" and "Hai Xing". As at the date of this report, the Group newly added 461 hospitals, 116 other medical institutions and 731 distributors to its PRC customer base, and the Group has a PRC customer base of 7,982 in aggregate (including 3,115 hospitals, 414 blood stations, 1,101 other medical units and 3,352 distributors) and an overseas customer base of 7,092 in aggregate (including 3,540 hospitals, 1,631 other medical units and 1,921 distributors).

PROPERTY, PLANT AND EQUIPMENT

The Group acquired property, plant and equipment during the year of 2021 at an aggregate cost of approximately RMB844,280,000 in order to enhance its production capacity. Details of movements in the property, plant and equipment of the Group are set out in note 15 to the financial statements.

董事欣然提呈本集團截至二零二一年十二月三十一日止年度的年報及經審核財務報表。

本公司於二零零零年十二月二十八日根據中國公司法在中國成立並註冊為股份有限公司。本公司H股自二零零四年二月二十七日起在香港聯合交易所有限公司（「聯交所」）GEM上市，並於二零一零年七月二十九日轉板至聯交所主板。於二零一八年八月七日，本公司完成H股全流通試點項目，將2,638,600,000股非上市股份或內資股轉換為H股並上市。於二零二一年十二月三十一日，已發行股本總額為4,522,332,324股H股及48,300,000股非上市內資股。

主要業務

本公司位於山東省，主要從事研發、生產及銷售一次性醫療器械產品及於中國經營融資租賃及保理業務。本集團的產品種類繁多，包括臨床護理、創傷管理、醫學檢驗、麻醉及手術、骨科產品、介入產品、藥品包裝及血液管理八個主要業務領域。本集團以自有品牌包括「潔瑞」、「威高骨科」、「亞華」、「邦德」及「海星」出售產品。於本報告日期，本集團國內客戶新增461家醫院、116家其他醫療機構以及731家經銷商，本集團的國內客戶總數為7,982家（包括醫院3,115家、血站414家、其他醫療單位1,101家和經銷商3,352家），海外客戶總數為7,092家（包括醫院3,540家、其他醫療單位1,631家和經銷商1,921家）。

物業、廠房及設備

本集團為提高產能而於二零二一年年內購置物業、廠房及設備的總成本約人民幣844,280,000元。有關本集團物業、廠房及設備的變動詳情，載於財務報表附註15。

SHARE CAPITAL

As at 31 December 2021, there was a total issued share capital of 4,522,332,324 H shares (the "H Shares") and 48,300,000 non-listed domestic shares (the "Non-listed Domestic Shares") of the Company.

The changes in share capital of the Company are set out in note 37 to the financial statements.

RESERVES AND DISTRIBUTABLE RESERVES

As at 31 December 2021, total reserves of the Group amounted to RMB18,810,028,000 (2020: RMB17,581,347,000).

Under the PRC laws and regulations, the Company's distributable reserves will be based on the lower of the amount calculated according to the PRC accounting principles and rules and the amount calculated according to the Hong Kong generally accepted accounting principles. As at 31 December 2021, the distributable reserves of the Company were approximately RMB8,220,181,000 (2020: RMB7,168,030,000).

DIRECTORS AND DIRECTORS' SERVICE CONTRACTS

The directors of the Company during the Year were:

Executive Directors

Mr. LONG Jing (*Chairman*)
Mr. CONG Rinan

Non-executive Director

Mr. TANG Zhengpeng
Mr. CHEN Lin
Mr. LIAN Xiaoming

Independent non-executive Directors

Mr. LO Wai Hung
Ms. FU Mingzhong
Ms. WANG Jinxia

股本

於二零二一年十二月三十一日，本公司全部已發行股本為4,522,332,324股H股份（「H股股份」）及48,300,000股非上市內資股（「非上市內資股」）。

本公司的股本變動載於財務報表附註37。

儲備及可供分派儲備

於二零二一年十二月三十一日，本集團儲備總額為人民幣18,810,028,000元（二零二零年：人民幣17,581,347,000元）。

根據中國的法律及條例，本公司可供分派的儲備將以按照中國會計原則及規則所計算金額與按照香港公認會計原則所計算金額中的較低者為基準。於二零二一年十二月三十一日，本公司可供分派的儲備約為人民幣8,220,181,000元（二零二零年：人民幣7,168,030,000元）。

董事及董事服務合約

本年度內，本公司的董事為：

執行董事

龍經先生 (*主席*)
叢日楠先生

非執行董事

湯正鵬先生
陳林先生
連小明先生

獨立非執行董事

盧偉雄先生
付明仲女士
王錦霞女士

DIRECTORS AND DIRECTORS' SERVICE CONTRACTS (continued)

Each of the directors entered into service agreements with the Company. The service contracts were signed for an initial term of three years, unless and until terminated by either party by giving notice to the other party with three months' notice in writing. In accordance with the Company's Articles of Association, the service agreements of all directors are renewable for successive three-year terms upon expiry.

The service agreements for directors do not stipulate for any amount of remuneration or bonus payment to be paid for services provided. The executive directors are paid with a fixed sum of annual salaries for holding positions in the Company and entitled to welfare benefits (including retirement benefits and medical insurance) in accordance with the relevant laws and regulations in the PRC. The non-executive director waived her directors' remuneration for the year ended 31 December 2021 and accepted a nominal annual fee of RMB1.00.

According to the respective service agreements entered into between the Company and each of three independent non-executive directors, each of Ms. Fu Mingzhong and Ms. Wang Jinxia received an annual fee of RMB120,000, and Mr. Lo Wai Hung received an annual fee of HK\$200,000.

Apart from the foregoing, no directors have a service contract with the Company which is not determinable by the Company within one year without payment of compensation (other than statutory compensation).

DIRECTORS' INTERESTS IN CONTRACTS

Save as disclosed, no transaction, arrangement or contract of significance in relation to the Group's business to which the Company, its fellow subsidiaries or its holding company or the Group was a party and in which a Director or an entity connected with a Director (with meetings as ascribed to it under the Listing Rules) had a material interest, whether directly or indirectly, were entered into or subsisted during or at the end of the year.

董事及董事服務合約 (續)

每名董事已與本公司訂立服務合約。服務合約已簽署初步為期三年，除非及直至任何一方給予另一方三個月的書面通知予以終止。根據本公司的組織章程細則，所有董事的服務協議均可於屆滿時再續三年。

董事的服務協議均無訂明其提供服務可獲取的任何酬金或花紅款額。執行董事獲支付固定年薪以擔任本公司職務，並根據中國有關法律和法規，有權享有各項福利待遇（包括退休福利及醫療保險）。非執行董事於截至二零二一年十二月三十一日止年度放棄其董事酬金，收取名義年度袍金人民幣1.00元。

根據本公司與三名獨立非執行董事各自訂立之有關服務協議，付明仲女士及王錦霞女士各自收取年度袍金人民幣120,000元，而盧偉雄先生收取年度袍金200,000港元。

除上述者外，董事概無與本公司訂立本公司不可於一年內未有支付賠償（法定賠償除外）而終止的服務合約。

董事於合約之權益

除披露者外，本公司、其同系附屬公司或其控股公司或本集團概無於年內或年末訂有任何董事或其關連實體（定義見上市規則）於當中直接或間接擁有任何重大權益且與本集團業務有關之重大交易、安排或合約。

DIRECTORS' INTERESTS AND LONG POSITIONS IN SHARES

董事於股份的權益及好倉

As at 31 December 2021, the interests of the directors in the share capital of the Company and their associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong ("SFO")), (i) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provision of the SFO); or (ii) which were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (iii) which were required to be notified to the Company and the Stock Exchange pursuant to the Model Code for Securities transactions by Directors of Listed Companies (the "Model Code") contained in the Listing Rules:

於二零二一年十二月三十一日，董事於本公司及其相聯法團（定義見香港法例第571章證券及期貨條例（「證券及期貨條例」）第XV部）之股本中擁有(i)根據證券及期貨條例第XV部第7及8分部須知會本公司及聯交所之權益（包括根據證券及期貨條例的相關條文彼等視作或被視為擁有的權益或淡倉），或(ii)將予記入本公司根據證券及期貨條例第352條須存置之登記冊之權益，或(iii)根據上市規則所載的上市公司董事進行證券交易的標準守則（「標準守則」）而須知會本公司及聯交所之權益如下：

(i) Long positions of listed Shares of RMB0.10 each of the Company

(i) 於本公司每股面值人民幣0.10元上市股份中的好倉

Name of Director	Types of interests	Capacity	Total number of H Shares	Approximate percentage of H Shares of the Company 佔本公司H股 概約百分比%	Total number of non-listed domestic Shares	Approximate percentage of the non-listed domestic Shares of the Company 佔本公司 非上市內資股 概約百分比%	Approximate percentage of the issued share capital of the Company 佔本公司 已發行股本的 概約百分比%
董事姓名	權益類別	身份	H股總數	概約百分比%	非上市內資股 總數	非上市內資股 概約百分比%	已發行股本的 概約百分比%
Mr. Long Jing 龍經先生	Personal 個人	Beneficial owner 實益擁有人	960,000	0.0210	6,000,000	12.40	0.1500
Mr. Cong Rinan 叢日楠先生	Personal 個人	Beneficial owner 實益擁有人	400,000	0.0088	2,000,000	4.14	0.0500
Mr. Chen Lin 陳林先生	Personal 個人	Beneficial owner 實益擁有人	196,000	0.0043	-	-	0.0043

DIRECTORS' INTERESTS AND LONG POSITIONS IN SHARES (continued)

董事於股份的權益及好倉 (續)

(ii) Long positions in the registered capital of holding company, Weigao Holding, an associated corporation of the Company

(ii) 於控股公司威高集團公司(本公司相聯法團)註冊資本的好倉

Name of director	Capacity	Amount of registered capital	Approximate percentage of the registered capital of Weigao Holding 佔威高集團公司註冊資本概約百分比
董事姓名	身份	註冊資本金額	概約百分比
Weihai Weigao International Medical Investment Holding Company Limited* (Note) 威海威高國際醫療投資控股有限公司(附註)	Registered owner 登記擁有人	1,078,000,000	89.83%
Mr. Chen Lin 陳林先生	Beneficial owner 實益擁有人	9,760,000	0.81%

Note: 威海威高國際醫療投資控股有限公司 (Weihai Weigao International Medical Investment Holding Company Limited*) is owned as to 51.7% by Mr. Chen Xueli and 7.4% by Mr. Chen Lin (Mr. Chen Xueli is father of Mr. Chen Lin).

附註：威海威高國際醫療投資控股有限公司由陳學利先生及陳林先生(陳學利先生為陳林先生的父親)分別擁有51.7%及7.4%。

PURCHASE, SALE OR REDEMPTION OF SECURITIES

At no time during the Year were rights to acquire benefits by means of the acquisition of shares in or debenture of the Company granted to any directors or their respective associates or were any such rights exercised by them; or was the Company, its holding company or any subsidiaries of its holding company or fellow subsidiaries a party to any arrangement to enable the directors of the Company to acquire such rights in the Company or any other body corporate.

SUBSTANTIAL SHAREHOLDERS

As at 31 December 2021, the register of substantial shareholders maintained by the Company pursuant to Section 336 of the SFO recorded that other than the interests disclosed above in respect of certain Directors, the following shareholder had notified the Company of relevant interest in the issued share capital of the Company.

Name of Shareholder	Capacity	Number of H shares	Percentage of total issued share capital
股東名稱	身份	H股數目	佔已發行股本總額的百分比
Weigao Holding Company Limited 威高集團有限公司	Beneficial owner 實益擁有人	2,099,755,676	45.94%

Save as disclosed above, the following shareholders have disclosed their relevant interests or long positions in the issued share capital of the Company.

購買、出售或贖回證券

於本年度內任何時間，概無任何董事或彼等各自的聯繫人獲授以收購本公司股份或債券方式獲利的權利，而彼等亦無行使任何該等權利；或本公司、其控股公司或其控股公司的任何附屬公司或同系附屬公司的任何附屬公司概無訂立任何安排，使本公司董事可收購於本公司或任何其他法人團體的該等權利。

主要股東

於二零二一年十二月三十一日，按本公司根據證券及期貨條例第336節存置的主要股東登記冊所示，除上文披露有關若干董事的權益外，下列股東已知會本公司其於本公司已發行股本中的有關權益。

除上文披露者外，下列股東已披露彼等於本公司已發行股本中擁有的相關權益或好倉。

SUBSTANTIAL SHAREHOLDERS (continued)

主要股東 (續)

Name of substantial shareholder 主要股東名稱	Number of H shares interested 擁有權益 H股數目	% of Issued Share Capital 佔已發行 股本百分比
Mr. Chen Xueli 陳學利先生	2,099,755,676(L)	45.94(L)
Weihai Weigao International Medical Investment Holding Company Limited# 威海威高國際醫療投資控股有限公司	2,099,755,676(L)	45.94(L)
Weigao Holding Company Limited# 威高集團有限公司	2,099,755,676(L)	45.94(L)

Note: (L) – Long Position

* Source: Website of Hong Kong Stock Exchange

For identification purpose only

附註：(L)–好倉

* 資料來源：香港聯交所網站

僅供識別

MAJOR CUSTOMERS AND SUPPLIERS

主要客戶及供應商

In 2021, sales to the Group's five largest customers accounted for 3.8% of the total sales for the Year and sales to the largest customer included therein accounted for 1.0% of the total sales of the Year. Purchases from the Group's five largest suppliers accounted for 19.1% of the total purchases for the Year and purchases from the largest supplier included therein accounted for 6.4% of the total purchases of the Year. During the Year, none of the directors of the Company or any of their associates or any shareholders (which to the knowledge of the directors, own more than 5% of the Company's issued share capital) had any beneficial interest in the top five customers and suppliers of the Group.

於二零二一年，向本集團五大客戶的銷售佔本年度總銷售3.8%，而向其中最大客戶的銷售則佔本年度總銷售1.0%。向本集團五大供應商所作採購佔本年度總採購額19.1%，而向其中最大供應商所作採購則佔本年度總採購6.4%。本年度內，本公司董事、其任何聯繫人或據董事所知擁有本公司已發行股本5%以上的任何股東概無於本集團五大客戶及供應商中擁有任何實益權益。

SHARE-BASED PAYMENTS

(A) Share Award Scheme of the Company

On 17 November 2014, the Company's share award scheme (the "Incentive Share Scheme") was adopted by the extraordinary general meeting. The maximum number of non-listed Shares which may be issued under the share award scheme would be 223,818,616, which represent 5% of the existing issued share capital of the Company or approximately 4.76% of the issued share capital of the Company as enlarged by the issue of the 223,818,616 non-listed shares, respectively, as incentive shares to key personnel of the Group, and other persons as approved by the Remuneration Committee (the "Selected Employee"), in batches in subsequent years. The life of the Incentive Share Scheme is for 10 years starting from 17 November 2014. Details of the Incentive Share Scheme are set out in the Company's announcement dated 15 August 2014.

According to the Incentive Share Scheme, the incentive shares will be granted to the Selected Employee, subject to non-market performance vesting conditions.

According to the Incentive Share Scheme, for Selected Employee with a domestic identity, the trustee will administer the incentive shares, which may be organised in forms of companies owned by the employees, limited partnership, or qualified trust companies in the PRC, or for Selected Employee with a foreign identity, the trustee will hold the incentive shares outside the PRC.

On 11 December 2015, the Company granted first 45,960,000 incentive shares to 111 Selected Employees. On 4 January 2016, the trustees subscribed the 45,960,000 shares with the consideration of RMB101,112,000 at the issue price of RMB2.20 per share.

以股份為基礎付款

(A) 本公司股份激勵計劃

於二零一四年十一月十七日，本公司通過股東特別大會採納股份激勵計劃（「激勵股份計劃」）。根據股份激勵計劃可發行非上市股份之最多數目將為223,818,616股，分別相當於本公司現有已發行股本5%或經發行223,818,616股非上市股份擴大後本公司已發行股本約4.76%，於隨後年度向本集團主要人員及薪酬委員會批准的其他人（「受益人」）分批發行作為激勵股份。激勵股份計劃之年期為自二零一四年十一月十七日起計十年。激勵股份計劃之詳情載於本公司日期為二零一四年八月十五日之公佈內。

根據激勵股份計劃，激勵股份將在非市場業績歸屬條件的規限下授予受益人。

根據激勵股份計劃，就持有境內身份的受益人而言，受託人將管理激勵股份，其可能以僱員擁有的公司、於中國的有限合夥公司或合資格信託公司的方式作出，或就持有境外身份的受益人而言，受託人將在中國境外持有激勵股份。

於二零一五年十二月十一日，本公司首次授出45,960,000股激勵股份予111名受益人。於二零一六年一月四日，受託人以每股股份人民幣2.20元之發行價認購45,960,000股股份，代價為人民幣101,112,000元。

SHARE-BASED PAYMENTS (continued)

(A) Share Award Scheme of the Company
(continued)

The fair value of the incentive shares as at grant date amounted to RMB104,121,000 which determined by market price of listing shares of the Company.

For grants of shares that are satisfying specified vesting conditions, the difference between the fair value and the issue price of the vested shares is expensed on a straight-line basis over the periods in which services are expected to be rendered by the relevant employees. The Group recognised the incentive share expenses of approximately RMB3,572,000 (2020: RMB7,903,000) into the profit or loss during the current year.

Three limited partnerships (named Weihai Chang Hong Enterprise Management Consulting Centre (Limited Partnership) (威海長弘企業管理諮詢中心(有限合夥)), Weihai Yang Fan Enterprise Management Consulting Centre (Limited Partnership) (威海揚帆企業管理諮詢中心(有限合夥)) and Weihai Hong Tu Enterprise Management Consulting Centre (Limited Partnership) (威海宏圖企業管理諮詢中心(有限合夥)), respectively) were set up for the purpose of administering the Incentive Share Scheme and holding the shares, and hereby regarded as trustees of the Company and consolidated to the Group accordingly.

Details of specific categories of share award are as follows:

	Date of grant 授出日期	Vesting period 歸屬期	Issue Price 發行價
Batch 1 第1批	11/12/2015 二零一五年十二月十一日	5 years 5年	RMB2.2 人民幣2.2元

Note: The granted shares are vested in five tranches with the vesting date on 31 December of each year from 2015 to 2019, the vested shares are excisable after two years lock up period following vested.

以股份為基礎付款 (續)

(A) 本公司股份激勵計劃 (續)

於授予日期之激勵股份之公平值人民幣104,121,000元乃經參考本公司上市股份之市價而釐定。

就授出須符合指定歸屬條件的股份而言，公平值與已歸屬股份發行價之間的差額於預期將由有關僱員提供服務的歸屬期內以直線法確認為開支。於本年度，本集團於損益確認激勵股份開支約人民幣3,572,000元（二零二零年：人民幣7,903,000元）。

就管理激勵股份計劃及持有股份設立之三間有限合夥公司（即分別為威海長弘企業管理諮詢中心（有限合夥）、威海揚帆企業管理諮詢中心（有限合夥）及威海宏圖企業管理諮詢中心（有限合夥）），據此被視為本公司之受託人及因此於本集團綜合入賬。

具體股份激勵類別的詳情如下：

附註： 授出的股份將分5批予以歸屬，歸屬日期為二零一五年至二零一九年各年之十二月三十一日，已歸屬股份可於歸屬後兩年鎖定期屆滿後予以行使。

SHARE-BASED PAYMENTS (continued)

(A) Share Award Scheme of the Company (continued)

As of 31 December 2021, the outstanding incentive shares under the Incentive Share Scheme were 16,904,000 (2020: 23,564,000), included 9,922,000 exercisable shares (2020: 9,570,000).

During the year ended 31 December 2021, the trustees repurchased 9,108,000 shares (2020: 9,064,000), which would be taken up by the Selected Employees with the net consideration of RMB20,293,000 (2020: RMB52,571,000) at the price of RMB4.43 per share (2020: RMB8.00). The repurchased shares are held by the trustees for the benefit of the Share Award Scheme, to grant or sell to other selected employees.

During the year ended 31 December 2021, the trustees sold 6,660,000 repurchased shares for a total consideration of RMB94,170,000 (2020: 22,396,000 repurchase shares for a total consideration of RMB259,745,000, certain of which were used to settle the loan provided by the controlling shareholder and the interest thereon).

On 21 October 2021, the trustees subscribed the newly issued 48,300,000 non-listed domestic shares with the total consideration of RMB172,914,000 at the issue price of RMB3.58 per share. On 24 December 2021, the Company granted 48,300,000 incentive shares to 83 Selected Employees.

Based on the Share Award Scheme of the Company, the Company will repurchase the shares granted to the Selected Employees when the Selected Employees are not satisfying specified vesting conditions. The total consideration paid by the Selected Employees are recognised as liabilities, and will only be reversed by portion to other reserve when the shares are vested each year.

以股份為基礎付款 (續)

(A) 本公司股份激勵計劃 (續)

截至二零二一年十二月三十一日，激勵股份計劃項下之尚未行使激勵股份為16,904,000股(二零二零年：23,564,000股)，包括9,922,000股可行使股份(二零二零年：9,570,000股)。

截至二零二一年十二月三十一日止年度，受託人以每股人民幣4.43元(二零二零年：人民幣8.00元)的價格回購擬由受益人所接納的9,108,000股股份(二零二零年：9,064,000股)，代價淨額為人民幣20,293,000元(二零二零年：人民幣52,571,000元)。回購股份由受託人為股份激勵計劃的利益持有，以向其他受益人授出或出售。

截至二零二一年十二月三十一日止年度，受託人以人民幣94,170,000元的總代價出售6,660,000股回購股份(二零二零年：以人民幣259,745,000元的總代價出售22,396,000股回購股份，部分回購股份用於清償控股股東提供的貸款及其利息)。

於二零二一年十月二十一日，受託人以每股股份人民幣3.58元之發行價認購新發行的48,300,000股非上市內資股，總代價為人民幣172,914,000元。於二零二一年十二月二十四日，本公司授出48,300,000股激勵股份予83名受益人。

根據本公司的股份激勵計劃，本公司會在受益人未達到指定歸屬條件時回購已授予受益人的股份。受益人所支付的總代價確認為負債，並僅將於每年股份歸屬時撥回部分至其他儲備。

SHARE-BASED PAYMENTS (continued)

(A) Share Award Scheme of the Company
(continued)

The fair value of the incentive shares as at grant date amounted to RMB197,490,000 which determined by market price of listing shares of the Company.

For grants of shares that are satisfying specified vesting conditions, the difference between the fair value and the issue price of the vested shares is expensed on a straight-line basis over the periods in which services are expected to be rendered by the relevant employees. The Group recognised the incentive share expenses of approximately RMB41,275,000 (2020: nil) into the profit or loss during the current year.

Nine limited partnerships were set up for the purpose of administering the Incentive Share Scheme and holding the shares, and hereby regarded as trustees of the Company and consolidated to the Group accordingly.

Details of specific categories of share award are as follows:

	Date of grant 授出日期	Vesting period 歸屬期	Issue Price 發行價
Batch 2 第2批	24/12/2021 二零二一年十二月二十四日	5 years 5年	RMB3.58 人民幣3.58元

以股份為基礎付款 (續)

(A) 本公司股份激勵計劃 (續)

於授予日期之激勵股份之公平值人民幣197,490,000元乃經參考本公司上市股份之市價而釐定。

就授出須符合指定歸屬條件的股份而言，公平值與已歸屬股份發行價之間的差額於預期將由有關僱員提供服務的歸屬期內以直線法確認為開支。於本年度，本集團於損益確認激勵股份開支約人民幣41,275,000元（二零二零年：無）。

就管理激勵股份計劃及持有股份設立之九間有限合夥公司，據此被視為本公司之受託人及因此於本集團綜合入賬。

具體股份激勵類別的詳情如下：

SHARE-BASED PAYMENTS (continued)

(b) Share Option Scheme by WW Cayman

On July 26 2018, WW Medical and Healthcare Company Limited (“WW Cayman”), a subsidiary of the Company, adopted a non-qualified share option plan (the “Share Option Scheme”) for the primary purpose of providing incentives to directors and eligible employees of WW Cayman and its subsidiaries, which shall be valid and effective for a period of 10 years commencing from the adoption date. Under the Share Option Scheme, a committee designated by the board of directors of the WW Cayman may from time to time in its sole discretion grant options to the eligible employees.

The total number of shares in respect of which options may be granted under the Share Option Scheme is not permitted to exceed 8% of the shares of WW Cayman in issue at closing date. Unless approved by the shareholders of the Company, the total number of shares issued and to be issued upon exercise of the options granted to each participant (including both exercised and outstanding options) in any 12-month period must not exceed 1% of WW Cayman’s shares in issue.

As at 31 December 2021, the number of shares in respect of which options had been granted and remained outstanding under the Scheme was 2,654,859, representing 7% (2020: 2,166,213, representing 7%) of the shares at that date.

No consideration is payable on the grant of an option. Options may be exercised at any time after vesting and will be cancelled if not exercised before the 10th anniversary of the date of grant.

The exercise price of each batch of option is determined with reference to the total cash consideration paid by the Company in the formation of WW Cayman for the acquisition of Argon, taking into account the relevant costs and expenses involved, but in no event shall be less than the fair market value of a share of stock in WW Cayman on the date of grant.

以股份為基礎付款 (續)

(b) WW Cayman的購股權計劃

於二零一八年七月二十六日，本公司附屬公司WW Medical and Healthcare Company Limited (「WW Cayman」) 採納非限定購股權計劃(「購股權計劃」)，其主要目的是為WW Cayman及其附屬公司的董事及合資格僱員提供激勵，自採用日期起10年內有效。根據購股權計劃，WW Cayman董事會指定的委員會可不時全權酌情向合資格僱員授出購股權。

根據購股權計劃可授出購股權的相關股份總數不得超過交割日期已發行的WW Cayman股份的8%。除非獲本公司股東批准，授予各參與者的購股權(包括已行使和未行使的購股權)獲行使而於任何12個月期間內已發行及將予發行的股份總數不得超過WW Cayman已發行股份的1%。

於二零二一年十二月三十一日，計劃項下已授出及尚未行使購股權的相關股份數目為2,654,859股，佔於該日期股份總數的7% (二零二零年：2,166,213股，佔7%)。

授出購股權無需支付代價。購股權可於歸屬後的任何時間行使，且倘未於授出日期起滿10年之前獲行使，則將被註銷。

每批購股權的行使價乃經參考本公司成立WW Cayman以收購愛琅所支付的現金代價總額，計及涉及的相關成本及開支釐定，惟無論如何不得低於授出日期WW Cayman股票的公平市場價值。

SHARE-BASED PAYMENTS (continued)

以股份為基礎付款 (續)

(b) Share Option Scheme by WW Cayman
(continued)

(b) WW Cayman的購股權計劃 (續)

Details of specific categories of options are as follows:

具體購股權類別詳情如下：

	Date of grant 授出日期	Vesting period 歸屬期	Exercise Price 行使價
Time-based options 時間基準購股權	26/07/2018 二零一八年 七月二十六日	4 years 4年	USD10.00 10.00美元
Time-based options 時間基準購股權	30/10/2019 二零一九年 十月三十日	4 years 4年	USD10.00 10.00美元
Time-based options 時間基準購股權	13/03/2020 二零二零年 三月十三日	4 years 4年	USD10.00 10.00美元
Time-based options 時間基準購股權	30/07/2021 二零二一年 七月三十日	4 years 4年	USD10.00 10.00美元
Performance-based options 表現基準購股權	26/07/2018 二零一八年 七月二十六日	4 years 4年	USD10.00 10.00美元
Performance-based options 表現基準購股權	30/10/2019 二零一九年 十月三十日	4 years 4年	USD10.00 10.00美元
Performance-based options 表現基準購股權	13/03/2020 二零二零年 三月十三日	4 years 4年	USD10.00 10.00美元
Performance-based options 表現基準購股權	30/07/2021 二零二一年 七月三十日	4 years 4年	USD10.00 10.00美元

The following table discloses movements of the share options held by employees during the year:

下表披露年內僱員所持購股權的變動情況：

Option type		Outstanding at 1/1/2021 於二零二一年 一月一日 尚未行使	Granted during year 年內授出	Forfeited during year 年內沒收	Outstanding at 31/12/2021 二零二一年 十二月三十一日 尚未行使
Time-based options 時間基準購股權		1,446,725	180,000	(29,075)	1,597,650
Performance-based options 表現基準購股權		719,488	337,721	-	1,057,209
		2,166,213	517,721	(29,075)	2,654,859

SHARE-BASED PAYMENTS (continued)

以股份為基礎付款 (續)

(b) Share Option Scheme by WW Cayman
(continued)

(b) WW Cayman的購股權計劃 (續)

During the year ended 31 December 2021, options were granted on 30 July 2021. The estimated fair value of the time-based options granted on that date is USD4.64. The estimated fair value of the performance-based options on that date is USD4.64.

於截至二零二一年十二月三十一日止年度，購股權於二零二一年七月三十日獲授出。於該日期授出的時間基準購股權的估計公平值為4.64美元。於該日期的表現基準購股權的估計公平值為4.64美元。

The fair value of the options was calculated using the Black-Scholes pricing model. The inputs into the model were as follows:

購股權之公平值採用布萊克-斯克爾斯定價模型計算。模型的輸入數據如下：

	2021 二零二一年	2020 二零二零年
Weighted average share price 加權平均股價	10.00	10.00
Exercise price 行使價	10.00	10.00
Expected volatility 預期波動率	40%	40%
Expected life 預期年期	7 years 年	7 years 年
Risk-free rate 無風險利率	2.95%	2.95%

Expected volatility was determined by using the historical volatility of the comparable companies over the previous 7 years (2020: 7 years). The expected life used in the model has been adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations.

預期波動率乃通過使用過去7年(二零二零年：7年)可資比較公司的歷史波動率確定。基於管理層的最佳估計，模型中使用的預期年期已根據不可轉移性、行使限制及行為考慮因素的影響作出調整。

SHARE-BASED PAYMENTS (continued)

(b) Share Option Scheme by WW Cayman (continued)

The Group recognised the total expense of USD4,108,000 (equivalent to RMB26,506,000) for the year ended 31 December 2021 (2020: USD2,267,000, equivalent to RMB15,801,000) in relation to share options granted under the Share Option Scheme by WW Cayman.

(c) Share Award Scheme by Weigao Orthopaedic

On 9 May 2020, a share award scheme was adopted by the extraordinary general meeting of Weigao Orthopaedic (the "Weigao Orthopaedic Share Award Scheme"). A total number of 3,300,000 shares of Weigao Orthopaedic were awarded to the eligible senior management and employees (the "Eligible Employees"), which representing 0.92% shareholding of Weigao Orthopaedic.

The issue price of Weigao Orthopaedic Share Award Scheme is RMB15 per share, the total consideration amounted to RMB49,500,000. 60% of consideration was covered by the loan provided by Weihai Hongyangrui to the Eligible Employees, and the remaining 40% was funded by themselves.

Details of the shares awarded are as follows:

Performance-based awards
表現基準獎勵

以股份為基礎付款 (續)

(b) WW Cayman的購股權計劃 (續)

本集團就根據WW Cayman的購股權計劃授出的購股權確認截至二零二一年十二月三十一日止年度總開支為4,108,000美元(相等於人民幣26,506,000元)(二零二零年:2,267,000美元,相等於人民幣15,801,000元)。

(c) 威高骨科的股份激勵計劃

於二零二零年五月九日,威高骨科股東特別大會採納股份激勵計劃(「威高骨科股份激勵計劃」)。合共3,300,000股威高骨科股份授予合資格高級管理層及僱員(「合資格僱員」),佔威高骨科股權的0.92%。

威高骨科股份激勵計劃的發行價為每股人民幣15元,總代價為人民幣49,500,000元,其中60%的代價由威海弘陽瑞向合資格僱員提供的貸款支付,其餘40%由其自身出資。

獲獎勵股份詳情如下:

	Date of grant 授出日期	Vesting period 歸屬期
Performance-based awards 表現基準獎勵	9/05/2020 二零二零年 五月九日	4 years 4年

SHARE-BASED PAYMENTS (continued)

以股份為基礎付款 (續)

(c) Share Award Scheme by Weigao Orthopaedic
(continued)

(c) 威高骨科的股份激勵計劃 (續)

Based on the Weigao Orthopaedic Share Award Scheme, as the subsidiary of the Company will repurchase the shares granted to the Eligible Employees when the Eligible Employees are not satisfying specified vesting conditions, the total consideration paid by the Eligible Employees are recognised as liabilities, and will only be reversed by portion to other reserve when the shares are vested each year.

根據威高骨科股份激勵計劃，由於本公司附屬公司會在合資格僱員未達到指定歸屬條件時回購已授予合資格僱員的股份，故合資格僱員所支付的總代價確認為負債，並僅將於每年股份歸屬時撥回部分至其他儲備。

The estimated fair value of the performance-based awards on the grant date is RMB19.8 per share. The difference between the fair value and the issue price of the vested shares is expensed on a straight-line basis over the periods in which services are expected to be rendered by the Eligible Employees. During the year ended 31 December 2021, Weigao Orthopaedic recognised a share awards expense of approximately RMB5,139,000 into the profit or loss (2020: RMB6,958,000).

表現基準獎勵於授出日期的估計公平值為每股人民幣19.8元。已歸屬股份的公平值與發行價之間的差額於合資格僱員預計提供服務的期間內按直線法支銷。於截至二零二一年十二月三十一日止年度，威高骨科將股份獎勵費用約人民幣5,139,000元（二零二零年：人民幣6,958,000元）計入損益。

CONTINUING CONNECTED TRANSACTIONS ENTERING OF SUPPLEMENTAL LOGISTIC AND DISTRIBUTION SERVICES FRAMEWORK AGREEMENT

Reference is made to the announcement of the Company dated 26 August 2020 and the circular of the Company dated 22 September 2020 in relation to, among others, the Logistic and Distribution Services Framework Agreement. On 27 August 2021, the Group entered into the Supplemental Logistic and Distribution Services Framework Agreement to revise the annual cap from RMB1,400 million to RMB2,500 million for the year ending 31 December 2021. All other terms as stipulated in the Logistic and Distribution Services Framework Agreement remain unchanged.

CONTINUING CONNECTED TRANSACTIONS ENTERING OF LOGISTIC SUPPORT SERVICES AGREEMENT

Reference is made to the announcements of the Company dated 5 December 2018, 27 September 2019, 18 December 2019, 20 December 2019, 26 August 2020, 28 October 2020 and 2 November 2020 and the circulars of the Company dated 27 September 2019, 22 September 2020 and 16 November 2020 in relation to, among others, the continuing connected transactions agreements, including the Purchase Framework Agreement, the Deposit Services Agreement, the Finance Leasing and Factoring Framework Agreement, Sales Framework Agreement, the Services Framework Agreement and the Tenancy Framework Agreement (the "CCT Agreements"). On 16 November 2021, the Company and/or its subsidiaries entered into the Supplemental Agreements with Weigao Holding and/or its subsidiaries and associates ("Weigao Holding Group") (i) to extend the agreement terms of the CCT Agreements to 31 December 2023; and (ii) to propose new annual caps for the years ending 31 December 2022 and 2023 (wherever applicable).

持續關連交易 訂立補充委託配送服務框架協議

茲提述本公司日期為二零二零年八月二十六日之公告及本公司日期為二零二零年九月二十二日之通函，內容有關(其中包括)委託配送服務框架協議。於二零二一年八月二十七日，本集團訂立補充委託配送服務框架協議，以修訂截至二零二一年十二月三十一日止年度之年度上限，由人民幣1,400,000,000元修訂至人民幣2,500,000,000元。委託配送服務框架協議中所規定之所有其他條款維持不變。

持續關連交易 訂立物流支持服務協議

茲提述本公司日期為二零一八年十二月五日、二零一九年九月二十七日、二零一九年十二月十八日、二零一九年十二月二十日、二零二零年八月二十六日、二零二零年十月二十八日及二零二零年十一月二日之公告以及本公司日期為二零一九年九月二十七日、二零二零年九月二十二日及二零二零年十一月十六日之通函，內容有關(其中包括)持續關連交易協議，包括採購框架協議、存款服務協議、融資租賃及保理框架協議、銷售框架協議、服務框架協議及租賃框架協議(「持續關連交易協議」)。於二零二一年十一月十六日，本公司及／或其附屬公司與威高集團公司及／或其附屬公司及聯營公司(「威高集團」)訂立補充協議，以(i)將持續關連交易協議之協議期限延長至二零二三年十二月三十一日；及(ii)建議截至二零二二年及二零二三年十二月三十一日止各年度的新年度上限(倘適用)。

CONTINUING CONNECTED TRANSACTIONS

持續關連交易

1. Supplemental purchase framework agreement

On 16 November 2021, the Company entered into the Supplemental Purchase Framework Agreement with Weigao Holding to (i) extend the agreement term for two years to 31 December 2023; and (ii) new annual caps of RMB1,300 million and RMB1,500 million for the years ending 31 December 2022 and 2023, respectively. Purchases of medical based products, including but not limited to, medical equipment, medical raw materials, medical packaging materials, pharmaceutical and medical devices by the Group from the Weigao Holding Group. The annual cap for purchase transactions of the Company from Weigao Holding Group shall not exceed RMB1,400.0 million for the year ended 31 December 2021. During the Year, the actual amount of transactions in relation to purchase transactions under the Supplemental Purchase Framework Agreement was approximately RMB1,031.8 million.

2. Logistic support services framework agreement with logistic company

On 16 November 2021, the Company entered into the Logistic Support Services Framework Agreement with Logistic Company for a term of two years from 1 January 2022 to 31 December 2023, pursuant to which the Company agrees to subscribe, or procure its subsidiaries to subscribe, and Logistic Company agrees to provide or procure its subsidiaries to provide integrated medical device supply chain logistic services. Logistic Company Group delivers the Group's products to its customers (such as hospitals), collects payment from the customers on behalf of the Group and settles the amount paid by the customers (net of the logistic service fees charged by Logistic Company Group) with the Group.

1. 補充採購框架協議

於二零二一年十一月十六日，本公司與威高集團公司訂立補充採購框架協議，以(i)將協議期限延長兩年，至二零二三年十二月三十一日；及(ii)建議截至二零二二年及二零二三年十二月三十一日止各年度的新年度上限分別為人民幣1,300,000,000元及人民幣1,500,000,000元。本集團向威高集團採購醫療產品，包括（但不限於）醫療設備、醫療原材料、醫療包裝材料、藥品及醫療器械。截至二零二一年十二月三十一日止年度，本公司自威高集團採購的交易年度上限不超過人民幣1,400,000,000元。於年內，補充採購框架協議項下採購交易的實際交易金額約為人民幣1,031,800,000元。

2. 與物流公司訂立物流支持服務框架協議

於二零二一年十一月十六日，本公司與物流公司訂立物流支持服務框架協議，自二零二二年一月一日至二零二三年十二月三十一日為期兩年，據此，本公司同意採購或促使其附屬公司採購，而物流公司同意提供或促使其附屬公司提供綜合醫療器械供應鏈物流服務。物流公司集團將本集團的產品交付予其客戶（如醫院），代本集團向客戶收取款項並與本集團結算客戶支付的金額（扣除物流公司集團收取的物流服務費）。

CONTINUING CONNECTED TRANSACTIONS
(continued)

2. Logistic support services framework agreement with logistic company (continued)

The Group negotiates and agrees the pricing of medical consumables and devices products directly with hospitals and nominate logistic operators (including the Weigao Holding Group) to deliver the products. Logistic operators collect the payment from the hospitals on behalf of the Group and the logistic operators settle the payment received from the hospitals with the Group on a back-to-back basis. The settlement amount between the logistic operators and the Group is the net amount after deducting the logistic services fees charged by the logistic operators from the gross amount paid by hospitals. Pursuant to the Logistic Support Services Framework Agreement, the logistic service fee charged by Logistic Company Group represents 3% of the total amount paid by hospitals. The logistic service fee of 3% is determined by the Company and Logistic Company after arm's length negotiations and with reference to the market fees charged by other independent logistic operators providing similar services as well as the fees charged by Logistic Company to its independent customers in its ordinary course of business. The Proposed Annual Caps in respect of the logistic service fees charged by Logistic Company are RMB155 million and RMB186 million for the year ending 31 December 2022 and 2023.

The annual cap for logistic support services of the Company shall not exceed RMB2,500.0 million. During the Year, the actual amount settled with Logistic Company Group for the product sales to hospitals under Logistic Support Services Framework Agreement with logistic company was approximately RMB2,156 million.

持續關連交易 (續)

2. 與物流公司訂立物流支持服務框架協議 (續)

本集團直接與醫院磋商並協定醫療耗材及器械產品的價格，並指定物流運營商(包括威高集團)交付產品。物流運營商代本集團向醫院收取款項，並按背對背基準與本集團結算自醫院收取的款項。物流運營商與本集團之間的結算金額乃自醫院支付的總金額扣除物流運營商收取的物流服務費後的淨額。根據物流支持服務框架協議，物流公司集團收取的物流服務費為醫院支付的總金額的3%。3%的物流服務費由本公司與物流公司經公平磋商並參考其他提供類似服務的獨立物流運營商收取的市場費用以及物流公司於其一般業務過程中向其獨立客戶收取的費用後確定。截至二零二二年及二零二三年十二月三十一日止年度有關物流公司收取的物流服務費的建議年度上限為人民幣155,000,000元及人民幣186,000,000元。

本公司物流支持服務的年度上限應不超過人民幣2,500,000,000元。於年內，與物流公司訂立物流支持服務框架協議項下與物流公司集團結算向醫院銷售產品的實際金額約為人民幣2,156,000,000元。

CONTINUING CONNECTED TRANSACTIONS

(continued)

3. Supplemental deposit services agreement

Under the Deposit Services Agreement, Lanhai Bank agrees to provide deposit services to the Group and the Group agrees to utilize such deposit services. On 16 November 2021, the Company entered into the Supplemental Deposit Services Agreement with Lanhai Bank to (i) extend the agreement term for one year to 31 December 2023; and (ii) propose new annual cap of RMB300 million for the year ending 31 December 2023. Except for the extension of the duration of the agreement and the proposition of the new annual cap for the year ending 31 December 2023, all other terms of the Deposit Services Agreement remain unchanged. The annual cap (maximum daily balance of deposits (including the interests accrued thereon)) for the year ended 31 December 2021 was RMB300.0 million and the actual maximum daily balance of deposits (including the interests accrued thereon) for the year ended 31 December 2021 was approximately RMB195.0 million.

持續關連交易 (續)

3. 補充存款服務協議

根據存款服務協議，藍海銀行同意向本集團提供存款服務，而本集團同意使用有關存款服務。於二零二一年十一月十六日，本公司與藍海銀行訂立補充存款服務協議，以(i)將協議期限延長一年至二零二三年十二月三十一日；及(ii)建議截至二零二三年十二月三十一日止年度的新年度上限為人民幣300,000,000元。除延長協議期限，以及截至二零二三年十二月三十一日止年度建議新的年度上限外，存款服務協議之所有其他條款維持不變。截至二零二一年十二月三十一日止年度，年度上限（每日最高存款結餘（包括其應計利息））為人民幣300,000,000元，以及截至二零二一年十二月三十一日止年度，實際每日最高存款結餘（包括其應計利息）約為人民幣195,000,000元。

CONTINUING CONNECTED TRANSACTIONS
(continued)

持續關連交易 (續)

4. Supplemental finance leasing and factoring framework agreement

Under the Finance Leasing and Factoring Framework Agreement, the Group agrees to provide finance leasing and recourse and non-recourse factoring and other commercial factoring services to Weigao Holding Group. On 16 November 2021, 山東威高融資租賃有限公司 (Shandong Weigao Financial Leasing Co., Ltd.) and 上海威高融資租賃有限公司 (Shanghai Weigao Financing Lease Co., Ltd.), both are subsidiaries of the Company, entered into the Supplemental Finance Leasing and Factoring Framework Agreement with Weigao Holding to (i) extend the agreement term for two years to 31 December 2023; and (ii) propose new annual caps of RMB500 million for each of the years ending 31 December 2022 and 2023. Except for the extension of the duration of the agreement and the proposition of the new annual caps for the years ending 31 December 2022 and 2023, all other terms of the Finance Leasing and Factoring Framework Agreement remain unchanged. The annual cap in respect of the finance leasing and factoring business contemplated under the Finance Leasing and Factoring Framework Agreement (as supplemented by the Supplemental Finance Leasing and Factoring Framework Agreement) for the year ended 31 December 2021 was RMB500.0 million and the actual aggregate value of finance leasing and factoring amount for the year ended 31 December 2021 was approximately RMB499.3 million.

4. 補充融資租賃及保理框架協議

根據融資租賃及保理框架協議，本集團同意向威高集團提供融資租賃和有追索權及無追索權保理以及其他商業保理服務。於二零二一年十一月十六日，山東威高融資租賃有限公司及上海威高融資租賃有限公司（均為本公司之附屬公司）與威高集團公司訂立補充融資租賃及保理框架協議，以(i)將協議期限延長兩年為二零二三年十二月三十一日；及(ii)建議截至二零二二年及二零二三年十二月三十一日止年度各年的新年度上限為人民幣500,000,000元。除延長協議期限，以及截至二零二二年及二零二三年十二月三十一日止年度建議新的年度上限外，融資租賃及保理框架協議之所有其他條款維持不變。融資租賃及保理框架協議（經補充融資租賃及保理框架協議補充）項下擬進行之融資租賃及保理業務截至二零二一年十二月三十一日止年度的年度上限為人民幣500,000,000元，以及截至二零二一年十二月三十一日止年度的融資租賃及保理金額的實際總值約為人民幣499,300,000元。

CONTINUING CONNECTED TRANSACTIONS

(continued)

5. Supplemental sales framework agreement

Under the Sales Framework Agreement, the Company agrees to sell or procure its subsidiaries to sell, and Weigao Holding agrees to purchase or procure its subsidiaries to purchase products including but not limited to, medical devices, carton box and moulding. On 16 November 2021, the Company entered into the Supplemental Sales Framework Agreement with Weigao Holding to (i) extend the agreement term for two years to 31 December 2023; and (ii) propose new annual caps of RMB500 million for each of the years ending 31 December 2022 and 2023. Except for the extension of the duration of the agreement and the proposition of the new annual caps for the years ending 31 December 2022 and 2023, all other terms of the Sales Framework Agreement remain unchanged. The annual cap for the sales transaction from the Group to Weigao Holding shall not exceed RMB500.0 million for the year ended 31 December 2021, During the Year, the actual transaction amounts of sales by the Group to Weigao Holding Group for the year ended 31 December 2021 was approximately RMB436.9 million.

持續關連交易 (續)

5. 補充銷售框架協議

根據銷售框架協議，本公司同意出售或促使其附屬公司出售，而威高集團公司同意採購或促使其附屬公司採購產品，包括（但不限於）醫療器械、硬紙盒及模具。於二零二一年十一月十六日，本公司與威高集團公司訂立補充銷售框架協議，以(i)將協議期限延長兩年二零二三年十二月三十一日；及(ii)建議截至二零二二年及二零二三年十二月三十一日止年度各年的新年度上限為人民幣500,000,000元。除延長協議期限，以及截至二零二二年及二零二三年十二月三十一日止年度建議新的年度上限外，銷售框架協議之所有其他條款維持不變。截至二零二一年十二月三十一日止年度，本集團向威高集團公司銷售交易的年度上限不得超過人民幣500,000,000元。於年內，本集團向威高集團銷售的實際交易金額於截至二零二一年十二月三十一日止年度約為人民幣436,900,000元。

CONTINUING CONNECTED TRANSACTIONS
(continued)

6. Supplemental services framework agreement

Under the Services Framework Agreement, the Company agrees to subscribe or procure its subsidiaries to subscribe, and Weigao Holding agrees to provide or procure its subsidiaries to provide services including but not limited to, dormitory, catering services and hotel services. On 16 November 2021, the Company entered into the Supplemental Services Framework Agreement with Weigao Holding to (i) extend the agreement term for two years to 31 December 2023; and (ii) propose new annual caps of RMB40 million and RMB50 million for the years ending 31 December 2022 and 2023, respectively. Except for the extension of the duration of the agreement and the proposition of the new annual caps for the years ending 31 December 2022 and 2023, all other terms of the Services Framework Agreement remain unchanged. The annual cap for the services transaction provided from the Group to Weigao Holding shall not exceed RMB90.0 million for the year ended 31 December 2021. During the Year, the actual transaction amounts for the services provided by Weigao Holding Group to the Group for the year ended 31 December 2021 was approximately RMB13.6 million.

持續關連交易 (續)

6. 補充服務框架協議

根據服務框架協議，本公司同意採購或促使其附屬公司採購，而威高集團公司同意提供或促使其附屬公司提供服務，包括（但不限於）宿舍、餐飲服務及酒店服務。於二零二一年十一月十六日，本公司與威高集團公司訂立補充服務框架協議，以(i)將協議期限延長兩年二零二三年十二月三十一日；及(ii)建議截至二零二二年及二零二三年十二月三十一日止年度的新年度上限分別為人民幣40,000,000元及人民幣50,000,000元。除延長協議期限，以及截至二零二二年及二零二三年十二月三十一日止年度建議新的年度上限外，服務框架協議之所有其他條款維持不變。截至二零二一年十二月三十一日止年度，本集團向威高集團公司提供服務交易的年度上限不得超過人民幣90,000,000元。於年內，威高集團向本集團提供服務的實際交易金額於截至二零二一年十二月三十一日止年度約為人民幣13,600,000元。

CONTINUING CONNECTED TRANSACTIONS

(continued)

7. Supplemental tenancy framework agreement

Under the Tenancy Framework Agreement, the Group agrees to lease its premises located at industrial zone at Chucun in Weihai in Shandong Province, the PRC to Weigao Holding Group and receive rentals therefrom. On 16 November 2021, the Company entered into the Supplemental Tenancy Framework Agreement with Weigao Holding to (i) extend the agreement term for two years to 31 December 2023; and (ii) propose new annual caps of RMB25 million for each of the years ending 31 December 2022 and 2023. Except for the extension of the duration of the agreement and the proposition of the new annual caps for the years ending 31 December 2022 and 2023, all other terms of the Tenancy Framework Agreement remain unchanged. The annual cap for the rental received by the Group from Weigao Holding Group for the year ended 31 December 2021 shall not exceed RMB25.0 million and the actual transaction amounts for the rental received by the Group from Weigao Holding Group for the year ended 31 December 2021 was approximately RMB8.7 million.

持續關連交易 (續)

7. 補充租賃框架協議

根據租賃框架協議，本集團同意向威高集團出租其位於中國山東省威海初村工業區之物業，並從中收取租金。於二零二一年十一月十六日，本公司與威高集團公司訂立補充租賃框架協議，以(i)將協議期限延長兩年，至二零二三年十二月三十一日；及(ii)建議截至二零二二年及二零二三年十二月三十一日止各年度的新年度上限為人民幣25,000,000元。除延長協議期限，以及截至二零二二年及二零二三年十二月三十一日止年度建議新的年度上限外，租賃框架協議之所有其他條款維持不變。於截至二零二一年十二月三十一日止年度，本集團自威高集團收取租金之年度上限將不得超過人民幣25,000,000元及於截至二零二一年十二月三十一日止年度，本集團自威高集團收取租金之實際交易金額約為人民幣8,700,000元。

CONFIRMATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

Pursuant to Rule 14A.55 of the Listing Rules, the independent non-executive Directors had reviewed the above continuing connected transactions and confirmed that the transactions had been entered into:

- (i) in the ordinary and usual course of the Group's business;
- (ii) on normal commercial terms or better;
- (iii) in accordance with the terms of the respective agreements governing such transactions that are fair and reasonable and in the interests of the Company and shareholders as a whole.

ASSURANCE PROCEDURES PERFORMED BY AUDITOR OF THE COMPANY

Pursuant to Rule 14A.56 of the Listing Rules, the Board appointed the auditor of the Company to report on the above continuing connected transactions between the Company and the connected persons for the year ended 31 December 2021. The auditor of the Company was engaged in accordance with Hong Kong Standard on Assurance Engagements 3000 (Revised) "Assurance Engagements Other Than Audits or Reviews of Historical Financial Information" and with reference to Practice Note 740 "Auditor's Letter on Continuing Connected Transactions under the Hong Kong Listing Rules" issued by the HKICPA and reported the following conclusion to the Board:

獨立非執行董事之確認

根據上市規則第14A.55條，本公司的獨立非執行董事已審閱上述持續關連交易，並確認該等交易：

- (i) 於本集團一般及日常業務過程中訂立；
- (ii) 一般商業條款或更佳條款訂立；
- (iii) 按照公平合理及符合本公司及股東整體利益的條款根據規管交易各協議訂立。

本公司核數師執行的鑒證程序

根據上市規則第14A.56條，董事會委任本公司核數師就上述截至二零二一年十二月三十一日止年度之本公司與關連人士之持續關連交易進行匯報。本公司已根據香港鑒證業務準則第3000號（經修訂）「審計或審閱歷史財務資料以外的鑒證工作」，並參照香港會計師公會頒佈的實務說明第740號「關於香港上市規則所述持續關連交易的核數師函件」委聘核數師，並向董事會呈報以下結論：

ASSURANCE PROCEDURES PERFORMED BY AUDITOR OF THE COMPANY (continued)

Based on the foregoing, in respect of the continuing connected transactions of the Company: (i) have received approval from the Board; (ii) were conducted in accordance to the pricing policy; (iii) have been entered into in accordance with the relevant agreement governing such transactions; and (iv) have not exceeded the cap amount for the financial year ended 31 December 2021 disclosed in the relevant announcements. Having reviewed the subject continuing connected transactions, the independent non-executive directors of the Company, pursuant to Chapter 14A of the Listing Rules on the requirement to carry out an annual review on the continuing connected transactions, confirmed that the transactions were made in the ordinary and usual course of business of the Company, on normal commercial terms and in accordance with the Framework Agreements governing them on terms that were fair and reasonable and in the interests of the shareholders of the Company as a whole.

COMPETITION AND CONFLICT OF INTERESTS

None of the Directors or the management shareholders as defined under the "Listing Rules" of the Company or their respective associates has any interest in a business which competes or may compete with the business of the Group or has any other conflict of interests with the Group.

BOARD PRACTICES AND PROCEDURES

The Code on Corporate Governance Practices (the "CCGP") contained in the Listing Rules which set out the principles of good corporate governance and the Company is required to comply with the code provisions of the CCGP. The Company fully admitted that good corporate governance, as part of the Company's culture, can create values to the Group and the Shareholders efficiently. The Board is committed to continuing to enhance the standards of corporate governance within the Group and to ensure that the Group conducts its businesses in an honest and responsible manner. The Group has adopted practices which meets the code provisions of the CCGP.

本公司核數師執行的鑒證程序 (續)

基於上文所述，有關本公司之持續關連交易：(i)已獲董事會批准；(ii)已根據定價政策進行；(iii)已根據規管該等交易之有關協議進行；及(iv)並無超過有關公佈所披露之截至二零二一年十二月三十一日止財政年度之上限金額。本公司之獨立非執行董事根據上市規則第14A章之規定就持續關連交易進行年度檢討，在檢討上述持續關連交易後，確認該等交易屬本公司之日常業務，按照一般商業條款及根據有關該等框架協議條款進行，該等條款屬公平合理，且符合本公司股東之整體利益。

競爭及利益衝突

本公司的董事或管理層股東（定義見「上市規則」）或其各自的聯繫人概無在與本集團業務構成或可能構成競爭或與本集團有任何其他利益衝突的業務中有任何權益。

董事會常規及程序

上市規則所載企業管治常規守則（「企業管治常規守則」）列明良好企業管治的準則，本公司須遵守企業管治常規守則的守則條文。本公司完全認同作為本公司文化一部分的良好企業管治，可有效地為本集團及股東創造價值。董事會將繼續致力提升本集團的企業管治水平，確保本集團以誠實負責的態度經營業務。本集團已採納符合企業管治常規守則條文的慣例。

SEPARATE LISTING OF SHANDONG WEIGAO ORTHOPAEDIC DEVICE COMPANY LIMITED

Shandong Weigao Orthopaedic Device Company Limited (“Weigao Orthopaedic”) (688161.SH), a non-wholly owned subsidiary of the Company, completed its listing application on the Science and Technology Innovation Board of the Shanghai Stock Exchange and the initial public offering of the ordinary shares, with total net proceeds of RMB1,382,285,000 from the initial public offering on 30 June 2021.

CHANGE OF BOARD COMPOSITION AND SENIOR MANAGEMENT

Pursuant to rule 13.51B of the Listing Rules, the change of information on director and senior management during the year ended 31 December 2021:-

1. Mr. CHEN Lin has been appointed as a non-executive director of the Company with effect from 8 March 2021.
2. Mr. TANG Zhengpeng has been appointed as a non-executive director of the Company with effect from 8 March 2021.
3. Mr. ZHANG Huawei has resigned as executive director, chairman of the Board and authorized representative of the Company with effect from 30 March 2021.
4. Mr. WANG Yi has resigned as executive director of the Company with effect from 30 March 2021.
5. Mr. LONG Jing has resigned as chief executive officer of the Company with effect from 30 March 2021. Mr. Long has been appointed as Chairman and authorised representative of the Company with effect from 30 March 2021.
6. Mr. CONG Rinan has been appointed as a chief executive officer of the Company with effect from 30 March 2021. Mr. Cong has been appointed as an executive director of the Company with effect from 24 May 2021.
7. Mr. LIAN Xiaoming has been appointed as a non-executive director of the Company with effect from 24 May 2021.

山東威高骨科材料股份有限公司獨立上市

本公司非全資附屬公司山東威高骨科材料股份有限公司（「威高骨科」，688161.SH）完成其於上海證券交易所科創板上市申請及普通股之首次公開發售，於二零二一年六月三十日首次公開發售所得款項淨額總額為人民幣1,382,285,000元。

董事會組成及高級管理層之變動

根據上市規則第13.51B條，董事及高級管理層資料於截至二零二一年十二月三十一日止年度之變動載列如下：

1. 陳林先生已獲委任為本公司之非執行董事，自二零二一年三月八日起生效。
2. 湯正鵬先生已獲委任為本公司之非執行董事，自二零二一年三月八日起生效。
3. 張華威先生已辭任本公司之執行董事、董事會主席兼授權代表，自二零二一年三月三十日起生效。
4. 王毅先生已辭任本公司執行董事，自二零二一年三月三十日起生效。
5. 龍經先生已辭任本公司行政總裁，自二零二一年三月三十日起生效。龍先生已獲委任為本公司主席兼授權代表，自二零二一年三月三十日起生效。
6. 叢日楠先生已獲委任為本公司行政總裁，自二零二一年三月三十日起生效。叢先生已獲委任為本公司執行董事，自二零二一年五月二十四日起生效。
7. 連小明先生已獲委任為本公司非執行董事，自二零二一年五月二十四日起生效。

COMPLIANCE WITH THE MODEL CODE FOR DIRECTORS' SECURITIES TRANSACTIONS

The Company has adopted the Model Code as set out in Appendix 10 of the Listing Rules as the standard for securities transactions by Directors. The Company has made enquiries of all the Directors and all the Directors confirmed that they have complied with the required standards set out in the Model Code and its code of conduct regarding directors' securities transactions.

INTERNAL CONTROL

Directors are responsible for reviewing the internal control and risk management system of the Company periodically to ensure its effectiveness and efficiency. With the support of the internal audit department, they will review the practices, procedures, expenditure and internal control of the Company and its subsidiaries on a regular basis. The management will regularly monitor the concerns as reported by the internal audit department to ensure appropriate remedial measures have been implemented. The Board or senior management can also request the internal audit group to review the specific scope of concerns and report the significant findings of such review to the Board and the audit committee.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the Year, there was no purchase, sale or redemption of its securities by the Company or any of its subsidiaries.

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive right under the Company's articles of association and the laws of the PRC, which would oblige the Company to offer new shares on a pro-rata basis to existing shareholders.

DIVERSITY OF DIRECTORS

The Company has adopted its diversity policy with respect to the composition of the Board. In assessing candidates running for directorships, the Nomination Committee will consider a number of factors, including but not limited to gender, age, educational background, professional experience, technical expertise and the ability to fulfill the requirements of the Board. Details on the biographies and experience of the Directors are set out on pages 77 to 81 of this report.

遵守董事進行證券交易的標準守則

本公司已採納上市規則附錄十所載的標準守則作為董事進行證券交易的標準。本公司已向全體董事作出查詢，而全體董事亦已確認彼等一直遵守標準守則所載標準及其有關董事進行證券交易的行為守則。

內部監控

董事負責定期檢討本公司的內部監控及風險管理系統，確保其有效性及效率。在內部核數部門的支持下，董事定期對本公司及其附屬公司的常規、程序、開支及內部監控進行檢討。管理層將定期監察內部核數部門所匯報的關注事項，確保實施適當的補救措施。董事會或高級管理人員亦可要求內部審核小組對特定的關注範圍進行檢討，並向董事會及審核委員會匯報重要的檢討結果。

購買、出售或贖回本公司上市證券

於年內，本公司或其任何附屬公司概無購買、出售或贖回其證券。

優先購買權

根據本公司的公司章程細則和中國法律，概無有關優先購買權之條文規定本公司須向現有股東按比例發售新股份。

董事多元化

本公司已採納有關董事會組成之董事會成員多元化政策。提名委員會於評估董事候選人時將考慮多項因素，包括但不限於性別、年齡、教育背景、專業經驗、技術專長及達至董事會之要求之能力。董事履歷及經驗詳情載於本報告第77至81頁。

PUBLIC FLOAT AND MARKET CAPITALIZATION

Based on the publicly available information known to the Company and to the best of the Directors' knowledge, as of the date of this report, the public float of the Company is in compliance with that stipulated under Rule 8.08 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited. As at 31 December 2021, the market capitalization of the Company was approximately HK\$44.0 billion.

DIRECTORS RESPONSIBILITIES IN PREPARING THE GROUP'S FINANCIAL STATEMENTS

The Directors acknowledged the responsibility for preparing the accounts and have confirmed that the preparation of the Group's financial statement is in compliance with the relevant regulations and applicable accounting standards.

In preparing the financial statements for the Year, the Directors adopted appropriate and consistent accounting policies and made prudent and reasonable judgments and estimations.

The financial statements for the Year have been prepared by the Directors on a going concern basis. There are no material uncertainties relating to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. A statement by the external auditors of the Company regarding their reporting responsibilities on the accounts of the Group is set out in the "Independent Auditor's Report" in this annual report.

AUDITORS

A resolution will be proposed at the forthcoming Annual General Meeting to re-appoint Deloitte Touche Tohmatsu as the auditors of the Company.

On behalf of the Board
LONG Jing
Chairman

Weihai, Shandong, the PRC
14 April 2022

公眾持股量及市值

根據本公司所知之公眾可得資料及就董事所深知，於本報告日期，本公司之公眾持股量符合香港聯合交易所有限公司證券上市規則第8.08條訂明之規定。於二零二一年十二月三十一日，本公司之市值約為440億港元。

董事就編製本集團財務報表承擔之責任

董事承認有編製賬目的責任及已確認本集團財務報表的編製符合有關法規及適用之會計準則。

於編製本年度財務報表時，董事已採用適當及一致的會計政策，並已作出審慎和合理的判斷與估計。

董事已按持續經營基準編製本年度的財務報表。並無可能對本公司持續經營的能力構成重大疑問的事件或情況相關的重大不明朗因素存在。本公司的外聘核數師就其對本集團的賬目應負的報告責任發出的聲明，已載於本年報「獨立核數師報告書」內。

核數師

在應屆股東週年大會上，將會呈交一項決議案，以重新委任德勤·關黃陳方會計師行作為本公司的核數師。

代表董事會
龍經
主席

中國山東威海
二零二二年四月十四日

OVERVIEW

The Board of Directors of the Company recognize the importance of incorporating elements of good corporate governance in the management structures and internal control procedures of the Group so as to achieve effective accountability. This report outlines the principles and the code provisions of the Code on Corporate Governance Practices (the “Code”) contained in the Listing Rules, which have been adopted by the Group since its listing on 28 February 2004.

COMPLIANCE WITH THE MODEL CODE FOR DIRECTORS’ SECURITIES TRANSACTIONS

The Company has adopted the Model Code as set out in Appendix 10 of the Listing Rules as the standard for securities transactions by Directors. The Company has made specific enquiries of all the Directors and all the Directors confirmed that they have complied with the required standards set out in the Model Code and its code of conduct regarding directors’ securities transactions throughout the year of 2021.

The following summarizes the corporate governance practices of the Company:

The Board of Directors

The Board takes responsibility to oversee all major matters of the Company, including the formulation and approval of overall business strategies, internal control and risk management systems, and monitoring the performance of the senior management. The management is responsible for the daily operations of the Group under the leadership of the Chief Executive Officer. The Directors have the responsibility to act objectively in the interests of the Company.

概覽

本公司董事會深知在本集團的管理架構及內部監控程序引入優良的企業管治元素的重要性，藉以達致有效的問責性。本報告概述上市規則所載的企業管治常規守則（「守則」）的原則及守則條文，本集團已自其於二零零四年二月二十八日上市以來採納該原則及守則條文。

遵守董事進行證券交易的標準守則

本公司已採納上市規則附錄十所載的標準守則作為董事進行證券交易的標準。本公司已向全體董事作出特定查詢，而全體董事亦已確認彼等在二零二一年度一直遵守標準守則所載標準及其有關董事進行證券交易的行為守則。

以下概述本公司的企業管治常規：

董事會

董事會負責監察本公司的所有重要事宜，包括制定及批准整體業務策略、內部監控及風險管理系統，以及監督高級管理人員的表現。管理層在行政總裁的領導下負責本集團的日常營運。董事負責以本公司利益客觀行事。

**COMPLIANCE WITH THE MODEL CODE FOR
DIRECTORS' SECURITIES TRANSACTIONS**

(continued)

The Board of Directors (continued)

As of the date of this report, the Board comprises eight Directors, including two executive Director, three non-executive Directors and three independent non-executive Directors.

Executive Directors:

Mr. LONG Jing (*Chairman*)
Mr. CONG Rinan

Non-executive Director:

Mr. TANG Zhengpeng
Mr. CHEN Lin
Mr. LIAN Xiaoming

Independent non-executive Directors:

Mr. LO Wai Hung
Ms. FU Mingzhong
Ms. WANG Jinxia

**遵守董事進行證券交易的標準
守則 (續)**

董事會 (續)

截至本報告日期，董事會由八名董事組成，包括兩名執行董事、三名非執行董事以及三名獨立非執行董事。

執行董事：

龍經先生 (主席)
叢日楠先生

非執行董事：

湯正鵬先生
陳林先生
連小明先生

獨立非執行董事：

盧偉雄先生
付明仲女士
王錦霞女士

COMPLIANCE WITH THE MODEL CODE FOR DIRECTORS' SECURITIES TRANSACTIONS

(continued)

The Board of Directors (continued)

In compliance of Rule 3.10(1) of the Listing Rules, the Board currently comprises three independent non-executive Directors. Pursuant to paragraph 12B of the Appendix 16 of the Listing Rules, each of the independent non-executive Directors has confirmed by annual confirmation that he/she has complied with the independence criteria set out in Rules 3.13 of the Listing Rules. The Director consider that all three independent non-executive Directors are independent under these independence criteria and are capable to effectively exercise independent judgment. Amongst the three independent non-executive Directors, Mr. Lo Wai Hung has the appropriate professional qualifications and accounting and related financial management expertise required under Rule 3.10 (2) of the Listing Rules.

Board Meetings

Regular Board meetings were held two times during this year to review and approve financial and operating performance, interim and annual results. Ad-hoc meetings will also be convened if necessary to discuss the overall strategy as well as the operation and financial performance of the Group. Notice of board meeting will be sent to all Directors at least 14 days prior to a regular board meeting. Reasonable notice will be given to Directors for ad-hoc board meetings. Directors may participate either in person or through electronic means of communications.

The Company will adopt the practice to provide relevant materials to all the Directors relating to the matters brought before the meetings. All the Directors will be provided with sufficient resources to discharge their duties, and, upon reasonable requests, the Directors will be able to seek independent professional advice in appropriate circumstances, at the Company's expenses. All Directors will have the opportunity to include matters in the agenda for Board meetings.

遵守董事進行證券交易的標準守則 (續)

董事會 (續)

為符合上市規則第3.10(1)條，董事會目前包括三名獨立非執行董事。根據上市規則附錄十六第12B段，各獨立非執行董事均已以年度確認書確認，彼符合上市規則第3.13條所載獨立身份標準。董事認為，根據此等獨立身份標準，全部三名獨立非執行董事均為獨立人士，能有效作出獨立判斷。在三名獨立非執行董事中，盧偉雄先生具備上市規則第3.10(2)條所規定的適當專業資格及會計以及相關財務管理專業知識。

董事會會議

年內，本公司舉行兩次董事會定期會議，以審核及批准財務及經營業績、中期及年度業績。需要時亦會召開臨時會議，以商討整體策略以及本集團的營運和財務表現。全體董事將於舉行定期董事會會議前最少十四天獲發董事會會議通告，而臨時董事會會議通告則於合理時間內派發予董事。董事可親身或通過電子通訊方式出席。

本公司於大會前向所有董事提供會上討論事項的相關資料。全體董事將獲得充分的資源以履行其職責，並在合理的要求下，董事可於合適情況下尋求獨立專業意見，費用由本公司承擔。全體董事均有機會於董事會會議議程內加入議題。

**COMPLIANCE WITH THE MODEL CODE FOR
DIRECTORS' SECURITIES TRANSACTIONS**

(continued)

**遵守董事進行證券交易的標準
守則 (續)**

Board Meetings (continued)

Number of Board meetings held during the year 2021: two.

The attendance of each Director at Board meetings during the year ended 31 December 2021 was as follows:

董事會會議 (續)

於二零二一年度舉行的董事會會議次數：2次。

截至二零二一年十二月三十一日止年度，各董事出席董事會會議的情況載列如下：

**Attendance
in 2021
於二零二一年
的出席率**

Executive Directors:

Mr. LONG Jing (*Chairman*)
Mr. CONG Rinan

執行董事：

龍經先生 (主席)
叢日楠先生

100%
100%

Non-executive Director:

Mr. TANG Zhengpeng
Mr. CHEN Lin
Mr. LIAN Xiaoming

非執行董事：

湯正鵬先生
陳林先生
連小明先生

100%
100%
100%

Independent non-executive Directors:

Mr. LO Wai Hung
Ms. FU Mingzhong
Ms. WANG Jinxia

獨立非執行董事：

盧偉雄先生
付明仲女士
王錦霞女士

100%
100%
100%

Minutes of the Board and the committee meetings are recorded, and final version are submitted to Directors for review within reasonable time after the meetings, normally 14 days after the meetings.

董事會及委員會會議均備有記錄，而最終稿在大會後合理時間內（一般為大會後十四日內）送交董事審閱。

Secretary of the Board assists the chairman to establish meeting agenda, and each Director may request inclusion of items in the agenda.

董事會秘書協助主席編製會議議程，而各董事可要求在議程內加入議題。

COMPLIANCE WITH THE MODEL CODE FOR DIRECTORS' SECURITIES TRANSACTIONS

(continued)

Board Meetings (continued)

Matters on transactions where Directors are considered having conflict of interests or material interests will not be dealt with by way of written resolutions. The Directors concerned can express views but will not be counted in the quorum of meetings and shall abstain from voting on the relevant resolution(s).

All Directors have access to the company secretary who is responsible for ensuring that the Board procedures are complied with, and advising the Board on compliance matters.

Minutes of the Board and the committee meetings are kept by the company secretary and are open for inspection by Directors.

Chairman and Chief Executive Officer

Under provision A2.1 of the Code, the roles of the Chairman and the Chief Executive Officer should be separate and should not be performed by the same individual. Mr. Long Jing is the Chairman of the Board and an executive Director of the Group's business. Mr. Cong Rinan is the Chief Executive Officer of the Company.

The Chairman of the Board is appointed by the Board itself, who is responsible for the leadership of the effective operation of the Board, and ensuring that all major and appropriate issues are discussed by the Board on a timely basis and in a constructive manner. The Chief Executive Officer is appointed by the Board. He is responsible for the management of daily operations of the Company and the implementation of the strategies and plans determined by the Board.

Experience

The executive Directors and non-executive Directors possess administrative leadership, diversified knowledge and extensive management experience in the industry. The independent non-executive Directors possess extensive knowledge, experience and judgment in different areas. The Board will seriously consider the objective views of the independent non-executive Directors for making decisions, and regard this as an effective guidance for the Group's business direction.

遵守董事進行證券交易的標準守則 (續)

董事會會議 (續)

對於董事被視為存在利益衝突或擁有重大權益的交易事宜，將不會通過書面決議案方式處理。有關董事可在會上表達意見，但不會計入會議法定人數，並須就有關決議案放棄表決。

全體董事均可接觸公司秘書，而公司秘書負責確保董事會程序得以遵守，並就合規事宜向董事會提供意見。

董事會及委員會會議的會議記錄均由公司秘書保存，而董事可隨時查閱。

主席與行政總裁

根據守則第A2.1條條文，主席及行政總裁的職責應分開且不得由同一人士擔任。龍經先生為董事會主席兼本集團業務之執行董事。叢日楠先生為本公司的行政總裁。

董事會主席由董事會自行委任，負責領導董事會，並使其有效運作，同時確保董事會以適時及具建設性的方式討論所有主要及適當的事項。行政總裁由董事會委任，負責管理本公司的日常業務以及執行董事會釐定的戰略及計劃。

經驗

執行董事和非執行董事具有行政領導能力、多元化知識及豐富行業管理經驗。獨立非執行董事擁有不同領域的豐富知識、經驗及判斷力。董事會作決策時將認真考慮獨立非執行董事的客觀意見，以此作為本集團業務方針的有效指引。

COMPLIANCE WITH THE MODEL CODE FOR DIRECTORS' SECURITIES TRANSACTIONS

(continued)

Directors' responsibility

The Board manages the business of the Company on behalf of its shareholders. The Directors consider that they are obliged to fulfill their responsibilities in a prudent, diligent and faithful manner, so as to create value for shareholders and safeguard the best interests of the Company and its shareholders.

Remuneration Committee

The Company established a remuneration committee on 12 August 2005 in accordance with the requirement of the Code. The remuneration committee comprises three independent non-executive Directors, namely Mr. Lo Wai Hung, Ms. Fu Mingzhong and Ms. Wang Jinxia and one non-executive director Mr. Tang Zhengpeng.

The remuneration committee has reviewed the remuneration policy, the performance and the remuneration of executive Directors and members of senior management, the existing terms of service contracts of the executive Directors. The objective of the remuneration policy is to ensure that the Company is able to attract, retain and motivate high-caliber staff, which is vital to the success of the Company.

In reviewing and determining the remuneration packages of the executive Directors and members of senior management, the remuneration committee considers their responsibilities, skills, expertise and contribution to the Group's performance and whether remuneration packages are competitive and sufficient to ensure that the Group is able to attract and retain the best available executive talent.

Remuneration of Directors is subject to annual assessment and recommendation by the Remuneration Committee to the Board for further review and approval, which is subsequently subject to shareholders' approval at annual general meeting. The primary goal of the remuneration policy on executive Directors remuneration packages is to enable the Company to retain and motivate executive Directors by linking their compensation with performance as measured against corporate objectives. Under the policy, a Director is not allowed to approve his own remuneration.

遵守董事進行證券交易的標準守則 (續)

董事責任

董事會代表其股東管理本公司業務。董事認為，彼等須謹慎、勤勉且忠誠地履行職責，為股東創造價值，維護本公司及其股東的最佳利益。

薪酬委員會

本公司已根據守則規定於二零零五年八月十二日成立薪酬委員會。薪酬委員會由三名獨立非執行董事盧偉雄先生、付明仲女士、王錦霞女士及一名非執行董事湯正鵬先生組成。

薪酬委員會已檢討薪酬政策、執行董事及高級管理層成員的表現及薪酬，以及執行董事的服務合約現有條款。薪酬政策的目標是確保本公司能吸納、挽留及激勵優秀員工，而此對本公司的成功十分重要。

在審閱及釐定執行董事及高級管理層成員的薪酬時，薪酬委員會將考慮他們的職責、技能、專業知識及對本集團業績作出的貢獻，以及薪酬待遇是否具競爭能力，以及是否足以保證本集團能吸引及挽留頂尖的行政人才。

董事酬金須由薪酬委員會進行年度評估並將建議提交董事會，董事會進一步審議並批准之後再提呈股東週年大會經股東批准後方可作實。執行董事的酬金組合政策主旨是使本公司執行董事的酬金及其表現與公司目標掛鉤有助激勵執行董事的工作表現及留任。根據該政策，董事不可批准其本身的薪酬。

COMPLIANCE WITH THE MODEL CODE FOR DIRECTORS' SECURITIES TRANSACTIONS

(continued)

Remuneration Committee (continued)

During the Year, two meetings have been held by the remuneration committee. All members of the remuneration committee attended the meeting during which the remuneration package of directors, supervisors and senior management of the Company for the year 2021. The chairman of the remuneration committee reports the findings and provides recommendations to the Board after each meeting.

During the Year, the remuneration committee has convened two meeting and the attendance of each remuneration committee member is set out below:

遵守董事進行證券交易的標準守則 (續)

薪酬委員會 (續)

於本年度，薪酬委員會舉行過二次會議。所有薪酬委員會成員均參加了會議。會議審議通過了本公司二零二一年度董事、監事及高級管理人員薪金方案。薪酬委員會主席於每次會議後向董事會匯報討論結果，並提供建議。

於本年度，薪酬委員會共召開二次會議，薪酬委員會各成員的出席率如下：

		Attendance in 2021 於二零二一年 的出席率
Independent non-executive Directors	獨立非執行董事	
Mr. LO Wai Hung	盧偉雄先生	100%
Ms. FU Mingzhong	付明仲女士	100%
Ms. WANG Jinxia	王錦霞女士	100%
Non-executive Director	非執行董事	
Mr. TANG Zhengpeng	湯正鵬先生	100%

Nomination Committee

The Company established a nomination committee on 21 May 2012 in accordance with the requirement of the Code. The nomination committee comprises Mr. Lo Wai Hung, Ms. Fu Mingzhong and Ms. Wang Jinxia and one non-executive director Mr. Tang Zhengpeng. The chairman of the nomination committee is Mr. Lo Wai Hung. The terms of reference of the nomination committee have been defined. The principal duties include:

- to review the structure, size and composition (including the skills, knowledge and experience) of the Board at least annually and make recommendations on any proposed changes to the Board to complement the Company's corporate strategy.

提名委員會

本公司已根據守則規定於二零一二年五月二十一日成立提名委員會。提名委員會由盧偉雄先生、付明仲女士、王錦霞女士及一名非執行董事湯正鵬先生組成。盧偉雄先生為提名委員會主席。提名委員會之職權範圍已界定。主要職責包括：

- 至少每年檢討董事會的架構、人數及組成 (包括技能、知識及經驗方面)，並就任何為配合本公司的公司策略而擬對董事會作出的任何變動提出建議。

COMPLIANCE WITH THE MODEL CODE FOR DIRECTORS' SECURITIES TRANSACTIONS

(continued)

Nomination Committee (continued)

- to identify individuals suitably qualified to become Board members and select or make recommendations to the Board on the selection of individuals nominated for directorships.
- to assess the independence of independent non-executive directors.
- to make recommendations to the Board on the appointment or re-appointment of directors and succession planning for directors, in particular the chairman of the Board and the chief executive.

The Nomination Committee provided with sufficient resources to perform its duties and shall have access to independent professional advice if necessary. All members of the Nomination Committee have access to the advice and services of the company secretary, and separate and independent access to the Company's senior management for obtaining necessary information.

Each of the Directors of the Company has entered into a service contract with the Company for a specific term of three years, and are subject to retirement by rotation and re-election in accordance with the Articles of Association of the Company.

The Company has not experienced any casual vacancy for members of the Board. In the event that there is such circumstance, the Director appointed to fill a casual vacancy should be subject to election by shareholders at the first general meeting after his appointment.

The Board selects and nominates Director candidates based on whether they possess the skills and experience needed for the Group's development.

遵守董事進行證券交易的標準 守則 (續)

提名委員會 (續)

- 物色具備合適資格成為董事會成員的人士，並挑選提名有關人士出任董事或就此向董事會提供意見。
- 評核獨立非執行董事的獨立性。
- 就董事委任或重新委任以及董事（尤其是董事會主席及行政總裁）繼任計劃向董事會提出建議。

提名委員會已獲提供充足資源以履行其職責，及在有需要時可尋求獨立專業意見。提名委員會的所有成員均可聯絡公司秘書及獲取其服務，個別成員亦可聯絡本公司的高級管理人員以獲取所需資料。

本公司各董事均與本公司訂立一份指定任期為三年的服務合約，並須根據本公司的組織章程細則輪值告退及膺選連任。

本公司未曾出現過董事會成員臨時空缺的情況。倘出現該等情況，為填補臨時空缺而獲委任的董事將在接受委任後的首次股東大會上接受股東選舉。

董事會根據本集團發展需要的技能與經驗來挑選及提名董事候選人。

COMPLIANCE WITH THE MODEL CODE FOR DIRECTORS' SECURITIES TRANSACTIONS

(continued)

During the Year, the nomination committee has convened one meeting and the attendance of each nomination committee member is set out below:

遵守董事進行證券交易的標準守則 (續)

於本年度，提名委員會共召開一次會議，提名委員會各成員的出席率如下：

**Attendance
in 2021
於二零二一年
的出席率**

Independent non-executive Directors

Mr. LO Wai Hung
Ms. FU Mingzhong
Ms. WANG Jinxia

獨立非執行董事

盧偉雄先生
付明仲女士
王錦霞女士

100%
100%
100%

Non-executive Director

Mr. TANG Zhengpeng

非執行董事

湯正鵬先生

100%

Corporate Governance Committee

The Company established a corporate governance committee on 30 May 2013. The corporate governance committee comprises Mr. Lo Wai Hung, Ms. Fu Mingzhong and Ms. Wang Jinxia as members. Mr. Long Jing has been appointed as the chairman of the committee with effect from 30 March 2021. The terms of reference of the corporate governance committee have been defined. The principal duties include:

- (a) to develop and review the Company's policies and practices on corporate governance and make recommendations to the Board;
- (b) to review and monitor the training and continuous professional development of directors and senior management;
- (c) to review and monitor the Company's policies and practices on compliance with legal and regulatory requirements;
- (d) to develop, review and monitor the code of conduct and compliance manual (if any) applicable to employees and directors; and
- (e) to review the Company's compliance with the Code and disclosure in the corporate governance report.

企業管治委員會

本公司於二零一三年五月三十日成立企業管治委員會。企業管治委員會包括盧偉雄先生、付明仲女士及王錦霞女士(作為成員)。龍經先生已獲委任為委員會主席，自二零二一年三月三十日起生效。企業管治委員會之職權範圍已界定。主要職責包括：

- (a) 制定及檢討本公司的企業管治政策及常規，並向董事會提出建議；
- (b) 檢討及監察董事及高級管理人員的培訓及持續專業發展；
- (c) 檢討及監察本公司在遵守法律及監管規定方面的政策及常規；
- (d) 制定、檢討及監察僱員及董事的操守準則及合規手冊(如有)；及
- (e) 檢討本公司遵守守則的情況及在企業管治報告內的披露。

COMPLIANCE WITH THE MODEL CODE FOR DIRECTORS' SECURITIES TRANSACTIONS

(continued)

The Corporate Governance Committee will be provided with sufficient resources to perform its duties and shall have access to independent professional advice if necessary. All members of the Corporate Governance Committee will have access to the advice and services of the company secretary and separate and independent access to the Company's senior management for obtaining necessary information.

During the Year, the corporate governance committee has convened one meeting. The attendance of each Director is set out below:

遵守董事進行證券交易的標準守則 (續)

企業管治委員會將獲提供充足資源以履行其職責，及在有需要時可尋求獨立專業意見。企業管治委員會的所有成員將可聯絡公司秘書及獲取其意見及服務，個別成員亦可聯絡本公司的高級管理人員以獲取所需資料。

於本年度，企業管治委員會共召開一次會議，各董事的出席率如下：

Attendance in 2021 於二零二一年的 出席率

Director	執行董事	
Mr. LONG Jing	龍經先生	100%
Independent non-executive Directors	獨立非執行董事	
Mr. LO Wai Hung	盧偉雄先生	100%
Ms. FU Mingzhong	付明仲女士	100%
Ms. WANG Jinxia	王錦霞女士	100%

ACCOUNTABILITY AND AUDIT

Financial Reporting

All Directors are provided with explanations and information by the management of the Company so as to enable them to have discussions and make assessment at Board meetings.

All Directors acknowledge the responsibility for the preparation of its accounts, with the responsibility statement in respect to the financial reports made by the Directors set out in this annual report. The auditors have also made a statement about their responsibilities in the auditor's report.

The Board presents a comprehensive, balanced and understandable assessment on the position and prospects of the Group in all shareholder communications.

問責及核數

財務報告

全體董事均能夠獲得本公司管理層提供的解釋及資料，以供其在董事會會議上討論與評審。

全體董事均知悉其編製賬目的責任，於本年報內載有董事就財務報告作出的責任聲明。核數師亦已於核數師報告中就彼等的責任作出了聲明。

董事會於所有股東通訊中，對本集團的狀況及前景作出了全面、均衡及易於理解的評估。

ACCOUNTABILITY AND AUDIT (continued)

Internal control

Directors are responsible for reviewing the internal control and risk management system of the Company periodically to ensure its effectiveness and efficiency. With the support of the internal audit department, they will review the practices, procedures, expenditure and internal control of the Company and its subsidiaries on a regular basis. The management will regularly monitor the concerns as reported by the internal audit department to ensure appropriate remedial measures have been implemented. The Board or senior management can also request the internal audit group to review the specific scope of concerns and report the significant findings of such review to the Board and the audit committee.

The Board has conducted a review of the effectiveness of the system of internal control of the Group.

The Board has considered the adequacy of resources, qualifications and experience of staff of the Company's accounting and financial reporting function, and their training program and budget.

Audit Committee

As at the date of this report, the audit committee of the Company comprises three independent non-executive Directors, namely Mr. Lo Wai Hung (chairman of the audit committee), Ms. Fu Mingzhong and Ms. Wang Jinxia and one non-executive director Mr. Tang Zhengpeng. The terms of reference of the audit committee have been clearly defined. Its principal responsibilities include:

- To be primarily responsible for making recommendations to the Board regarding the appointment, reappointment and removal of external auditors; to formulate the remuneration and terms of engagement of external auditors and to propose the Board to submit the same at the general meeting for consideration. To approve the remuneration and terms of engagement of the external auditors when the general meeting is authorizing the Board to determine the remuneration of the auditors, and to address any questions regarding the resignation or retirement of that auditor.

問責及核數 (續)

內部監控

董事負責定期檢討本公司的內部監控及風險管理系統，確保其有效性及效率。在內部核數部門的支持下，彼等將定期對本公司及其附屬公司的常規、程序、開支及內部監控進行檢討。管理層將定期監察內部核數部門所匯報的關注事項，確保實施適當的補救措施。董事會或高級管理人員亦可要求內部審核小組對特定的關注範圍進行檢討，並向董事會及審核委員會匯報重要的檢討結果。

董事會已審查本集團內部監控系統的有效性。

董事會已考慮資源的充足性、本公司會計及財務報告部門員工的資歷及經驗以及彼等的培訓計劃及預算。

審核委員會

截至本報告日期，本公司的審核委員會由三位獨立非執行董事盧偉雄先生（審核委員會主席）、付明仲女士、王錦霞女士及一名非執行董事湯正鵬先生組成。審核委員會的職權範圍已清晰界定，其主要職責包括：

- 主要負責就外聘核數師的委任、重新委任及罷免向董事會提供建議；制訂外聘核數師的薪酬及聘用條款，並提請董事會提交股東大會審議。在股東大會授權董事會釐定核數師的薪酬時，批准外聘核數師的薪酬及聘用條款；及處理任何有關核數師辭職或退任的問題。

ACCOUNTABILITY AND AUDIT (continued)

Audit Committee (continued)

- To review and oversee the independence and objectivity of engaging external auditors and the effectiveness of the audit process in accordance with applicable standards. The Committee shall discuss with the auditors regarding the nature and scope of the audit and the relevant reporting obligations before commencing the audit.
- To develop and implement policy in engaging external auditors to provide non-auditing services. For the purpose of this requirement, external auditors includes any entity that is under common control, ownership or management with that audit firm or any entity that a reasonable and informed third party knowing all relevant information would reasonably conclude to be part of the audit firm domestically or internationally. The Committee shall report to the Board, in respect of any matters in which it considers that an action or improvement is needed and to make recommendations as to the steps to be taken.
- To monitor the completeness of the financial statements of the Company and the annual report and accounts and half-year report of the Company and to review the significant opinion of the respective financial reporting contained therein. In this regard, the committee will review the relevant statements and reports of the respective annual report and accounts and half-year report of the Company before submitting the same to the Board.
- To oversee the financial reporting system and internal control procedures of the Company.

問責及核數 (續)

審核委員會 (續)

- 按適用的標準檢討及監察委聘外聘核數師是否獨立客觀及核數程序是否有效。委員會應於核數工作開始前與核數師討論核數性質及範疇及有關申報責任。
- 就外聘核數師提供非核數服務制定政策，並予以執行。就此規定而言，外聘核數師包括與該核數公司處於同一控制權、所有權或管理權之下的任何機構，或一個合理知悉所有有關資料的第三方，在合理情況下會斷定該機構屬於該核數公司的本土或國際業務的一部分的任何機構。委員會應就其認為必須採取的行動或改善的事項向董事會報告，並建議可採取的步驟。
- 監察本公司的財務報表及本公司年度報告及賬目及半年度報告的完整性，並審閱當中所載有關財務申報的重大意見。在這方面，委員會在向董事會提交有關本公司年度報告及賬目及半年度報告前審閱有關報表及報告。
- 監管本公司財務申報制度及內部監控程序。

ACCOUNTABILITY AND AUDIT (continued)

Audit Committee (continued)

During the Year, the audit committee has convened five meetings, at which, they have primarily discussed and reviewed the interim and annual results and have discussed and considered the internal control procedures of the Group. The attendance of each Director is set out below:

		Attendance in 2021 於二零二一年 的出席率
Independent non-executive Directors	獨立非執行董事	
Mr. LO Wai Hung	盧偉雄先生	100%
Ms. FU Mingzhong	付明仲女士	100%
Ms. WANG Jinxia	王錦霞女士	100%
Non-executive Director	非執行董事	
Mr. TANG Zhengpeng	湯正鵬先生	100%

The scope of responsibilities of the audit committee is available on the websites of Company and the Stock Exchange of Hong Kong Limited.

There was no disagreement between the audit committee and the Board in respect of the selection, appointment, resignation or removal of external auditors during the year of 2021.

The audit committee can consult independent professional advice in accordance with stated procedures at the expense of the Company.

In 2021, the audit fees paid to the external auditors by the Company was approximately RMB7,677,000.

Mandate Granted to the Board

The Board should assume the responsibility for the leadership and monitoring of the Company, and is collectively responsible for promoting the success of the Company. The responsibilities of the Board are defined explicitly in the Articles of Association of the Company.

問責及核數 (續)

審核委員會 (續)

於本年度，審核委員會共召開五次會議，會上主要討論與審閱中期及年度業績，並就本集團內部監控程序進行了討論與審議。各董事的出席率如下：

		Attendance in 2021 於二零二一年 的出席率
Independent non-executive Directors	獨立非執行董事	
Mr. LO Wai Hung	盧偉雄先生	100%
Ms. FU Mingzhong	付明仲女士	100%
Ms. WANG Jinxia	王錦霞女士	100%
Non-executive Director	非執行董事	
Mr. TANG Zhengpeng	湯正鵬先生	100%

審核委員會的職權範圍可於本公司及香港聯合交易所有限公司網站查閱。

於二零二一年度，審核委員會與董事會在外聘核數師的挑選、委聘、辭任或罷免方面並無分歧。

審核委員會可按既定程序諮詢獨立專業意見，費用由本公司支付。

於二零二一年，本公司向外聘核數師支付的核數費用約為人民幣7,677,000元。

董事會的授權

董事會應負有領導及監控本公司的責任，同時集體負責促進本公司成功。董事會的職權已在本公司的組織章程細則內清晰界定。

ACCOUNTABILITY AND AUDIT (continued)

Mandate Granted to the Board (continued)

- (1) to be responsible for convening shareholders' meetings and report on its work at shareholders' meetings;
- (2) to implement the resolutions passed at shareholders' meetings;
- (3) to determine the business plans and investment plans of the Company;
- (4) to formulate the annual fiscal budgets and final accounts of the Company;
- (5) to formulate profit distribution proposals and loss recovery proposals of the Company;
- (6) to formulate proposals for increasing or reducing of the registered capital of the Company and proposals for issue of debentures of the Company;
- (7) to draft proposals for the merger, division and dissolution of the Company;
- (8) to determine the establishment of the internal management bodies of the Company;
- (9) to appoint or dismiss the general manager of the Company, and to appoint or dismiss the deputy general manager and other senior management, including the person in charge of finance, pursuant to the recommendations of the general manager, as well as to determine their compensations;
- (10) to formulate the basic management system of the Company;
- (11) to formulate proposals for amendments to the Articles of Association of the Company; and
- (12) to exercise other functions as stipulated by the Articles of Association or granted by the shareholders' meetings.

問責及核數 (續)

董事會的授權 (續)

- (一) 負責召集股東大會，並於股東大會報告工作；
- (二) 執行股東大會通過的決議案；
- (三) 決定本公司的經營計劃和投資方案；
- (四) 制訂本公司的年度財務預算方案及決算方案；
- (五) 制訂本公司的利潤分配方案和彌補虧損方案；
- (六) 制訂本公司增加或削減註冊資本的方案以及發行本公司債券的方案；
- (七) 擬定本公司合併、分拆及解散的方案；
- (八) 決定本公司內部管理機構的組成；
- (九) 聘任或解聘本公司總經理，並根據總經理的推薦，聘任或解聘副總經理和其他高級管理人員（包括財務負責人），並釐定其報酬；
- (十) 制訂本公司的基本管理制度；
- (十一) 制訂本公司組織章程細則的修改方案；及
- (十二) 行使組織章程細則規定或股東大會授予的其他職能。

ACCOUNTABILITY AND AUDIT (continued)

Mandate Granted to the Board (continued)

The Board has granted authority to the chief executive officer to implement the following strategies and to be responsible for the day-to-day operation:

- (1) to be in charge of the management of production and operation and to organize the implementation of the resolutions of the Board;
- (2) to organize the implementation of the annual business plans and investment plans of the Company;
- (3) to draft proposals for the establishment of internal management bodies of the Company;
- (4) to draft the basis management system of the Company;
- (5) to formulate the basic rules and regulations of the Company;
- (6) to propose the appointment or removal of the deputy general manager and other senior management, including the person in charge of finance, of the Company;
- (7) to appoint or dismiss the management personnel other than those required to be appointed or dismissed by the Board; and
- (8) to exercise other functions granted by the Articles of Association and the Board.

The chief executive officer grants authorisation to chief financial officer, and senior management within his terms of reference.

The Board is supported by four committees, namely the audit committee, the remuneration committee, nomination committee and corporate governance committee. Each of the committees has its defined terms of reference covering its duties, rights and functions. The chairman of the respective committees report to the Board regularly and make recommendations on matters discussed as appropriate.

問責及核數 (續)

董事會的授權 (續)

董事會授權行政總裁執行以下各項策略及負責日常業務：

- (一) 負責生產經營管理工作並組織實施董事會決議案；
- (二) 組織實施本公司年度經營計劃和投資方案；
- (三) 擬訂本公司內部管理機構的組成方案；
- (四) 擬訂本公司的基本管理制度；
- (五) 制訂本公司的基本規章；
- (六) 提請聘任或罷免本公司副總經理和其他高級管理人員(包括財務負責人)；
- (七) 聘任或解聘管理人員，惟應由董事會聘任或解聘者除外；及
- (八) 行使組織章程細則和董事會授予的其他職權。

行政總裁在其職權範圍內向財務總監及高級管理人員授權。

董事會下設四個委員會：即審核委員會、薪酬委員會、提名委員會及企業管治委員會。每個委員會各有涵蓋其責任、權利和職能的職權範圍。各委員會的主席會定期向董事會匯報，並按情況需要就討論事宜提出建議。

ACCOUNTABILITY AND AUDIT (continued)

Investor Relations

The Company is committed to a policy of open and regular communication and reasonable disclosure of information to its shareholders. Information of the Company is disseminated to the shareholders in the following manner:

- delivery of the interim and annual results and reports to all shareholders;
- publication of announcements on the interim and annual results on the Stock Exchange website, and issue of other announcements and shareholders' circulars in accordance with the continuing disclosure obligations under the Listing Rules; and
- the general meeting of the Company is also an effective communication channel between the Board and shareholders.

The Board has maintained an on-going dialogue with Shareholders and investors, and will regularly review this policy to ensure its effectiveness. Information will be communicated to Shareholders and investors mainly through the Company's financial reports (interim and annual announcements and reports), annual general meetings and other general meetings that may be convened, as well as by making available all the information submitted by the Company to the website of the Stock Exchange and its corporate communications on the Company's website. Shareholders can direct their questions about their shareholdings to the Company's branch share registrar in Hong Kong. Shareholders and investors may at any time make a request for the Company's information to the extent such information is publicly available.

Communications with shareholders

Separate resolutions are proposed at general meetings on each substantially separate issue, including the election of individual Director.

The shareholders' meeting provides an effective forum for shareholders to exchange views with the Board. The chairman, together with the chairmen or members of the audit committee, the remuneration committee and nomination committee are available to answer shareholders' questions.

問責及核數 (續)

與投資者關係

本公司堅持採取開誠的態度，定期與股東溝通，並向股東作出合理的資料披露。本公司資料以下列方式向股東傳達：

- 向全體股東送呈中期及年度業績與報告；
- 在聯交所網站上刊發有關中期及年度業績的公佈及根據上市規則的持續披露規定刊發的其他公佈及股東通函；及
- 本公司的股東大會亦為董事會與股東之間進行有效溝通的渠道之一。

董事會會持續與股東及投資者保持對話，亦會定期檢討本政策，以確保其有效性。本公司向股東及投資者傳達資訊的主要渠道為：本公司的財務報告(中期及年度公佈及報告)、股東週年大會及其他可能召開的股東大會，並將所有本公司呈交予聯交所網站的資料，以及公司通訊登載於本公司網站。股東如對名下持股有任何問題，可向本公司的香港股份過戶登記分處提出。股東及投資者可隨時要求索取本公司的公開資料。

與股東的溝通

每項實際獨立的事宜，均會在股東大會上以個別決議案提呈，包括個別董事的選舉。

股東大會為股東提供一個有效的場合，以與董事會交流意見。主席以及審核委員會、薪酬委員會及提名委員會的主席或成員將會在大會上解答股東的提問。

ACCOUNTABILITY AND AUDIT (continued)

Communications with shareholders (continued)

The procedures demanding for a poll and the rights of shareholders to demand for a poll are included in the notice of shareholders' meeting and the accompanying circular. The relevant procedures are explained at the shareholders' meetings.

The external auditor has been appointed as the scrutineer to ensure the votes cast are properly counted and recorded.

The results of the poll have been posted on the websites of the Stock Exchange of Hong Kong Limited and the Company on the business day following the meeting.

Furthermore, the Company continues to enhance the ongoing communications amongst the shareholders, investors and analysts, including:

- establishing specialized bodies and employing staff to serve investors and analysts and answer their relevant questions;
- arranging site visits to the production bases of the Company in order to keep them abreast of the operations and the latest developments of the Company;
- collecting and analyzing, in a timely manner, the respective opinions and recommendations on the operations of the Company given by securities analysts and investors and compiling them into reports periodically, and selectively adopting them in the operations of the Company;
- providing relevant information, including introduction to the Company, the Board and corporate governance, results of the Company, financial summary, marketing materials of the Company and press releases on the website of the Company; and
- taking the initiative to communicate with various parties, particularly following the announcement of interim, annual results and substantial investment decisions, organizing briefings, press conferences and one-on-one interviews with investment institutions. Besides, the Company also regularly communicates with investors on an one-on-one basis.

問責及核數 (續)

與股東的溝通 (續)

要求以投票方式表決的程序及股東可要求以投票方式表決的權利載於股東大會通告及隨附的通函內。有關程序亦會於股東大會上解釋。

已委任外聘核數師擔任監票員，以確保所有票數均適當點算及記錄在案。

投票表決結果已於大會後首個營業日刊登在香港聯合交易所有限公司及本公司網站上。

此外，本公司亦不斷加強與股東，投資者及分析員的持續溝通，其中包括：

- 設置專門機構及聘請人員接待投資者和分析員並解答彼等提出的相關問題；
- 安排彼等到本公司的生產基地進行實地考察，便於彼等及時了解本公司的經營情況及業務發展的最新動向；
- 本公司及時收集並分析證券分析員及投資者對本公司營運的各種意見及建議，定期匯集成報告，並在本公司的營運中有選擇地加以採納；
- 提供有關資料，包括本公司簡介、董事會及企業管治、本公司業績、財務摘要、本公司推介材料及刊載於本公司網站的新聞稿等；及
- 本公司主動與各方人士溝通，特別是在中期、年度業績公佈及作出重大投資決策事項後，舉行推介會、記者招待會以及與投資機構單對單會談。除此，本公司亦定期與投資者進行單對單的溝通。

RISK MANAGEMENT AND INTERNAL CONTROL

The Board acknowledges that it is their responsibility for the risk management and internal control systems and reviewing their effectiveness, and such systems are designed to manage rather than eliminate the risk of failure to achieve business objectives. The Audit Committee assists the Board in fulfilling its oversight and corporate governance roles in relation to the Group's financial, operational, compliance, risk management and internal controls, and internal audit functions. The Board has responsibility to ensure the Group maintains sound and effective controls to safeguard its assets and shareholders' investment.

The Group has internal control systems to formalize the risk management of the Group, to build up a standard and effective risk management system to manage risk and to provide reasonable assurance against material misstatement or loss. Appropriate policies and controls have been designed and established to ensure the assets are safeguarded against improper use or disposal, relevant rules and regulations are adhered to and complied with, reliable financial and accounting records are maintained in accordance with relevant accounting standards and regulatory reporting requirement and key risks that may impact on the Group's performance are appropriately managed.

風險管理及內部監控

董事會承認其須對風險管理及內部監控系統負責，並有責任檢討該等系統的有效性。該等系統旨在管理而非消除未能達成業務目標的風險。審核委員會協助董事會履行其於本集團財務、營運、合規、風險管理及內部監控以及內部審核功能方面的監管及企業管治角色。董事會有責任確保本集團維持健全有效的監控以保障其資產及股東投資。

本集團擁有內部監控系統以規範本集團的風險管理，建立標準及有效的風險管理系統以管理風險及合理保證並無重大失實陳述或損失。適當的政策及監控經已訂立及制定，以確保保障資產不會在未經許可下使用或處置，依從及遵守相關規則及規例，根據相關會計標準及監管申報規定保存可靠的財務及會計記錄，以及適當地管理可能影響本集團表現的主要風險。

RISK MANAGEMENT AND INTERNAL CONTROL (continued)

The Group has established an organizational structure with defined levels of responsibility and reporting procedures. The Company has retained an independent professional firm as external advisor to assist the Company to perform an assessment on risk management and internal control mechanism of the Group. We have our own Internal Audit Department to fulfil the requirement of internal audit function. Together with the supports from the external advisor, the internal audit function can facilitate the Audit Committee and the Board of Directors in ascertaining the effectiveness of the Group's risk management and internal control systems on an annual and ongoing basis. During the year ended 31 December 2021, the Group has conducted an annual risk assessment which identified respective strategic risks, operational risks, financial risks and compliance risks for each of the major business segment of the Group. Risk factors were analysed and consolidated at the Group level. Based on the risk assessment results following a risk based methodology audit approach, a three-years' audit plan was devised which prioritized the risks identified into annual audit projects. The Group's internal audit department performed the annual reviews in accordance with the audit plan with a view to assisting the Board and the Audit Committee to evaluate the effectiveness of the Group's risk management and internal control systems.

The Group strictly regulates the handling and dissemination of inside information as set out in information disclosure policy to ensure potential inside information remains confidential until such information is appropriately approved and the dissemination of such information is efficiently and consistently made.

Based on the risk management and internal control systems established and maintained by the Group, the work performed by the internal audit department, the Audit Committee and the Board are of the view that the Group has maintained adequate and effective risk management and internal control system during the year ended 31 December 2021.

風險管理及內部監控 (續)

本集團已建立一個具備明確職責等級及報告程序的組織架構。本公司已委聘獨立專業公司擔任外部顧問，協助本公司對本集團風險管理及內部監控系統進行評估。我們擁有自己的內部審核部門履行內部審核功能規定。連同外部顧問的支持，內部審核部門可幫助審核委員會及董事會，每年及持續地確定風險管理及內部監控系統的有效性。截至二零二一年十二月三十一日止年度，本集團已進行年度風險評估，可識別本集團各主要業務分部的相關策略風險、經營風險、財務風險及合規風險。風險因素乃於本集團層面進行分析及綜合。根據風險評估結果及風險導向的審核方法，本集團已制定一個三年審核計劃，可據此將所識別之風險優先列入年度審核項目。本集團內部審核部門根據審核計劃進行年度檢討，旨在協助董事會及審核委員會評估本集團風險管理及內部監控系統的有效性。

誠如信息披露政策所載，本集團嚴格監管內幕消息的處理及發佈，以確保潛在內幕消息在獲適當批准披露前維持保密，並以有效率及一致的方式發佈有關消息。

根據本集團建立及維持的風險管理及內部監控系統，有關工作由內部審核部門進行，審核委員會及董事會認為，本集團已於截至二零二一年十二月三十一日止年度維持有效及充分的風險管理及內部監控系統。

DIRECTOR'S TRAINING

Directors' continuous training and development

Directors should participate in continuous professional development to develop and refresh their knowledge and skills. This is to ensure that their contribution into the Board remains informed and relevant. The directors are committed to complying with the Corporate Governance Code A6.5 on directors' training. All directors have participated in continuous professional development by attending seminars and/or studying materials to director's duties and responsibility and provided a record of training they received for the financial year ended 31 December 2021 to the Company.

The Directors are regularly briefed on the amendments to or updates on the relevant laws, rules and regulations. In addition, the Company has been encouraging the Directors and senior executives to enrol in a wide range of professional development courses or seminars relating to the Listing Rules, companies ordinance or act and corporate governance practices organised by professional bodies and independent auditors so that they can continuously update and further improve their relevant knowledge and skills.

董事之培訓

董事之持續培訓及發展

董事須參與持續專業發展，以深造及更新彼等的知識及技能。此為確保彼等向董事會作出知情及相關之貢獻。董事承諾遵守有關董事培訓之企業管治守則第A6.5條。全體董事均透過出席與董事職責及責任有關之研討會及／或研習資料以參與持續專業發展，並已向本公司提供其於截至二零二一年十二月三十一日止財政年度所接受培訓之記錄。

董事定期均會獲知會相關法例、規則及規例之修訂或最新版本。此外，本公司一直鼓勵董事及高級行政人員報讀由專業團體及獨立核數師舉辦有關上市規則、公司條例或法例及企業管治常規之廣泛專業發展課程及講座，使彼等可持續更新及進一步提高其相關知識及技能。

DIRECTOR'S TRAINING (continued)

董事之培訓 (續)

Directors' continuous training and development (continued)

董事之持續培訓及發展 (續)

From time to time, Directors are provided with written materials to develop and refresh their professional skills; the company secretary also organises and arranges seminars on the latest development of applicable laws, rules and regulations for the Directors to assist them in discharging their duties.

董事將不時獲提供旨在制定及更新其專業技能之書面材料；公司秘書亦會為董事舉辦及安排有關適用法例、規則及規例最新發展之講座，以協助彼等履行其職責。

According to the records maintained by the Company, the Directors received the following training with an emphasis on the roles, functions and duties of a director of a listed company in compliance with the new requirement of the CG Code on continuous professional development during the Year:

根據本公司存置之記錄，為符合企業管治守則關於持續專業發展之新規定，董事於本年度內接受以下重點在於上市公司董事之角色、職能及職責之培訓：

Corporate Governance/Updates on laws, rules and regulations 企業管治／關於法例、規則及規例之更新

Read materials 閱讀材料	Attend workshops 出席研討會
------------------------	---------------------------

Executive Directors

執行董事

Mr. LONG Jing (*Chairman*)
Mr. CONG Rinan

龍經先生 (主席)
叢日楠先生

✓

✓

✓

✓

Non-executive Director

非執行董事

Mr. TANG Zhengpeng
Mr. CHEN Lin
Mr. LIAN Xiaoming

湯正鵬先生
陳林先生
連小明先生

✓

✓

✓

✓

✓

✓

Independent non-executive Directors

獨立非執行董事

Mr. LO Wai Hung
Ms. FU Mingzhong
Ms. WANG Jinxia

盧偉雄先生
付明仲女士
王錦霞女士

✓

✓

✓

✓

✓

✓

DIRECTORS' LIABILITIES INSURANCE

The Company has arranged appropriate insurance cover for Directors' liabilities in respect of potential legal actions against the Directors arising out of corporate activities of the Group pursuant to Code Provision A.1.8 of the new Corporate Governance Code. Such directors' liability insurance will be reviewed and renewed annually.

Throughout the year ended 31 December 2021, no claim has been made against the Directors.

COMPANY SECRETARY

Ms. Wong Miu Ling, Phillis was appointed as the company secretary of the Company with effective from 26 May 2006. All Directors have access to the advice and services of the company secretary. During the year ended 31 December 2021, Ms. Wong Miu Ling, Phillis has taken no less than 15 hours of relevant professional trainings to update her skills and knowledge.

CHANGE OF BOARD LOT

The board lot size for trading in the Shares of the Company on the Stock Exchange has been changed from 4,000 H Shares to 400 H Shares with effect from 9:00 a.m. on 5 November 2021.

CHANGE IN CONSTITUTIONAL DOCUMENTS

During the Year, amendments to the Articles of Association with shareholders approval have been made on 8 March 2021 and 24 September 2021 regarding the change of registered capital and the change of scope of operations of the Company respectively. An updated version of Articles of Association of the Company is available on the websites of the Company and the Stock Exchange of Hong Kong Limited.

董事責任保險

本公司已按照新企業管治守則之守則條文第A.1.8條，就董事可能因本集團企業活動而面對之潛在法律行動作適當董事責任投保安排。有關董事責任保險將每年檢討及續保。

於截至二零二一年十二月三十一日止整個年度並無針對董事之申索。

公司秘書

黃妙玲女士已獲委任為本公司公司秘書，自二零零六年五月二十六日起生效。所有董事均可獲公司秘書提供意見及服務。截至二零二一年十二月三十一日止年度，黃妙玲女士已接受不少於15個小時的相關專業培訓以更新其技能及知識。

更改每手買賣單位

本公司股份於聯交所之每手買賣單位已由4,000股H股更改為400股H股，由二零二一年十一月五日上午九時正起生效。

憲章文件變更

於年內，本公司分別於二零二一年三月八日及二零二一年九月二十四日就變更註冊資本及變更經營範圍對組織章程細則作出修訂並獲得股東批准。本公司組織章程細則之更新版本可於本公司及香港聯合交易所有限公司網站查閱。

BOARD OF DIRECTORS

Executive Directors

Mr. LONG Jing, aged 48, is the chairman of the Board and executive director of the Company. Mr. Long joined the Company in July 2005 and served as the manager of sales management department and vice-general manager of sales of the Company until August 2018. He was the chief executive officer of the Company from August 2018 to March 2021. He has been an executive director of the Company since December 2018 to date, a director of Shandong Weigao Orthopaedic Device Company Limited (stock code: 688161) from March 2020 to date and the chairman of the Board of the Company from March 2021 to date. Prior to joining the Company, Mr. Long served as the sales chief of 山東省塑料工業總公司 (Shandong Plastic Materials Industry Company*) from 1996 to 2002. Mr. Long obtained a bachelor degree in marketing from Shandong Economic University and a master degree in business administration from Shandong University. He also obtained the Chinese professional qualification of Certified Public Accountant (CPA), with nearly 20 years of experiences in sales and operation management in the medical device industry.

Mr. CONG Rinan, aged 41, the executive director and chief executive officer of the Company. Mr. Cong joined the Company in August 2003. He served as supervisor, deputy manager and manager of the syringe production workshop until December 2013. During the period from January 2014 to December 2014, Mr. Cong served as the assistant to the chief executive officer of the Company. From January 2015 to December 2018, he served as the deputy general manager of the clinical care business unit of the Company; from January 2019 to March 2021, he has been the general manager of the clinical care business unit; he has been the chief executive officer of the Company from March 2021 until present; he has been the executive director of the Company from May 2021 until present. Mr. Cong obtained a bachelor's degree in applied chemistry from Yantai University and a master's degree in engineering from Harbin Institute of Technology. He completed the Master of Business Administration (MBA) program at Renmin University of China in 2019 and obtained the title of senior engineer of medical device professional, with nearly 20 years of experience in production and operation management in the medical device industry.

董事會

執行董事

龍經先生，48歲，本公司董事會主席兼執行董事。龍先生於二零零五年七月加入本公司，至二零一八年八月，歷任本公司銷售管理部經理、銷售副總經理等職務；於二零一八年八月至二零二一年三月，任本公司行政總裁；於二零一八年十二月至今任本公司執行董事；於二零二零年三月至今，任山東威高骨科材料股份有限公司(股份代碼：688161)董事；於二零二一年三月至今，任本公司董事會主席。於加入本公司之前，龍先生於一九九六年至二零零二年在山東省塑料工業總公司擔任銷售主管。龍先生獲得山東經濟學院市場營銷專業學士學位，山東大學工商管理碩士學位，並取得中國註冊會計師(CPA)專業資格，擁有近二十年醫療器械行業銷售及運營管理經驗。

叢日楠先生，41歲，本公司執行董事兼行政總裁。叢先生於二零零三年八月加入本公司，至二零一三年十二月，歷任注射器生產車間主任、副經理、經理；於二零一四年一月至二零一四年十二月，任本公司行政總裁助理；於二零一五年一月至二零一八年十二月，任本公司臨床護理事業部副總經理；於二零一九年一月至二零二一年三月，任臨床護理事業部總經理；於二零二一年三月至今，任本公司行政總裁；於二零二一年五月至今，任本公司執行董事。叢先生獲得煙台大學應用化學專業學士學位，哈爾濱工業大學工程碩士學位，並於二零一九年修讀完中國人民大學工商管理碩士(MBA)課程，取得醫療器械專業高級工程師職稱，擁有近二十年醫療器械行業生產及運營管理經驗。

DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT 董事、監事及高級管理人員

BOARD OF DIRECTORS (continued)

Non-executive Directors

Mr. TANG Zhengpeng, aged 51, is the vice chairman of the Board and a non-executive director of the Company. Mr. Tang joined the Weigao Holding in December 2017 and currently is a director of Weihai Weigao International Medical Investment Holdings Co., Ltd. and the vice chairman of Weigao Holding; and a director and vice chairman of Weihai Huadong Automation Co., Ltd (a company listed on the Shenzhen Stock Exchange, stock code 002248) in March 2018 and from July 2018 to present. Prior to joining Weigao Holding, Mr. Tang was the assistant to the president of Bank of Communications, Weihai Branch, the president of Minsheng Bank, Weihai Branch and the assistant to the president of China Minsheng Bank, Qingdao Branch. Mr. Tang graduated from Shandong University majoring in business administration and completed the EMBA program of China Europe International Business School in 2019, with over 20 years of experience in banking and corporate finance management.

Mr. CHEN Lin, aged 46, is a non-executive director of the Company. Mr. Chen joined Weigao Holding in September 2000 and has served as assistant general manager and general manager of Weigao Holding and currently is a director of Weihai Weigao International Medical Investment Holdings Co., Ltd. and the chairman of Weigao Holding. Mr. Chen graduated from Shandong University, Weihai with a degree in economic management and completed a Master of Business Administration (MBA) program at Renmin University of China in 2004, with over 20 years of operation management experience in the medical device industry.

Mr. LIAN Xiaoming, aged 50, is a non-executive director of the Company. Mr. Lian joined Weigao Holding in February 2016, and currently serves as the director of Weihai Weigao International Medical Investment Holdings Co., Ltd. and Weigao Group Co., Ltd.. In March 2018 and from May 2018 to present, Mr. Lian is the director and chairman of Weihai Huadong Automation Co., Ltd (a company listed on the Shenzhen Stock Exchange, stock code 002248). Prior to joining Weigao Holding, Mr. Lian served as the customer manager of Weihai Branch of agricultural Bank of China, the vice president of Weihai Branch of China Minsheng Bank and the general manager of the investment banking department of the Qingdao branch of China Minsheng Bank. Mr. Lian graduated from Shandong University with a law degree and has over 20 years of experience in banking and corporate capital operations.

董事會 (續)

非執行董事

湯正鵬先生，51歲，本公司董事會副主席兼非執行董事。湯先生於二零一七年十二月加入威高集團公司，現任威海威高國際醫療投資控股有限公司董事、威高集團公司副董事長；於二零一八年三月及二零一八年七月至今，任威海華東數控股份有限公司（一家於深圳證券交易所上市的公司，股份代碼：002248）董事及副董事長。於加入威高集團公司之前，湯先生曾擔任交通銀行威海分行行長助理、民生銀行威海分行行長、民生銀行青島分行行長助理等職務。湯先生畢業於山東大學工商管理專業，並於二零一九年修讀完中歐國際工商學院EMBA課程，擁有超過二十年銀行業及公司財務管理方面的經驗。

陳林先生，46歲，本公司非執行董事。陳先生於二零零零年九月加入威高集團公司，曾任威高集團公司助理總經理、總經理等職務，現任威海威高國際醫療投資控股有限公司董事、威高集團公司董事長。陳先生畢業於威海大學經濟管理專業，並於二零零四年修讀完中國人民大學工商管理碩士（MBA）課程，擁有超過二十年的醫療器械行業運營管理經驗。

連小明先生，50歲，本公司非執行董事。連先生於二零一六年二月加入威高集團公司，現任威海威高國際醫療投資控股有限公司董事、威高集團公司董事；於二零一八年三月及二零一八年五月至今，任威海華東數控股份有限公司（一家於深圳證券交易所上市的公司，股份代碼：002248）董事及董事長。於加入威高集團公司之前，連先生曾任農業銀行威海分行客戶經理、民生銀行威海分行副行長、民生銀行青島分行投行部總經理等職務。連先生畢業於山東大學法律專業，擁有超過二十年銀行業及公司資本運作經驗。

BOARD OF DIRECTORS (continued)

董事會 (續)

Independent Non-executive Directors

獨立非執行董事

Mr. LO Wai Hung, aged 62, obtained a bachelor degree in Commerce from James Cook University of North Queensland, Australia in 1985. Mr. Lo is an associate member of Chartered Accountants Australia and New Zealand and a fellow member of Hong Kong Institute of Certified Public Accountants. Mr. Lo was appointed as an independent non-executive director, the chairman of audit committee, the chairman of remuneration committee, the chairman of nomination committee and a member of corporate governance committee of the Company. Mr. Lo is also an independent non-executive director of Talent Property Group Limited (stock code:760) and C Cheng Holdings Limited (stock code: 1486), Tibet Water Resources Limited (stock code: 1115) since 28 September 2021, China New Town Development Company Limited (stock code: 1278) since 30 December 2021. Mr. Lo is also a non-executive director of SY Holdings Group Limited (formerly known as Sheng Ye Capital Limited) (stock code: 6069) since 10 December 2021. Mr. Lo was also an independent non-executive director of Lerthai Group Limited (formerly known as LT Commercial Real Estate Limited) (Stock code: 112) since March 2017 till November 2018. The shares of these companies are listed on the Stock Exchange of Hong Kong Limited. Mr. Lo was also an independent director of China Merchant Property Development Co. Ltd since 2011 and the shares of which were ceased from listing on the Shenzhen Stock Exchange on 30 December 2015.

盧偉雄先生，62歲，於一九八五年獲澳洲北崑士蘭詹姆斯庫克大學(James Cook University of North Queensland)頒授商學學士學位。盧先生為澳洲及新西蘭特許會計師公會會員及香港會計師公會資深會員。盧先生獲委任為本公司獨立非執行董事、審核委員會主席、薪酬委員會主席、提名委員會主席及企業管治委員會成員。盧先生亦為新天地產集團有限公司(股份代號：760)、思城控股有限公司(股份代號：1486)、自二零二一年九月二十八日出任西藏水資源有限公司(股份代號：1115)及自二零二一年十二月三十日出任中國新城鎮發展有限公司(股份代號：1278)之獨立非執行董事。盧先生亦自二零二一年十二月十日出任盛業控股集團有限公司(前稱盛業資本有限公司)(股份代號：6069)之非執行董事。盧先生於二零一七年三月至二零一八年十一月亦擔任勒泰集團有限公司(前稱勒泰商業地產有限公司)(股份代號：112)之獨立非執行董事。該等公司之股份均於香港聯合交易所有限公司上市。盧先生自二零一一年起亦擔任招商局地產控股股份有限公司(其股份於二零一五年十二月三十日停止於深圳證券交易所上市)之獨立董事。

DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT 董事、監事及高級管理人員

BOARD OF DIRECTORS (continued)

Independent Non-executive Directors (continued)

Ms. FU Mingzhong, aged 72, senior economist and has over 40 years of working experience, particular in the area of management experience in the pharmaceutical and healthcare products industry. Ms. Fu obtained a master's degree in engineering from the Harbin Institute of Technology in March 1995. Ms. Fu was previously a deputy workshop director, the office head and the vice factory manager of The Third Harbin Pharmaceutical Factory from June 1972 to March 1992. Ms. Fu was a director of Harbin City Pharmaceutical Group and the general manager of Harbin Pharmaceutical Company Limited from March 1992 to December 1997. She was also a deputy general manager of China Medicines Group from December 1997 to January 1999 and she was a director of China Medicines Group Corporation from January 1999 to October 2009 respectively. Ms. Fu was the executive deputy general manager of China National Pharmaceutical industry Corporation from January 1999 to January 2001. Ms. Fu was the chairman of National Medicines Company Limited (a company listed on the Shanghai Stock Exchange) from January 2001 to February 2008. Ms. Fu has been a director of Shenzhen Accord Pharmaceutical Company Ltd. (a company listed on the Shenzhen Stock Exchange) since April 2008 and was the chairman from April 2008 to December 2008. Ms. Fu has also been a director of Sinopharm Industrial Investment Co., Ltd. from July 2008 to December 2010. Ms. Fu was the general manager, deputy chairman and director of Sinopharm Group Co. Ltd. (a company listed on the Hong Kong Stock Exchange) during the period from January 2006 to December 2009, and December 2009 to November 2010 respectively.

Ms. Fu is currently the honorary chairman and the director of the expert committee of China Association of Pharmaceutical Commerce.

董事會 (續)

獨立非執行董事 (續)

付明仲女士，72歲，高級經濟師並擁有逾四十年工作經驗，尤其是於藥品及保健品行業方面之管理經驗。付女士於一九九五年三月獲得哈爾濱工業大學工學碩士學位。付女士自一九七二年六月至一九九二年三月歷任哈爾濱製藥三廠之車間副主任、辦公室主任及副廠長。付女士曾自一九九二年三月至一九九七年十二月擔任哈藥集團之董事及哈爾濱市醫藥公司之總經理。彼亦分別於一九九七年十二月至一九九九年一月擔任中國醫藥(集團)公司之副總經理及一九九九年一月至二零零九年十月擔任中國醫藥集團之董事。付女士於一九九九年一月至二零零一年一月擔任中國醫藥工業公司常務副總經理，並於二零零一年一月至二零零八年二月擔任國藥集團藥業股份有限公司(一間於上海證券交易所上市之公司)之董事長。付女士自二零零八年四月起亦一直擔任深圳一致藥業有限公司(一間於深圳證券交易所上市之公司)之董事，並於二零零八年四月至二零零八年十二月擔任其董事長。付女士亦自二零零八年七月至二零一零年十二月擔任國藥產業投資有限公司之董事。付女士於二零零六年一月至二零零九年十二月及二零零九年十二月至二零一零年十一月期間分別擔任國藥控股有限公司(一間於香港聯交所上市之公司)總經理、副董事長及董事。

付女士現時亦為中國醫藥商業協會名譽會長專家委員會主任。

BOARD OF DIRECTORS (continued)

董事會 (續)

Independent Non-executive Directors (continued)

獨立非執行董事 (續)

Ms. WANG Jinxia, aged 68, an independent non-executive Director of the Company. Ms. Wang is a senior economist and has over 40 years of working experience, especially the management experience in the pharmaceutical commerce and pharmaceutical industry. Ms. Wang obtained a bachelor degree in economics (經濟學學士) from Dongbei University of Finance and Economics in July 1983 and was assigned to work in State Pharmaceutical Administration of China Pharmaceutical Company (國家醫藥管理局中國醫藥公司). Ms. Wang was deputy director of the finance division, director of the information division of China Pharmaceutical Company (中國醫藥公司), the general secretary and the vice president of China Association of Pharmaceutical Commerce (中國醫藥商業協會) and the person in charge of the pharmaceutical chains branch of China Association of Pharmaceutical Commerce (中國醫藥商業協會連鎖藥店分會). She is also a senior advisor of China Nonprescription Medicines Association (中國非處方藥協會).

王錦霞女士，68歲，本公司之獨立非執行董事。王女士為高級經濟師及擁有逾四十年工作經驗，尤其於藥品流通及醫藥行業的管理經驗。王女士於一九八三年七月在東北財經大學獲得經濟學學士學位，被分配到國家醫藥管理局中國醫藥公司工作。王女士曾任中國醫藥公司財務處副處長、信息處處長、中國醫藥商業協會秘書長及副會長以及中國醫藥商業協會連鎖藥店分會負責人。彼亦為中國非處方藥協會高級顧問。

Currently, Ms. Wang also acts as the independent director of Xinjiang Ready Health Industry Co., Ltd. (新疆同濟堂健康產業股份有限公司) (stock code: 600090) and the independent director of Zhejiang Wecome Pharmaceutical Company Limited (浙江維康藥業股份有限公司) (stock code: 300878).

王女士現亦任新疆同濟堂健康產業股份有限公司 (股份代號：600090) 獨立董事，浙江維康藥業股份有限公司 (股份代號：300878) 獨立董事。

DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT 董事、監事及高級管理人員

BOARD OF DIRECTORS (continued)

Supervisors

The Company has a committee of Supervisors whose primary duty is to supervise the senior management of the Company, including the Board, Directors, managers and other senior officers. The function of the committee of Supervisors is to ensure that the senior management of the Company acts in the interests of the Company, and does not violate the rights of the Company's shareholders and employees. The committee of Supervisors reports to the shareholders in general meetings. The articles of association provides that the committee of Supervisors has the right to investigate the Group's financial affairs; to supervise the directors, general manager and other senior officers of the Company in the event that they contravene any laws, administrative regulations or the articles of association in the performance of their duties; to require the Directors, general managers and other senior management to rectify any activities committed by them that is harmful to the interests of the Company; to examine financial reports, result reports, profit distribution plans and other financial documents prepared by the Board to be submitted to shareholders in general meeting, and in appropriate cases, to appoint certified accountants or certified practicing auditors in the name of the Company to assist in such review; to propose the convening of extraordinary general meetings of shareholders; to represent the Company during negotiations with the Directors or to initiate legal proceedings against the Directors; and other functions and powers given by the shareholders in general meeting. The committee of Supervisors currently comprises the following three members:

Mr. HU Yunyong, aged 53, is the chairman of the Supervisory Committee and a shareholder representative supervisor of the Company. Mr. Hu joined Weigao Holding in 1999 and has served as the corporate affairs manager, assistant to general manager and director of Weigao Holding. Mr. Hu graduated from 海軍電子工程學院 (the Navy's Electronic Engineering College) with a bachelor's degree and passed the national unified qualification exam in laws.

董事會 (續)

監事

本公司設有監事會，主要職責為監督本公司的高級管理人員，包括董事會、董事、經理及其他高級主管人員。監事會職能為確保本公司高級管理人員依據本公司的利益行事，且不會損害本公司股東及僱員的利益。監事會在股東大會上向股東匯報。組織章程細則規定監事會有權調查本集團的財務狀況；監督本公司董事、總經理及其他高級管理人員在履行彼等的職責時不會違反任何法律、行政法規或組織章程細則；要求董事、總經理及其他高級管理人員停止進行有違本公司利益的活動；審核董事會編製並於股東大會向股東呈交的財務報告、業績報告、溢利分配計劃及其他財務文件，並在適當情況下，代表本公司委聘執業會計師或執業核數師協助有關審核工作；建議召開股東特別大會；代表本公司與董事磋商或對董事提出法律訴訟；以及股東在股東大會上所授予的其他職權。目前，監事會由以下三名成員組成：

胡雲涌先生，53歲，本公司監事會主席兼股東代表監事。胡先生於一九九九年加入威高集團公司至今，歷任威高集團公司法務經理、總經理助理、總監等職務。胡先生於海軍電子工程學院本科畢業，通過國家統一法律職業資格考試。

DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT 董事、監事及高級管理人員

BOARD OF DIRECTORS (continued)

Supervisors (continued)

Ms. GU Meijun, aged 45, a shareholder representative supervisor of the Company. Ms. Gu joined Weigao Holding in 1996 and held positions such as accounting supervisor, accounting manager, assistant to general manager, and chief accountant of Weigao Holding. Ms. Gu has been a supervisor of Weihai Huadong Automation Co., Ltd (a company listed on the Shenzhen Stock Exchange, stock code: 002248) from March 2021 to date. Ms. Gu graduated from Beijing Information Technology Institute with a bachelor's degree in financial management and passed the middle-level accountant title examination.

Mr. YUE Chunliang, aged 41, is the employee representative supervisor of the Company. Mr. Yue joined the Company in 2005 and has served as the supervisor of the R&D department of the Company, the manager of the production department of the infusion sets of branch company, and the manager of the procurement center. Mr. Yue obtained a degree in Polymer Materials and Engineering from the University of Yantai.

Senior Management

Mr. WU Xuefeng, aged 44, the chief financial officer of the Company. Mr. Wu joined the finance department of the Company in July 2001. He served as the manager of the manufacturing finance department and the manager of the sales finance department of the Company until July 2012; from July 2012 to October 2013, he was the manager of the risk management department of Weigao Holding; from October 2013 to February 2017, he was the financial controller of the pharmaceutical distribution business department of Weigao Holding; and from February 2017 to present, he has been the financial controller of the Company. Mr. Wu obtained a bachelor degree in finance management from the University of QiQiHar in Heilongjiang Province and obtained a master degree in business management from the Missouri State University, the United States, with more than 20 years of experience in the accounting and finance management.

董事會 (續)

監事 (續)

谷美君女士，45歲，本公司股東代表監事。谷女士於一九九六年加入威高集團公司至今，歷任威高集團公司會計主管、會計經理、總經理助理、總會計師等職務。谷女士於二零二一年三月至今，任威海華東數控股份有限公司（一家於深圳證券交易所上市的公司，股份代碼：002248）監事。谷女士於北京信息工程專修學院財務管理專業本科畢業，通過中級會計師職稱考試。

岳春良先生，41歲，本公司職工代表監事。岳先生於二零零五年加入本公司至今，歷任本公司研發部主管、輸液器分公司生產部經理、採購中心經理等職務。岳先生獲得煙台大學高分子材料與工程學士學位。

高級管理層

吳雪峰先生，44歲，本公司財務總監。吳先生於二零零一年七月加入本公司財務部，至二零一二年七月，歷任本公司製造財務部經理、銷售財務部經理；二零一二年七月至二零一三年十月，任威高集團公司風險管理部經理；二零一三年十月至二零一七年二月，任威高集團公司醫藥分銷事業部財務總監；二零一七年二月至今，任本公司財務總監。吳先生獲得黑龍江省齊齊哈爾大學財務管理學學士學位，美國密蘇里州立大學企業管理碩士學位，擁有超過二十年的會計及財務管理方面的經驗。

DIRECTORS, SUPERVISORS AND SENIOR MANAGEMENT 董事、監事及高級管理人員

BOARD OF DIRECTORS (continued)

Senior Management (continued)

Mr. LU Junqiang, aged 48, a director and a general manager of Shandong Weigao Orthopaedic Device Company Limited (stock code: 688161). Mr. Lu joined Weigao Orthopaedic in January 2018 as the deputy general sales manager of Weigao Orthopaedic and has been the director and general manager of Weigao Orthopaedic in September 2018 and from September 2019 to present. Prior to joining Weigao Orthopaedic, Mr. Lu served as the regional manager, sales manager of Eastern China and deputy general manager of the medical devices products business division of the Group since October 2000. Mr. Lu obtained a master's degree of business administration from the University of Wales in the United Kingdom and has more than 20 years of experience in sales and operation management in the medical device industry.

Mr. NI Shili, aged 60, a director and a general manager of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd.. Mr. Ni joined the Company in May 1995. He worked as the product sales manager for the infusion sets of the Company until December 2004 and product sales manager for pharma packaging materials of the Company from January 2005 to March 2009, respectively. He serves as the general manager of the pharma packaging materials division since April 2009 to date. Mr. Ni graduated from Heilongjiang Radio and TV University majoring in marketing and is a professional intermediate engineer in medical technology with nearly 30 years of sales and operation management experience in the medical device and pharma packaging industry.

Ms. WONG Miu Ling, Phillis, aged 53, is the company secretary of the Company. Ms. Wong joined the Company in May 2006. She is a Chartered Secretary and fellow members of both The Hong Kong Institute of Chartered Secretaries and the Chartered Governance Institute (formerly known as The Institute of Chartered Secretaries and Administrators). Ms. Wong has over 25 years of experience in corporate finance and management.

董事會 (續)

高級管理層 (續)

盧均強先生，48歲，山東威高骨科材料股份有限公司(股份代碼：688161)董事兼總經理。盧先生於二零一八年一月加入威高骨科，任威高骨科銷售副總經理；於二零一八年九月及二零一九年九月至今，任威高骨科董事及總經理。於加入威高骨科之前，盧先生自二零零零年十月起曾在本集團擔任大區經理、華東區銷售經理及醫療器械產品事業部副總經理。盧先生獲得英國威爾士大學工商管理碩士學位，擁有超過二十年的醫療器械行業銷售及運營管理經驗。

倪世利先生，60歲，山東威高普瑞醫藥包裝有限公司董事兼總經理。倪先生於一九九五年五月加入本公司，至二零零四年十二月任本公司輸液器產品銷售經理；於二零零五年一月至二零零九年三月任本公司藥品包裝材料產品銷售經理；於二零零九年四月至今任藥品包裝材料事業部總經理。倪先生畢業於黑龍江廣播電視大學市場營銷專業，醫藥技術專業中級工程師，擁有近三十年醫療器械及醫藥包裝行業的銷售及運營管理經驗。

黃妙玲女士，53歲，本公司公司秘書，於二零零六年五月加入本公司。黃女士為特許秘書及香港特許秘書公會及英國特許公司治理公會(前稱特許秘書及行政人員公會)資深會員。黃女士於企業融資及管理方面積逾二十五年經驗。



**TO THE SHAREHOLDERS OF
SHANDONG WEIGAO GROUP MEDICAL POLYMER
COMPANY LIMITED**

山東威高集團醫用高分子製品股份有限公司

(A joint stock limited company established in the People's Republic of China)

**致山東威高集團醫用高分子製品股份
有限公司股東**

(於中華人民共和國成立的股份有限公司)

OPINION

We have audited the consolidated financial statements of Shandong Weigao Group Medical Polymer Company Limited (the "Company") and its subsidiaries (collectively referred to as "the Group") set out on pages 91 to 311, which comprise the consolidated statement of financial position as at 31 December 2021, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2021, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAAs") issued by the HKICPA. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the HKICPA's Code of Ethics for Professional Accountants ("the Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

意見

本行已完成審核第91至311頁所載山東威高集團醫用高分子製品股份有限公司（「貴公司」）及其附屬公司（統稱為「貴集團」）的綜合財務報表，該等綜合財務報表包括於二零二一年十二月三十一日的綜合財務狀況表、及截至該日止年度的綜合損益及其他全面收入報表、綜合權益變動報表及綜合現金流量報表，及該等綜合財務報表附註（包括主要會計政策的概要）。

本行認為，綜合財務報表按照香港會計師公會（「香港會計師公會」）頒佈的香港財務報告準則（「香港財務報告準則」）真實及公平地反映貴集團於二零二一年十二月三十一日的綜合財務狀況，以及截至該日止年度的綜合財務表現及其綜合現金流量狀況，並已依據香港公司條例的披露規定妥為編製。

意見基準

本行是按照香港會計師公會頒佈的香港核數準則（「香港核數準則」）進行審核工作。本行於該等標準項下之責任進一步詳述於本報告「核數師就審核綜合財務報表須承擔的責任」一節。根據香港會計師公會的專業會計師道德守則（「守則」），本行獨立於貴集團，並根據守則履行吾等其他道德責任。本行相信，吾等所取得的審核憑證已足夠及適當地為吾等的審核意見提供基礎。

KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter 關鍵審核事項

Impairment assessment of goodwill 商譽減值評估

We identified impairment assessment of the goodwill of interventional products cash generating unit in relation to Argon Medical Devices Holding, Inc. ("Argon") amounting to RMB2,928,886,000 as a key audit matter due to its significance to the consolidated financial statements and the significant management estimate involved in assessing the impairment of goodwill.

吾等已確認有關愛琅醫療器械控股有限公司（「愛琅」）的介入產品現金產生單位之商譽（金額為人民幣2,928,886,000元）減值評估作為關鍵審核事項，乃由於其對於綜合財務報表具有重大影響及評估商譽減值時涉及重大的管理層估計。

In estimating the recoverable amount of the cash generating unit to which goodwill has been allocated, the management has made a number of significant assumptions in the value in use calculation. The key assumptions mainly include discount rate and revenue growth rates applied.

於估計商譽獲分配的現金產生單位之可回收金額時，管理層於使用價值計算中使用若干重大假設。關鍵假設主要包括所使用的貼現率和收入增長率。

Details of significant judgments and assumptions in the impairment assessment are disclosed in notes 5 and 18 to the consolidated financial statements.

減值評估中的重大判斷及假設詳情於綜合財務報表附註5及18中披露。

關鍵審核事項

關鍵審核事項為吾等的專業判斷中，審核本期綜合財務報表中最重要的事項。本行於審核整體綜合財務報表及就此形成意見時處理此等事項，而不會就此等事項單獨發表意見。

How our audit addressed the key audit matter 處理關鍵審核事項之方法

Our procedures in relation to the impairment assessment of the goodwill of interventional products cash generating unit from acquisition of Argon included:

吾等就收購愛琅的介入產品現金產生單位之商譽減值評估的審核程序包括：

- Understanding the internal controls relevant to the impairment assessment of the goodwill;
- 了解與商譽減值評估有關之內部控制；
- Evaluating the valuation methodology and long-term growth rate with the assistance of our internal valuation specialists;
- 在內部估值專家的協助下評估估值方法及長期增長率；
- Evaluating the discount rate, including developing a range of independent estimates and comparing those with the discount rate selected by the management, with the assistance of our internal valuation specialists; and
- 在我們內部估值專家的協助下評估貼現率，包括編製一系列獨立估算，並將其與管理層選擇的貼現率比較；及
- Evaluating the revenue growth rates by comparing with historical performance and industry data.
- 通過與過往表現及行業數據比較評估收入增長率。

OTHER INFORMATION

The directors of the Company are responsible for the other information. The other information comprises the information included in the annual report, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF DIRECTORS AND THOSE CHARGED WITH GOVERNANCE FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

其他資料

貴公司董事對其他資料負責。其他資料包括年報內所載的資料，惟不包括綜合財務報表及吾等就此作出之核數師報告。

吾等對綜合財務報表作出的意見並未涵蓋其他資料。吾等不對其他資料發表任何形式的核證結論。

就審核綜合財務報表而言，吾等的責任是閱讀其他資料，從而考慮其他資料是否與綜合財務報表或吾等在審核過程中獲悉的資料存在重大不符，或似乎存在重大錯誤陳述。倘若吾等基於已完成的工作認為其他資料出現重大錯誤陳述，吾等須報告該事實。吾等就此並無任何事項須報告。

董事及治理層就綜合財務報表須承擔的責任

貴公司董事須負責根據香港會計師公會頒佈的香港財務報告準則及香港公司條例的披露規定編製真實而公平的綜合財務報表，並對董事認為為使綜合財務報表的編製不存在由於欺詐或錯誤而導致的重大錯誤陳述所需的內部控制負責。

在編製綜合財務報表時，董事負責評估貴集團持續經營的能力，並在適用情況下披露與持續經營有關的事項，以及使用持續經營為會計基礎，除非董事有意貴集團清盤或停止經營，或別無其他實際的替代方案。

治理層須負責監督貴集團的財務報告過程。

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSA's will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSA's, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.

核數師就審核綜合財務報表須承擔的責任

本行的目標乃對綜合財務報表整體是否存在由於欺詐或錯誤而導致的重大錯誤陳述取得合理保證，並出具包括本行意見的核數師報告，並按照協定的委聘條款僅向閣下（作為整體）報告，除此之外本報告別無其他目的。本行概不就本報告的內容對任何其他人士負責或承擔責任。合理保證為高水平的保證，但不能保證按照香港核數準則進行的審核總能發現重大錯誤陳述。錯誤陳述可以由欺詐或錯誤引起，如果合理預期其單獨或匯總起來可能影響綜合財務報表使用者依賴綜合財務報表所作出的經濟決定，則有關的錯誤陳述可被視作重大。

作為根據香港核數準則進行審核其中一環，本行運用專業判斷，保持專業懷疑態度。本行亦：

- 識別及評估由於欺詐或錯誤而導致綜合財務報表存在重大錯誤陳述的風險，設計及執行審核程序以應對該等風險，以及獲取充足及適當的審核憑證，作為本行意見的基礎。由於欺詐可能涉及串謀、偽造、蓄意遺漏、虛假陳述，或凌駕於內部控制之上，因此未能發現因欺詐而導致出現重大錯誤陳述的風險高於未能發現因錯誤而導致出現重大錯誤陳述的風險。
- 了解與審核相關的內部控制，以設計在有關情況下屬適當的審核程序，但目的並非對集團內部控制的有效性發表意見。

**AUDITOR'S RESPONSIBILITIES FOR THE
AUDIT OF THE CONSOLIDATED FINANCIAL
STATEMENTS** (continued)

**核數師就審核綜合財務報表須承
擔的責任 (續)**

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.
- 評估董事所採用會計政策的適當性以及作出會計估計及相關披露的合理性。
- 對董事採用持續經營會計基礎的適當性作出結論，並根據所獲取的審核憑證，確定是否存在與事項或情況有關的重大不確定性，從而可能導致 貴集團的持續經營能力產生重大疑慮。倘本行認為存在重大不確定性，則有必要在核數師報告中提請使用者注意綜合財務報表中的相關披露。假若有關的披露不足，則修訂本行的意見。本行的結論乃基於直至核數師報告日止所取得的審核憑證。然而，未來事項或情況可能導致 貴集團不能持續經營業務。
- 評估綜合財務報表的整體列報方式、結構及內容(包括披露)事項以及綜合財務報表是否公平反映相關交易及事項。
- 貴集團內實體或業務活動的財務資料獲取充足適當的審核憑證，以便對綜合財務報表發表意見。本行負責 貴集團審核的方向、監督及執行。本行為審核意見承擔全部責任。

INDEPENDENT AUDITOR'S REPORT

獨立核數師報告書

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in the independent auditor's report is Tung Wai Lung Ricky.

Deloitte Touche Tohmatsu
Certified Public Accountants

Hong Kong
14 April 2022

核數師就審核綜合財務報表須承 擔的責任 (續)

本行與治理層溝通審核的計劃範圍及時間以及重大審核發現等，其中包括本行在審核中識別出內部控制的任何重大不足之處。

本行亦向治理層提交聲明，表明本行已符合有關獨立性的相關專業道德要求，並與彼等溝通可能合理被認為會影響本行獨立性的所有關係及其他事項，以及在適用的情況下為消除威脅而採取的行動或相關的防範措施。

從與治理層溝通的事項中，本行確定該等對本期綜合財務報表的審計最為重要的事項，因而構成關鍵審計事項。本行在核數師報告中闡釋該等事項，除非法律或規例不允許公開披露該等事項，或在極端罕見的情況下，合理預期倘於本行之報告中註明某事項造成的負面後果超過產生的公眾利益，則本行決定不應在報告中註明該事項。

出具獨立核數師報告的審核項目合夥人為董偉龍。

德勤•關黃陳方會計師行
執業會計師

香港
二零二二年四月十四日

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

綜合損益及其他全面收入報表

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

		NOTES	Year ended 31/12/2021 RMB'000	Year ended 31/12/2020 RMB'000 (restated)
		附註	截至 二零二一年 十二月 三十一日 止年度 人民幣千元	截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)
Revenue	收入	6	13,151,719	11,622,337
Cost of sales	銷售成本		(5,882,315)	(5,122,766)
Gross profit	毛利		7,269,404	6,499,571
Other income, gains and losses	其他收入、收益及虧損	7	(64,157)	313,438
Impairment losses under expected credit loss model, net of reversal	預期信貸虧損模型下之減值虧損 (扣除撥回)	8	(26,982)	(35,244)
Selling expense	銷售開支		(2,661,695)	(2,529,156)
Administrative expenses	行政開支		(1,111,777)	(1,088,964)
Research and development expenses	研發開支		(492,133)	(424,422)
Finance costs	融資成本	9	(140,396)	(178,935)
Share of results of an associate	應佔一間聯營公司業績		69,988	9,171
Share of results of joint ventures	應佔合營企業業績		(531)	-
Profit before tax	除稅前溢利		2,841,721	2,565,459
Income tax expense	所得稅開支	10	(415,093)	(358,422)
Profit for the year	年內溢利		2,426,628	2,207,037
Other comprehensive expense	其他全面開支			
<i>Item that may be reclassified subsequently to profit or loss:</i>	<i>其後可重新分類至損益之項目：</i>			
Exchange differences arising on translation of foreign operations	換算海外業務產生之匯兌差額		(81,482)	(264,843)
Total comprehensive income for the year	年內全面收入總額		2,345,146	1,942,194
Profit for the year attributable to owners of the Company	本公司擁有人應佔年內溢利		2,244,778	2,086,783
Profit for the year attributable to non-controlling interests	非控股權益應佔年內溢利		181,850	120,254
			2,426,628	2,207,037

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

綜合損益及其他全面收入報表

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

		NOTES	Year ended 31/12/2021 RMB'000	Year ended 31/12/2020 RMB'000 (restated)
		附註	截至 二零二一年 十二月 三十一日 止年度 人民幣千元	截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)
Total comprehensive income for the year attributable to:	下列各項應佔年內全面收入總額：			
Owners of the Company	本公司擁有人		2,174,977	1,842,137
Non-controlling interests	非控股權益		170,169	100,057
			2,345,146	1,942,194
Earnings per share	每股盈利			
Basic (RMB per share)	基本 (每股人民幣元)	14	0.50	0.46
Diluted (RMB per share)	攤薄 (每股人民幣元)		0.50	0.46

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

綜合財務狀況表

At 31 December 2021 於二零二一年十二月三十一日

	NOTES	31/12/2021 RMB'000	31/12/2020 RMB'000 (restated)
	附註	二零二一年 十二月 三十一日 人民幣千元	二零二零年 十二月 三十一日 人民幣千元 (經重列)
Non-current assets	非流動資產		
Property, plant and equipment	物業、廠房及設備	15 5,719,370	5,362,665
Right-of-use assets	使用權資產	16 476,317	435,512
Investment properties	投資物業	17 133,788	136,710
Goodwill	商譽	18 3,348,497	3,414,210
Deposits paid for acquiring property, plant and equipment	就收購物業、廠房及設備之已付按金	467,730	300,903
Intangible assets	無形資產	19 1,798,577	2,055,460
Interests in an associate	於一間聯營公司的權益	20 1,138,901	1,068,912
Interests in joint ventures	於合營企業的權益	21 180,757	181,927
Financial assets at fair value through profit or loss	按公平值計入損益計量之金融資產	22 100,943	108,420
Deferred tax assets	遞延稅項資產	23 156,462	140,058
Finance lease receivables	應收融資租賃款項	24 40,959	85,160
Loan receivables	應收貸款	25 318,811	213,101
Prepayments	預付款項	27 79,353	88,170
Other non-current assets	其他非流動資產	7(e) 293,247	-
		14,253,712	13,591,208
Current assets	流動資產		
Inventories	存貨	26 1,734,557	1,562,853
Loan receivables	應收貸款	25 428,514	232,873
Trade and other receivables	應收貿易賬款及其他應收款項	27 6,045,579	5,958,479
Debt instruments at fair value through other comprehensive income	按公平值計入其他全面收益計量之債務工具	28 419,752	469,610
Finance lease receivables	應收融資租賃款項	24 85,122	136,908
Financial assets at fair value through profit or loss	按公平值計入損益計量之金融資產	22 10,000	-
Pledged bank deposits	已抵押銀行存款	29 760,895	340,129
Bank balances and cash	銀行結餘及現金	30 6,628,927	5,665,656
		16,113,346	14,366,508
Current liabilities	流動負債		
Financial liabilities at fair value through profit or loss	按公平值計入損益計量之金融負債	22 56,694	21,031
Trade and other payables	應付貿易賬款及其他應付款項	31 3,952,044	3,812,454
Contract liabilities	合約負債	32 310,866	313,373
Borrowings	借款	33 601,328	297,890
Tax payable	應付稅項	149,633	129,154
Deferred income	遞延收入	35 8,816	7,861
Lease liabilities	租賃負債	36 22,988	8,583
Provisions	撥備	10,606	7,699
		5,112,975	4,598,045
Net Current Assets	流動資產淨額	11,000,371	9,768,463
Total Assets less Current Liabilities	總資產減流動負債	25,254,083	23,359,671

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

綜合財務狀況表

At 31 December 2021 於二零二一年十二月三十一日

		NOTES	31/12/2021 RMB'000	31/12/2020 RMB'000 (restated)
		附註	二零二一年 十二月 三十一日 人民幣千元	二零二零年 十二月 三十一日 人民幣千元 (經重列)
Capital and Reserves	資本及儲備			
Share capital	股本	37	457,063	452,233
Reserves	儲備		18,810,028	17,581,347
Equity attributable to owners of the Company	本公司擁有人應佔權益		19,267,091	18,033,580
Non-controlling interests	非控股權益		1,640,359	845,108
Total Equity	權益總額		20,907,450	18,878,688
Non-current Liabilities	非流動負債			
Financial liabilities at fair value through profit or loss	按公平值計入損益計量之金融負債	22	199	64,847
Borrowings	借款	33	2,462,688	3,001,289
Bonds payable	應付債券	34	992,549	991,121
Other payable	其他應付款項	31	-	37,125
Deferred income	遞延收入	35	84,765	70,898
Deferred tax liabilities	遞延稅項負債	23	222,620	291,797
Lease liabilities	租賃負債	36	57,857	22,115
Contract liabilities	合約負債	32	3,305	1,791
Provision	撥備	7(e)	522,650	-
			4,346,633	4,480,983
			25,254,083	23,359,671

The consolidated financial statements on pages 91 to 311 were approved and authorised for issue by the board of directors on 14 April 2022 and are signed on its behalf by:

第91至311頁的綜合財務報表已獲董事會於二零二二年四月十四日批准及授權刊發，並由以下董事代表董事會簽署：

LONG Jing
龍經

DIRECTOR
董事

CONG Rinan
叢日楠

DIRECTOR
董事

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

綜合權益變動報表

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

		Attributable to owners of the Company 本公司擁有人應佔									
		Share capital	Share premium reserve	Statutory surplus reserve	Translation reserve	Share- based payments reserve	Other reserves	Retained profits	Total	Non- controlling interests	Total Equity
		RMB'000	RMB'000	RMB'000 (Note a)	RMB'000	RMB'000	RMB'000 (Note b)	RMB'000	RMB'000	RMB'000	RMB'000
		股本	股份溢價 儲備	法定盈餘 儲備	匯兌儲備	以股份 為基礎付款 儲備	其他儲備	保留溢利	總計	非控股權益	權益總額
		人民幣千元	人民幣千元	人民幣千元 (附註a)	人民幣千元	人民幣千元	人民幣千元 (附註b)	人民幣千元	人民幣千元	人民幣千元	人民幣千元
At 31 December 2019	於二零一九年十二月三十一日	452,233	2,575,060	257,956	144,076	92,401	764,830	11,893,944	16,180,500	811,436	16,991,936
Restatements due to business combination under common control in 2021 (note 3)	因二零二一年同一控制下的業務合併而重列 (附註3)	-	-	-	7,299	-	423,000	34,134	464,433	-	464,433
At 1 January 2020 (restated)	於二零二零年一月一日 (經重列)	452,233	2,575,060	257,956	151,375	92,401	1,187,830	11,928,078	16,644,933	811,436	17,456,369
Profit for the year (restated)	本年度溢利 (經重列)	-	-	-	-	-	-	2,086,783	2,086,783	120,254	2,207,037
Other comprehensive expense for the year (restated)	年內其他全面開支 (經重列)	-	-	-	(244,646)	-	-	-	(244,646)	(20,197)	(264,843)
Total comprehensive income for the year (restated)	年內全面收入總額 (經重列)	-	-	-	(244,646)	-	-	2,086,783	1,842,137	100,057	1,942,194
Consideration for business combination under common control in 2020 (note c)	二零二零年同一控制下的業務合併之代價 (附註c)	-	-	-	-	-	10,575	-	10,575	14,115	24,690
Disposal of partial interest in a subsidiary	出售於一間附屬公司之部分權益	-	-	-	-	-	(1,278)	-	(1,278)	1,278	-
Debt waiver	免除債務	-	-	-	-	-	(2,189)	-	(2,189)	2,189	-
Acquired interest in a subsidiary from non-controlling shareholder (note d)	自非控股股東收購的一間附屬公司的權益 (附註d)	-	-	-	-	-	(84,402)	-	(84,402)	(124,727)	(209,129)
Adoption of share award scheme (note 38 (c))	採納股份激勵計劃 (附註38(c))	-	-	-	-	-	(19,187)	-	(19,187)	19,187	-
Recognition of equity-settled share-based payments (note 38)	確認以權益結算之以股份為基礎付款 (附註38)	-	-	-	-	27,696	-	-	27,696	2,966	30,662
Repurchase of shares under a share award scheme (note 38 (a))	根據股份激勵計劃回購股份 (附註38(a))	-	-	-	-	(20,536)	(32,035)	-	(52,571)	-	(52,571)
Recognition of sales of repurchased shares under a share award scheme (note 38 (a))	確認出售根據股份激勵計劃的回購股份 (附註38(a))	-	-	-	-	-	203,133	-	203,133	-	203,133
Exchange of non-monetary assets (note e)	非貨幣性資產交換 (附註e)	-	-	-	-	-	13,447	-	13,447	3,255	16,702
Acquisition of a subsidiary (note 39)	收購一間附屬公司 (附註39)	-	-	-	-	-	-	-	-	17,033	17,033
Dividends recognised as distribution (note 13)	確認為分派的股息 (附註13)	-	-	-	-	-	-	(553,349)	(553,349)	(3,200)	(556,549)
Others	其他	-	-	-	-	-	4,635	-	4,635	1,519	6,154
At 31 December 2020 (restated)	於二零二零年十二月三十一日 (經重列)	452,233	2,575,060	257,956	(93,271)	99,561	1,280,529	13,461,512	18,033,580	845,108	18,878,688
At 1 January 2021 (restated)	於二零二一年一月一日 (經重列)	452,233	2,575,060	257,956	(93,271)	99,561	1,280,529	13,461,512	18,033,580	845,108	18,878,688
Profit for the year	本年度溢利	-	-	-	-	-	-	2,244,778	2,244,778	181,850	2,426,628
Other comprehensive expense for the year	年內其他全面開支	-	-	-	(69,801)	-	-	-	(69,801)	(11,681)	(81,482)
Total comprehensive income for the year	年內全面收入總額	-	-	-	(69,801)	-	-	2,244,778	2,174,977	170,169	2,345,146
Consideration for business combination under common control in 2021 (note c)	二零二一年同一控制下的業務合併之代價 (附註c)	-	-	-	-	-	(1,202,366)	-	(1,202,366)	-	(1,202,366)
Deemed disposal of partial interest in a subsidiary (note f)	視作出售於一間附屬公司之部分權益 (附註f)	-	-	-	-	-	761,120	-	761,120	621,165	1,382,285
Adoption of share award scheme (note 38 (a) (d))	採納股份激勵計劃 (附註38(a)(d))	4,830	168,084	-	-	-	(160,539)	-	12,375	-	12,375
Recognition of equity-settled share-based payments (note 38)	確認以權益結算之以股份為基礎付款 (附註38)	-	-	-	-	72,575	-	-	72,575	3,917	76,492
Repurchase of shares under a share award scheme (note 38 (a))	根據股份激勵計劃回購股份 (附註38(a))	-	-	-	-	(20,636)	343	-	(20,293)	-	(20,293)
Recognition of sales of repurchased shares under a share award scheme (note 38 (a))	確認出售根據股份激勵計劃的回購股份 (附註38(a))	-	-	-	-	-	88,411	-	88,411	-	88,411
Dividends recognised as distribution (note 13)	確認為分派的股息 (附註13)	-	-	-	-	-	-	(653,288)	(653,288)	-	(653,288)
At 31 December 2021	於二零二一年十二月三十一日	457,063	2,743,144	257,956	(163,072)	151,500	767,498	15,053,002	19,267,091	1,640,359	20,907,450

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

綜合權益變動報表

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

Notes:

附註：

(a) The Articles of Association of the Company and its subsidiaries established in PRC (as defined in note 1) require the appropriation of 10% of profit after taxation (prepared under the generally accepted accounting principles in the PRC) each year to the statutory surplus reserve until the balance reaches 50% of the registered share capital. According to the provisions of the Articles of Association of the PRC companies, in normal circumstances, the statutory surplus reserve shall only be used for making up losses, capitalisation into capital and expansion of its production and operation. For the capitalisation of statutory surplus reserve into capital, the remaining amount of such reserve shall not be less than 25% of the registered capital.

(a) 本公司及其於中國成立之附屬公司的組織章程細則(定義見附註1)規定將其各年稅後溢利(根據中國公認會計原則編製)的10%分派至法定盈餘儲備,直至法定盈餘儲備的結餘達註冊股本的50%為止。根據中國公司的組織章程細則的條文規定,在一般情況下,法定盈餘儲備僅可用作彌補虧損、撥充股本及擴充生產及營運。將法定盈餘儲備撥充股本後,該儲備的餘額不得低於註冊股本的25%。

(b) Other reserves mainly represent the difference between the amounts by which the non-controlling interests are adjusted and the fair value of the consideration paid to acquire the additional interest in subsidiaries, and the cost of the ordinary shares held by the trustees under a share award scheme.

(b) 其他儲備主要指就收購附屬公司額外權益經調整的非控股權益的金額與所支付的代價的公平值之間的差額,及受託人根據股份激勵計劃持有普通股的成本之間的差額。

(c) During the year ended 31 December 2020, the Group had a business combination under common control. Prior to the combination, in April 2020, Weihai Weigao International Medical Investment Holding Company had an capital injection amounting to RMB24,690,000 to Shandong Weigao Pharmaceutical Packaging Co., Ltd.

(c) 截至二零二零年十二月三十一日止年度,本集團進行共同控制下的業務合併。於合併前,威海威高國際醫療投資控股有限公司於二零二零年四月向山東威高醫藥包裝製品有限公司(Shandong Weigao Pharmaceutical Packaging Co., Ltd.)注資人民幣24,690,000元。

During the year ended 31 December 2021, the Group had a business combination under common control. Details of the business combination under common control are set out in note 3.

截至二零二一年十二月三十一日止年度,本集團進行共同控制下的業務合併。有關共同控制下業務合併的詳情載於附註3。

(d) During the year ended 31 December 2020, the subsidiaries of the Company acquired 94.29% interests in Weihai Hongyangrui Information Technology Center (Limited Partnership) ("Weihai Hongyangrui") and indirectly acquired 6.14% interests in Shandong Weigao Orthopedic Device Company Limited ("Weigao Orthopaedic") with a net cash consideration of RMB209,129,000.

(d) 截至二零二零年十二月三十一日止年度,本公司附屬公司以淨現金代價人民幣209,129,000元收購威海弘陽瑞信息技術中心(有限合夥)(「威海弘陽瑞」)94.29%權益,並間接收購山東威高骨科材料股份有限公司(「威高骨科」)6.14%權益。

(e) During the year ended 31 December 2020, the subsidiary of the Company entered into agreements for sale and purchase of properties with Weigao Holding Company Limited, the controlling shareholder of the Company. The sales and purchases constituted as an equity transaction of non-monetary in nature. The difference between the carrying value of the property disposed and the total of cash consideration received and the carrying value of the property purchased were recognised in other reserves.

(e) 截至二零二零年十二月三十一日止年度,本公司附屬公司與本公司控股股東威高集團有限公司訂立物業買賣協議。該等買賣構成非貨幣性質的股權交易。所出售物業的賬面值與已收現金代價及所購買物業賬面值總額的差額於其他儲備中確認。

(f) On 30 June 2021, Weigao Orthopaedic, the subsidiary of the Company, completed its listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange and the initial public offering of the ordinary shares (the "Offering"). Weigao Orthopaedic received total net proceeds of RMB1,382,285,000 from the Offering, among which RMB761,120,000 were recognised in other reserves.

(f) 於二零二一年六月三十日,本公司的附屬公司威高骨科完成於上海證券交易所科技創新板上市及普通股初始公開發售(「發售」)。威高骨科自發售收取總所得款項淨額人民幣1,382,285,000元,其中人民幣761,120,000元於其他儲備確認。

CONSOLIDATED STATEMENT OF CASH FLOWS

綜合現金流量報表

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

	Year ended 31/12/2021 RMB'000	Year ended 31/12/2020 RMB'000 (restated)
	截至 二零二一年 十二月 三十一日 止年度 人民幣千元	截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)
OPERATING ACTIVITIES		
Profit before tax	2,841,721	2,565,459
Adjustments for:		
Interest income	(72,171)	(65,955)
Finance costs	140,396	178,935
Depreciation of property, plant and equipment	446,172	424,746
Depreciation of right-of-use assets	31,092	20,690
Depreciation of investment properties	5,216	6,276
Allowances for credit losses	26,982	35,244
Allowances for property, plant and equipment	-	2,571
Allowances for intangible assets	-	4,295
Allowances for inventories	6,956	10,452
Amortisation of intangible assets	241,333	257,249
Share-based payment expenses	76,492	30,662
Share of results of an associate	(69,988)	(9,171)
Share of results of joint ventures	531	-
Gain on deemed disposal of investment in an associate	-	(3,325)
Gain on disposal of financial assets at fair value through profit or loss	-	(29,809)
Gain from early repayment of an interest-free loan from an associate of the Company	-	(16,856)
Gain on release of escrow account	-	(98,542)
Loss/(gain) on disposal of property, plant and equipment	2,937	(1,677)
Loss on currency option	6,289	-
Release of deferred income	(18,539)	(7,680)
(Gain)/loss from changes in fair value of financial assets at fair value through profit or loss	(3,323)	84,364
Exchange loss	52,549	39,977
	3,714,645	3,427,905
Movements in working capital		
Increase in inventories	(178,270)	(261,501)
Increase in trade and other receivables	(59,907)	(1,007,316)
Decrease in finance lease receivables	93,526	87,822
(Increase)/decrease in loan receivables	(308,967)	187,513
Decrease/(increase) in debt instruments at fair value through other comprehensive income	49,858	(42,251)
Increase in other non-current assets	(296,995)	-
(Decrease)/increase in trade and other payables	(63,394)	580,493
(Decrease)/increase in contract liabilities	(993)	169,823
Increase in deferred income	33,361	34,175
Increase in provisions	526,847	-

CONSOLIDATED STATEMENT OF CASH FLOWS

綜合現金流量報表

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

		Year ended 31/12/2021 RMB'000	Year ended 31/12/2020 RMB'000 (restated)
		截至 二零二一年 十二月 三十一日 止年度 人民幣千元	截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)
Cash generated from operations	經營所得現金	3,509,711	3,176,663
Income taxes paid	已付所得稅	(474,548)	(388,263)
NET CASH FROM OPERATING ACTIVITIES	經營業務所得現金淨額	3,035,163	2,788,400
INVESTING ACTIVITIES	投資業務		
Purchases of property, plant and equipment	購買物業、廠房及設備	(602,953)	(606,692)
Purchases of intangible assets	購買無形資產	(46,198)	(60,027)
Purchases of right-of-use assets	購買使用權資產	-	(39,714)
Payment of investment properties	投資物業款項	-	(8,719)
Deposits paid for acquiring property, plant and equipment	就收購物業、廠房及設備支付的按金	(467,731)	(300,903)
Net cash (outflow)/inflow on acquisition of a subsidiary (note 39)	收購一間附屬公司的現金(流出) / 流入淨額(附註39)	(10,287)	465
Proceeds from disposal of property, plant and equipment	出售物業、廠房及設備所得款項	38,390	48,904
Interest received	已收利息	61,454	53,253
Withdrawal of pledged bank deposits	提取已抵押銀行存款	680,080	682,550
Placement of pledged bank deposits	存入已抵押銀行存款	(1,100,846)	(700,756)
Disposal of financial assets at fair value through profit or loss	出售按公平值計入損益之金融資產	(38,275)	750
Purchase of financial assets at fair value through profit or loss	購買按公平值計入損益之金融資產	3,800	-
Investment in joint ventures	於合營企業的投資	-	(181,927)
Origination of loan receivables	發放應收貸款	-	(46,727)
Repayment of loan receivables	償還應收貸款	3,192	1,543,126
NET CASH (USED IN) FROM INVESTING ACTIVITIES	投資業務(所用)所得現金淨額	(1,479,374)	383,583

CONSOLIDATED STATEMENT OF CASH FLOWS

綜合現金流量報表

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

		Year ended 31/12/2021 RMB'000 截至 二零二一年 十二月 三十一日 止年度 人民幣千元	Year ended 31/12/2020 RMB'000 (restated) 截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)
FINANCING ACTIVITIES	融資業務		
Repayments of borrowings	償還借款	(706,641)	(2,447,007)
Repayments of lease liabilities	償還租賃負債	(25,837)	(13,249)
Proceeds received from issued bonds	自己發行債券收到的 所得款項	-	990,000
New borrowings raised	新增加之借款	519,009	559,784
Interest paid	已付利息	(127,069)	(181,892)
Dividends paid	已付股息	(653,288)	(701,349)
Capital injection by non-controlling shareholders	非控股股東注資	1,382,285	24,690
Proceeds from adoption of share award scheme	採納股份激勵計劃所得款項	172,914	49,500
Acquired interest in subsidiary from non-controlling shareholder	自非控股股東收購的 附屬公司權益	-	(209,129)
Release of escrow account	解除託管賬戶	-	72,486
Repurchase of shares under a share award scheme	根據股份激勵計劃回購股份	(72,864)	-
Sales of repurchase of shares under a share award scheme	出售根據股份激勵計劃的 回購股份	88,411	209,263
Repayments of loans raised from a holding company	償還自控股公司籌集之貸款	-	(146,938)
Net cash flow on business combination under common control (note 3)	共同控制下的業務合併之 現金流量淨額 (附註3)	(1,115,000)	-
NET CASH USED IN FINANCING ACTIVITIES	融資業務所用之現金淨額	(538,080)	(1,793,841)
NET INCREASE IN CASH AND CASH EQUIVALENTS	現金及現金等價物增加淨額	1,017,709	1,378,142
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	於年初的現金及現金等價物	5,665,656	4,344,469
Effect of foreign exchange rate changes	外匯匯率變動的影響	(54,438)	(56,955)
CASH AND CASH EQUIVALENTS AT END OF YEAR, represented by bank balances and cash	於年末的現金及現金等價物， 指銀行結餘及現金	6,628,927	5,665,656

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

1. GENERAL INFORMATION

Shandong Weigao Group Medical Polymer Company Limited (the “Company”) was established and registered as a joint stock company with limited liability in the People’s Republic of China (the “PRC”) under the Company Law of the PRC on 28 December 2000 and its shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”). Its immediate holding company is Weigao Holding Company Limited (“Weigao Holding”), a company registered in the PRC with limited liability. Its ultimate controlling party is Chen Xue Li. The address of the registered office and principal place of business of the Company is No. 18, Xing Shan Road, Weihai, Shandong Province, PRC.

The Company and its subsidiaries (hereinafter collectively referred to as the “Group”) are principally engaged in the research and development, production and sale of medical device products, orthopaedic products, interventional products, pharma packaging products and blood management products, and operate financing business.

The consolidated financial statements are presented in Renminbi (“RMB”), which is the functional currency of the Company.

1. 一般資料

山東威高集團醫用高分子製品股份有限公司(「本公司»)於二零零零年十二月二十八日根據中華人民共和國(「中國»)公司法在中國成立及註冊為股份有限公司，及其股份於香港聯合交易所有限公司(「聯交所»)主板上市。本公司直接控股公司為威高集團有限公司(「威高集團公司»),其為於中國註冊的有限責任公司。其最終控股方為陳學利。本公司之註冊辦事處及主要營業地點為中國山東省威海興山路18號。

本公司及其附屬公司(以下統稱「本集團»)主要從事研究及開發、生產及銷售醫療器械產品、骨科產品、介入產品、藥品包裝產品及血液管理產品，及經營融資業務。

綜合財務報表以本公司的功能貨幣人民幣(「人民幣»)呈列。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

2. APPLICATION OF AMENDMENTS TO HONG KONG FINANCIAL REPORTING STANDARDS (“HKFRSs”)

Amendments to HKFRSs that are mandatorily effective for the current year

In the current year, the Group has applied the following amendments to HKFRSs issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”) for the first time, which are mandatorily effective for the annual period beginning on or after 1 January 2021 for the preparation of the consolidated financial statements:

Amendments to HKFRS16	<i>Covid-19-Related Rent Concessions</i>
Amendments to HKFRS 9, HKAS 39, HKFRS 7, HKFRS 4 and HKFRS 16	<i>Interest Rate Benchmark Reform – Phase 2</i>

In addition, the Group applied the agenda decision of the IFRS Interpretations Committee (the “Committee”) of the International Accounting Standards Board issued in June 2021 which clarified the costs an entity should include as “estimated costs necessary to make the sale” when determining the net realisable value of inventories.

The application of the amendments to HKFRSs in the current year has had no material impact on the Group’s financial positions and performance for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

2. 應用香港財務報告準則（「香港財務報告準則」）修訂本

於本年度強制生效的香港財務報告準則修訂本

於本年度，本集團已首次應用香港會計師公會（「香港會計師公會」）頒佈的下列香港財務報告準則修訂本，有關準則於二零二一年一月一日或之後開始的年度期間強制生效，以編製綜合財務報表：

香港財務報告準則第16號（修訂本）	與Covid-19相關的租金優惠
香港財務報告準則第9號、香港會計準則第39號、香港財務報告準則第7號、香港財務報告準則第4號及香港財務報告準則第16號（修訂本）	利率基準改革-第二階段

此外，本集團應用國際會計準則理事會於二零二一年六月頒佈的國際財務報告準則詮釋委員會（「委員會」）的議程決定，該決定澄清實體釐定存貨可變現淨值時須列作「進行銷售所需之估計成本」的成本。

本年度內應用香港財務報告準則修訂本對本集團於本年度及過往年度的財務狀況及表現及／或該等綜合財務報表所載的披露並無造成重大影響。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

2. APPLICATION OF AMENDMENTS TO HONG KONG FINANCIAL REPORTING STANDARDS (“HKFRSs”) (continued)

New and amendments to HKFRSs in issue but not yet effective

The Group has not early applied the following new and amendments to HKFRSs that have been issued but are not yet effective:

HKFRS 17	Insurance Contracts and the related Amendments ³
Amendments to HKFRS 3	Reference to the Conceptual Framework ²
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture ⁴
Amendments to HKFRS 16	Covid-19-Related Rent Concessions beyond 30 June 2021 ¹
Amendments to HKAS 1	Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 (2020) ³
Amendments to HKAS 1 and HKFRS Practice Statement 2	Disclosure of Accounting Policies ³
Amendments to HKAS 8	Definition of Accounting Estimates ³
Amendments to HKAS 12	Deferred Tax related to Assets and Liabilities arising from a Single Transaction ³
Amendments to HKAS 16	Property, Plant and Equipment – Proceeds before Intended Use ²
Amendments to HKAS 37	Onerous Contracts – Cost of Fulfilling a Contract ²
Amendments to HKFRSs	Annual Improvements to HKFRSs 2018-2020 ²

2. 應用香港財務報告準則（「香港財務報告準則」）修訂本（續）

已頒佈但尚未生效的新訂香港財務報告準則及修訂本

本集團尚未提早應用下列已頒佈但尚未生效的新訂香港財務報告準則及修訂本：

香港財務報告準則第17號	保險合約及相關修訂本 ³
香港財務報告準則第3號（修訂本）	提述概念框架 ²
香港財務報告準則第10號及香港會計準則第28號（修訂本）	投資者與其聯營公司或合營企業之資產出售或投入 ⁴
香港財務報告準則第16號（修訂本）	二零二一年六月三十日後與Covid-19相關的租金優惠 ¹
香港會計準則第1號（修訂本）	負債分類為流動或非流動及相關香港詮釋第5號的修訂本（二零二零年） ³
香港會計準則第1號及香港財務報告準則實務報告第2號（修訂本）	會計政策披露 ³
香港會計準則第8號（修訂本）	會計估計之定義 ³
香港會計準則第12號（修訂本）	與單一交易產生之資產及負債相關之遞延稅項 ³
香港會計準則第16號（修訂本）	物業、廠房及設備—擬定用途前的所得款項 ²
香港會計準則第37號（修訂本）	有償合約—履行合約的成本 ²
香港財務報告準則（修訂本）	香港財務報告準則之年度改進（二零一八年至二零二零年） ²

2. APPLICATION OF AMENDMENTS TO HONG KONG FINANCIAL REPORTING STANDARDS (“HKFRSs”) (continued)

New and amendments to HKFRSs in issue but not yet effective (continued)

- 1 Effective for annual periods beginning on or after 1 April 2021.
- 2 Effective for annual periods beginning on or after 1 January 2022.
- 3 Effective for annual periods beginning on or after 1 January 2023.
- 4 Effective for annual periods beginning on or after a date to be determined.

Except for the new and amendments to HKFRSs mentioned below, the directors of the Company anticipate that the application of all other new and amendments to HKFRSs will have no material impact on the consolidated financial statements in the foreseeable future.

Amendments to HKAS 1 Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 (2021)

The amendments provide clarification and additional guidance on the assessment of right to defer settlement for at least twelve months from reporting date for classification of liabilities as current or non-current, which:

- specify that the classification of liabilities as current or non-current should be based on rights that are in existence at the end of the reporting period. Specifically, the amendments clarify that:
 - (i) the classification should not be affected by management intentions or expectations to settle the liability within 12 months; and
 - (ii) if the right is conditional on the compliance with covenants, the right exists if the conditions are met at the end of the reporting period, even if the lender does not test compliance until a later date; and

2. 應用香港財務報告準則（「香港財務報告準則」）修訂本（續）

已頒佈但尚未生效的新訂香港財務報告準則及修訂本（續）

- 1 於二零二一年四月一日或之後開始的年度期間生效。
- 2 於二零二二年一月一日或之後開始的年度期間生效。
- 3 於二零二三年一月一日或之後開始的年度期間生效。
- 4 於待釐定日期或之後開始的年度期間生效。

除下文所述的新訂香港財務報告準則及修訂本外，本公司董事預期應用所有其他新訂香港財務報告準則及修訂本，於可預見未來將不會對綜合財務報表構成重大影響。

香港會計準則第1號（修訂本）負債分類為流動或非流動及相關香港詮釋第5號的修訂（二零二一年）

該等修訂就評估自報告日期起至少十二個月之延遲結算權利提供澄清及額外指引，以將負債分類為流動或非流動，當中：

- 訂明負債應根據報告期末存有的權利分類為流動或非流動。該等修訂特別澄清：
 - (i) 該分類不受管理層在十二個月內結清負債之意圖或預期所影響；及
 - (ii) 倘若該權利以遵守契諾為條件，則即使貸款人在較後日期才測試是否符合條件，該權利在報告期末符合條件之情況下仍然存在；及

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

2. APPLICATION OF AMENDMENTS TO HONG KONG FINANCIAL REPORTING STANDARDS (“HKFRSs”) (continued)

Amendments to HKAS 1 Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 (2021) (continued)

- clarify that if a liability has terms that could, at the option of the counterparty, result in its settlement by the transfer of the entity's own equity instruments, these terms do not affect its classification as current or non-current only if the entity recognises the option separately as an equity instrument applying HKAS 32 Financial Instruments: Presentation.

In addition, Hong Kong Interpretation 5 was revised as a consequence of the Amendments to HKAS 1 to align the corresponding wordings with no change in conclusion.

As at 31 December 2021, the Group's right to defer settlement for borrowings and bonds payable of RMB1,978,178,000 are subject to compliance with certain financial ratios within 12 months from the reporting date. Such borrowings were classified as non-current as the Group met such ratios at 31 December 2021. Pending clarification on the application of relevant requirements of the amendments, the Group will further assess the potential impacts of the amendments in relation to the borrowings with financial and other covenants. The impacts on application, if any, will be disclosed in the Group's future consolidated financial statements.

Except for as disclosed above, the application of the amendments will not result in reclassification of the Group's other liabilities as at 31 December 2021.

2. 應用香港財務報告準則（「香港財務報告準則」）修訂本（續）

香港會計準則第1號（修訂本）負債分類為流動或非流動及相關香港詮釋第5號的修訂（二零二一年）（續）

- 澄清倘負債具有可由對手選擇透過轉讓實體本身的權益工具進行結清之條款，則僅當實體採用香港會計準則第32號「金融工具：呈列」將選擇權單獨確認為權益工具時，該等條款方不會影響其分類為流動或非流動。

此外，香港詮釋第5號因香港會計準則第1號之修訂而予以修改，以使相應措辭一致，但結論不變。

於二零二一年十二月三十一日，本集團遞延結算借款及應付債券人民幣1,978,178,000元的權利受限於遵守自報告日期起計十二個月內的若干財務比率。由於本集團於二零二一年十二月三十一日達到該比率，該等借款分類為非流動。待澄清相關規定修訂的應用後，本集團將進一步評估有關借款之修訂對財務或其他契諾的潛在影響。應用的影響（如有）將於本集團日後的綜合財務報表披露。

除上文所述者外，於二零二一年十二月三十一日應用修訂將不會導致本集團重新分類其他負債

3. MERGER ACCOUNTING AND RESTATEMENTS

The Group accounts for all its business combinations involving entities under common control using the principles of merger accounting.

During the year ended 31 December 2021, Shandong Weigao Blood Technology, the subsidiary of the Company acquired 100% interests in Wego Healthcare Fund Holding Corporation (“Wego Healthcare”) from Weigao Holding with a total net cash consideration of RMB1,202,366,000 (the “Post – Acquisition”). The Company acquired control over Wego Healthcare on 3 March 2021.

Wego Healthcare was incorporated in the United States on 15 November 2016, and it is an investment holding company. The principal assets of Wego Healthcare are (i) 100% interest in Rad Source Technologies, Inc (“Rad Source”); and (ii) 19.8% interest in Weihai Shangyuan Phase 1 Venture Capital Partnership (Limited Partnership) (“Weihai Shangyuan Fund”).

Rad Source is engaged in production of proprietary X-ray based irradiation machines that are used for blood irradiation, cannabis industry, small animal research and other research applications.

3. 合併會計與重列

本集團對其所有涉及共同控制下實體之業務合併，均採用合併會計法原則入賬。

截至二零二一年十二月三十一日止年度，本公司附屬公司山東威高血液技術向威高集團公司收購於Wego Healthcare Fund Holding Corporation (「Wego Healthcare」) 的全部權益，總現金代價淨額為人民幣1,202,366,000元 (「收購後事項」)。本公司於二零二一年三月三日獲得Wego Healthcare的控制權。

Wego Healthcare於二零一六年十一月十五日於美國註冊成立並為一家投資控股公司。Wego Healthcare的主要資產為(i)Rad Source Technologies, Inc (「Rad Source」) 之全部權益；及(ii)威海尚元壹期創業投資合夥企業 (有限合夥) (「威海尚元基金」) 之19.8%權益。

Rad Source從事生產用於血液輻射、大麻行業、小型動物研究及其他研究設備的X射線輻照儀專利產品。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

3. MERGER ACCOUNTING AND RESTATEMENTS (continued)

Through step acquisition, Weigao Holding obtained 100% interests in Wego Healthcare on 24 December 2018 with a cash consideration of RMB423,000,000 ("Acquisition"). Since 24 December 2018, thereby the Group and Wego Healthcare came under common control of Weigao Holding. Since Wego Healthcare and the Group are under common control by Weigao Holding before and after the Post – Acquisition, the Group has applied the principles of merger accounting with reference to Accounting Guideline 5 Merger Accounting for Common Control Combinations to the Acquisition issued by the HKICPA as if the common control combination had been effected since 24 December 2018.

The consolidated statement of financial position of the Group as at 31 December 2020 have been restated to include the assets and liabilities of Wego Healthcare as if they were within the Group since 24 December 2018. The consolidated statement of profit or loss and other comprehensive income and the consolidated statement of cash flows for the year ended 31 December 2020 have also been restated to include the results and the cash flows of Wego Healthcare since Wego Healthcare and the Group were under common control by Weigao Holding from 24 December 2018.

The effects of the application of merger accounting on the consolidated statement of profit or loss and other comprehensive income for the year ended 31 December 2020 are as follows. Line items that were not affected by the changes have not been included.

3. 合併會計與重列 (續)

通過階段收購，威高集團公司於二零一八年十二月二十四日以現金代價人民幣423,000,000元獲得Wego Healthcare的全部權益（「收購事項」）。因此，自二零一八年十二月二十四日起，本集團及Wego Healthcare由威高集團公司共同控制。由於於收購後事項前後Wego Healthcare及本集團由威高集團公司共同控制，本集團已就收購事項應用合併會計準則並參考香港會計師公會頒佈的會計指引第5號共同控制下業務合併的合併會計處理，猶如共同制下的業務合併已自二零一八年十二月二十四日起生效。

本集團於二零二零年十二月三十一日的綜合財務狀況表已重列，以包括Wego Healthcare的資產及負債，猶如該等資產及負債自二零一八年十二月二十四日起已在本集團內。由於Wego Healthcare及本集團自二零一八年十二月二十四日起已由威高集團公司共同控制，故截至二零二零年十二月三十一日止年度的綜合損益及其他全面收入報表及綜合現金流量報表亦已重列，以包括自Wego Healthcare的業績及現金流量。

採用合併會計法對截至二零二零年十二月三十一日止年度之綜合損益及其他全面收入報表之影響如下。未受變動影響的項目並未列入。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

3. MERGER ACCOUNTING AND RESTATEMENTS (continued)

3. 合併會計與重列 (續)

		The year ended 31 December 2020 as previously reported RMB'000 截至 二零二零年 十二月三十一 止年度 (如先前呈報) 人民幣千元	Adjustments RMB'000 調整 人民幣千元	The year ended 31 December 2020 as restated RMB'000 截至 二零二零年 十二月三十一 止年度 (經重列) 人民幣千元
Revenue	收入	11,345,252	277,085	11,622,337
Cost of sales (note)	銷售成本 (附註)	(5,011,774)	(110,992)	(5,122,766)
Gross profit	毛利	6,333,478	166,093	6,499,571
Other income, gains and losses	其他收入、收益及虧損	312,480	958	313,438
Selling and distribution expense	銷售及分銷開支	(2,511,894)	(17,262)	(2,529,156)
Administrative expenses	行政開支	(1,021,623)	(67,341)	(1,088,964)
Research and development expenses	研發開支	(411,404)	(13,018)	(424,422)
Profit before tax	除稅前溢利	2,496,029	69,430	2,565,459
Income tax expense	所得稅開支	(345,638)	(12,784)	(358,422)
Profit for the year	年內溢利	2,150,391	56,646	2,207,037
Exchange differences arising on translation	換算產生之匯兌差額	(231,998)	(32,845)	(264,843)
Total comprehensive income for the year	年內全面收入總額	1,918,393	23,801	1,942,194
Profit for the year attributable to:	年內溢利下列各項應佔：			
Owners of the Company	本公司擁有人	2,030,137	56,646	2,086,783
Non-controlling interests	非控股權益	120,254	-	120,254
		2,150,391	56,646	2,207,037
Total comprehensive income for the year attributable to:	年內全面收入總額下列各項應佔：			
Owners of the Company	本公司擁有人	1,818,336	23,801	1,842,137
Non-controlling interests	非控股權益	100,057	-	100,057
		1,918,393	23,801	1,942,194

note: The comparative figures of distribution expenses have been reclassified to cost of sales to conform with the current year's presentation of the consolidated financial statements.

附註：分銷開支之可資比較數據已重新分類至銷售成本以符合本年度綜合財務報表之呈列方式。

The basic and diluted earnings per share during the year ended 31 December 2020 changed from RMB0.45 per share to RMB0.46 per share due to the application of merger accounting.

由於採用合併會計法，截至二零二零年十二月三十一日止年度的每股基本及攤薄盈利自每股人民幣0.45元變為每股人民幣0.46元。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

3. MERGER ACCOUNTING AND RESTATEMENTS (continued)

The effects of the application of merger accounting on the consolidated statement of financial position as at 31 December 2020 are summarised below. Line items that were not affected by the changes have not been included.

3. 合併會計與重列 (續)

採用合併會計法對於二零二零年十二月三十一日之綜合財務狀況表之影響概列如下。未受變動影響的項目並未列入。

		As at 31 December 2020 as previously reported RMB'000 於二零二零年 十二月三十一日 (如先前呈報) 人民幣千元	Adjustments RMB'000 調整 人民幣千元	As at 31 December 2020 as restated RMB'000 於二零二零年 十二月三十一日 (經重列) 人民幣千元
Non-current assets	非流動資產			
Property, plant and equipment	物業、廠房及設備	5,333,298	29,367	5,362,665
Goodwill	商譽	3,195,785	218,425	3,414,210
Intangible assets	無形資產	1,959,616	95,844	2,055,460
Interests in a joint venture	於一間合營企業的權益	154,000	27,927	181,927
Finance lease receivables	應收融資租賃款項	84,969	191	85,160
Total Non-current assets	非流動資產總額	13,219,454	371,754	13,591,208
Current assets	流動資產			
Inventories	存貨	1,504,126	58,727	1,562,853
Trade and other receivables	應收貿易賬款及其他應收款項	5,927,876	30,603	5,958,479
Finance lease receivables	應收融資租賃款項	136,270	638	136,908
Bank balances and cash	銀行結餘及現金	5,514,331	151,325	5,665,656
Total Current assets	流動資產總額	14,125,215	241,293	14,366,508
Current liabilities	流動負債			
Trade and other payables	應付貿易賬款及其他應付款項	3,759,169	53,285	3,812,454
Contract liabilities	合約負債	279,140	34,233	313,373
Tax payable	應付稅項	125,742	3,412	129,154
Provisions	撥備	-	7,699	7,699
Total Current liabilities	流動負債總額	4,499,416	98,629	4,598,045
Net Current Assets	流動資產淨額	9,625,799	142,664	9,768,463
Total Assets less Current Liabilities	總資產減流動負債	22,845,253	514,418	23,359,671
Capital and reserves	資本及儲備			
Reserve	儲備	17,093,113	488,234	17,581,347
Equity attributable to owners of the Company	本公司擁有人應佔權益	17,545,346	488,234	18,033,580
Non-controlling interests	非控股權益	845,108	-	845,108
Total Equity	權益總額	18,390,454	488,234	18,878,688
Non-Current liabilities	非流動負債			
Deferred tax liabilities	遞延稅項負債	267,404	24,393	291,797
Contract liabilities	合約負債	-	1,791	1,791
Total Non-Current liabilities	非流動負債總額	4,454,799	26,184	4,480,983

3. MERGER ACCOUNTING AND RESTATEMENTS (continued)

During the year ended 31 December 2020, the Group's subsidiary Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd ("Weigao Purui") acquired 100% interests in Shandong Weigao Pharmaceutical Packaging Co., Ltd. ("Weigao Packaging") from Weigao International. Weigao International agreed to make a total capital contribution in the amount of RMB66,110,000 to Weigao Purui, and upon the completion of such capital contribution, Weigao International has in turn held 4.1% interests of Weigao Purui. The capital contribution was settled by a transfer of the entire equity capital of the Weigao Packaging to Weigao Purui. The acquisition was completed on 20 November 2020.

Weigao Packaging is engaged in the production and sale of pharmaceutical packaging materials including multi-layer co-extrusion cast film, three-layer co-extrusion film for infusion, and composite film for blister packaging.

Weigao Packaging which was established by Weigao International on 18 March 2011, and thereby the Group and Weigao Packaging came under common control of Weigao International. Since Weigao Packaging and the Group has been under common control by Weigao International before and after the acquisition, the Group has applied the principles of merger accounting with reference to Accounting Guideline 5 Merger Accounting for Common Control Combinations to the Acquisition issued by the HKICPA as if the common control combination had been effected since the establishment of Weigao Packaging.

3. 合併會計與重列 (續)

於截至二零二零年十二月三十一日止年度，本集團附屬公司山東威高普瑞醫藥包裝有限公司（「威高普瑞」）向威高國際收購山東威高醫藥包裝製品有限公司（「威高包裝」）100%股權。威高國際同意向威高普瑞合計注資人民幣66,110,000元，而於該注資完成後，威高國際持有威高普瑞4.1%的權益。出資額以轉讓威高包裝全部股權予威高普瑞的方式結算。收購於二零二零年十一月二十日完成。

威高包裝從事生產及銷售藥品包裝材料，包括多層共擠鑄膜、三層共擠輸液用膜，以及吸塑用複合膜。

威高包裝由威高國際於二零一一年三月十八日成立，因此本集團及威高包裝由威高國際共同控制。由於威高包裝及本集團於收購事項前後均已由威高國際共同控制，故本集團參考香港會計師公會發佈的會計指引第5號共同控制合併下的合併會計處理對收購事項採用合併會計原則，猶如共同控制合併自威高包裝成立起已進行。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES

4.1 Basis of preparation of consolidated financial statements

The consolidated financial statements have been prepared in accordance with HKFRSs issued by the HKICPA. For the purpose of preparation of the consolidated financial statements, information is considered material if such information is reasonably expected to influence decisions made by primary users. In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“Listing Rules”) and by the Hong Kong Companies Ordinance.

The consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies set out below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

4. 編製綜合財務報表基準及主要會計政策

4.1 編製綜合財務報表基準

綜合財務報表乃按照香港會計師公會頒佈之香港財務報告準則編製。就編製綜合財務報表之目的而言，當可合理預期該等資料會影響主要使用者之決策，該等資料則被視為屬重大。此外，綜合財務報表載有香港聯合交易所有限公司證券上市規則（「上市規則」）及香港公司條例規定的適用披露。

除於各報告期末若干金融工具按公平值計量外，綜合財務報表乃以歷史成本為基礎編製，如下文載列之會計政策所述。

歷史成本一般以換取貨品及服務所作出代價之公平值為基準。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.1 Basis of preparation of consolidated financial statements (continued)

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Group takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in these consolidated financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of HKFRS 2 Share-based Payment, leasing transactions that are accounted for in accordance with HKFRS 16 Lease, and measurements that have some similarities to fair value but are not fair value, such as net realisable value in HKAS 2 Inventories or value in use in HKAS 36 Impairment of Assets.

For financial instruments which are transacted at fair value and a valuation technique that unobservable inputs is to be used to measure fair value in subsequent periods, the valuation technique is calibrated so that at initial recognition the results of the valuation technique equals the transaction price.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.1 編製綜合財務報表基準 (續)

公平值指市場參與者之間於計量日期進行的有序交易中出售一項資產所收取的價格或轉移一項負債所支付的價格，無論該價格為直接觀察得出或採用其他估值技術作出的估計。在對資產或負債的公平值作出估計時，本集團考慮了市場參與者於計量日期為該資產或負債進行定價時將會考慮的該等特徵。在該等綜合財務報表中計量及／或披露的公平值均按此基礎予以確定，惟香港財務報告準則第2號以股份為基準付款範圍內的以股份為基礎付款交易、根據香港財務報告準則第16號租賃入賬的租賃交易、以及與公平值類似但並非公平值的計量（例如，香港會計準則第2號存貨中的可變現淨值或香港會計準則第36號資產減值中的使用價值）除外。

就於隨後期間按公平值及將使用不可觀察輸入數據計量公平值的估值技術交易的金融工具而言，估值技術會予以校準，以便在首次確認時使估值技術結果與交易價相等。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.1 Basis of preparation of consolidated financial statements (continued)

In addition, for financial reporting purposes, fair value measurements are categorised into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

4.2 Significant accounting policies

Basis of consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company:

- has power over the investee;
- is exposed, or has rights, to variable returns from its involvement with the investee; and
- has the ability to use its power to affect its returns.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.1 編製綜合財務報表基準 (續)

此外，就財務報告而言，公平值計量根據公平值計量的輸入數據可觀察程度及公平值計量的輸入數據對其整體的重要性分類為第一級、第二級或第三級，概述如下：

- 第一級輸入數據指該實體於計量日期可以取得的相同資產或負債於活躍市場的報價（未經調整）；
- 第二級輸入數據指就資產或負債直接或間接地可觀察的輸入數據（第一級內包括的報價除外）；及
- 第三級輸入數據指資產或負債的不可觀察輸入數據。

4.2 主要會計政策

綜合基準

綜合財務報表包含本公司以及本公司及其附屬公司所控制的實體的財務報表。當本公司符合以下情況，即取得控制權：

- 有權控制被投資方；
- 因其參與被投資方業務而獲得或有權獲得可變回報；及
- 有能力以其權力影響其回報。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Basis of consolidation (continued)

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Group gains control until the date when the Group ceases to control the subsidiary.

Profit or loss and each item of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies.

All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

Non-controlling interests in subsidiaries are presented separately from the Group's equity therein, which represent present ownership interests entitling their holders to a proportionate share of net assets of the relevant subsidiaries upon liquidation.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

綜合基準 (續)

倘有事實及情況顯示上述三項控制權要素有一項或多項出現變動，則本集團會重新評估其是否控制被投資方。

附屬公司於本集團取得附屬公司的控制權時開始綜合入賬，並於本集團喪失對附屬公司的控制權時終止。特別是，年內收購或出售附屬公司的收入及開支自本集團取得控制權當日起直至本集團不再控制附屬公司之日止於綜合損益及其他全面收益表列賬。

損益及各其他全面收入項目歸屬於本公司擁有人及非控股權益。附屬公司的全面收入總額會歸屬於本公司擁有人及非控股權益，即使其將導致非控股權益為赤字結餘。

本集團於必要時會對附屬公司的財務報表作出調整，以使附屬公司的會計政策與本集團的會計政策相符一致。

與本集團成員公司間交易有關的所有集團內資產及負債、權益、收入、開支及現金流量均於綜合賬目時悉數對銷。

於附屬公司之非控股權益與本集團於當中的權益分開呈列，指現時擁有之權益且賦予持有人權利於清盤時按比例分佔相關附屬公司淨資產。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Basis of consolidation (continued)

Changes in the Group's interests in existing subsidiaries

Changes in the Group's interests in subsidiaries that do not result in the Group losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Group's relevant components of equity and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries, including re-attribution of relevant reserves between the Group and the non-controlling interests according to the Group's and the non-controlling interests' proportionate interests.

Any difference between the amount by which the non-controlling interests are adjusted, and the fair value of the consideration paid or received is recognised directly in equity and attributed to owners of the Company.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

綜合基準 (續)

本集團於現有附屬公司的擁有權益的變動

並無導致本集團失去附屬公司控制權的本集團於附屬公司的擁有權益變動，乃按權益交易入賬。本集團相關權益部分(包括儲備)及非控股權益的賬面金額，乃予以調整以反映彼等於附屬公司相關權益的變動，包括按照本集團與非控股權益之權益比例，將本集團與非控股權益之間相關儲備重新歸屬。

重新分配相關權益部分後非控股權益數額的調整額與已付或已收代價公平值之間的任何差額，乃於權益直接確認，並歸本公司擁有人。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Basis of consolidation (continued)

Changes in the Group's interests in existing subsidiaries (continued)

When the Group loses control of a subsidiary, the assets and liabilities of that subsidiary and non-controlling interest (if any) are derecognised. A gain or loss is recognised in profit or loss and is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the carrying amount of the assets (including goodwill), and liabilities of the subsidiary attributable to the owners of the Company. All amounts previously recognised in other comprehensive income in relation to that subsidiary are accounted for as if the Group had directly disposed of the related assets or liabilities of the subsidiary (i.e. reclassified that to profit or loss or transferred to another category of equity as specified/permitted by applicable HKFRSs). The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under HKFRS 9 Financial Instruments or, when applicable, the cost on initial recognition of an investment in an associate or a joint venture.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

綜合基準 (續)

本集團於現有附屬公司的擁有權益的變動 (續)

當本集團失去一間附屬公司之控制權時，盈虧於損益內確認，並按：(i)已收代價公平值及任何保留權益公平值總額與(ii)本公司擁有人應佔之附屬公司資產(包括商譽)及負債以及任何非控股權益之先前賬面值之差額計算。所有先前於其他全面收益確認之有關該附屬公司之款項，將按猶如本集團已直接出售該附屬公司之相關資產或負債入賬(適用香港財務報告準則之規定／許可條文重新分類至損益或轉撥至另一類權益)。於失去控制權當日在前附屬公司保留之任何投資之公平值根據香港財務報告準則第9號金融工具，在其後入賬時被列作初步確認之公平值，或(如適用)初步確認於聯營公司或共同控制實體之投資之成本。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Business combinations or asset acquisitions

Optional concentration test

The Group can elect to apply an optional concentration test, on a transaction-by-transaction basis, that permits a simplified assessment of whether an acquired set of activities and assets is not a business. The concentration test is met if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. The gross assets under assessment exclude cash and cash equivalents, deferred tax assets, and goodwill resulting from the effects of deferred tax liabilities. If the concentration test is met, the set of activities and assets is determined not to be a business and no further assessment is needed.

Asset acquisitions

When the Group acquires a group of assets and liabilities that do not constitute a business, the Group identifies and recognises the individual identifiable assets acquired and liabilities assumed by allocating the purchase price first to financial assets/financial liabilities at the respective fair values, the remaining balance of the purchase price is then allocated to the other identifiable assets and liabilities on the basis of their relative fair values at the date of purchase. Such a transaction does not give rise to goodwill or bargain purchase gain.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

業務合併或資產收購

可選集中度測試

本集團可選擇以逐項交易基準應用可選集中度測試，可對所收購之一組活動及資產是否並非一項業務作簡化評估。倘所收購總資產的公允值幾乎全部都集中在單一可識別資產或一組類似可識別資產中，則符合集中度測試。評估之總資產不包括現金及現金等價物、遞延稅項資產、及由遞延稅項負債影響產生之商譽。倘符合集中度測試，該組活動及資產被釐定為並非業務及毋須作進一步評估。

資產收購

倘本集團收購一組不構成一項業務之資產及負債，本集團通過將購買價首先按彼等各自的公平值分配至金融資產/金融負債，識別及確認個別可識別的已收購資產及承擔的負債，購買價的剩餘結餘屆時按購買日期彼等相關公平值分配至其他可識別資產及負債。該交易不會產生商譽或溢價購買收益。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Business combinations or asset acquisitions (continued)

Business combinations

Acquisitions of businesses, other than business combination under common control, are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity interests issued by the Group in exchange for control of the acquiree. Acquisition-related costs are generally recognised in profit or loss as incurred.

Except for certain recognition exemptions, the identifiable assets acquired and liabilities assumed must meet the definitions of an asset and a liability in the Framework for the Preparation and Presentation of Financial Statements (replaced by the Conceptual Framework for Financial Reporting issued in October 2010).

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

業務合併或資產收購 (續)

業務合併

收購業務(共同控制下的業務合併除外)以收購法入賬。於業務合併轉移之代價以公平值計量,其計算乃按於收購日期本集團轉移資產、本集團向被收購方之前擁有人所承擔之負債及本集團用以換取被收購方之控制權而發行之股本權益之公平值總和。收購相關成本一般在發生時於損益中確認。

除若干確認豁免外,可識別之已收購資產及已承擔負債須符合財務報表編製及呈列框架(由二零一零年十月頒佈的財務報告概念框架取代)中資產及負債之定義。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Business combinations or asset acquisitions (continued)

Business combinations (continued)

At the acquisition date, the identifiable assets acquired and the liabilities assumed are recognised at their fair value, except that:

- deferred tax assets or liabilities, and assets or liabilities related to employee benefit arrangements are recognised and measured in accordance with HKAS 12 Income Taxes and HKAS 19 Employee Benefits respectively;
- lease liabilities are recognised and measured at the present value of the remaining lease payments (as defined in HKFRS 16) as if the acquired leases were new leases at the acquisition date, except for leases for which (a) the lease term ends within 12 months of the acquisition date; or (b) the underlying asset is of low value. Right-of-use assets are recognised and measured at the same amount as the relevant lease liabilities, adjusted to reflect favourable or unfavourable terms of the lease when compared with market terms.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

業務合併或資產收購 (續)

業務合併 (續)

於收購日期，可識別之已收購資產及已承擔負債乃按公平值確認，惟：

- 遞延稅項資產或負債及員工福利安排之相關資產或負債分別按照香港會計準則第12號所得稅及香港會計準則第19號僱員福利來確認和計量；
- 租賃負債按剩餘租賃付款（定義見香港財務報告準則第16號）的現值確認及計量，猶如收購的租賃於收購日為新租賃，惟(a)租賃期限於收購日期12個月內結束；或(b)相關資產為低價值的租賃除外。使用權資產按與相關租賃負債相同的金額確認及計量，並進行調整以反映與市場條件相比租賃的有利或不利條款。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Business combinations or asset acquisitions (continued)

Business combinations (continued)

Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net amount of the identifiable assets acquired and the liabilities assumed as at acquisition date. If, after re-assessment, the net amount of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognised immediately in profit or loss as a bargain purchase gain.

Non-controlling interests that are present ownership interests and entitle their holders to a proportionate share of the relevant subsidiary's net assets in the event of liquidation are initially measured at the non-controlling interests' proportionate share of the recognised amounts of the acquiree's identifiable net assets or at fair value.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

業務合併或資產收購 (續)

業務合併 (續)

商譽乃按已轉移之代價，被收購方之非控股權益金額及收購方以往持有被收購方之股本權益(如有)之公平值的總和，超出於收購日期可識別之已收購資產及已承擔負債之淨額計量。倘重新評估後，可識別之已收購資產及已承擔負債之淨額，超出已轉移之代價、被收購方之非控股權益金額及收購方以往持有被收購方之股本權益(如有)之公平值的總和時，超出之金額即時於損益中確認為議價收購收益。

屬現有擁有權益並賦予持有人可於清盤時按比例攤佔相關附屬公司之資產淨額之非控股權益，按非控股權益比例攤佔被收購方之可識別淨資產之已確認金額或按公平值作初始計量。計量基準之選擇乃按逐筆交易為基礎作出。其他類型之非控股權益，乃按公平值計量。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Merger accounting for business combination involving businesses under common control

The consolidated financial statements incorporate the financial statements items of the combining businesses in which the common control combination occurs as if they had been combined from the date when the combining businesses first came under the control of the controlling party.

The net assets of the combining businesses are consolidated using the existing book values from the controlling party's perspective. No amount is recognised in respect of goodwill or bargain purchase gain at the time of common control combination.

The consolidated statement of profit or loss and other comprehensive income includes the results of each of the combining businesses from the earliest date presented or since the date when the combining businesses first came under the common control, where this is a shorter period.

The comparative amounts in the consolidated financial statements are presented as if the businesses had been combined at the beginning of the previous reporting period or when they first came under common control, whichever is shorter.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

涉及共同控制業務的業務合併的合併會計法

綜合財務報表包括發生共同控制合併的合併業務的財務報表項目，猶如該等合併業務自其首次受控制方控制當日起已經合併。

對於控制方而言，合併業務的資產淨值乃按現有賬面值進行合併。共同控制合併時並無就商譽或溢價收購利得確認金額。

綜合損益及其他全面收入報表包括自最早呈列日期或合併業務首次受共同控制當日（以期限較短者為準）起各合併業務的業績。

合併財務報表中的比較數額乃按猶如有關業務已於先前報告期初或首次受共同控制時（以期限較短者為準）合併的方式呈列。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Goodwill

Goodwill arising on an acquisition of a business is carried at cost as established at the date of acquisition of the business (see the accounting policy above) less accumulated impairment losses, if any.

For the purposes of impairment testing, goodwill is allocated to each of the Group's relevant cash-generating units (or group of cash-generating units) that is expected to benefit from the synergies of the combination, which represent the lowest level at which the goodwill is monitored for internal management purposes and not larger than an operating segment.

A cash-generating unit (or group of cash-generating units) to which goodwill has been allocated is tested for impairment annually or more frequently when there is indication that the unit may be impaired. For goodwill arising on an acquisition in a reporting period, the cash-generating unit (or group of cash-generating units) to which goodwill has been allocated is tested for impairment before the end of that reporting period. If the recoverable amount is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill and then to the other assets on a pro-rata basis based on the carrying amount of each asset in the unit (or group of cash-generating units).

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

商譽

收購業務產生之商譽按收購業務日期的成本(見上述會計政策)減任何累計減值虧損(如有)列賬。

就減值測試而言，商譽會分配至預期可受惠於收購的協同效益的本集團之各有關現金產生單位或現金產生單位組合，而該單位或單位組合指就內部管理目的監控商譽的最低水平且不超過經營分類。

獲分配商譽的現金產生單位(或現金產生單位組合)會每年或於有跡象顯示該單位可能出現減值時更頻繁進行減值測試。就報告期內收購所產生的商譽而言，獲分配商譽的現金產生單位(或現金產生單位組合)會於該報告期末前進行減值測試。倘可收回金額低於其賬面值，則減值虧損會先分配以調減任何商譽的賬面值，其後則按該單位(或現金產生單位組合)內各項資產的賬面值的比例分配至該單位的其他資產。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Goodwill (continued)

On disposal of the relevant cash-generating unit or any of the cash-generating unit within the group of cash-generating units, the attributable amount of goodwill is included in the determination of the amount of profit or loss on disposal. When the Group disposes of an operation within the cash-generating unit (or a cash-generating unit within a group of cash-generating units), the amount of goodwill disposed of is measured on the basis of the relative values of the operation (or the cash-generating unit) disposed of and the portion of the cash-generating unit (or the group of cash-generating units) retained.

The Group's policy for goodwill arising on the acquisition of an associate and joint venture is described below.

Investments in an associate and joint venture

An associate is an entity over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies.

A joint venture is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the joint arrangement. Joint control is the contractually agreed sharing of control of an arrangement, which exists only when decisions about the relevant activities require unanimous consent of the parties sharing control.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

商譽 (續)

於出售相關現金產生單位或現金產生單位組別中任何現金產生單位時，商譽的應佔金額計入釐定的出售損益金額。當本集團出售現金產生單位(或現金產生單位組別中的一個現金產生單位)內的業務時，所出售商譽金額按所出售業務(或現金產生單位)與所保留現金單位(或現金產生單位組別)部分的相對價值計量。

本集團有關收購聯營公司及合營企業產生的商譽的政策載於下文。

於聯營公司及合營企業的投資

聯營公司指本集團對其擁有重大影響力的實體。重大影響力是有權參與被投資方的財務及經營決策，而不是控制或共同控制該等政策。

合營企業指一項合營安排，對安排擁有共同控制權之訂約方據此對合營安排之資產淨值擁有權利。共同控制指按照合約協定對一項安排所共有之控制，共同控制僅在有關活動要求享有控制權之訂約方作出一致同意之決定時存在。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Investments in an associate and joint venture (continued)

The results and assets and liabilities of an associate and joint venture are incorporated in these consolidated financial statements using the equity method of accounting. The financial statements of an associate and joint ventures used for equity accounting purposes are prepared using uniform accounting policies as those of the Group for like transactions and events in similar circumstances. Under the equity method, an investment in an associate or joint venture is initially recognised in the consolidated statement of financial position at cost and adjusted thereafter to recognise the Group's share of the profit or loss and other comprehensive income of the associate or joint venture. Changes in net assets of the associate/joint venture other than profit or loss and other comprehensive income are not accounted for unless such changes resulted in changes in ownership interest held by the Group. When the Group's share of losses of an associate or joint venture exceeds the Group's interest in that associate or joint venture (which includes any long-term interests that, in substance, form part of the Group's net investment in the associate or joint venture), the Group discontinues recognising its share of further losses. Additional losses are recognised only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the associate or joint venture.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

於聯營公司及合營企業的投資 (續)

聯營公司及合營企業之業績、資產及負債利用權益會計法載入該等綜合財務報表內。作會計權益法用途的聯營公司及合營企業的財務報表乃按與本集團就同類交易及同類情況下事項的統一會計政策編製。根據權益法，於聯營公司或合營企業的投資乃初步於綜合財務狀況表按成本值確認，並於其後作出調整以確認本集團應佔聯營公司或合營企業的損益及其他全面收益。損益及其他全面收益除外，聯營公司／合營企業的淨資產變動不會入賬，除非該等變動導致本集團持有的所有權權益出現變動。當本集團應佔一間聯營公司或合營企業虧損超出本集團於該聯營公司或合營企業的權益時（包括任何實際上構成本集團於聯營公司或合營企業投資淨值一部分的長期權益），本集團會終止確認其應佔的進一步虧損。當本集團產生法定或推定責任或代表聯營公司或合營企業付款時，方會確認額外虧損。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Investments in an associate and joint venture (continued)

An investment in an associate or a joint venture is accounted for using the equity method from the date on which the investee becomes an associate or a joint venture. On acquisition of the investment in an associate or a joint venture, any excess of the cost of the investment over the Group's share of the net fair value of the identifiable assets and liabilities of the investee is recognised as goodwill, which is included within the carrying amount of the investment. Any excess of the Group's share of the net fair value of the identifiable assets and liabilities over the cost of the investment, after reassessment, is recognised immediately in profit or loss in the period in which the investment is acquired.

The Group assesses whether there is an objective evidence that the interest in an associate or a joint venture may be impaired. When any objective evidence exists, the entire carrying amount of the investment (including goodwill) is tested for impairment in accordance with HKAS 36 as a single asset by comparing its recoverable amount (higher of value in use and fair value less costs of disposal) with its carrying amount. Any impairment loss recognised is not allocated to any asset, including goodwill, that forms part of the carrying amount of the investment. Any reversal of that impairment loss is recognised in accordance with HKAS 36 to the extent that the recoverable amount of the investment subsequently increases.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

於聯營公司及合營企業的投資 (續)

於被投資方成為一家聯營公司或合營企業當日，對於聯營公司或合營企業的投資採用權益法入賬。於收購一間聯營公司或合營企業的投資時，投資成本超過本集團分佔該被投資方可識別資產及負債公平淨值的任何部分乃確認為商譽，並計入投資之賬面值。本集團應佔可識別資產及負債的公平淨值超出投資成本的任何差額，於重新評估後即時於投資被收購之期間於損益確認。

本集團評估是否有客觀證據表明於聯營公司或合營企業的權益可能出現減值。如存在任何客觀證據，則將投資的全部賬面值（包括商譽）作為單一資產根據香港會計準則第36號，透過比較其可收回金額（使用價值與公平值減銷售成本之較高者）與賬面值而測試有否減值。任何確認的減值虧損並未分配予任何資產（包括商譽），屬投資賬面值之一部份。倘其後投資的可收回金額增加，則根據香港會計準則第36號確認該減值虧損的撥回。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Investments in an associate and joint venture (continued)

When the Group reduces its ownership interest in an associate or joint venture but the Group continues to use the equity method, the Group reclassifies to profit or loss the proportion of the gain or loss that had previously been recognised in other comprehensive income relating to that reduction in ownership interest if that gain or loss would be reclassified to profit or loss on the disposal of the related assets or liabilities.

When a group entity transacts with an associate or joint venture of the Group, profits and losses resulting from the transactions with the associate or joint venture are recognised in the Group's consolidated financial statements only to the extent of interests in the associate or joint venture that are not related to the Group.

Revenue from contracts with customers

The Group recognises revenue when (or as) a performance obligation is satisfied, i.e. when "control" of the goods or services underlying the particular performance obligation is transferred to the customer.

A performance obligation represents a good or service (or a bundle of goods or services) that is distinct or a series of distinct goods or services that are substantially the same.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

於聯營公司及合營企業的投資 (續)

當本集團減少其於聯營公司或合營企業之所有者權益但本集團繼續採用權益法時，本集團將此前計入其他全面收益內與任何減少所有者權益相關之收益或虧損部份重新分類至損益（前提為此項收益或虧損於出售相關資產或負債時將重新分類至損益）。

倘集團實體與本集團聯營公司或合營企業進行交易，則與聯營公司或合營企業進行交易所產生之溢利及虧損乃按與本集團無關之於聯營公司或合營企業之權益於本集團之綜合財務報表內確認。

客戶合約收入

本集團於完成履約責任時（即當貨品或服務按特定履約責任之「控制權」轉移予客戶時）確認收入。

履約責任指個別的商品或服務（或一組商品或服務）或一系列大致相同的個別商品或服務。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Revenue from contracts with customers
(continued)

Control is transferred over time and revenue is recognised over time by reference to the progress towards complete satisfaction of the relevant performance obligation if one of the following criteria is met:

- the customer simultaneously receives and consumes the benefits provided by the Group's performance as the Group performs;
- the Group's performance creates and enhances an asset that the customer controls as the Group performs; or
- the Group's performance does not create an asset with an alternative use to the Group and the Group has an enforceable right to payment for performance completed to date.

Otherwise, revenue is recognised at a point in time when the customer obtains control of the distinct good or service.

A contract asset represents the Group's right to consideration in exchange for goods or services that the Group has transferred to a customer that is not yet unconditional. It is assessed for impairment in accordance with HKFRS 9. In contrast, a receivable represents the Group's unconditional right to consideration, i.e. only the passage of time is required before payment of that consideration is due.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

客戶合約收入 (續)

倘符合以下其中一項條件，則控制權隨時間轉移，而收入將參照完全履行相關履約責任的進展情況而隨時間確認：

- 於本集團履約時，客戶同時收取及耗用本集團履約所帶來的利益；
- 於本集團履約時，自本集團之履約產生及提升一項由客戶控制的資產；或
- 本集團之履約並無產生對本集團有替代用途的資產，且本集團可享有強制執行權利，以收回至今已履約部份的款項。

否則，收入於客戶取得明確商品或服務的控制權時確認。

合約資產指本集團就向客戶換取本集團已轉讓的商品或服務收取代價的權利（尚未成為無條件）。其根據香港財務報告準則第9號評估減值。相反，應收款項指本集團收取代價的無條件權利，即代價僅隨時間推移即成為到期支付。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Revenue from contracts with customers (continued)

A contract liability represents the Group's obligation to transfer goods or services to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer.

A contract asset and a contract liability relating to the same contract are accounted for and presented on a net basis.

Variable consideration

For contracts that contain variable consideration (i.e. sales with a right of return), the Group estimates the amount of consideration to which it will be entitled using the expected value method, which better predicts the amount of consideration to which the Group will be entitled.

The estimated amount of variable consideration is included in the transaction price only to the extent that it is highly probable that such an inclusion will not result in a significant revenue reversal in the future when the uncertainty associated with the variable consideration is subsequently resolved.

At the end of each reporting period, the Group updates the estimated transaction price (including updating its assessment of whether an estimate of variable consideration is constrained) to represent faithfully the circumstances present at the end of each reporting period and the changes in circumstances during each reporting period.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

客戶合約收入 (續)

合約負債指本集團因已自客戶收取代價(或到期的代價金額)，而須向客戶轉讓商品或服務之責任。

與相同合約有關的合約資產及合約負債按淨額入賬及呈列。

可變代價

對於包含可變代價之合約(即附帶退貨權的銷售)，本集團採用預期價值法(該方法能更好的預測本集團將享有的代價金額)估計其將有權獲得之代價金額。

可變代價之估計金額乃計入交易價內，前提是計入後有很大可能不會導致於未來(當與可變代價相關之不確定性於其後變得確定時)出現顯著收入撥回。

於各報告期末時，本集團會更新估計交易價(包括更新其就可變代價之估計是否有限度而作出之評估)，以忠實反映於各報告期末之現況及於各報告期間之情況變動。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Revenue from contracts with customers
(continued)

Sale with a right of return/exchange

For a sale of products with a right of return/exchange for dissimilar products, the Group recognises all of the following:

- (a) revenue for the transferred products in the amount of consideration to which the Group expects to be entitled (therefore, revenue would not be recognised for the products expected to be exchanged);
- (b) a contract liability; and
- (c) an asset (and corresponding adjustment to cost of sales) for its right to recover products from customers and are presented as right to returned goods asset.

Principal versus agent

When another party is involved in providing goods or services to a customer, the Group determines whether the nature of its promise is a performance obligation to provide the specified goods or services itself (i.e. the Group is a principal) or to arrange for those goods or services to be provided by the other party (i.e. the Group is an agent).

The Group is a principal if it controls the specified good or service before that good or service is transferred to a customer.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

客戶合約收入 (續)

附帶退貨／換貨權的銷售

就附有退回／更換不同產品權利的產品銷售而言，本集團確認以下各項：

- (a) 按本集團預計有權收取的代價金額確認已轉讓產品的收益 (因此，將不會就預計換貨的產品確認收益)；
- (b) 合約負債；及
- (c) 就其自客戶收回產品的權利確認資產 (及對銷售成本作相應調整)，並呈列為擁有被退回產品資產的權利。

主事人與代理人

倘向客戶提供商品或服務涉及另一方，本集團會釐定其承諾性質是否為其本身提供指定商品或服務的履約責任 (即本集團為主事人)，抑或是安排另一方提供該等商品或服務 (即本集團為代理人)。

倘本集團於向客戶轉移指定商品或服務前控制該商品或服務，則為主事人。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Revenue from contracts with customers (continued)

Principal versus agent (continued)

The Group is an agent if its performance obligation is to arrange for the provision of the specified good or service by another party. In this case, the Group does not control the specified good or service provided by another party before that good or service is transferred to the customer. When the Group acts as an agent, it recognises revenue in the amount of any fee or commission to which it expects to be entitled in exchange for arranging for the specified goods or services to be provided by the other party.

Leases

Definition of a lease

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

For contracts entered into or modified on or after the date of initial application or arising from business combinations, the Group assesses whether a contract is or contains a lease based on the definition under HKFRS 16 at inception, modification date or acquisition date, as appropriate. Such contract will not be reassessed unless the terms and conditions of the contract are subsequently changed.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

客戶合約收入 (續)

主事人與代理人 (續)

倘本集團的履約責任為安排另一方提供指定商品或服務，則為代理人。在這一情況下，本集團於指定商品或服務轉讓予客戶之前，不控制由另一方提供的該商品或服務。倘本集團作為代理人行事，其所確認收入的金額為就安排另一方提供指定商品或服務作為交換應收取的任何費用或佣金。

租賃

租賃的定義

倘合約為換取代價而授予在一段期間內已識別資產的使用控制權，則該合約屬於租賃或包含租賃。

就於首次應用日期或之後訂立或修改或業務合併所致的合約而言，本集團於開始、修改日期或收購日期(倘適用)根據香港財務報告準則第16號項下的定義評估合約是否屬於租賃或包含租賃，惟倘合約條款及條件隨後有所變動，該合約將不獲重新評估。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Leases (continued)

The Group as a lessee

Short-term leases and leases of low-value assets

The Group applies the short-term lease recognition exemption to leases of buildings and equipment that have a lease term of 12 months or less from the commencement date and do not contain a purchase option. It also applies the recognition exemption for lease of low-value assets. Lease payments on short-term leases and leases of low-value assets are recognised as expense on a straight-line basis over the lease term.

Right-of-use assets

The cost of right-of-use asset includes:

- the amount of the initial measurement of the lease liability;
- any lease payments made at or before the commencement date, less any lease incentives received;
- any initial direct costs incurred by the Group; and
- an estimate of costs to be incurred by the Group in dismantling and removing the underlying assets, restoring the site on which it is located or restoring the underlying asset to the condition required by the terms and conditions of the lease.

Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

租賃 (續)

本集團作為承租人

短期租賃及低價值資產租賃

本集團將短期租賃確認豁免應用於租期自開始日期起為12個月或以下的樓宇及設備租賃，且並不包括購買選擇權。其亦對低價值資產租賃應用確認豁免。短期租賃及低價值資產租賃之租賃付款於租期內按直線法確認為開支。

使用權資產

使用權資產的成本包括：

- 租賃負債初始計量的金額；
- 於開始日期或之前作出的任何租賃付款減去所收取的任何租賃優惠；
- 本集團產生的任何初始直接成本；及
- 本集團拆除及移除相關資產、還原該資產所處位置或將相關資產恢復至租賃條款及條件規定的狀況將產生的預計成本。

使用權資產按成本減去任何累計折舊及減值虧損計量，並就租賃負債的任何重新計量予以調整。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Leases (continued)

The Group as a lessee (continued)

Right-of-use assets (continued)

Right-of-use assets in which the Group is reasonably certain to obtain ownership of the underlying leased assets at the end of the lease term are depreciated from commencement date to the end of the useful life. Otherwise, right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term.

The Group presents right-of-use assets as a separate line item on the consolidated statement of financial position.

Refundable rental deposits

Refundable rental deposits paid are accounted under HKFRS 9 and initially measured at fair value. Adjustments to fair value at initial recognition are considered as additional lease payments and included in the cost of right-of-use assets.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

租賃 (續)

本集團作為承租人 (續)

使用權資產 (續)

本集團合理確定於租賃期結束時將取得相關已租賃資產所有權的使用權資產自開始日期起至可使用年期結束止予以折舊。否則，使用權資產於其估計可使用年期及租賃期（以較短者為準）按直線法折舊。

本集團將使用權資產於綜合財務狀況表內單獨呈列。

可退還租賃按金

已付可退還的租賃按金按香港財務報告準則第9號入賬，並初步按公平值計量。初始確認時對公平值的調整被視為額外租賃付款並包含於使用權資產之成本中。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Leases (continued)

The Group as a lessee (continued)

Lease liabilities

At the commencement date of a lease, the Group recognises and measures the lease liability at the present value of lease payments that are unpaid at that date. In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable.

The lease payments include:

- fixed payments (including in-substance fixed payments) less any lease incentives receivable;
- amounts expected to be payable by the Group under residual value guarantees;
- the exercise price of a purchase option if the Group is reasonably certain to exercise the option.

After the commencement date, lease liabilities are adjusted by interest accretion and lease payments.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

租賃 (續)

本集團作為承租人 (續)

租賃負債

於租賃開始日期，本集團按當日未支付的租賃付款的現值確認及計量租賃負債。在計算租賃付款的現值時，倘租賃中隱含的利率不易釐定，則本集團使用在租賃開始日期的增量借款利率。

租賃付款包括：

- 固定付款（包括實質固定付款）減任何應收租賃優惠；
- 剩餘價值擔保下本集團預期應付的金額；
- 倘本集團合理確定將行使購買選擇權的行權價。

於開始日期後，租賃負債按利息累增及租賃付款調整。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Leases (continued)

The Group as a lessee (continued)

Lease liabilities (continued)

The Group remeasures lease liabilities (and makes a corresponding adjustment to the related right-of-use assets) whenever:

- the lease term has changed or there is a change in the assessment of exercise of a purchase option, in which case the related lease liability is remeasured by discounting the revised lease payments using a revised discount rate at the date of reassessment.
- the lease payments change due to changes in market rental rates following a market rent review in which cases the related lease liability is remeasured by discounting the revised lease payments using the initial discount rate.

The Group presents lease liabilities as a separate line item on the consolidated statement of financial position.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

租賃 (續)

本集團作為承租人 (續)

租賃負債 (續)

倘出現以下情況，本集團重新計量租賃負債（並對相關使用權資產作出相應調整）：

- 租賃期變動或行使購買權的評估變動，在各情況下，相關租賃負債透過於重新評估當日使用經修訂貼現率貼現經修訂租賃付款而重新計量。
- 租賃付款因進行市場租金調查後市場租金變動而出現變動，在此情況下，相關租賃負債透過使用初始貼現率貼現經修訂租賃付款而重新計量。

本集團在綜合財務狀況表中將租賃負債作為單獨的項目呈列。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Leases (continued)

The Group as a lessee (continued)

Lease modifications

The Group accounts for a lease modification as a separate lease if:

- the modification increases the scope of the lease by adding the right to use one or more underlying assets; and
- the consideration for the leases increases by an amount commensurate with the stand-alone price for the increase in scope and any appropriate adjustments to that stand-alone price to reflect the circumstances of the particular contract.

For a lease modification that is not accounted for as a separate lease, the Group remeasures the lease liability based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

租賃 (續)

本集團作為承租人 (續)

租賃修改

倘出現以下情況，本集團將租賃修改按單獨租賃入賬：

- 修改透過增加一項或多項相關資產的使用權而擴大租賃範圍；及
- 租賃代價增加的金額為與範圍擴大相稱之獨立價格金額及反映特定合約情況而對獨立價格作出的任何適當調整。

就不按單獨租賃入賬的租賃修改而言，本集團透過於修改生效日期使用經修訂貼現率貼現經修訂租賃付款，根據經修訂租賃的租賃期，重新計量經修訂租賃。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Leases (continued)

The Group as lessor

Classification and measurement of leases

Leases for which the Group is a lessor are classified as finance or operating leases. Whenever the terms of the lease transfer substantially all the risks and rewards incidental to ownership of an underlying asset to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

Amounts due from lessees under finance leases are recognised as receivables at commencement date at amounts equal to net investments in the leases, measured using the interest rate implicit in the respective leases. Initial direct costs are included in the initial measurement of the net investments in the leases. Interest income is allocated to accounting periods so as to reflect a constant periodic rate of return on the Group's net investment outstanding in respect of the leases.

Rental income from operating leases is recognised in profit or loss on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset, and such costs are recognised as an expense on a straight-line basis over the lease term.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

租賃 (續)

本集團作為出租人

租賃之分類及計量

本集團為出租人之租賃乃分類為融資或經營租賃。當租賃條款將相關資產擁有權附帶的絕大部分風險及回報轉移至承租人時，該合約乃分類為融資租賃。所有其他租賃乃分類為經營租賃。

根據融資租賃應收承租人的款項於開始日期確認為應收款項，其金額等於租賃淨投資，並使用各個租賃中隱含的利率計量。初始直接成本包括在租賃淨投資的初始計量中。利息收入被分配至會計期間，以反映本集團有關租賃的未償還淨投資的固定定期收益率。

經營租約的租金收入以直線法按有關租約年期於損益中確認。於磋商及安排經營租約時引致的初步直接成本乃加至租賃資產的賬面值，及相關成本按租約年期以直線法確認為開支。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Leases (continued)

The Group as lessor (continued)

Refundable rental deposits

Refundable rental deposits received are accounted for under HKFRS 9 and initially measured at fair value. Adjustments to fair value at initial recognition are considered as additional lease payments from lessees.

Sale and leaseback transactions

The Group applies the requirements of HKFRS 15 to assess whether sale and leaseback transaction constitutes a sale by the Group.

The Group as a buyer-lessor

For a transfer of asset that does not satisfy the requirements of HKFRS 15 to be accounted for as a sale of asset, the Group as a buyer-lessor does not recognise the transferred asset and recognises a loan receivable equal to the transfer proceeds within the scope of HKFRS 9.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

租賃 (續)

本集團作為出租人 (續)

可退還租賃按金

已收到的可退還租賃按金根據香港財務報告準則第9號進行核算，並初始按公平值計量。初始確認時的公平值調整視為承租人的額外租賃付款額。

售後租回交易

本集團將按香港財務報告準則第15號的規定評估售後租回交易是否構成本集團的銷售。

本集團作為買方出租人

就不符合香港財務報告準則第15號入賬作資產出售規定的資產轉讓，本集團作為買家—出租人不會確認獲轉讓資產，而確認相等於香港財務報告準則第9號範圍內轉讓所得款項的應收貸款。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Foreign currencies

In preparing the financial statements of each individual group entity, transactions in currencies other than the functional currency of that entity (foreign currencies) are recognised at the rates of exchanges prevailing on the dates of the transactions. At the end of the reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences arising on the settlement of monetary items, and on the retranslation of monetary items, are recognised in profit or loss in the period in which they arise, except for exchange differences on monetary items receivable from or payable to a foreign operation for which settlement is neither planned nor likely to occur (therefore forming part of the net investment in the foreign operation), which are recognised initially in other comprehensive income and reclassified from equity to profit or loss on disposal or partial disposal of the Group's interests in associates and joint ventures.

For the purposes of presenting the consolidated financial statements, the assets and liabilities of the Group's foreign operations are translated into the presentation currency of the Group (i.e. RMB) using exchange rate prevailing at the end of each reporting period. Income and expenses items are translated at the average exchange rates for the year. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated in equity under the heading of translation reserve (attributed to non-controlling interests as appropriate).

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

外幣

在編製各個別集團實體的財務報表時，以實體功能貨幣以外貨幣(外幣)進行的交易按交易日通用的匯率記錄。於報告期末，以外幣列值的貨幣項目以該日通用的匯率重新換算。以外幣歷史成本計算的非貨幣項目不會重新換算。

結算及重新換算貨幣項目時產生的匯兌差額會於產生期間在損益確認，惟應收或應付海外業務的貨幣項目的匯兌差額除外，就此，有關結算未納入計劃中亦無可能產生(因此形成海外業務投資淨額部分)，且就出售或部份出售本集團於聯營公司及合營企業權益而初步於其他全面收益中確認並自權益中重新分類至損益。

為呈報綜合財務報表，本集團海外業務的資產及負債乃按報告期末的通用匯率換算為本集團的呈列貨幣(即人民幣)，而其收支按年內平均匯率換算。所產生的匯兌差額(如有)會在其他全面收入確認並於權益內的匯兌儲備項下累計(倘適用，則歸屬於非控股權益)。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Foreign currencies (continued)

In addition, in relation to a partial disposal of a subsidiary that does not result in the Group losing control over the subsidiary, the proportionate share of accumulated exchange differences are re-attributed to non-controlling interests and are not recognised in profit or loss. For all other partial disposals (i.e. partial disposals of associate that does not result in the Group losing significant influence), the proportionate share of the accumulated exchange differences is reclassified to profit or loss.

Goodwill and fair value adjustments on identifiable assets acquired and liabilities assumed arising on an acquisition of a foreign operation are treated as assets and liabilities of that foreign operation and translated at the rate of exchange prevailing at the end of each reporting period. Exchange differences arising are recognised in other comprehensive income.

Borrowing cost

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets until such time as the assets are substantially ready for their intended use or sale.

Any specific borrowing that remain outstanding after the related asset is ready for its intended use or sale is included in the general borrowing pool for calculation of capitalisation rate on general borrowings. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation.

All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

外幣 (續)

此外，倘部分出售附屬公司並不會導致本集團失去對該附屬公司之控制權，按比例所佔累計匯兌差額乃重新歸於非控股權益，且不會於損益確認。就所有其他部分出售（即並不導致本集團失去重大影響力之聯營公司部分出售）而言，按比例所佔之累計匯兌差額乃重新分類至損益。

收購境外業務及承擔負債產生的可辨認資產商譽及公平值調整均視為該境外業務的資產及負債，按各報告期末的現行匯率換算。所產生的匯兌差額於其他全面收益確認。

借貸成本

收購、建造或生產合資格資產所直接產生的借貸成本乃撥充該等資產的成本，直至有關資產大致上可作擬定用途或銷售為止，而合資格資產為需較長時間預備以用於擬定用途或銷售的資產。

於相關資產準備用於其釐定用途或出售後仍未償還的任何特定借款計入一般借款池，以計算一般借款的資本化比率。特定借貸於撥作合資格資產的支出前用作臨時投資所賺取的投資收入，會從可撥充資本的借貸成本中扣除。

所有其他借貸成本於其產生年度在損益中確認。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Government grants

Government grants are not recognised until there is reasonable assurance that the Group will comply with the conditions attaching to them and that the grants will be received.

Government grants are recognised in profit or loss on a systematic basis over the periods in which the Group recognises as expenses the related costs for which the grants are intended to compensate. Specifically, government grants whose primary condition is that the Group should purchase, construct or otherwise acquire non-current assets are recognised as deferred income in the consolidated statement of financial position and transferred to profit or loss on a systematic and rational basis over the useful lives of the related assets.

Government grants related to income that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Group with no future related costs are recognised in profit or loss in the period in which they become receivable. Such grants are presented under "other income".

Retirement benefit costs

Payments to defined contribution retirement benefit plans and state-managed retirement benefit schemes are recognised as an expense when employees have rendered service entitling them to the contributions.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

政府補助

在合理地保證本集團會遵守政府補助的附帶條件以及將會得到補助後，政府補助方會予以確認。

政府補助按系統化基準於本集團將由補助擬補償的相關成本確認為開支的各期間在損益內確認。具體而言，主要條件為本集團應購買、興建或以其他方式收購非流動資產的政府補助乃於綜合財務狀況表確認為遞延收入並且在有關資產的可使用年期內有系統及合理地轉移至損益內。

用作補償本集團已產生支出或虧損或旨在為本集團提供即時財務資助(而無未來相關成本)之應收的收入有關政府補助，乃於應收期間於損益內確認。有關補助呈列於「其他收入」。

退休福利成本

向定額供款退休福利計劃、國家管理退休金計劃付款均在僱員提供服務可獲供款時確認為開支。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Short-term employee benefits

Short-term employee benefits are recognised at the undiscounted amount of the benefits expected to be paid as and when employees rendered the services. All short-term employee benefits are recognised as an expense unless another HKFRS requires or permits the inclusion of the benefit in the cost of an asset.

Share-based payments

Equity-settled share-based payment transactions

Shares/Share options granted to employees

Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of equity instruments at the grant date.

The fair value of the equity-settled share-based payments determined at the grant date without taking into consideration of all non-market vesting considerations is expensed on a straight-line basis over the vesting period based on the Group's estimate of equity instruments that will eventually vest, with a corresponding increase in equity (share-based payments reserve). At the end of the reporting period, the Group revises its estimates of the number of equity instruments expected to vest based on assessment of all relevant non-market vesting condition. The impact of the revision of the original estimates, if any, is recognised in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to share-based payments reserve.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

短期僱員福利

短期僱員福利按僱員提供福利時預期將支付的福利未貼現金額確認。所有短期僱員福利確認為開支，除非其他香港財務報告準則要求或准許將福利納入資產的成本。

以股份為基礎付款

以股權結算之股份基礎付款交易

授予僱員之股份/購股權計劃

向僱員及提供類似服務之其他人士作出之以股權結算之股份基礎付款乃按股本工具於授出日期之公平值計量。

不計及所有非市場歸屬代價，以股權結算之股份基礎付款於授出日期釐定之公平值乃於歸屬期內按直線法根據本集團將最終歸屬的股本工具的估計支銷，並相應增加權益（股份付款儲備）。於報告期末，本集團根據對所有相關非市場歸屬條件的評估修訂其對預期歸屬的股本工具數目的估計。修訂原先估計的影響（如有）於損益內確認，因此，累計開支反映經修訂估計，並對以股份為基礎付款儲備作相應調整。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Share-based payments (continued)

Equity-settled share-based payment transactions (continued)

Shares/Share options granted to employees (continued)

When the award shares/share options are exercised, the amount previously recognised in share-based payments reserve will be transferred to other reserve. When the award shares/share options are forfeited after the vesting date or are still not exercised at the expiry date, the amount previously recognised in share-based payments reserve will be transferred to retained profits.

When shares granted are vested, the amount previously recognised in share-based payments reserve will be transferred to other reserve.

Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit before tax because of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

以股份為基礎付款 (續)

以股權結算之股份基礎付款 交易 (續)

授予僱員之股份/購股權計劃 (續)

倘獎勵股份/購股權獲行使，先前於股份付款儲備內確認之金額將轉撥至其他儲備。倘獎勵股份/購股權於歸屬日期後或直至到期日仍未獲行使而獲沒收，先前於股份付款儲備內確認之金額將轉撥至保留溢利。

倘授出的股份獲歸屬，先前於股份付款儲備內確認之金額將轉撥至其他儲備。

稅項

所得稅開支指現時應付的稅項及遞延稅項總和。

現時應付的稅項以年內的應納稅溢利為基礎。由於於其他年度應納稅或可扣稅的收支及不應納稅或不可扣稅的項目，應納稅溢利有別於除稅前溢利。本集團目前的稅務責任乃採用報告期末已製定或大致上已製定的稅率計算。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Taxation (continued)

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary difference to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. In addition, deferred tax liabilities are not recognised if the temporary difference arises from the initial recognition of goodwill.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

稅項 (續)

遞延稅項就綜合財務報表內資產及負債的賬面值與用以計算應納稅溢利的相關稅基的暫時差額而確認。遞延稅項負債一般就所有應納稅暫時差額確認。倘有應納稅溢利將可用以抵銷可動用可扣稅暫時差額，遞延稅項資產一般就所有可扣稅暫時差額確認。倘暫時差額來自一項不會影響應納稅溢利或會計溢利的交易的其他資產及負債的初步確認（業務合併除外），則該等資產及負債不會予以確認。此外，倘初步確認商譽產生暫時差額，則遞延稅項發債予以確認。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Taxation (continued)

Deferred tax liabilities are recognised for taxable temporary differences associated with investments in subsidiaries and an associate and interests in joint ventures, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments and interests are only recognised to the extent that it is probable that there will be sufficient taxable profits against which to utilise the benefits of the temporary differences and they are expected to reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at the end of the reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realised, based on tax rate (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

稅項 (續)

遞延稅項負債乃按因於附屬公司及聯營公司之投資及於合營企業的權益而產生的應課稅暫時差額而確認，惟若本集團可令暫時差額撥回及暫時差額有可能未必於可見將來撥回之情況除外。與該等投資及權益相關的可扣稅暫時差額所產生的遞延稅項資產僅於可能有足夠應課稅溢利可以使用暫時差額的益處且預計於可見將來可以撥回時確認。

於各報告期末審閱遞延稅項資產的賬面值，及倘應納稅溢利不再足夠收回全部或部分資產，即減少遞延稅項資產的賬面值。

遞延稅項資產及負債乃根據於報告期末已實施或大致上已實施的稅率(及稅法)，按預期於負債清償或資產變現期間適用的稅率計算。

遞延稅項負債與資產的計算，反映按照本集團於報告期末時預期收回或清償資產及負債賬面值的方式所產生稅務結果。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Taxation (continued)

For the purposes of measuring deferred tax for leasing transactions in which the Group recognises the right-of-use assets and the related lease liabilities, the Group first determines whether the tax deductions are attributable to the right-of-use assets or the lease liabilities.

For leasing transactions in which the tax deductions are attributable to the lease liabilities, the Group applies HKAS 12 Income Taxes requirements the leasing transaction as a whole. Temporary differences relating to right-of-use assets and lease liabilities are assessed on a net basis. Excess of depreciation on right-of-use assets over the lease payments for the principal portion of lease liabilities resulting in net deductible temporary differences.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied to the same taxable entity by the same taxation authority.

Current and deferred tax is recognised in profit or loss, except when it relates to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognised in other comprehensive income or directly in equity respectively. Where current tax or deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

稅項 (續)

就計量本集團確認使用權資產及相關租賃負債的租賃交易的遞延稅項而言，本集團首先釐定稅項扣減是否歸因於使用權資產或租賃負債。

就租賃交易（其減稅歸屬於租賃負債）而言，本集團對租賃交易整體應用香港會計準則第12號所得稅之規定。使用權資產與租賃負債之臨時差額以淨額估算。由於使用權資產折舊超過租賃負債主要部分之租金，而導致可扣除臨時淨差額。

當有法定可執行權利將當期稅項資產抵銷當期稅項負債時，以及當它們與同一稅務機關對同一應課稅實體徵收的所得稅有關時，遞延所得稅資產和負債均予以抵銷。

即期及遞延稅項於損益內確認，惟倘即期及遞延稅項涉及於其他全面收益或直接在權益確認項目，則即期及遞延稅項亦會分別於其他全面收益或直接於權益內確認。倘因業務合併之初步會計方法而產生即期或遞延稅項，有關稅務影響會計入業務合併之會計方法內。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Property, plant and equipment

Property, plant and equipment are tangible assets that are held for use in the production or supply of goods or services, or for administrative purposes (other than properties under construction as described below). Property, plant and equipment are stated in the consolidated statement of financial position at cost less subsequent accumulated depreciation and subsequent accumulated impairment losses, if any.

Freehold land is stated at cost less any recognised impairment loss. Freehold land is not depreciated.

Surgical instruments produced by the Group that are dedicated for use with the Group's orthopaedic implant products commence depreciation upon they are provided to the distributors that in the location for their intended use.

Buildings in the course of construction for production, supply or administrative purposes are carried at cost, less any recognised impairment loss. Costs include any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management and, for qualifying assets, borrowing costs capitalised in accordance with the Group's accounting policy. Depreciation of these assets, on the same basis as other property assets, commences when the assets are ready for their intended use.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

物業、廠房及設備

物業、廠房及設備為持有用於生產或供應貨物或服務的有形資產，或用於行政用途之樓宇（不包括下文所述的在建物業），物業、廠房及設備乃按照成本減其後累計折舊及其後累計減值虧損（如有）於綜合財務狀況表列賬。

自由保有土地按成本減任何已確認減值虧損列賬。自由保有土地未折舊。

本集團所生產專門配合本集團的骨科植入物產品使用的手術工具將於提供予所在地的分銷商作其擬定用途時開始計提折舊。

在建以作生產、供應及行政用途的樓宇按成本減任何已確認減值虧損列賬。成本包括使資產達到能夠按照管理層擬定的方式開展經營所必要的位置及條件而直接產生的任何成本，及就合資格資產而言，根據本集團會計政策資本化的借款成本。該等資產按與其他物業資產相同的基準，於該等資產可投入作擬定用途時開始計提折舊。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Property, plant and equipment (continued)

Ownership interests in leasehold land and building

When the Group makes payments for ownership interests of properties which includes both leasehold land and building elements, the entire consideration is allocated between the leasehold land and the building elements in proportion to the relative fair values at initial recognition.

To the extent the allocation of the relevant payments can be made reliably, interest in leasehold land that is presented as “right-of-use assets” in the consolidated statement of financial position. When the consideration cannot be allocated reliably between non-lease building element and undivided interest in the underlying leasehold land, the entire properties are classified as property, plant and equipment.

Depreciation is recognised so as to write off the cost of assets (other than freehold land and construction in progress) less their residual values over their estimated useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for a prospective basis.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in profit or loss.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

物業、廠房及設備 (續)

於租賃土地及樓宇的擁有權權益

當本集團就於物業的擁有權權益(包括租賃土地及樓宇成分)付款時,全部代價於租賃土地及樓宇成分之間按初始確認時的相對公平值的比例分配。

於相關付款能夠可靠分配的情況下,租賃土地的權益於綜合財務狀況表內呈列為「使用權資產」。當代價無法在相關租賃土地的非租賃樓宇成分及未分割權益之間可靠分配時,整項物業分類為物業、廠房及設備。

折舊乃確認以撇銷按直線法在其估計可使用年期內的資產(自由土地及在建資產除外)成本減其剩餘價值。估計可使用年期、殘值和折舊方法會在每個報告期末覆核,並採用未來適用法對任何估計變更的影響進行核算。

物業、廠房及設備項目於出售或預期日後繼續使用資產時不再產生經濟利益時終止確認。處置或報廢物業、廠房及設備項目所產生的損益釐定為資產的銷售所得款項與賬面值的差額並於損益中確認。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Investment properties

Investment properties are properties held to earn rentals and/or for capital appreciation.

Investment properties are initially measured at cost, including any directly attributable expenditure. Subsequent to initial recognition, investment properties are stated at cost less subsequent accumulated depreciation and any accumulated impairment losses. Depreciation is recognised so as to write off the cost of investment properties over their estimated useful lives and after taking into account of their estimated residual value, using the straight-line method.

An investment property is derecognised upon disposal or when the investment property is permanently withdrawn from use and no future economic benefits are expected from its disposal. Any gain or loss arising on derecognition of the property (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in profit or loss in the period in which the property is derecognised.

Transfers

Transfers to, or from, investment property when, and only when, there is a change in use, evidenced by end of owner-occupation, for a transfer from owner-occupied property to investment property; or commencement of owner-occupation, for a transfer from investment property to owner-occupied property.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

投資物業

投資物業指持作賺取租金及／或作資本增值的物業。

投資物業初步乃以成本(包括任何直接應佔開支)計值。初步確認後,投資物業乃按成本減其後累計折舊及任何累計減值虧損計值。確認折舊以便於經考慮投資物業的估計剩餘價值後採用直線法按估計使用年限撇銷其成本。

當投資物業出售或永久停止使用及預計不會從出售該項物業中獲得未來經濟收益時,即取消確認該項投資物業。取消確認某項物業所產生的任何收益或虧損(按出售所得款項淨額與該資產的賬面值兩者之差額計算),於取消確認物業的期間於損益表中確認。

轉移

當且僅當存在業主佔用結束而自業主佔用物業轉至投資物業;或開始業主佔用而自投資物業轉至業主佔用物業證明用途改變時,才可轉入或轉出投資物業。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 Significant accounting policies (continued)

4.2 主要會計政策 (續)

Intangible assets

無形資產

Intangible assets acquired separately

獨立收購的無形資產

Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortisation and accumulated impairment losses. Amortisation is recognised on a straight-line basis over their estimated useful lives. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

個別收購且具備有限可使用年期的無形資產按成本減累計攤銷及任何累計減值虧損入賬。攤銷於其估計可使用年期內按直線基準確認。估計可使用年期及攤銷法於各報告期末檢討，而估計之任何變動影響按未來適用法予以入賬。

Internally-generated intangible assets – research and development expenditure

內部產生無形資產－研發開支

Expenditure on research activities is recognised as an expense in the period in which it is incurred.

研究活動的支出在其產生的期間內列為一項開支。

An internally-generated intangible asset arising from development activities (or from the development phase of an internal project) is recognised if, and only if, all of the following have been demonstrated:

當且僅當以下所有各項得到證明時，開發活動（或內部項目的開發階段）引致的內部產生的無形資產方予以確認：

- the technical feasibility of completing the intangible asset so that it will be available for use or sale;
- the intention to complete the intangible asset and use or sell it;
- the ability to use or sell the intangible asset;

- 在技術上可完成該無形資產以使其能使用或出售；
- 有完成該無形資產並使用或出售的意圖；
- 有能力使用或出售該無形資產；

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Intangible assets (continued)

Internally-generated intangible assets – research and development expenditure (continued)

- how the intangible asset will generate probable future economic benefits;
- the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
- the ability to measure reliably the expenditure attributable to the intangible asset during its development.

The amount initially recognised for internally-generated intangible asset is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognised, development expenditure is recognised in profit or loss in the period in which it is incurred.

Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortisation and accumulated impairment losses (if any), on the same basis as intangible assets that are acquired separately.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

無形資產 (續)

內部產生無形資產－研發開支 (續)

- 該無形資產如何產生潛在未來經濟利益；
- 具有足夠技術、財務及其他資源，以完成該無形資產的開發，並使用或出售該無形資產；及
- 歸屬於該無形資產開發階段的支出能可靠計量。

內部產生的無形資產的初步確認金額是自無形資產首次滿足上述確認條件的日期後所產生支出的總額。如果不能確認內部產生的無形資產，則開發支出應於其產生期間於損益中確認。

在初步確認後，內部產生的無形資產採用與獨立收購的無形資產相同的基準，按成本減累計攤銷及累計減值虧損（如有）呈報。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Intangible assets (continued)

Intangible assets acquired in a business combination

Intangible assets acquired in a business combination and recognised separately from goodwill are initially recognised at their fair value at the acquisition date (which is regarded as their cost).

Subsequent to initial recognition, intangible assets acquired in a business combination with finite useful lives are reported at cost less accumulated amortisation and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.

Derecognition of intangible assets

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains and losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognised in profit or loss when the asset is derecognised.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

無形資產 (續)

於業務合併中收購的無形資產

於業務合併中收購的無形資產乃以獨立於商譽的方式確認，並於收購日期初步按公平值(被視為其成本)確認。

於初步確認後，於業務合併中收購且具備有限可使用年期的無形資產按成本減累計攤銷及累計減值虧損根據與獨立收購無形資產的相同基準呈報。

取消確認無形資產

無形資產於出售或當預期使用或出售時不會帶來未來經濟利益時取消確認。終止確認無形資產所產生的收益或虧損乃以出售所得款項淨額與該項資產賬面值之間的差額計量，並於該項資產終止確認時於損益表中確認。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Impairment on property, plant and equipment, right-of-use assets, and intangible assets other than goodwill

At the end of the reporting period, the Group reviews the carrying amounts of its property, plant and equipment, right-of-use assets, intangible assets with finite useful lives to determine whether there is any indication that these assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the relevant asset is estimated in order to determine the extent of the impairment loss, (if any).

The recoverable amount of property, plant and equipment, right-of-use assets, and intangible assets are estimated individually, when it is not possible to estimate the recoverable amount individually, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

In addition, the Group assesses whether there is indication that corporate assets may be impaired. If such indication exists, corporate assets are also allocated to individual cash-generating units, when a reasonable and consistent basis of allocation can be identified, or otherwise they are allocated to the smallest group of cash generating units for which a reasonable and consistent allocation basis can be established.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset (or a cash-generating unit) for which the estimates of future cash flows have not been adjusted.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

除商譽外之物業、廠房及設備、使用權資產及無形資產減值

於報告期末，本集團審閱其有限使用年期之物業、廠房及設備、使用權資產及無形資產之賬面值，以確定是否有任何跡象顯示該等資產出現減值虧損。倘有任何該等跡象存在，將估計相關資產之可收回金額以釐定其減值虧損 (如有)。

物業、廠房及設備、使用權資產及無形資產的可回收金額單獨估計，倘不能估計個別資產之可收回金額時，本集團則估計該資產所屬之現金產生單位之可收回金額。

此外，本集團對是否有跡象顯示公司資產可能出現減值進行評估。倘存在有關跡象，於可識別合理及一致的分配基準時，公司資產亦會分配至個別現金產生單位，否則會被分配至最小之現金產生單位組合 (就其可制定合理及一致的分配基準時)。

可收回金額為公平值減出售成本及使用價值之較高者。評估使用價值時，乃使用能反映現行市場所評估金錢之時間價值之稅前貼現率貼現至其現在價值，而該資產 (或現金產生單位) 之預計未來現金流量則未有調整相關風險。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Impairment on property, plant and equipment, right-of-use assets, and intangible assets other than goodwill (continued)

If the recoverable amount of an asset (or a cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or a cash-generating unit) is reduced to its recoverable amount. For corporate assets or portion of corporate assets which cannot be allocated on a reasonable and consistent basis to a cash-generating unit, the Group compares the carrying amount of a group of cash-generating units, including the carrying amounts of the corporate assets or portion of corporate assets allocated to that group of cash-generating units, with the recoverable amount of the group of cash-generating units. In allocating the impairment loss, the impairment loss is allocated first to reduce the carrying amount of any goodwill (if applicable) and then to the other assets on a pro-rata basis based on the carrying amount of each asset in the unit or the group of cash-generating units. The carrying amount of an asset is not reduced below the highest of its fair value less costs of disposal (if measurable), its value in use (if determinable) and zero. The amount of the impairment loss that would otherwise have been allocated to the asset is allocated pro rata to the other assets of the unit or the group of cash-generating units. An impairment loss is recognised immediately in profit or loss.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

除商譽外之物業、廠房及設備、使用權資產及無形資產減值 (續)

倘一項資產(或現金產生單位)之估計可收回金額低於其賬面值,則該資產(或現金產生單位)之賬面值將調低至其可收回金額。就未能按合理一致的基準分配至現金產生單位的企業資產或部分企業資產,本集團會比較一個組別的現金產生單位賬面值(包括已分配至該組現金產生單位的企業資產或部分企業資產的賬面值)與該組現金產生單位的可收回金額。於分配減值虧損時,首先分配減值虧損以減少任何商譽的賬面值(如適用),然後按比例根據該單位或本集團現金產生單位各資產的賬面值分配至其他資產。資產賬面值不得減少至低於其公平值減出售成本(如可計量)、其使用價值(如可釐定)及零之中的最高值。已另行分配至資產之減值虧損數額按比例分配至該單位其他資產。減值虧損會即時於損益確認。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Impairment on property, plant and equipment, right-of-use assets, and intangible assets other than goodwill (continued)

Where an impairment loss subsequently reverses, the carrying amount of the asset (or a cash-generating unit or a group of cash-generating units) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or a cash-generating unit or the group of cash-generating units) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss.

Inventories

Inventories are stated at the lower of cost and net realisable value. Costs of inventories are determined on the weighted average method. Net realisable value represents the estimated selling price for inventories less all estimated costs of completion and costs necessary to make the sale. Costs necessary to make the sale include incremental costs directly attributable to the sale and non-incremental costs which the Group must incur to make the sale.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

除商譽外之物業、廠房及設備、使用權資產及無形資產減值 (續)

倘減值虧損其後撥回，該項資產（或現金產生單位或本集團現金產生單位）之賬面值將增加至其經修訂之估計可收回金額，惟增加後之賬面值不得超過倘若該資產（或現金產生單位或本集團現金產生單位）於過往年度並無確認減值虧損所釐定之賬面值。減值虧損撥回隨即於損益內確認。

存貨

存貨按成本與可變現淨值兩者中較低者列賬。存貨成本按加權平均法釐定。可變現淨值指存貨估計售價減所有估計完成成本及就進行銷售而言屬必要的成本。進行銷售的必要成本包括銷售直接應佔的增量成本及為進行銷售本集團須產生的非增量成本。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Provisions

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that the Group will be required to settle that obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (where the effect of the time value of money is material).

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Provisions for the expected cost of assurance-type warranty obligations under the relevant contracts with customers for sales of products are recognised at the date of sale of the relevant products, at the directors' best estimate of the expenditure required to settle the Group's obligation.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

撥備

當本集團因某一已發生事件而承擔現時責任(法定或推定)，而本集團很可能須履行該責任，且責任金額能可靠地估計時，便會確認撥備。

確認為撥備的金額為於報告期末履行現時責任所需代價的最佳估計，當中計及與責任有關的風險及不明朗因素。當撥備使用履行現時責任所需估計現金流量計量時，其賬面值為該等現金流量的現值(倘金錢時間價值的影響屬重大)。

倘結算撥備所需的部分或全部經濟利益預計可自第三方收回，且幾乎肯定能收回償付金額及應收款項能可靠計量，則應收款項確認為資產。

為進行產品銷售的有關客戶合約項下的保證類型擔保責任的預計成本撥備於有關產品銷售日期，按董事履行本集團責任所需開支的最佳估計確認。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Contingent liabilities

A contingent liability is a present obligation arising from past events but is not recognised because the amount of the obligation cannot be measured with sufficient reliability.

Where the Group is jointly and severally liable for an obligation, the part of the obligation that is expected to be met by other parties is treated as a contingent liability and it is not recognised in the consolidated financial statements.

The Group assesses continually to determine whether an outflow of resources embodying economic benefits has become probable. If it becomes probable that an outflow of future economic benefits will be required for an item previously dealt with as a contingent liability, a provision is recognised in the consolidated financial statements in the reporting period in which the change in probability occurs, except in the extremely rare circumstances where no reliable estimate can be made.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

或有負債

或有負債為過往事件產生的現時責任，惟由於責任之金額不能充分可靠的計量而未進行確認。

倘本集團共同或個別地對一項責任負責，則預計將由另一訂約方履行的一部分責任將視作或有負債及不會於綜合財務報表確認。

本集團持續評估或有負債以釐定帶有經濟利益的資源流出是否已成為可能。倘若其可能需要就一項先前作為或有負債處理之項目付出未來經濟利益，則於可能出現變動之報告期間之綜合財務報表內確認撥備，惟在不能作出可靠估計的極少數情況下則除外。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments

Financial assets and financial liabilities are recognised when a group entity becomes a party to the contractual provisions of the instrument. All regular way purchases or sales of financial assets are recognised and derecognised on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the market place.

Financial assets and financial liabilities are initially measured at fair value except for trade receivables arising from contracts with customers which are initially measured in accordance with HKFRS 15. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets or financial liabilities at fair value through profit or loss ("FVTPL")) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognised immediately in profit or loss.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具

金融資產及金融負債乃於某集團實體成為工具合約條文的訂約方時確認。金融資產的所有日常買賣乃按交易日基準確認及終止確認。常規方式買賣乃指遵循一般法規或市場慣例在設定的時限內交付資產的金融資產買賣。

金融資產及金融負債初步按公平值計量，根據香港財務報告準則第15號初始計量的來自客戶合約的應收貿易賬款除外。收購或發行金融資產及金融負債（按公平值計入損益（「按公平值計入損益」）計量的金融資產或金融負債除外）直接應佔的交易成本乃於初步確認時，計入金融資產或金融負債的公平值內或自當中扣除（如適用）。收購按公平值計入損益計量的金融資產或金融負債直接產生的交易成本即時於損益中確認。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

The effective interest method is a method of calculating the amortised cost of a financial asset or financial liability and of allocating interest income and interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts and payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial asset or financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Interest/dividend income which are derived from the Group's ordinary course of business are presented as other income.

Financial assets

Classification and subsequent measurement of financial assets

Financial assets that meet the following conditions are subsequently measured at amortised cost:

- the financial asset is held within a business model whose objective is to collect contractual cash flows; and
- the contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

實際利率法是計算金融資產或金融負債攤銷成本及按有關期間分配利息收入及利息開支的方法。實際利率是將估計日後現金收入及付款(包括所付或所收屬於實際利率組成部分的一切費用及代價、交易成本及其他溢價或折扣)按金融資產或金融負債的預期年期或(如適用)較短期間準確貼現至初步確認時賬面淨值的利率。

本集團日常業務產生的利息／股息收入列示為其他收入。

金融資產

金融資產的分類及後續計量

符合下列條件的金融資產其後按攤銷成本計量：

- 金融資產乃按旨在收取合約現金流量的業務模式持有；及
- 合約條款於指定日期產生純粹為支付未償還本金及利息的現金流量。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Classification and subsequent measurement of financial assets (continued)

Financial assets that meet the following conditions are subsequently measured at fair value through other comprehensive income (“FVTOCI”):

- the financial asset is held within a business model whose objective is achieved by both selling and collecting contractual cash flows; and
- the contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

All other financial assets are subsequently measured at FVTPL.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產的分類及後續計量 (續)

符合下列條件的金融資產其後按公平值計入其他全面收益計量(「按公平值計入其他全面收益計量」):

- 金融資產乃按旨在同時出售及收取合約現金流量的金融資產的業務模式持有；及
- 合約條款於指定日期產生純粹為支付未償還本金及利息的現金流量。

所有其他金融資產其後按公平值計入損益計量。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Classification and subsequent measurement of financial assets (continued)

(i) Amortised cost and interest income

Interest income is recognised using the effective interest method for financial assets measured subsequently at amortised cost and debt instruments subsequently measured at FVTOCI. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired (see below). For financial assets that have subsequently become credit-impaired, interest income is recognised by applying the effective interest rate to the amortised cost of the financial asset from the next reporting period. If the credit risk on the credit-impaired financial instrument improves so that the financial asset is no longer credit-impaired, interest income is recognised by applying the effective interest rate to the gross carrying amount of the financial asset from the beginning of the reporting period following the determination that the asset is no longer credit-impaired.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產的分類及後續計量 (續)

(i) 攤銷成本及利息收入

其後按攤銷成本及債務工具計量的金融資產及其後按公平值計入其他全面收益計量的應收款項的利息收入乃使用實際利息法予以確認。利息收入乃對一項金融資產賬面總值應用實際利率予以計算，惟其後出現信貸減值的金融資產除外（見下文）。就其後出現信貸減值的金融資產而言，自下一報告期起，利息收入乃對金融資產攤銷成本應用實際利率予以確認。倘信貸減值金融工具的信貸風險好轉，使金融資產不再出現信貸減值，於釐定資產不再出現信貸減值後，自報告期開始起利息收入乃對金融資產賬面總值應用實際利率予以確認。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Classification and subsequent measurement of financial assets (continued)

- (ii) Debt instruments classified as at FVTOCI

Subsequent changes in the carrying amounts for debt instruments classified as at FVTOCI as a result of interest income calculated using the effective interest method are recognised in profit or loss. All other changes in the carrying amount of these debt instruments are recognised in other comprehensive income and accumulated under the heading of reserve. Impairment allowances are recognised in profit or loss with corresponding adjustment to other comprehensive income without reducing the carrying amounts of these debt instruments. When these debt instruments are derecognised, the cumulative gains or losses previously recognised in other comprehensive income are reclassified to profit or loss.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產的分類及後續計量 (續)

- (ii) 分類為按公平值計入其他全面收益計量之債務工具

由於按實際利率法計算的利息收入而分類為按公平值計入其他全面收益計量之債務工具的賬面值的後續變動在損益中確認。該等債務工具賬面值的的所有其他變動均於其他全面收益中確認，並於儲備項下累計。減值準備於損益中確認，並在不減少該等債務工具賬面值的的情況下對其他全面收益作出相應調整。當終止確認該等債務工具時，先前於其他全面收益確認的累計收益或虧損將重新分類至損益。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Classification and subsequent measurement of financial assets (continued)

(iii) Financial assets at FVTPL

Financial assets that do not meet the criteria for being measured at amortised cost or FVTOCI are measured at FVTPL.

Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair value gains or losses recognised in profit or loss. The net gain or loss recognised in profit or loss includes any dividend or interest earned on the financial asset and is included in the “other income, gains and losses” line item.

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9

The Group performs impairment assessment under expected credit loss (“ECL”) model on financial assets (including trade and other receivables, loan receivables and debt instruments at FVTOCI, pledged bank deposits, bank balances and cash), and other items (finance lease receivables and financial guarantee contracts) which are subject to impairment assessment under HKFRS 9. The amount of ECL is updated at each reporting date to reflect changes in credit risk since initial recognition.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產的分類及後續計量 (續)

(iii) 按公平值計入損益計量之金融資產

金融資產如不符合按攤銷成本計量或按公平值計入其他全面收益計量的計量標準，則按公平值計入損益計量。

於各報告期末，按公平值計入損益計量之金融資產按公平值計量，而任何公平值收益或虧損於損益中確認。於損益中確認的收益或虧損淨額包括就金融資產所賺取的任何股息或利息，並計入「其他收入、收益及虧損」項目內。

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值

本集團根據預期信貸虧損（「預期信貸虧損」）模式對根據香港財務報告準則第9號進行減值評估的金融資產（包括應收貿易賬款及其他應收款項、應收貸款及按公平值計入其他全面收益計量之債務工具、已抵押銀行存款以及銀行結餘及現金）及其他項目（應收融資租賃款項及金融擔保合約）進行減值評估。預期信貸虧損的金額於各呈報日期更新，以反映自首次確認起的信貸風險變動。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (continued)

Lifetime ECL represents the ECL that will result from all possible default events over the expected life of the relevant instrument. In contrast, 12-month ECL ("12m ECL") represents the portion of lifetime ECL that is expected to result from default events that are possible within 12 months after the reporting date. Assessment are done based on the Group's historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current conditions at the reporting date as well as the forecast of future conditions.

The Group always recognises lifetime ECL for trade receivables and lease receivables. The ECL for these assets are assessed individually for debtors with significant balances and/or collectively using a provision matrix with appropriate groupings.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值(續)

整個週期的預期信貸虧損指相關工具於預計年期內所有可能的違約事件將產生的預期信貸虧損。相反，12個月預期信貸虧損(「12個月預期信貸虧損」)指於呈報日期後12個月內可能發生的違約事件預計產生的該部分整個週期的預期信貸虧損。評估乃根據本集團過往信貸虧損經驗為基礎，並就債務人特定因素、整體經濟環境及報告日期當前及未來情況預測的評估作出調整。

本集團一直就應收貿易賬款及應收租賃款項確認整個週期的預期信貸虧損。對債務人具有重大結餘的該等資產的預期信貸虧損單獨進行評估及／或一併使用合適組別的撥備矩陣進行評估。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (continued)

For all other instruments, the Group measures the loss allowance equal to 12m ECL, unless there has been a significant increase in credit risk since initial recognition, in which case the Group recognises lifetime ECL. The assessment of whether lifetime ECL should be recognised is based on significant increases in the likelihood or risk of a default occurring since initial recognition.

(i) Significant increase in credit risk

In assessing whether the credit risk has increased significantly since initial recognition, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition. In making this assessment, the Group considers both quantitative and qualitative information that is reasonable and supportable, including historical experience and forward-looking information that is available without undue cost or effort.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值 (續)

對於所有其他工具，本集團按12個月預期信貸虧損的相同金額計量該財務工具的損失撥備，除非當自首次確認以來信貸風險顯著上升，在此情況下，本集團確認整個週期的預期信貸虧損。評估整個週期的預期信貸虧損是否應確認乃基於自首次確認以來發生違約的可能性或風險顯著上升。

(i) 信貸風險顯著上升

於評估信貸風險是否自初始確認以來顯著上升時，本集團會將金融工具於呈報日期發生違約的風險與金融工具於初始確認日期發生違約的風險進行比較。作出評估時，本集團會考慮合理及具支持性的定量及定性資料，包括過往經驗及可以合理成本及努力獲得的前瞻性資料。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (continued)

(i) Significant increase in credit risk (continued)

In particular, the following information is taken into account when assessing whether credit risk has increased significantly:

- an actual or expected significant deterioration in the financial instrument's external (if available) or internal credit rating;
- significant deterioration in external market indicators of credit risk, e.g. a significant increase in the credit spread, the credit default swap prices for the debtor;
- existing or forecast adverse changes in business, financial or economic conditions that are expected to cause a significant decrease in the debtor's ability to meet its debt obligations;
- an actual or expected significant deterioration in the operating results of the debtor;
- an actual or expected significant adverse change in the regulatory, economic, or technological environment of the debtor that results in a significant decrease in the debtor's ability to meet its debt obligations.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值(續)

(i) 信貸風險顯著上升(續)

具體而言，在評估信貸風險是否顯著上升時，會考慮以下資料：

- 金融工具外部(如有)或內部信貸評級的實際或預期顯著惡化；
- 信貸風險的外界市場指標顯著惡化，例如：債務人的信貸息差、信貸違約掉期價格大幅上升；
- 現有或預期的商業、金融或經濟狀況的不利變動，導致債務人償還債項能力大幅下降；
- 債務人經營業績的實際或預期顯著惡化；
- 債務人的監管、經濟或技術環境有實際或預期的重大不利變動，導致債務人償還債項的能力大幅下降。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (continued)

(i) Significant increase in credit risk (continued)

Despite the foregoing, the Group assumes that the credit risk on a debt instrument has not increased significantly since initial recognition if the debt instrument is determined to have low credit risk at the reporting date. A debt instrument is determined to have low credit risk if i) it has a low risk of default, ii) the borrower has a strong capacity to meet its contractual cash flow obligations in the near term and iii) adverse changes in economic and business conditions in the longer term may, but will not necessarily, reduce the ability of the borrower to fulfil its contractual cash flow obligations. The Group's debt instruments at FVTOCI only comprise bills receivable that are issued and guaranteed by the reputable PRC banks and therefore are considered to be low credit risk.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值 (續)

(i) 信貸風險顯著上升 (續)

儘管如此，倘債務工具於呈報日期被確定信貸風險較低，則本集團假設該債務工具的信貸風險自初始確認以來並無大幅上升。倘若債務工具符合以下條件，則被確定信貸風險較低：i) 違約風險低，ii) 借款人於近期內具有雄厚實力履行其合約現金流責任，及iii) 經濟及商業狀況的不利變化從長遠來看，可能但未必會降低借款人履行合約現金流責任的能力。本集團之按公平值計入其他全面收益計量之債務工具僅包括由聲譽良好的中國銀行發行及擔保的應收票據且因此被視為具有較低信貸風險。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (continued)

For financial guarantee contracts, the date that the Group becomes a party to the irrevocable commitment is considered to be the date of initial recognition for the purposes of assessing impairment. The Group considers the changes in the risk that the specified debtor will default on the contract.

(i) Significant increase in credit risk

The Group regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes past due.

(ii) Definition of default

For internal credit risk management, the Group considers an event of default occurs when information developed internally or obtained from external sources indicates that the debtor is unlikely to pay its creditors, including the Group, in full (without taking into account any collaterals held by the Group).

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值(續)

就財務擔保合約而言，本集團不可撤回成為該承擔的相關方當日，被視為評估減值的首次確認日。本集團會考慮該特定債務人違約所引起的風險變動。

(i) 信貸風險顯著增加

本集團定期監控用以識別信貸風險有否顯著增加的標準之效益，且修訂標準(如適當)來確保標準能在金額逾期前識別信貸風險顯著增加。

(ii) 違約定義

就內部信貸風險管理而言，本集團認為，違約事件在內部制訂或得自外界來源的資料顯示債務人不大可能悉數向債權人(包括本集團)還款(未計及本集團所持任何抵押品)時發生。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (continued)

(iii) Credit-impaired financial assets

A financial asset is credit-impaired when one or more events that have a detrimental impact on the estimated future cash flows of that financial asset have occurred. Evidence that a financial asset is credit-impaired includes observable data about the following events:

- a) significant financial difficulty of the issuer or the borrower;
- b) a breach of contract, such as a default or past due event;
- c) the lender(s) of the borrower, for economic or contractual reasons relating to the borrower's financial difficulty, having granted to the borrower a concession(s) that the lender(s) would not otherwise consider;
- d) it is becoming probable that the borrower will enter bankruptcy or other financial reorganisation; or
- e) the disappearance of an active market for that financial asset because of financial difficulties.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值 (續)

(iii) 信用減值金融資產

金融資產在一項或以上事件 (對該金融資產估計未來現金流量構成不利影響) 發生時維持信用減值。金融資產維持信用減值的證據包括有關下列事件的可觀察數據：

- a) 發行人或借款人的重大財困；
- b) 違反合約 (如違約或逾期事件)；
- c) 借款人的貸款人因有關借款人財困的經濟或合約理由而向借款人批出貸款人不會另行考慮的優惠；
- d) 借款人將可能陷入破產或其他財務重組；或
- e) 由於出現財務困難，金融資產活躍市場消失。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (continued)

(iv) Write-off policy

The Group writes off a financial asset when there is information indicating that the counterparty is in severe financial difficulty and there is no realistic prospect of recovery, for example, when the counterparty has been placed under liquidation or has entered into bankruptcy proceedings. Financial assets written off may still be subject to enforcement activities under the Group's recovery procedures, taking into account legal advice where appropriate. A write-off constitutes a derecognition event. Any subsequent recoveries are recognised in profit or loss.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值(續)

(iv) 撇銷政策

資料顯示對手方處於嚴重財困及無實際收回可能時(例如對手方被清盤或已進入破產程序時)，本集團則撇銷金融資產。經考慮法律意見後(倘合適)，遭撇銷的金融資產可能仍須按本集團收回程序進行強制執行活動。撇銷構成取消確認事項。任何其後收回在損益中確認。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (continued)

(v) Measurement and recognition of ECL

The measurement of ECL is a function of the probability of default, loss given default (i.e. the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data and forward-looking information. Estimation of ECL reflects an unbiased and probability-weighted amount that is determined with the respective risks of default occurring as the weights. The Group uses a practical expedient in estimating ECL on trade receivables and finance lease receivables using a provision matrix taking into consideration historical credit loss experience and forward looking information that is available without undue cost or effort.

Generally, the ECL is the difference between all contractual cash flows that are due to the Group in accordance with the contract and the cash flows that the Group expects to receive, discounted at the effective interest rate determined at initial recognition. For a lease receivable, the cash flows used for determining the ECL is consistent with the cash flows used in measuring the lease receivable in accordance with HKFRS 16.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值 (續)

(v) 預期信貸虧損之計量及確認

預期信貸虧損之計量為違約概率、違約虧損 (即違約時虧損大小) 及違約時風險敞口之函數。違約概率及違約虧損之評估乃基於歷史數據及前瞻性資料。預期信貸虧損的預估乃無偏概率加權平均金額，以各自發生違約的風險為權重確定。本集團使用可行權宜方法，運用撥備矩陣預估應收貿易賬款之預期信貸虧損及應收融資租賃款項，當中考慮過往信貸損失經驗及毋須繁苛成本或工作即可獲得之前瞻性資料。

一般而言，預期信貸虧損為根據合約應付本集團的所有合約現金流與本集團預期將收取的現金流之間的差額，並按初始確認時釐定的實際利率貼現。就租賃應收款項而言，釐定預期信貸虧損所用的現金流與根據香港財務報告準則第16號租賃計量租賃應收款項所用的現金流一致。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (continued)

- (v) Measurement and recognition of ECL (continued)

For a financial guarantee contract, the Group is required to make payments only in the event of a default by the debtor in accordance with the terms of the instrument that is guaranteed. Accordingly, the ECL is the present value of the expected payments to reimburse the holder for a credit loss that it incurs less any amounts that the Group expects to receive from the holder, the debtor or any other party.

Lifetime ECL for certain trade receivables and finance lease receivables are considered on a collective basis taking into consideration past due information and relevant credit information such as forward looking macroeconomic information.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值(續)

- (v) 預期信貸虧損之計量及確認(續)

就財務擔保合約而言，本集團僅須在債務人違反所擔保工具條款的情況下付款。因此，預期信貸虧損乃補償持有人就所產生信貸損失之預期款項之現值，減任何本集團預期從該持有人、債務人或任何其他方所收取之任何金額。

若干應收貿易賬款及應收融資租賃款項的存續期預期信貸虧損為計及逾期資料及相關信貸資料(包括前瞻性宏觀經濟資料)共同作考慮。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (continued)

(v) Measurement and recognition of ECL (continued)

For collective assessment, the Group takes into consideration the following characteristics when formulating the grouping:

- Past-due status;
- Nature, size and industry of debtors; and
- External credit ratings where available.

The grouping is regularly reviewed by management to ensure the constituents of each group continue to share similar credit risk characteristics.

Interest income is calculated based on the gross carrying amount of the financial asset unless the financial asset is credit impaired, in which case interest income is calculated based on amortised cost of the financial asset.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值 (續)

(v) 預期信貸虧損之計量及確認 (續)

就共同評估而言，本集團於制定分組時將計及以下特點：

- 逾期狀況；
- 貸方性質、規模及所處行業；及
- 外部信貸評級 (倘有)。

歸類工作經管理層定期檢討，以確保各組別成份繼續分擔類似信貸風險特性。

利息收入乃根據金融資產的總賬面值計算，惟金融資產出現信貸減值則除外，在此情況下，利息收入根據金融資產的攤銷成本計算。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Impairment of financial assets and other items subject to impairment assessment under HKFRS 9 (continued)

- (v) Measurement and recognition of ECL (continued)

For financial guarantee contracts, the loss allowances are recognised at the higher of the amount of the loss allowance determined in accordance with HKFRS 9; and the amount initially recognised less, where appropriate, cumulative amount of income recognised over the guarantee period.

Except for investments in debt instruments that are measured at FVTOCI and financial guarantee contracts, the Group recognises an impairment gain or loss in profit or loss for all financial instruments by adjusting their carrying amount, with the exception of receivables from factoring business, loan receivables and trade and other receivables where the corresponding adjustment through a loss allowance account.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

金融資產及香港財務報告準則第9號須進行減值評估之其他項目之減值(續)

- (v) 預期信貸虧損之計量及確認(續)

就財務擔保合約而言，虧損撥備乃根據香港財務報告準則第9號釐定之虧損撥備與初步確認金額當中較高者，減去(倘適用)擔保期間所確認累計收入。

除按公平值計入其他全面收益計量的債務工具及金融擔保合約的投資外，本集團通過調整金融資產的賬面值於損益中確認所有金融工具的減值收益或虧損，惟保理業務應收款項、應收貸款以及應收貿易賬款及其他應收款項除外，在此情況下，有關相應調整透過虧損撥備賬確認。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial assets (continued)

Derecognition of financial assets

The Group derecognises a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity. If the Group retains substantially all the risks and rewards of ownership of a transferred financial asset, the Group continues to recognise the financial asset and also recognises a collateralised borrowing for the proceeds received.

On derecognition of a financial asset measured at amortised cost, the difference between the asset's carrying amount and the sum of the consideration received and receivable is recognised in profit or loss.

On derecognition of an investment in a debt instrument classified as at FVTOCI, the cumulative gain or loss previously accumulated in the reserve is reclassified to profit or loss.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融資產 (續)

終止確認金融資產

倘從資產收取現金流量之合約權利已到期，或金融資產已轉讓且本集團已將其於金融資產擁有權之絕大部份風險及回報轉移至另一實體，則金融資產將被取消確認。倘若本集團保留已轉讓金融資產擁有權之絕大部份風險及回報，則本集團繼續確認金融資產並同時就所得收益確認抵押借款。

當以攤銷成本計量的金融資產終止確認時，資產的賬面值與已收及應收代價款項總額之間的差額將於損益中確認。

於終止確認分類為按公平值計入其他全面收益計量的債務工具投資時，先於儲備中累計的累計收益或虧損將重新分類至損益。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial liabilities and equity

Classification as debt or equity

Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融負債及權益

分類為負債或權益

負債及股本工具乃根據合約安排的性質與金融負債及股本工具的定義分類為金融負債或權益。

股本工具

股本工具乃證明實體於扣減所有負債後的資產中擁有剩餘權益之任何合約。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial liabilities and equity (continued)

Financial liabilities at FVTPL

Financial liabilities are classified as at FVTPL when the financial liability is (i) contingent consideration of an acquirer in a business combination to which HKFRS 3 applies, (ii) held for trading or (iii) it is designated as at FVTPL.

A financial liability is held for trading if:

- it has been acquired principally for the purpose of repurchasing it in the near term; or
- on initial recognition it is part of a portfolio of identified financial instruments that the Group manages together and has a recent actual pattern of short-term profit-taking; or
- it is a derivative, except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument.

Financial liabilities at amortised cost

Financial liabilities including borrowings, bonds payable and trade and other payables are subsequently measured at amortised cost, using the effective interest method.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融負債及權益 (續)

按公平值計入損益計量之金融負債

倘金融負債是(i)香港財務報告準則第3號所適用的企業合併中通過收購方確認的或有對價，(ii)為交易而持有或(iii)被指定為按公平值計入損益計量，則應歸類為按公平值計入損益計量之金融負債。

滿足下述條件的金融負債應被歸類為交易而持有之金融負債：

- 發生金融負債的目的主要是為近期購回；或
- 在初始確認時是本集團集中管理的可辨認金融工具組合的一部分，並且近期實際採用短期獲利方式對該組合進行管理；或
- 是一項衍生工具，但為金融擔保合約或被指定為有效對沖工具的衍生工具除外。

按攤銷成本計量之金融負債

金融負債(包括借款、應付債券以及應付貿易賬款及其他應付款項)其後按攤銷成本採用實際利率法計量。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial liabilities and equity (continued)

Financial guarantee contracts

A financial guarantee contract is a contract that requires the issuer to make specified payments to reimburse the holder for a loss it incurs because a specified debtor fails to make payments when due in accordance with the terms of a debt instrument. Financial guarantee contract liabilities are measured initially at their fair values. It is subsequently measured at the higher of:

- the amount of the loss allowance determined in accordance with HKFRS 9; and
- the amount initially recognised less, where appropriate, cumulative amortisation recognised over the guarantee period.

Derecognition of financial liabilities

The Group derecognises financial liabilities when, and only when, the Group's obligations are discharged, cancelled or have expired. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in profit or loss.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融負債及權益 (續)

財務擔保合約

財務擔保合約乃要求發行人根據一項債務工具之條款，因特定債務人未能於到期日償還款項而需支付特定款項以補償合約持有人所招致損失之一項合約。財務擔保合約於首次確認時以其公平值計量。於首次確認後則以下列較高者計量：

- 按香港財務報告準則第9號所確定虧損撥備金額；及
- 於首次確認之金額減於擔保期間之累計攤銷(如適用)。

終止確認金融負債

當及僅當本集團的責任獲解除、取消或屆滿時，本集團便會終止確認金融負債。終止確認的金融負債的賬面值與已付及應付代價之間的差額於損益中確認。

4. BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

4.2 Significant accounting policies (continued)

Financial instruments (continued)

Financial liabilities and equity (continued)

Changes in the basis for determining the contractual cash flows as a result of interest rate benchmark reform

For changes in the basis for determining the contractual cash flows of a financial liability to which the amortised cost measurement applies as a result of interest rate benchmark reform, the Group applies the practical expedient to account for these changes by updating the effective interest rate, such change in effective interest rate normally has no significant effect on the carrying amount of the relevant financial liability.

A change in the basis for determining the contractual cash flows is required by interest rate benchmark reform if and only if, both these conditions are met:

- the change is necessary as a direct consequence of interest rate benchmark reform; and
- the new basis for determining the contractual cash flows is economically equivalent to the previous basis (ie the basis immediately preceding the change).

Derivative financial instruments

Derivatives are initially recognised at fair value at the date when derivative contracts are entered into and are subsequently remeasured to their fair value at the end of the reporting period. The resulting gain or loss is recognised in profit or loss.

4. 編製綜合財務報表基準及主要會計政策 (續)

4.2 主要會計政策 (續)

金融工具 (續)

金融負債及權益 (續)

因利率基準改革而導致釐定合約現金流基準之變動

就因利率基準改革而導致釐定按攤銷成本計量之金融負債之合約現金流基準之變動而言，本集團採用可行權宜方法，以更新實際利率將該等變動入賬。此實際利率之變動一般而言對相關金融負債之賬面值並無顯著影響。

僅當符合下述兩個條件時，釐定合約現金流之基準須因應利率基準改革而變動：

- 該變動是利率基準改革之直接後果；及
- 釐定合約現金流之新基準在經濟上等同於先前基準（即緊接變動前之基準）。

衍生金融工具

衍生工具初步按衍生工具合約訂立日期的公平值確認，其後按其於報告期末的公平值重新計量。所產生的收益或虧損即時於損益中確認。

5. KEY SOURCES OF ESTIMATION UNCERTAINTY

The following are the key assumptions concerning the future, and other key sources of estimation uncertainty at the end of the reporting period, that may have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year.

Impairment assessment of goodwill

Determining whether goodwill is impaired requires an estimation of the recoverable amount of the cash-generating unit (or group of cash-generating units) to which goodwill has been allocated, which is the higher of the value in use or fair value less costs of disposal. The value in use calculation requires the Group to estimate the future cash flows expected to arise from the cash-generating unit (or group of cash-generating units) and a suitable discount rate in order to calculate the present value.

Where the actual future cash flows are less than expected, or changes in facts and circumstances which results in downward revision of future cash flows or upward revision of the discount rate, a material impairment loss/further impairment loss may arise. Details of the recoverable amount calculation are disclosed in note 18.

Provision associated with product liability claims

The subsidiary of the Group recorded a provision related to product liability claims that represent a significant management estimate which is highly dependent upon judgment and assumptions. The management of the Group developed an estimate of the expected gross liability based on actual claim numbers, as well as a series of management assumptions including injury alleged, the results of related litigation, and the degree of responsibility that may be inferred to the subsidiary of the Group. Considering the claims are still in the process, changes to these assumptions would result in adjustments to the amount of provision recognised. The details of the provision are disclosed in note 7(e).

5. 估計不明朗因素的主要來源

以下為有關未來的主要假設，而於各報告期末具有重大風險會導致資產及負債的賬面值於未來財政年度內需要作出重大調整的估計不確定因素的其他主要來源。

商譽減值評估

釐定商譽是否減值需要估計獲分配有關商譽之現金產生單位（或一組現金產生單位之可收回金額，即使使用價值或公允值減出售成本兩者之較高者。計算使用價值須要本集團對預期可自現金產生單位（或本集團現金產生單位）獲得之未來現金流量，以及適合計算所得現值之折現率作出估計。

倘未來實際現金流量較預期為少，或事實及情況有變以致未來現金流量向下調整或折現率向上調整，則可能產生重大減值虧損／進一步減值虧損。可回收金額計算詳情於附註18中披露。

與產品責任索賠相關的撥備

本集團附屬公司錄得與產品責任索賠有關的撥備，代表高度依賴判斷及假設的重大管理層估計。本集團管理層根據實際索賠數額以及一系列管理層假設，包括指稱的傷害、相關訴訟的結果以及可能推斷出的本集團附屬公司的責任程度，制定對預期負債總額的估計。考慮到索賠仍在進行中，該等假設的變化將導致對已確認的撥備數額的調整。撥備的詳情於附註7(e)中披露。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

6. REVENUE AND SEGMENT INFORMATION

6. 收入及分部資料

The Group is principally engaged in the research and development, production and sale of medical device products, orthopaedic products, interventional products, pharma packaging products, blood management products, and operates financing business.

For management purposes, the Group is currently organised into six operating divisions – medical device products, orthopaedic products, interventional products, pharma packaging products, blood management products and others, among which interventional products were produced by Argon. These divisions are the basis of the internal reports about components of the Group that are regularly reviewed by the chief operating decision maker (Managing Director) in order to allocate resources to segments and to assess their performance.

Principal activities of the Group's operating and reportable segments are as follows:

Medical device products	– production and sale of clinical care, wound management, medical testing, anesthesia and surgical related products and other consumables
Orthopaedic products	– production and sale of orthopaedic products
Interventional products	– production and sale of tumour and blood vessel interventional instruments
Pharma packaging products	– production and sale of pre-filled syringes and flushing syringes
Blood management products	– production and sale of blood collection, irradiation, storage, separation and sterilization products
Others	– finance lease and factoring business

本集團主要從事研發、生產及銷售醫療器械產品、骨科產品、介入產品、藥品包裝產品、血液管理產品，及經營融資業務。

就管理而言，本集團目前分為六個經營分部—醫療器械產品、骨科產品、介入產品、藥品包裝產品、血液管理產品及其他，其中介入產品由愛琅生產。該等分部乃按本集團各部的內部呈報基準劃分，定期由主要營運決策者（董事總經理）審核，以分配資源至分部並評估其表現。

本集團經營及可呈報分部的主要業務如下：

醫療器械產品	– 生產及銷售臨床護理、創傷護理、醫學檢驗、麻醉及手術相關產品以及其他耗材
骨科產品	– 生產及銷售骨科產品
介入產品	– 生產及銷售腫瘤及血管介入器械
藥品包裝產品	– 生產及銷售預充式注射器及沖管注射器
血液管理產品	– 生產及銷售血液採集、貯存、分離及滅菌消毒產品
其他	– 融資租賃及保理業務

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

6. REVENUE AND SEGMENT INFORMATION (continued)

6. 收入及分部資料 (續)

Segment revenues and results

The following is an analysis of the Group's revenue and results by reportable segments:

分部收益及業績

本集團按可報告分部分析之收益及業績如下：

For the year ended 31 December 2021

截至二零二一年十二月三十一日止年度

		Medical device products	Orthopaedic products	Interventional products	Pharma packaging products	Blood management products	Others	Eliminations	Total
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		醫療器械產品	骨科產品	介入產品	藥品包裝產品	血液管理產品	其他	抵減	合計
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Revenue	收入								
External sales	外部銷售	6,463,642	2,126,594	1,544,266	2,040,355	976,862	-	-	13,151,719
Inter-segment sales	內部分部銷售	109	-	-	-	-	-	(109)	-
Total	合計	6,463,751	2,126,594	1,544,266	2,040,355	976,862	-	(109)	13,151,719
Segment profit	分部溢利	927,418	761,831	151,200	855,265	169,932	74,576	-	2,940,222
Depreciation of investment properties	投資物業之折舊								(5,216)
Unallocated other income, gains and losses	未分配其他收入、收益及虧損								20,821
Rental income of investment properties	投資物業之租金收入								12,070
Interest income from bank deposits	銀行存款之利息收入								72,171
Gain from changes in fair value of financial instruments at FVTPL	按公平值計入損益計量之金融工具公平值變動收益								3,323
Share of results of an associate	應佔一間聯營公司業績								69,988
Share of results of joint ventures	應佔合營企業業績								(531)
Share-based payment expenses	以股份為基礎的付款開支								(41,275)
Net loss of litigation	訴訟損失淨額								(229,852)
Profit before tax	除稅前溢利								2,841,721

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

6. REVENUE AND SEGMENT INFORMATION (continued) 6. 收入及分部資料 (續)

Segment revenues and results (continued)

分部收益及業績 (續)

For the year ended 31 December 2020

截至二零二零年十二月三十一日止年度

		Medical device products RMB'000	Orthopaedic products RMB'000	Interventional products RMB'000	Pharma packaging products RMB'000	Blood management products RMB'000	Others RMB'000	Eliminations RMB'000	Total RMB'000
		醫療器械產品	骨科產品	介入產品	藥品包裝產品	血液管理產品	其他	抵減	合計
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Revenue	收入								
External sales	外部銷售	5,990,009	1,747,774	1,370,156	1,693,798	820,600	-	-	11,622,337
Inter-segment sales	內部分部銷售	639	5,827	2,602	-	8,225	-	(17,293)	-
Total	總計	5,990,648	1,753,601	1,372,758	1,693,798	828,825	-	(17,293)	11,622,337
Segment profit	分部溢利	1,070,702	529,239	26,443	554,729	142,988	64,309	-	2,388,410
Depreciation of investment properties	投資物業之折舊								(6,276)
Unallocated other income, gains and losses	未分配其他收入、收益及虧損								(46,957)
Rental income of investment properties	投資物業之租金收入								13,409
Interest income from bank deposits	銀行存款之利息收入								46,423
Loss from changes in fair value of financial instruments at FVTPL	按公平值計入損益計量之金融工具公平值變動虧損								(84,364)
Gain on disposal of financial assets at FVTPL	出售按公平值計入損益計量之金融資產的收益								29,809
Gain on release of escrow account	解除託管賬戶收益								98,542
Gain on novation of the Contracts	約務更替的收益								117,292
Share of results of an associate	應佔一間聯營公司業績								9,171
Profit before tax	除稅前溢利								2,565,459

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

6. REVENUE AND SEGMENT INFORMATION (continued)

Segment revenues and results (continued)

The accounting policies of the operating segments are the same as the Group's accounting policies described in note 4. Segment profit represents the profit earned by each segment without allocation of depreciation and rental income of investment properties, other income, gains and losses of the corporate function, interest income from bank, gain and loss from changes in fair value of financial instruments at FVTPL, gain on disposal of financial assets at FVTPL, gain on release of escrow account, gain on novation of the Contracts, share of results of an associate, share of results of joint ventures, share based payment expenses recognised for grantees of the management of the Group and net loss of litigation. This is the measure reported to the Managing Director for the purposes of resource allocation and performance assessment.

Inter-segment sales are charged at prevailing market rates.

Segment assets and liabilities

The following is an analysis of the Group's assets and liabilities by reportable and operating segments:

Segment assets

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
			(經重列)
Medical device products	醫療器械產品	9,949,083	9,432,657
Orthopaedic products	骨科產品	2,859,211	1,644,776
Interventional products	介入產品	5,645,171	5,641,033
Pharma packaging products	藥品包裝產品	2,252,660	1,903,253
Blood management products	血液管理產品	930,599	841,893
Others	其他	892,598	852,292
Total segment assets	分部總資產	22,529,322	20,315,904
Financial assets at FVTPL	按公平值計入損益計量之 金融資產	110,943	108,420
Interests in an associate	於一間聯營公司的權益	1,138,901	1,068,912
Interests in joint ventures	於合營企業的權益	180,757	181,927
Investment properties	投資物業	133,788	136,710
Deferred tax assets	遞延稅項資產	156,462	140,058
Pledged bank deposits	已抵押銀行存款	760,895	340,129
Bank balances and cash	銀行結餘及現金	5,355,990	5,665,656
Consolidated assets	綜合資產	30,367,058	27,957,716

6. 收入及分部資料 (續)

分部收益及業績 (續)

經營分部的會計政策與附註4所述的本集團會計政策相同。分部溢利指各分部所賺取的溢利，未計及投資物業之折舊及租金收入、企業職能的其他收入、收益及虧損、銀行利息收入、按公平值計入損益計量之金融工具公平值變動收益及虧損、出售按公平值計入損益計量之金融資產的收益、解除託管賬戶收益、約務更替的收益、應佔一間聯營公司業績、應佔合營企業業績、就本集團管理層之擔保確認之以股份為基礎的付款開支以及訴訟損失淨額。此為向董事總經理就資源分配及表現評估呈報的計量方式。

內部分部銷售按現行市場價格收取。

分部資產及負債

本集團按可報告及經營分部分析之資產及負債如下：

分部資產

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

6. REVENUE AND SEGMENT INFORMATION

(continued)

6. 收入及分部資料 (續)

Segment assets and liabilities (continued)

分部收益及業績 (續)

Segment liabilities

分部負債

		31/12/2021	31/12/2020
		RMB'000	RMB'000
			(restated)
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
			(經重列)
Medical device products	醫療器械產品	4,516,452	4,742,677
Orthopaedic products	骨科產品	844,824	705,248
Interventional products	介入產品	2,890,818	2,690,191
Pharma packaging products	藥品包裝產品	361,895	213,557
Blood management products	血液管理產品	297,418	215,752
Others	其他	58,649	84,428
Total segment liabilities	分部總負債	8,970,056	8,651,853
Deferred tax liabilities	遞延稅項負債	222,620	291,797
Financial liabilities at FVTPL	按公平值計入損益計量之 金融負債	56,893	85,878
Other payables	其他應付款項	210,039	49,500
Consolidated liabilities	綜合負債	9,459,608	9,079,028

For the purposes of monitoring segment performances and allocating resources between segments:

為監控分部表現及在分部之間分配資源：

- all assets are allocated to operating segments other than financial assets at FVTPL, interests in an associate, interests in joint ventures, investment properties, deferred tax assets, pledged bank deposits and part of bank balances and cash.
 - all liabilities are allocated to operating segments other than deferred tax liabilities, financial liabilities at FVTPL and part of other payables.
- 所有資產分配至經營分部，惟按公平值計入損益計量之金融資產、於一間聯營公司的權益、於合營企業的權益、投資物業、遞延稅項資產、已抵押銀行存款、部分銀行結餘及現金除外。
 - 所有負債分配至經營分部，惟遞延稅項負債、按公平值計入損益計量之金融負債及部分其他應付款項除外。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

6. REVENUE AND SEGMENT INFORMATION (continued)

6. 收入及分部資料 (續)

Other segment information

其他分部資料

For the year ended 31 December 2021

截至二零二一年十二月三十一日止
年度

		Medical device products	Orthopaedic products	Interventional products	Pharma packaging products	Blood management products	Others	Total
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		醫療器械產品	骨科產品	介入產品	藥品包裝產品	血液管理產品	其他	合計
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Amounts included in the measure of segment profit or segment assets:	計量分部溢利或分部資產時應計款項：							
Additions to property, plant and equipment	新增物業、廠房及設備	494,833	133,679	55,075	142,020	18,673	-	844,280
Allowances for credit losses	信貸虧損撥備	11,503	10,129	322	1,407	-	3,621	26,982
Allowances for inventories	存貨撥備	1,180	3,672	1,472	-	632	-	6,956
Amortisation of intangible assets	無形資產攤銷	257	6,603	221,765	821	11,887	-	241,333
Depreciation of property, plant and equipment	物業、廠房及設備折舊	186,119	82,668	17,523	128,251	31,502	109	446,172
Depreciation of right-of-use assets	使用權資產折舊	19,818	3,054	5,305	-	2,915	-	31,092
Loss/(gain) on disposal of property, plant and equipment	出售物業、廠房及設備虧損/(收益)	1,496	108	482	(49)	900	-	2,937
Research and development expenditure	研發開支	280,124	121,225	16,842	43,283	30,659	-	492,133
Share-based payment expenses	以股份為基礎的付款開支	2,886	5,139	26,506	268	418	-	35,217
Government grants	政府補助	(20,357)	(15,178)	(32)	(65)	-	-	(35,632)
Rebate of value added tax ("VAT")	增值稅(「增值稅」)退款	(76,438)	-	-	-	-	(1,143)	(77,581)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

6. REVENUE AND SEGMENT INFORMATION
(continued)

6. 收入及分部資料 (續)

Other segment information (continued)

其他分部資料 (續)

For the year ended 31 December 2020

截至二零二零年十二月三十一日止
年度

	Medical device products RMB'000	Orthopaedic products RMB'000	Interventional products RMB'000	Pharma packaging products RMB'000	Blood management products RMB'000 (restated)	Others RMB'000	Total RMB'000 (restated)
	醫療器械產品 人民幣千元	骨科產品 人民幣千元	介入產品 人民幣千元	藥品包裝產品 人民幣千元	血液管理產品 人民幣千元 (經重列)	其他 人民幣千元	合計 人民幣千元 (經重列)

Amounts included in the measure of segment profit or segment assets:	計量分部溢利或分部資產時應計 款項：							
Additions to property, plant and equipment	新增物業、廠房及設備	512,262	199,362	40,191	32,160	18,880	-	802,855
Allowances for credit losses	信貸虧損撥備	17,630	4,321	4,784	7,314	-	1,195	35,244
Allowances for inventories	存貨撥備	16	9,006	1,430	-	-	-	10,452
Allowances for property, plant and equipment	物業、廠房及設備撥備	-	2,571	-	-	-	-	2,571
Allowances for intangible assets	無形資產撥備	-	-	4,295	-	-	-	4,295
Amortisation of intangible assets	無形資產攤銷	1,052	3,353	240,221	-	12,623	-	257,249
Depreciation of property, plant and equipment	物業、廠房及設備折舊	221,649	111,788	15,225	55,351	20,556	177	424,746
Depreciation of right-of-use assets	使用權資產折舊	17,018	-	3,672	-	-	-	20,690
Gain on disposal of property, plant and equipment	出售物業、廠房及設備收益	(1,389)	(288)	-	-	-	-	(1,677)
Research and development expenditure	研發開支	256,023	84,878	14,754	33,496	35,271	-	424,422
Share-based payment expenses	以股份為基礎的付款開支	6,992	6,958	15,801	627	284	-	30,662
Government grants	政府補助	(15,694)	(1,138)	-	(2,792)	(336)	(106)	(20,066)
Rebate of VAT	增值稅退款	(77,065)	-	-	-	-	(4,609)	(81,674)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

6. REVENUE AND SEGMENT INFORMATION (continued)

Revenue from major products and services

The following is an analysis of the Group's revenue from its major products and services.

6. 收入及分部資料 (續)

主要產品及服務收入

以下為本集團來自其主要產品及服務之收入分析。

		Year ended 31/12/2021 RMB'000	Year ended 31/12/2020 RMB'000 (restated)
		截至 二零二一年 十二月 三十一日 止年度 人民幣千元	截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)
Sale of medical device products	銷售醫療器械產品		
– Clinical care	– 臨床護理	4,574,811	4,267,450
– Wound management	– 創傷護理	412,385	346,590
– Anesthesia and surgical related products	– 麻醉及手術相關產品	247,631	193,051
– Medical testing	– 醫學檢驗	294,833	275,780
– Other consumables	– 其他耗材	705,304	665,711
Sale of orthopaedic products	銷售骨科產品	2,126,594	1,747,774
Sale of interventional products	銷售介入產品	1,772,944	1,611,583
Sale of pharma packaging products	銷售藥品包裝產品	2,040,355	1,693,798
Sale of blood management products	銷售血液管理產品	976,862	820,600
		13,151,719	11,622,337

Information about major customers

There is no single customer contributing over 10% of total sales of the Group for both years.

主要客戶的資料

於兩個年度內，概無單一客戶銷售額超逾本集團總銷售額的10%。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

6. REVENUE AND SEGMENT INFORMATION (continued) **6. 收入及分部資料** (續)

Geographical information

Information about the Group's revenue from external customers is presented based on the location of the customers. Information about the Group's non-current assets is presented based on the geographical location of the assets.

地區資料

本集團來自外部客戶之收入之資料乃按客戶位置呈列。本集團非流動資產之資料乃按資產地理位置呈列。

		Revenue from external customers		Non-current assets	
		Year ended		31/12/2021	
		31/12/2021	31/12/2020	31/12/2021	31/12/2020
		RMB'000	RMB'000	RMB'000	RMB'000
			(restated)		(restated)
		來自外部客戶之收入		非流動資產	
		截至	截至	二零二一年	二零二零年
		十二月	十二月	十二月	十二月
		三十一日	三十一日	三十一日	三十一日
		止年度	止年度	止年度	止年度
		人民幣千元	人民幣千元	人民幣千元	人民幣千元
			(經重列)		(經重列)
PRC	中國	10,495,437	9,090,599	8,782,336	8,264,101
United States	美國	1,145,923	1,139,575	5,363,655	5,286,280
Europe, the Middle East and Africa	歐洲、中東及非洲	501,919	503,502	89,593	29,660
Other districts	其他地區	1,008,440	888,661	18,128	11,167
		13,151,719	11,622,337	14,253,712	13,591,208

Transaction price allocated to the remaining performance obligation for contracts with customers

As a practical expedient of HKFRS 15, the Group need not disclose the transaction price allocated to these unsatisfied contracts with customers that has an original expected duration of one year or less.

分配至客戶合約之餘下履約責任的交易價

作為香港財務報告準則第15號的權宜方式，本集團毋須披露分配至該等原預計期限為一年或更短的未履行客戶合約的交易價。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

7. OTHER INCOME, GAINS AND LOSSES

7. 其他收入、收益及虧損

		Year ended 31/12/2021 RMB'000	Year ended 31/12/2020 RMB'000 (restated)
		截至 二零二一年 十二月 三十一日 止年度 人民幣千元	截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)
Other income:	其他收入：		
Rebate of VAT (note a)	增值稅退款 (附註a)	77,581	81,674
Government grants (note b)	政府補助 (附註b)	35,632	20,066
Operating rental income	經營租金收入	12,070	13,409
Finance lease income	融資租賃收入	11,565	20,627
Interest income from bank deposits	銀行存款之利息收入	72,171	46,423
Interest income from factoring business	保理業務之利息收入	21,483	17,854
Interest income from loan receivables	應收貸款之利息收入	50,289	50,702
		280,791	250,755
Other gains and losses:	其他收益及虧損：		
Impairment losses on intangible assets	無形資產減值虧損	-	(4,295)
Impairment losses on inventories	存貨之減值虧損	(6,956)	(10,452)
Impairment losses on property, plant and equipment	物業、廠房及設備之減值虧損	-	(2,571)
Net exchange loss	匯兌虧損淨額	(39,357)	(39,977)
(Loss)/gain on disposal of property, plant and equipment	出售物業、廠房及設備 (虧損) / 收益	(2,937)	1,677
Gain on deemed disposal of investments in an associate (note 20)	視作出售於一間聯營公司之投資之收益 (附註20)	-	3,325
Gain/(loss) from changes in fair value of financial instruments measured at FVTPL	按公平值計入損益計量之金融工具公平值變動收益 / (虧損)	3,323	(84,364)
Gain on disposal of financial assets at FVTPL	出售按公平值計入損益計量之金融資產的收益	-	29,809
Donation paid	已付捐贈	(41,807)	(46,390)
Loss on currency option	貨幣期權虧損	(6,289)	-
Loss on Structured Cross Currency Swap	結構性交叉貨幣置換虧損	(22,453)	(16,322)
Gain from early repayment of an interest-free loan from an associate of the Company (note c)	提前償還來自本公司一間聯營公司的無息貸款的收益 (附註c)	-	16,856
Gain on release of escrow account	解除託管賬戶收益	-	98,542
Gain on novation of the Contracts (note d)	約務更替的收益 (附註d)	-	117,292
Net loss of litigation (note e)	訴訟損失淨額 (附註e)	(229,852)	-
Others	其他	1,380	(447)
		(344,948)	62,683
		(64,157)	313,438

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

7. OTHER INCOME, GAINS AND LOSSES (continued)

Notes:

- (a) As Weihai Jierui Medical Products Company Limited (“Jierui”), one of the subsidiary of the Company, was recognised as a “Social Welfare Entity”, the Tax Bureau in Weihai granted a rebate of VAT paid by Jierui with effect from 1 May 1999 on the basis of “payment first then rebate”. Pursuant to Caishui [2016] No.52 issued by the State Council, with effect from 1 May 2016, Jierui was granted a rebate of VAT determined with reference to the number of staff with physical disability. For each staff with physical disability, four times of the minimum salary approved by the local government in Weihai is granted to Jierui as rebate of VAT.

Pursuant to Caishui [2016] No.36, Weigao Financial Leasing Co., Ltd., one of the subsidiary of the Company, is entitled to immediate tax rebates upon collection when the actual VAT tax burden rate exceeds 3%.

- (b) During the year, government grants were awarded to the Group mainly for business development and certain research and development expenses occurred and were recognised as other income when the government grants were received. There were no unfulfilled conditions in the year in which they were recognised.
- (c) During the year ended 31 December 2020, Weihai Weigao Blood Purification Products Company (“Weigao Blood Purification”), the associate of the Company, early repaid the interest-free loan. The gain on early repayment of the loan receivable represents the difference between the carrying amount of the loan receivable derecognised and the consideration recovered.
- (d) During the year ended 31 December 2020, the Company sold several contracts (“Contracts”) to Weigao Holding with a consideration of USD17,921,000 (equivalent to RMB117,292,000) which the Company entered with NeuroVasc Technologies Inc. for design, research and development of medical devices in the year ended 31 December 2019. The consideration was fully settled in January 2021.

7. 其他收入、收益及虧損 (續)

附註：

- (a) 由於本公司的附屬公司威海潔瑞醫用製品有限公司(「潔瑞」)獲確認為「社會福利企業」，因此威海稅務局向潔瑞授出增值稅退稅，由一九九九年五月一日起生效，原則為「先付款後退還」。根據國務院發出之財稅[2016]第52號文件，由二零一六年五月一日起生效，潔瑞獲授予的增值稅退稅乃參考殘障員工之數目釐定。就每名殘障員工而言，潔瑞將獲授相當於由威海市地方政府所批准之最低薪金四倍之金額，作為增值稅退稅。

根據財稅[2016]第36號文件，本公司的附屬公司山東威高融資租賃有限公司有權於實際增值稅稅務負擔超過3%時，立即獲退稅款。

- (b) 年內，本集團主要就業務發展及產生的特定研發開支獲獎勵政府補助，並於收取政府補助時確認為其他收入。在確認年度內概無未達成條件。
- (c) 截至二零二零年十二月三十一日止年度，本公司聯營公司威海威高血液淨化製品公司(「威高血液淨化」)提前償還無息貸款。提前償還應收貸款的收益為終止確認的應收貸款賬面值與收回的代價之間的差額。
- (d) 截至二零二零年十二月三十一日止年度，本公司向威高集團公司出售若干合約(「合約」)，代價為17,921,000美元(相當於人民幣117,292,000元)，據此，本公司於截至二零一九年十二月三十一日止年度就醫療器械的設計及研發與NeuroVasc Technologies Inc.訂立合約。代價已於二零二一年一月全部結清。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

7. OTHER INCOME, GAINS AND LOSSES (continued)

Notes: (continued)

- (e) A subsidiary of the Group was defendant in a product liability claim ("Claims"). The Claims involve one of the Group's products. During the year ended 31 December 2021, the Group recorded a pre-tax charge of RMB522,650,000 for losses related to product liability litigation. The Group recorded these charges based on the best estimation of the injury alleged, the results of related litigation, and the degree of responsibility that may be inferred to the subsidiary of the Group. The subsidiary of the Group legally carries product liability insurance that covers losses asserted against the Claims. The amount of receivable is calculated according to contractual agreements, considering date of operation and claim date, and the degree of responsibility that may be inferred to the subsidiary of the Group. During the year ended 31 December 2021, the Group recorded an insurance receivable of RMB293,247,000. The net loss related to the Claims by considering the provision and insurance coverage is recorded with an amount of RMB229,852,000.

8. IMPAIRMENT LOSSES UNDER EXPECTED CREDIT LOSS MODEL, NET OF REVERSAL

7. 其他收入、收益及虧損 (續)

附註：(續)

- (e) 本集團一間附屬公司乃一宗產品責任索賠(「索賠」)的被告。該索賠涉及本集團其中一項產品。於截至二零二一年十二月三十一日止年度，本集團就與產品責任訴訟有關的損失錄得稅前費用人民幣522,650,000元。本集團根據對所稱傷害的最佳估計、相關訴訟的結果以及可能推斷出的本集團附屬公司的責任程度錄得此等費用。本集團附屬公司就索賠合法投購產品責任保險，涵蓋索賠中所主張的損失。應收款項的數額乃根據合同協定計算，計及操作日期及索賠日期，以及可能推斷出的本集團附屬公司的責任程度。於截至二零二一年十二月三十一日止年度，本集團錄得應收保險費人民幣293,247,000元。經計及撥備及保險涵蓋範圍，索賠相關的淨虧損金額為人民幣229,852,000元。

8. 預期信貸虧損模式下之減值虧損，扣除撥回

		Year ended 31/12/2021 RMB'000 截至 二零二一年 十二月 三十一日 止年度 人民幣千元	Year ended 31/12/2020 RMB'000 截至 二零二零年 十二月 三十一日 止年度 人民幣千元
Impairment losses (recognised)/ reverse on:	就下列項目(確認)／撥回的 減值虧損：		
– trade receivables	– 應收貿易賬款	(17,290)	(32,762)
– loan receivables	– 應收貸款	(7,721)	(9,232)
– other receivables	– 其他應收款項	4	8,138
– receivables from factoring business	– 來自保理業務之應收款項	382	423
– finance lease receivables	– 應收融資租賃款項	(2,357)	(1,811)
		(26,982)	(35,244)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

9. FINANCE COSTS

9. 融資成本

		Year ended 31/12/2021 RMB'000 截至 二零二一年 十二月 三十一日 止年度 人民幣千元	Year ended 31/12/2020 RMB'000 截至 二零二零年 十二月 三十一日 止年度 人民幣千元
Interest on bank loans and other borrowings	銀行貸款及其他借款利息	97,261	156,002
Interest on bonds payable	應付債券利息	39,467	21,230
Interest on lease liabilities	租賃負債利息	3,668	1,703
		140,396	178,935

10. INCOME TAX EXPENSE

10. 所得稅開支

		Year ended 31/12/2021 RMB'000 截至 二零二一年 十二月 三十一日 止年度 人民幣千元	Year ended 31/12/2020 RMB'000 (restated) 截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)
Current enterprise income tax	即期企業所得稅	485,922	404,304
Under/(over) provision in prior years	過往年度撥備不足／(超額撥備)	9,105	(13,359)
Deferred tax	遞延稅項	(79,934)	(32,523)
		415,093	358,422

Under the Law of the People's Republic of China on Enterprise Income Tax (the "EIT Law") and Implementation Regulation of the EIT Law, the tax rate of the Company and certain PRC subsidiaries is 15% for the years ended 31 December 2021 and 2020.

根據《中華人民共和國企業所得稅法》(「企業所得稅法」)及《企業所得稅法實施條例》，本公司及若干中國附屬公司於截至二零二一年及二零二零年十二月三十一日止年度之稅率為15%。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

10. INCOME TAX EXPENSE (continued)

Taxation arising in other jurisdictions is calculated at the rates prevailing in the relevant jurisdictions. The subsidiaries in the U.S. are subject to federal income tax at a tax rate of 21% and state income tax.

The Company, Jierui, Weigao Orthopaedic and Weigao Purui were recognised as Shandong Province New and High Technical Enterprises (山東省高新技術企業) from the year 2020 to 2022, and, the subsidiaries of the Company, Changzhou Jianli Bangde Medical Devices Co., Ltd. and Weihai Weigao Jiasheng Medical Devices Co., Ltd. were recognised as New and High Technical Enterprises from the year 2019 to 2021. In accordance with the “Notice of the State Tax Bureau of the Ministry of Finance Regarding Certain Preferential Treatment Policies on Enterprise Income Tax”, New and High Technical Enterprise was subject to income tax at a tax rate of 15%.

Jierui has been recognised as a “Social Welfare Entity”. Pursuant to Caishui [2016] No. 52 issued by the State Council, with effect from 1 May 2016, Social Welfare Entity is subject to income tax rate of 15%, and an amount equivalent to the total salaries paid to staff with physical disability is further deducted from the taxable income of Jierui. The tax charge provided for the years ended 31 December 2021 and 2020 were made after taking these tax incentives into account.

10. 所得稅開支 (續)

其他司法權區產生的稅項按相關司法權區的現行稅率計算。於美國的附屬公司須按21%的稅率繳納聯邦所得稅及須繳納州所得稅。

本公司、潔瑞、威高骨科及威高普瑞獲確認為二零二零年度至二零二二年度山東省高新技術企業，且本公司附屬公司常州健力邦德醫療器械有限公司及威海威高潔盛醫療器材有限公司獲確認為二零一九年度至二零二一年度高新技術企業。根據《財政部國家稅務總局關於企業所得稅若干優惠政策的通知》，高新技術企業可按15%稅率繳付所得稅。

潔瑞獲確認為「社會福利企業」。根據國務院發出之財稅[2016]第52號文件，自二零一六年五月一日起，社會福利企業須按15%稅率繳付所得稅，及相等於支付予殘障員工薪金總額之金額進一步自潔瑞的應課稅收入中扣減。截至二零二一年及二零二零年十二月三十一日止年度作出之稅項開支撥備已計及該等稅務優惠。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

10. INCOME TAX EXPENSE (continued)

10. 所得稅開支 (續)

The charge for the year can be reconciled to the profit before tax per the consolidated statement of profit or loss and other comprehensive income as follows:

本年度的支出與綜合損益及其他全面收入報表中的除稅前溢利對賬如下：

		Year ended 31/12/2021 RMB'000	Year ended 31/12/2020 RMB'000 (restated)
		截至 二零二一年 十二月 三十一日 止年度 人民幣千元	截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)
Profit before tax	除稅前溢利	2,841,721	2,565,459
Taxation at income tax rate of 15% (2020: 15%)	按15%所得稅稅率計算的稅項 (二零二零年：15%)	426,258	384,819
Tax effect of share of an associate	應佔一間聯營公司之稅務影響	(10,498)	(1,874)
Tax effect of share of joint ventures	應佔合營企業之稅務影響	89	-
Tax effect of income not taxable for tax purpose	就稅務而言毋須課稅收入之稅務影響	(2,378)	(27,036)
Effect of additional tax deduction for research and development expenses	有關研發費用之額外稅務扣減之影響	(57,906)	(42,380)
Additional tax benefit to a Social Welfare Entity	社會福利企業之額外稅務優惠	(4,900)	(4,549)
Utilisation of tax losses previously not recognised	動用過往未確認的稅項虧損	(3,375)	(5,576)
Utilisation of deductible temporary difference previously not recognised	動用過往未確認的可抵扣暫時性差異	(771)	-
Tax effect on tax losses and deductible temporary difference not recognised	未確認的稅項虧損及可抵扣暫時性差異的稅務影響	18,264	10,389
Tax effect on expenses not deductible for tax purpose	就稅務而言不可抵扣開支的稅務影響	23,833	15,737
State and local income taxes for U.S. subsidiaries	適用於美國附屬公司的國家及地方所得稅	(4,928)	4,717
Effect on different tax rates of subsidiaries	不同稅率對附屬公司的影響	22,300	37,534
Under/(over) provision in prior years	過往年度撥備不足 / (超額撥備)	9,105	(13,359)
Income tax expense for the year	年內所得稅開支	415,093	358,422

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

11. PROFIT FOR THE YEAR

11. 年內溢利

		Year ended 31/12/2021 RMB'000	Year ended 31/12/2020 RMB'000 (restated)
		截至 二零二一年 十二月 三十一日 止年度 人民幣千元	截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)
Profit for the year has been arrived at after charging and crediting:	年內溢利經扣除及計入下列項目後達致：		
Allowances for credit losses	信貸虧損撥備	26,982	35,244
Allowances for inventories	存貨撥備	6,956	10,452
Allowances for property, plant and equipment	物業、廠房及設備撥備	-	2,571
Allowances for intangible assets	無形資產撥備	-	4,295
Amortisation of intangible assets	無形資產攤銷	241,333	257,249
Auditors' remuneration	核數師酬金	7,677	7,567
Depreciation of property, plant and equipment	物業、廠房及設備折舊	446,172	427,317
Depreciation of investment properties	投資物業折舊	5,216	6,276
Depreciation of right-of-use assets	使用權資產折舊	31,092	20,690
Lease expenses related to short-term lease	與短期租賃有關的租賃開支	8,231	11,039
Lease liabilities interest expense	租賃負債利息支出	3,668	1,703
Cost of inventories recognised as an expense	確認為開支的存貨成本	5,882,315	5,122,766
Staff costs, including directors' and supervisors' remuneration	員工成本 (包括董事及監事薪酬)		
– Retirement benefits scheme contributions	– 退休福利計劃供款	133,812	92,515
– Salaries and other allowances	– 薪金及其他津貼	1,820,744	1,764,634
– Share-based payment expenses (note 38)	– 以股份為基礎的付款開支 (附註38)	76,492	30,662
Total staff costs	員工成本總額	2,031,048	1,887,811
Loss/(gain) on disposal of property, plant and equipment	出售物業、廠房及設備虧損/(收益)	2,937	(1,677)

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

12. DIRECTORS', SUPERVISORS' AND EMPLOYEES' EMOLUMENTS

12. 董事、監事及僱員酬金

Directors' and supervisors' emoluments

Details of the emoluments paid or payable by the entities comprising the Group to the directors, chief executive and supervisors of the Company are as follows:

董事及監事酬金

本集團實體已付或應付本公司董事、行政總裁及監事酬金詳情如下：

		Year ended 31/12/2021 截至二零二一年十二月三十一日止年度					
		Fee	Salaries and other allowances	Retirement benefits schemes contributions	Performance related bonus (note a)	Share-based payment expenses	Total
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		袍金	薪金及其他津貼	退休福利計劃供款	表現相關花紅(附註a)	以股份為基礎的付款開支	總計
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Chief executive and executive director	行政總裁兼執行董事						
Mr. Long Jing (note b)	龍經先生(附註b)	-	1,019	46	712	5,283	7,060
Mr. Cong Ri Nan (note d)	叢日楠先生(附註d)	-	903	45	526	1,709	3,183
		-	1,922	91	1,238	6,992	10,243
Executive directors	執行董事						
Mr. Zhang Hua Wei (note c)	張華威先生(附註c)	-	1,425	-	876	-	2,301
Mr. Wang Yi (note c)	王毅先生(附註c)	-	1,117	-	685	-	1,802
		-	2,542	-	1,561	-	4,103

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

12. DIRECTORS', SUPERVISORS' AND EMPLOYEES' EMOLUMENTS (continued)

12. 董事、監事及僱員酬金 (續)

Directors' and supervisors' emoluments (continued)

董事及監事酬金 (續)

		Year ended 31/12/2021 截至二零二一年十二月三十一日止年度					
		Fee	Salaries and other allowances	Retirement benefits schemes contributions	Performance related bonus (note a)	Share-based payment expenses	Total
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		袍金	薪金及其他津貼	退休福利計劃供款	表現相關花紅 (附註a)	以股份為基礎的付款開支	總計
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
Non-executive directors	非執行董事						
Mr. Chen Lin (note e)	陳林先生 (附註e)	-	-	-	-	-	-
Mr. Tang Zheng Peng (note e)	湯正鵬先生 (附註e)	-	-	-	-	-	-
Mr. Lian Xiao Ming (note f)	連小明先生 (附註f)	-	-	-	-	-	-
		-	-	-	-	-	-
Independent non-executive directors	獨立非執行董事						
Mr. Lo Wai Hung (note g)	盧偉雄先生 (附註g)	166	-	-	-	-	166
Mrs. Fu Ming Zhong (note g)	付明仲女士 (附註g)	120	-	-	-	-	120
Mrs. Wang Jin Xia (note g)	王錦霞女士 (附註g)	120	-	-	-	-	120
		406	-	-	-	-	406
Supervisors	監事						
Mr. Yue Chun Liang	岳春良先生	-	147	29	113	256	545
Mr. Hu Yun Yong	胡雲涌先生	-	-	-	-	-	-
Mrs. Gu Mei Jun	谷美君女士	-	-	-	-	-	-
		-	147	29	113	256	545
		406	4,611	120	2,912	7,248	15,297

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

12. DIRECTORS', SUPERVISORS' AND EMPLOYEES' EMOLUMENTS (continued)

12. 董事、監事及僱員酬金 (續)

Directors' and supervisors' emoluments
(continued)

董事及監事酬金 (續)

		Year ended 31/12/2020 截至二零二零年十二月三十一日止年度					
	Fee RMB'000 袍金 人民幣千元	Salaries and other allowances RMB'000 薪金及其他津貼 人民幣千元	Retirement benefits schemes contributions RMB'000 退休福利計劃供款 人民幣千元	Performance related bonus (note a) RMB'000 表現相關花紅(附註a) 人民幣千元	Share-based payment expenses RMB'000 以股份為基礎的付款開支 人民幣千元	Total RMB'000 總計 人民幣千元	
Chief executive and executive director	行政總裁兼執行董事						
Mr. Long Jing	龍經先生	-	859	35	641	399	1,934
Executive directors	執行董事						
Mr. Gong Jian Bo (note i)	弓劍波先生(附註i)	-	2,657	19	9,280	-	11,956
Mr. Zhang Hua Wei	張華威先生	-	1,425	-	760	-	2,185
Mr. Wang Yi	王毅先生	-	1,145	-	757	-	1,902
		-	5,227	19	10,797	-	16,043
Non-executive directors	非執行董事						
Mrs. Zhou Shu Hua (note i)	周淑華女士(附註i)	-	-	-	-	-	-
Mr. Chen Lin (note e)	陳林先生(附註e)	-	-	-	-	-	-
Mr. Tang Zheng Peng (note e)	湯正鵬先生(附註e)	-	-	-	-	-	-
		-	-	-	-	-	-

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

12. DIRECTORS', SUPERVISORS' AND EMPLOYEES' EMOLUMENTS (continued)

12. 董事、監事及僱員酬金 (續)

Directors' and supervisors' emoluments (continued)

董事及監事酬金 (續)

		Year ended 31/12/2020 截至二零二零年十二月三十一日止年度					
	Fee RMB'000	Salaries and other allowances RMB'000	Retirement benefits schemes contributions RMB'000	Performance related bonus (note a) RMB'000	Share-based payment expenses RMB'000	Total RMB'000	
	袍金 人民幣千元	薪金及 其他津貼 人民幣千元	退休福利 計劃供款 人民幣千元	表現 相關花紅 (附註a) 人民幣千元	以股份 為基礎的 付款開支 人民幣千元	總計 人民幣千元	
Independent non-executive directors	獨立非執行董事						
Mr. Lo Wai Hung	162	-	-	-	-	162	
Mrs. Fu Ming Zhong	108	-	-	-	-	108	
Mrs. Wang Jin Xia	108	-	-	-	-	108	
	378	-	-	-	-	378	
Supervisors	監事						
Mr. Yue Chun Liang	-	161	30	50	-	241	
Mr. Hu Yun Yong (note h)	-	-	-	-	-	-	
Mrs. Gu Mei Jun (note h)	-	-	-	-	-	-	
Mrs. Bi Dong Mei (note j)	-	-	-	-	-	-	
Mrs. Chen Xiao Yun (note i)	-	-	-	-	-	-	
	-	161	30	50	-	241	
	378	6,247	84	11,488	399	18,596	

Notes:

- (a) Approved by the Remuneration Committee, the performance related bonus payment is determined by reference to the individual performance of the directors and the chief executive. The chief executive, executive directors' emoluments shown above were for their services in connection with the management of the affairs of the Company and the Group. The non-executive directors' and supervisors' emoluments shown above were for their services as directors of the Company.
- (b) Mr. Long Jing has resigned as chief executive officer of the Company with effect from 30 March 2021. Mr. Long has been appointed as Chairman and authorised representative of the Company with effect from 30 March 2021.
- (c) Mr. Zhang Hua Wei and Mr. Wang Yi have resigned as executive director of the Company with effect from 30 March 2021.

附註：

- (a) 經薪酬委員會批准，表現相關花紅付款乃參考董事及行政總裁之個人表現而釐定。上述行政總裁及執行董事的酬金與彼等在管理本公司及本集團事務的服務有關。上述非執行董事及監事的酬金與彼等作為本公司董事的服務有關。
- (b) 龍經先生已辭任本公司行政總裁，自二零二一年三月三十日起生效。龍先生已獲委任為本公司主席兼授權代表，自二零二一年三月三十日起生效。
- (c) 張華威先生及王毅先生已辭任本公司執行董事，自二零二一年三月三十日起生效。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

12. DIRECTORS', SUPERVISORS' AND EMPLOYEES' EMOLUMENTS (continued)

Directors' and supervisors' emoluments (continued)

Notes: (continued)

- (d) Mr. Cong Ri Nan has been appointed as chief executive officer of the Company with effect from 30 March 2021, and has been appointed as executive director of the Company with effect from 24 May 2021.
- (e) Mr. Chen Lin and Mr. Tang Zheng Peng have been appointed as non-executive director of the Company with effect from 8 March 2021 by approval of extraordinary general meeting of the Company, which was firstly appointed by the Board of Director on 14 December 2020.
- (f) Mr. Lian Xiao Ming has been appointed as non-executive director of the Company with effect from 24 May 2021.
- (g) Mr. Lo Wai Hung, Mrs. Fu Ming Zhong and Mrs. Wang Jin Xia have been re-elected as an independent non-executive director of the Company with effect from 24 May 2021.
- (h) Mr. Hu Yun Yong and Mrs. Gu Mei Jun have been appointed as supervisor of the Company with effect from 22 July 2020.
- (i) Mr. Gong Jian Bo and Mrs. Zhou Shu Hua resigned from directorship on 14 December 2020.
- (j) Mrs. Bi Dong Mei and Mrs. Chen Xiao Yun have been worked for Weigao Holding since 2012, and the salaries and other allowances and retirement benefits schemes contributions were paid by Weigao Holding. During the year ended 31 December 2020, Mrs. Bi Dong Mei and Mrs. Chen Xiao Yun retired from their three years terms of office.

12. 董事、監事及僱員酬金 (續)

董事及監事酬金 (續)

附註：(續)

- (d) 董日楠先生已獲委任為本公司行政總裁，自二零二一年三月三十日起生效，及已獲任為本公司執行董事，自二零二一年五月二十四日起生效。
- (e) 經本公司股東特別大會批准，陳林先生及湯正鵬先生已獲委任為本公司非執行董事，自二零二一年三月八日起生效，及於二零二零年十二月十四日獲董事會首次委任。
- (f) 連小明先生已獲委任為本公司非執行董事，自二零二一年五月二十四日起生效。
- (g) 盧偉雄先生、付明仲女士及王錦霞女士已獲重選為本公司獨立非執行董事，自二零二一年五月二十四日起生效。
- (h) 胡雲涌先生及谷美君女士已獲委任為本公司監事，自二零二零年七月二十二日起生效。
- (i) 弓劍波先生及周淑華女士於二零二零年十二月十四日辭任董事職務。
- (j) 畢冬梅女士及陳曉雲女士自二零一二年起一直任職於威高集團公司，其薪金及其他津貼及退休福利計劃供款由威高集團公司支付。截至二零二零年十二月三十一日止年度，畢冬梅女士及陳曉雲女士從其三年任期退任。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

12. DIRECTORS', SUPERVISORS' AND EMPLOYEES' EMOLUMENTS (continued)

Five highest paid employees

The five highest paid employees of the Group during the year included one director (2020: one director), details of whose remuneration are set out above. Details of the remuneration for the year of the remaining four (2020: four) highest paid employees who are neither a director nor chief executive of the Group are as follows:

12. 董事、監事及僱員酬金 (續)

五名最高酬金僱員

於年內本集團五名最高薪酬僱員包括一名董事(二零二零年：一名董事)，其薪酬詳情載列於上文。其餘四名(二零二零年：四名)最高薪酬僱員(非本集團董事或主要行政人員)年內的薪酬詳情如下：

		Year ended 31/12/2021 RMB'000 截至 二零二一年 十二月 三十一日 止年度 人民幣千元	Year ended 31/12/2020 RMB'000 截至 二零二零年 十二月 三十一日 止年度 人民幣千元
Salaries and other benefits	薪金及其他津貼	21,155	29,767

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

12. DIRECTORS', SUPERVISORS' AND EMPLOYEES' EMOLUMENTS (continued)

12. 董事、監事及僱員酬金 (續)

Five highest paid employees (continued)

五名最高酬金僱員 (續)

The number of the highest paid employees who are not the directors of the Company whose remuneration fell within the following bands is as follows:

薪酬介乎於以下範圍且並非本公司董事之最高薪酬僱員人數如下：

Emoluments bands in Hong Kong Dollars ("HKD")	酬金範圍 (以港元 (「港元」) 計)	Year ended 31/12/2021 No. of employees 截至 二零二一年 十二月 三十一日 止年度 僱員人數	Year ended 31/12/2020 No. of employees 截至 二零二零年 十二月 三十一日 止年度 僱員人數
HKD3,500,001 to HKD4,000,000	3,500,001港元至4,000,000港元	1	-
HKD4,000,001 to HKD4,500,000	4,000,001港元至4,500,000港元	2	2
HKD6,000,001 to HKD6,500,000	6,000,001港元至6,500,000港元	-	1
HKD13,000,001 to HKD13,500,000	13,000,001港元至13,500,000港元	1	-
HKD14,500,001 to HKD15,000,000	14,500,001港元至15,000,000港元	-	1

During the year ended 31 December 2021, no emoluments were paid by the Group to any of the executive directors, non-executive director, independent non-executive directors, supervisors, or the five highest paid individuals as an inducement to join or upon joining the Group or as compensation for loss of office (2020:nil). None of the directors, supervisors and chief executive has waived any emoluments during the year ended 2021 (2020: nil).

於截至二零二一年十二月三十一日止年度內，本集團並無支付酬金予任何執行董事、非執行董事、獨立非執行董事、監事或五名最高薪酬僱員作為吸引加入本集團或於加入本集團時的獎勵，或作為離職補償 (二零二零年：無)。概無董事、監事及行政總裁於截至二零二一年止年度 (二零二零年：無) 放棄任何酬金。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

13. DIVIDENDS

13. 股息

		Year ended 31/12/2021 RMB'000 截至 二零二一年 十二月 三十一日 止年度 人民幣千元	Year ended 31/12/2020 RMB'000 截至 二零二零年 十二月 三十一日 止年度 人民幣千元
Dividends recognised as distribution during the year:	年內確認為分派的股息		
2021 Interim – RMB0.077 (2020: interim dividend – RMB0.062) per share	二零二一年中期股息每股人民幣0.077元(二零二零年：中期股息每股人民幣0.062元)	348,220	280,385
2020 Final – RMB0.068 (2019: final dividend – RMB0.061) per share	二零二零年末期股息每股人民幣0.068元(二零一九年：末期股息每股人民幣0.061元)	307,519	275,862
Total	總計	655,739	556,247
Less: distribution to the shares held by the trustees under a share award scheme (note 38(a))	減：向受託人根據股份激勵計劃持有之股份的分派(附註38(a))	2,451	2,898
		653,288	553,349

Subsequent to the end of the reporting period, a final dividend in respect of the year ended 31 December 2021 of RMB0.065 (2020: RMB0.068) per share, amounting to RMB297,091,000 (2020: RMB307,519,000) in total, has been proposed by the directors and is subject to approval by the shareholders in the forthcoming general meeting.

於報告期末後，董事建議派付截至二零二一年十二月三十一日止年度的末期股息每股人民幣0.065元(二零二零年：人民幣0.068元)，合共人民幣297,091,000元(二零二零年：人民幣307,519,000元)。該建議須經股東在即將舉行的股東大會上批准後，方可作實。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

14. EARNINGS PER SHARE

The calculation of the basic and diluted earnings per share attributable to owners of the Company is based on the following data:

Earnings figures are calculated as follows:

14. 每股盈利

本公司擁有人應佔每股基本及攤薄盈利乃根據下列數據計算：

盈利數據計算如下：

		Year ended 31/12/2021 RMB'000	Year ended 31/12/2020 RMB'000 (restated)
		截至 二零二一年 十二月 三十一日 止年度 人民幣千元	截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)
Profit for the year attributable to owners of the Company	本公司擁有人應佔年內溢利	2,244,778	2,086,783
Earnings for the purpose of basic earnings per share	就每股基本盈利而言的盈利	2,244,778	2,086,783
Effect of dilutive potential ordinary shares:	潛在攤薄普通股的影响：		
Adjustment to the share of profit of subsidiary based on dilution of their earnings per share	根據每股盈利的攤薄調整應佔附屬公司溢利	(923)	-
Earnings for the purpose of diluted earnings per share	每股攤薄盈利而言的盈利	2,243,855	2,086,783

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

14. EARNINGS PER SHARE (continued)

14. 每股盈利 (續)

		Year ended 31/12/2021 '000 截至 二零二一年 十二月 三十一日 止年度 千股	Year ended 31/12/2020 '000 截至 二零二零年 十二月 三十一日 止年度 千股
Number of shares	股份數目		
Number of shares for the purpose of basic earnings per share	就計算每股基本盈利而言的股份數目	4,500,994	4,489,196
Effect of dilutive potential ordinary shares:	普通股潛在攤薄的影響：		
Incentive shares	激勵股份	15,329	3,757
Weighted average number of ordinary shares for the purpose of diluted earnings per share	就計算每股攤薄盈利而言的普通股加權平均數	4,516,323	4,492,953

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

15. PROPERTY, PLANT AND EQUIPMENT

15. 物業、廠房及設備

		Construction In progress RMB'000	Buildings RMB'000	Plant and machinery RMB'000	Motor vehicles RMB'000	Furniture, Fixtures equipment and tools RMB'000	Freehold Land RMB'000	Total RMB'000
		在建工程 人民幣千元	建築物 人民幣千元	廠房及機器 人民幣千元	汽車 人民幣千元	傢俱、 固定裝置 及工具 人民幣千元	自由保有 土地 人民幣千元	總計 人民幣千元
COST	成本							
At 1 January 2020 (restated)	於二零二零年一月一日 (經重列)	971,464	3,066,065	1,835,303	100,909	847,565	8,504	6,829,810
Additions (restated)	添置 (經重列)	428,821	152,412	140,370	10,139	71,113	-	802,855
Transfer	轉撥	(338,701)	97,593	183,911	-	57,197	-	-
Transfer from investment properties	轉撥自投資物業	-	52,637	-	-	-	-	52,637
Transfer to investment properties	轉撥至投資物業	-	(29,146)	-	-	-	-	(29,146)
Acquisition of a subsidiary (note 39)	收購一間附屬公司 (附註39)	-	-	223	609	139	-	971
Disposals	出售	-	(64,035)	(14,816)	(3,334)	(74,652)	-	(156,837)
Exchange adjustments (restated)	匯兌調整 (經重列)	(2,939)	(3,588)	(7,041)	(138)	(3,432)	(550)	(17,688)
At 31 December 2020 (restated)	於二零二零年十二月 三十一日 (經重列)	1,058,645	3,271,938	2,137,950	108,185	897,930	7,954	7,482,602
Additions	添置	430,769	-	311,444	7,834	94,233	-	844,280
Transfer	轉撥	(911,271)	502,070	329,697	-	79,504	-	-
Transfer from investment properties	轉撥自投資物業	-	64,657	-	-	-	-	64,657
Transfer to investment properties	轉撥至投資物業	-	(60,695)	-	-	-	-	(60,695)
Acquisition of a subsidiary (note 39)	收購一間附屬公司 (附註39)	-	4,140	4,622	-	-	-	8,762
Disposals	出售	-	-	(22,611)	(42,847)	(60,874)	-	(126,332)
Exchange adjustments	匯兌調整	(1,002)	(1,187)	(2,790)	(127)	(1,604)	(182)	(6,892)
At 31 December 2021	於二零二一年十二月 三十一日	577,141	3,780,923	2,758,312	73,045	1,009,189	7,772	8,206,382

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

15. PROPERTY, PLANT AND EQUIPMENT

(continued)

15. 物業、廠房及設備 (續)

		Construction In progress RMB'000	Buildings RMB'000	Plant and machinery RMB'000	Motor vehicles RMB'000	Furniture, Fixtures equipment and tools RMB'000	Freehold Land RMB'000	Total RMB'000
		在建工程 人民幣千元	建築物 人民幣千元	廠房及機器 人民幣千元	汽車 人民幣千元	傢俱、 固定裝置 及工具 人民幣千元	自由保有 土地 人民幣千元	總計 人民幣千元
DEPRECIATION AND IMPAIRMENT	折舊及減值							
At 1 January 2020 (restated)	於二零二零年一月一日 (經重列)	8,205	408,948	871,764	44,663	466,691	-	1,800,271
Provided for the year (restated)	年內撥備 (經重列)	2,571	136,637	165,779	11,892	110,438	-	427,317
Transfer from investment properties	轉撥自投資物業	-	452	-	-	-	-	452
Transfer to investment properties	轉撥至投資物業	-	(2,344)	-	-	-	-	(2,344)
Eliminated on disposals	於出售時抵銷	-	(11,962)	(15,858)	(2,541)	(71,577)	-	(101,938)
Exchange adjustments (restated)	匯兌調整 (經重列)	-	(522)	(1,888)	(84)	(1,327)	-	(3,821)
At 31 December 2020 (restated)	於二零二零年十二月 三十一日 (經重列)	10,776	531,209	1,019,797	53,930	504,225	-	2,119,937
Provided for the year	年內撥備	-	119,339	195,168	7,571	124,094	-	446,172
Transfer from investment properties	轉撥自投資物業	-	10,226	-	-	-	-	10,226
Transfer to investment properties	轉撥至投資物業	-	(3,970)	-	-	-	-	(3,970)
Eliminated on disposals	於出售時抵銷	-	-	(12,460)	(17,394)	(53,848)	-	(83,702)
Exchange adjustments	匯兌調整	-	(207)	(724)	(25)	(695)	-	(1,651)
At 31 December 2021	於二零二一年十二月 三十一日	10,776	656,597	1,201,781	44,082	573,776	-	2,487,012
CARRYING VALUES	賬面值							
At 31 December 2021	於二零二一年十二月 三十一日	566,365	3,124,326	1,556,531	28,963	435,413	7,772	5,719,370
At 31 December 2020 (restated)	於二零二零年十二月 三十一日 (經重列)	1,047,869	2,740,729	1,118,153	54,255	393,705	7,954	5,362,665

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

15. PROPERTY, PLANT AND EQUIPMENT (continued)

The above items of property, plant and equipment, other than construction in progress and freehold land, are depreciated on a straight-line basis after taking into account of their estimated residual values and at the following rates per annum:

Buildings	3.2 – 9.5%
Plant and machinery	9.5 – 19.0%
Motor vehicles	19.0 – 31.7%
Furniture, fixtures equipment and tools	19.0 – 47.5%

As at 31 December 2021, total net book value of Property, Plant and Equipment served as collateral for the Group's borrowing amounted to RMB44,915,000 (2020: RMB44,318,000).

15. 物業、廠房及設備 (續)

上述的物業、廠房及設備項目(在建工程及自由保有土地除外)以直線法就計入其估計剩餘價值後,按下列年率折舊:

建築物	3.2 – 9.5%
廠房及機器	9.5 – 19.0%
汽車	19.0 – 31.7%
傢俱、固定裝置 及工具	19.0 – 47.5%

於二零二一年十二月三十一日,作為本集團借款抵押品的物業、廠房及設備的賬面淨值總額為人民幣44,915,000元(二零二零年:人民幣44,318,000元)。

16. RIGHT-OF-USE ASSETS

16. 使用權資產

		Leasehold land RMB'000 租賃土地 人民幣千元	Leased properties RMB'000 租賃物業 人民幣千元	Office equipment RMB'000 辦公室設備 人民幣千元	Total RMB'000 總計 人民幣千元
As at 31 December 2021	於二零二一年十二月三十一日				
Carrying amount	賬面值	396,468	78,730	1,119	476,317
As at 31 December 2020	於二零二零年十二月三十一日				
Carrying amount	賬面值	406,313	28,188	1,011	435,512
For the year ended 31 December 2021	截至二零二一年十二月三十一日止年度				
Depreciation charge	折舊費用	9,845	20,578	669	31,092
For the year ended 31 December 2020	截至二零二零年十二月三十一日止年度				
Depreciation charge	折舊費用	10,821	9,472	397	20,690

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

16. RIGHT-OF-USE ASSETS (continued)

16. 使用權資產 (續)

		Year ended 31/12/2021 RMB'000 截至 二零二一年 十二月 三十一日 止年度 人民幣千元	Year ended 31/12/2020 RMB'000 截至 二零二零年 十二月 三十一日 止年度 人民幣千元
Expense relating to short-term leases	短期租賃開支	8,231	11,039
Total cash outflow for leases	租賃現金流出總額	34,068	24,288
Additions to right-of-use assets	新增使用權資產	71,897	74,315
Arising on acquisition of a subsidiary (note 39)	收購一間附屬公司產生 (附註39)	-	5,014

For both years, the Group leases various offices and equipment for its operations. Lease contracts are entered into for fixed term of 1 year to 10 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. In determining the lease term and assessing the length of the non-cancellable period, the Group applies the definition of a contract and determines the period for which the contract is enforceable.

Details of the lease maturity analysis of lease liabilities are set out in note 36.

本集團於兩個年度租賃各種辦公室及設備用於營運。租賃合約按1至10年的固定期限訂立。租賃條款乃在個別基礎上磋商，包括各種不同條款及條件。於釐定租期及評估不可撤回期間的時長時，本集團應用合約的定義並釐定合約可強制執行的期間。

租賃負債的租賃到期時間分析詳情載於附註36。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

17. INVESTMENT PROPERTIES

17. 投資物業

		RMB'000 人民幣千元
<hr/>		
COST	成本	
At 1 January 2020	於二零二零年一月一日	185,713
Addition	添置	8,719
Transfer from property, plant and equipment	轉撥自物業、廠房及設備	29,146
Transfer to property, plant and equipment	轉撥至物業、廠房及設備	(52,637)
At 31 December 2020	於二零二零年十二月三十一日	<u>170,941</u>
Transfer from property, plant and equipment	轉撥自物業、廠房及設備	60,695
Transfer to property, plant and equipment	轉撥至物業、廠房及設備	<u>(64,657)</u>
At 31 December 2021	於二零二一年十二月三十一日	<u>166,979</u>
DEPRECIATION	折舊	
At 1 January 2020	於二零二零年一月一日	26,063
Provided for the year	年內撥備	6,276
Transfer from property, plant and equipment	轉撥自物業、廠房及設備	2,344
Transfer to property, plant and equipment	轉撥至物業、廠房及設備	(452)
At 31 December 2020	於二零二零年十二月三十一日	<u>34,231</u>
Provided for the year	年內撥備	5,216
Transfer from property, plant and equipment	轉撥自物業、廠房及設備	3,970
Transfer to property, plant and equipment	轉撥至物業、廠房及設備	<u>(10,226)</u>
At 31 December 2021	於二零二一年十二月三十一日	<u>33,191</u>
CARRYING VALUES	賬面值	
At 31 December 2021	於二零二一年十二月三十一日	<u>133,788</u>
At 31 December 2020	於二零二零年十二月三十一日	<u>136,710</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

17. INVESTMENT PROPERTIES (continued)

The fair value of the Group's investment properties of approximately RMB173,925,000 as at 31 December 2021 (2020: RMB177,724,000) has been determined by the Company.

The fair value was determined based on the income approach, where the market rentals of all lettable units of the properties are assessed and discounted at the market yield expected by investors for this type of properties. The market rentals are assessed by reference to the rentals achieved in the lettable units of the properties as well as other lettings of similar properties in the neighbourhood. The discount rate is determined by reference to the yields derived from analysing the sales transactions of similar commercial properties in the PRC and adjusted to take into account the market expectation from property investors to reflect factors specific to the Group's investment properties. There has been no change from the valuation technique used in the prior year.

In estimating the fair value of the properties, the highest and best use of the properties is their current use.

17. 投資物業 (續)

本集團投資物業於二零二一年十二月三十一日的公平值約為人民幣173,925,000元(二零二零年：人民幣177,724,000元)，該公平值已由本公司釐定。

公平值乃按收入法釐定，而物業所有可出租單位之市場租金則按投資者對此類物業預期之市場收益率評估及貼現。市場租金乃參考物業之可出租單位可得租金及該區其他類似物業之出租情況予以評估。貼現率乃參考中國同類商用物業之銷售交易分析所得之收益率予以釐定，並就物業投資者之市場預期作出調整，以反映本集團投資物業之特定因素。去年所用的估值方法並無變動。

於估計該等物業的公平值時，其最佳用途乃為其現有用途。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

17. INVESTMENT PROPERTIES (continued)

Details of the Group's investment properties and information about the fair value hierarchy as at the end of the reporting period are as follows:

The carrying value of investment properties shown above comprise of buildings erected on:

17. 投資物業 (續)

於報告期末，本集團有關公平值等級的投資物業及資料詳情如下：

以上所述投資物業的賬面值包括建於下述土地上之建築物：

		31/12/2021		31/12/2020	
		二零二一年十二月三十一日		二零二零年十二月三十一日	
		Carrying amount RMB'000 賬面值 人民幣千元	Fair value at level 3 hierarchy RMB'000 第三級公平值 人民幣千元	Carrying amount RMB'000 賬面值 人民幣千元	Fair value at level 3 hierarchy RMB'000 第三級公平值 人民幣千元
Land in PRC	於中國的土地				
Medium term lease	中期租約	133,788	173,925	136,710	177,724

The above investment properties are depreciated on a straight-line basis at 3.2% per annum.

上述投資物業按直線法以年率3.2%予以折舊。

18. GOODWILL

18. 商譽

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年 十二月 三十一日 人民幣千元	二零二零年 十二月 三十一日 人民幣千元 (經重列)
Cost	成本		
At 1 January	於一月一日	3,414,210	3,632,417
Arising on acquisition of a subsidiary (note 39)	收購一間附屬公司產生 (附註39)	7,637	3,281
Exchange adjustments	匯兌調整	(73,350)	(221,488)
At 31 December	於十二月三十一日	3,348,497	3,414,210

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

18. GOODWILL (continued)

Impairment testing on goodwill

The Group uses operating divisions as the basis for reporting segment information. For the purposes of impairment testing, goodwill has been allocated to the following groups of cash generating units ("CGUs"). The carrying amounts of goodwill as at 31 December 2021 and 2020 are as follows:

Medical device products	醫療器械產品
Orthopaedic products	骨科產品
Interventional products	介入產品
Blood management products	血液管理產品

The Group tests goodwill annually for impairment or more frequently if there are indications that goodwill might be impaired.

The management considers that groups of CGUs are represented by different groups of subsidiaries for the purpose of goodwill impairment testing.

The recoverable amounts of the groups of CGUs of medical device products have been determined based on a value in use calculation. The recoverable amount is based on the financial budget approved by management covering a 5-year period (2020: 5-year), and discount rate of 14% (2020: 14%). The cash flows for the following years are extrapolated using a steady 2.5% growth rate (2020: 2.5%). A key assumption for the value in use calculations is the budgeted growth rate, which is determined based on past performance and management's expectations for the market development.

18. 商譽 (續)

商譽減值測試

本集團使用經營分部作為其報告分部資料的基準。為進行減值測試，商譽被分配到以下現金產生單位（「現金產生單位」）組別。於二零二一年及二零二零年十二月三十一日，商譽之賬面值如下：

31/12/2021	31/12/2020
RMB'000	RMB'000
二零二一年	二零二零年
十二月	十二月
三十一日	三十一日
人民幣千元	人民幣千元
	(經重列)
32,215	32,215
173,966	173,966
2,928,886	2,989,604
213,430	218,425
3,348,497	3,414,210

本集團每年測試商譽減值，或倘有跡象顯示商譽可能已減值，則會更頻密測試減值。

就商譽減值測試而言，管理層認為現金產生單位組別指不同的附屬公司組別。

醫療器械產品之現金產生單位組別之可收回金額乃按使用價值計算而釐定。可收回金額以管理層批准之五年（二零二零年：五年）財政預算及貼現率14%（二零二零年：14%）為基礎。將來年度的現金流量採用2.5%（二零二零年：2.5%）的穩定增長率推算。計算使用價值之主要假設為預算增長率，乃按過往表現及管理層對市場發展之預期而釐定。

18. GOODWILL (continued)**Impairment testing on goodwill** (continued)

The recoverable amounts of the groups of CGUs of orthopaedic products have been determined based on a value in use calculation. The recoverable amount is based on the financial budget approved by management covering a 5-year period (2020: 5-year), and discount rate of 14% (2020: 14%). The cash flows for the following years are extrapolated using a steady 2.5% growth rate (2020: 2.5%). A key assumption for the value in use calculations is the budgeted growth rate, which is determined based on past performance and management's expectations for the market development.

The recoverable amounts of the groups of CGUs of interventional products have been determined based on a value in use calculation. The recoverable amount is based on the financial budget approved by management covering a 10-year period (2020:10-year), and discount rate of 11% (2020: 11%). The cash flows for the following years are extrapolated using a steady 2.5% growth rate (2020: 2%). A key assumption for the value in use calculations is the budgeted growth rate, which is determined based on past performance and management's expectations for the market development.

18. 商譽 (續)**商譽減值測試** (續)

骨科產品之現金產生單位組別之可收回金額乃按使用價值計算而釐定。可收回金額以管理層批准之五年(二零二零年：五年)財政預算及貼現率14%(二零二零年：14%)為基礎。將來年度的現金流量採用2.5%(二零二零年：2.5%)的穩定增長率推算。計算使用價值之主要假設為預算增長率，乃按過往表現及管理層對市場發展之預期而釐定。

介入產品之現金產生單位組別之可收回金額乃按使用價值計算而釐定。可收回金額以管理層批准之十年(二零二零年：十年)財政預算及貼現率11%(二零二零年：11%)為基礎。將來年度的現金流量採用2.5%(二零二零年：2%)的穩定增長率推算。計算使用價值之主要假設為預算增長率，乃按過往表現及管理層對市場發展之預期而釐定。

18. GOODWILL (continued)

Impairment testing on goodwill (continued)

The recoverable amounts of the groups of CGUs of Blood management products have been determined based on a value in use calculation. The recoverable amount is based on the financial budget approved by management covering a 5-year period (2020:5-year), and discount rate of 14.5% (2020: 14.5%). The cash flows for the following years are extrapolated using a steady 2.5% growth rate (2020: 2.5%). A key assumption for the value in use calculations is the budgeted growth rate, which is determined based on past performance and management's expectations for the market development.

The recoverable amount is significantly above the carrying amount of each CGUs. Management of the Group believes that any reasonably possible change in any of these assumptions would not result in impairment.

18. 商譽 (續)

商譽減值測試 (續)

血液管理產品之現金產生單位組別之可收回金額乃按使用價值計算而釐定。可收回金額以管理層批准之五年(二零二零年：五年)財政預算及貼現率14.5%(二零二零年：14.5%)為基礎。將來年度的現金流量採用2.5%(二零二零年：2.5%)的穩定增長率推算。計算使用價值之主要假設為預算增長率，乃按過往表現及管理層對市場發展之預期而釐定。

各現金產生單位的可收回金額大幅高於期賬面值。本集團管理層認為，任何該等假設的任何合理可能的變化均不會導致減值。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

19. INTANGIBLE ASSETS

19. 無形資產

		Development Costs RMB'000 開發成本 人民幣千元	Product Technology RMB'000 產品技術 人民幣千元	Customer Relationship RMB'000 客戶關係 人民幣千元	Trademarks RMB'000 商標 人民幣千元	Total RMB'000 總計 人民幣千元
COST	成本					
At 1 January 2020 (restated)	於二零二零年一月一日 (經重列)	43,836	1,466,681	1,203,557	181,381	2,895,455
Addition	添置	59,384	-	643	-	60,027
Acquisition of a subsidiary (note 39)	收購一間附屬公司 (附註39)	-	-	14,007	-	14,007
Exchange adjustments (restated)	匯兌調整 (經重列)	(6,622)	(89,990)	(77,901)	(11,734)	(186,247)
At 31 December 2020 (restated)	於二零二零年十二月三十一日 (經重列)	96,598	1,376,691	1,140,306	169,647	2,783,242
Addition	添置	29,405	2,144	-	-	31,549
Exchange adjustments	匯兌調整	(4,713)	(29,750)	(27,121)	(3,879)	(65,463)
At 31 December 2021	於二零二一年十二月三十一日	121,290	1,349,085	1,113,185	165,768	2,749,328
AMORTISATION	攤銷					
At 1 January 2020 (restated)	於二零二零年一月一日 (經重列)	-	259,152	224,650	29,504	513,306
Charge for the year (restated)	年內開支 (經重列)	-	121,044	120,968	15,237	257,249
Exchange adjustments (restated)	匯兌調整 (經重列)	-	(21,795)	(22,118)	(2,881)	(46,794)
At 31 December 2020 (restated)	於二零二零年十二月三十一日 (經重列)	-	358,401	323,500	41,860	723,761
Charge for the year	年內開支	-	115,249	112,020	14,064	241,333
Exchange adjustments	匯兌調整	-	(8,454)	(8,698)	(1,120)	(18,272)
At 31 December 2021	於二零二一年十二月三十一日	-	465,196	426,822	54,804	946,822
IMPAIRMENT	減值					
At 1 January 2020	於二零二零年一月一日	-	-	-	-	-
Addition	添置	4,295	-	-	-	4,295
Exchange adjustments	匯兌調整	(274)	-	-	-	(274)
At 31 December 2020	於二零二零年十二月三十一日	4,021	-	-	-	4,021
Exchange adjustments	匯兌調整	(92)	-	-	-	(92)
At 31 December 2021	於二零二一年十二月三十一日	3,929	-	-	-	3,929
CARRYING VALUES	賬面值					
At 31 December 2021	於二零二一年十二月三十一日	117,361	883,889	686,363	110,964	1,798,577
At 31 December 2020 (restated)	於二零二零年十二月三十一日 (經重列)	92,577	1,018,290	816,806	127,787	2,055,460

The above intangible assets have finite useful lives. Such intangible assets are amortised on a straight-line basis over the following periods:

Product technology	10-12 years
Customer relationship	8-11 years
Trademarks	11-12 years

As at 31 December 2021, total net book value of intangible assets served as collateral for the Group's borrowing amounted to RMB1,558,472,000 (2020: RMB1,819,386,000).

上述無形資產具有有限可使用年期。該等無形資產於以下期間按直線法攤銷：

產品技術	10-12年
客戶關係	8-11年
商標	11-12年

於二零二一年十二月三十一日，作為本集團借款抵押品的無形資產的賬面淨值總額為人民幣1,558,472,000元 (二零二零年：人民幣1,819,386,000元)。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

20. INTERESTS IN AN ASSOCIATE

20. 於一間聯營公司的權益

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
Cost of investment in an associate	投資聯營公司的成本	937,500	937,500
Share of post-acquisition profits and other comprehensive income	應佔收購後利潤及其他全面收入	201,401	131,412
		1,138,901	1,068,912

Details of the Group's associate at the end of the reporting period are as follow:

於報告期末，本集團的聯營公司詳情如下：

Name of entity	Country of incorporation/ registration	Principal place of business	Proportion of ownership interest held by the Group		Proportion of voting rights held by the Group		Principal activity
			31/12/2021	31/12/2020	31/12/2021	31/12/2020	
實體名稱	註冊成立/ 註冊所在國家	主要營業地點	本集團所持 所有者權益比例		本集團所持 投票權比例		主營業務
			二零二一年 十二月 三十一日	二零二零年 十二月 三十一日	二零二一年 十二月 三十一日	二零二零年 十二月 三十一日	
Shandong WEGO Blood Purification Products Co., Ltd ("Weigao Blood") *	PRC	PRC	28.0871%	28.0871%	28.0871%	28.0871%	Manufacturing of medical blood purification treatments and related consumables
山東威高血液淨化製品有限公司 (「威高血液淨化」) *	中國	中國					製造醫學血液淨化處理及相關消耗品

* Former name as Weihai Weigao Blood Purification Products Company

* 原稱為威海威高血液淨化製品有限公司

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

20. INTERESTS IN AN ASSOCIATE (continued)

20. 於一間聯營公司的權益 (續)

Summarised financial information of the associate

Summarised financial information in respect of the Group's associate is set out below. The summarised financial information represents amounts shown in the associate's financial statements prepared in accordance with HKFRSs.

The associate is accounted for using the equity method in the consolidated financial statements.

Weigao Blood Purification

聯營公司之財務資料概要

有關本集團的一間聯營公司之財務資料概要載列如下。財務資料概要指於根據香港財務報告準則編製之聯營公司財務報表中列示之金額。

聯營公司使用權益法於綜合財務報表入賬。

威高血液淨化

		31/12/2021 RMB'000 二零二一年 十二月 三十一日 人民幣千元	31/12/2020 RMB'000 二零二零年 十二月 三十一日 人民幣千元
Current assets	流動資產	1,910,875	1,731,177
Non-current assets	非流動資產	4,204,651	4,026,691
Current liabilities	流動負債	(2,057,789)	(1,710,356)
Non-current liabilities	非流動負債	(131,922)	(441,936)
		Year ended 31/12/2021 RMB'000 截至 二零二一年 十二月 三十一日 止年度 人民幣千元	Year ended 31/12/2020 RMB'000 截至 二零二零年 十二月 三十一日 止年度 人民幣千元
Revenue	收入	3,078,505	2,715,439
Profit for the year	本年度溢利	249,182	65,944
Profit for the year attributable to owners of the Weigao Blood Purification	威高血液淨化擁有人應佔本年度溢利	249,182	65,944

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

20. INTERESTS IN AN ASSOCIATE (continued)

Weigao Blood Purification (continued)

Reconciliation of the above summarised financial information to the carrying amount of the interest in the associate recognised in the consolidated financial statement:

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
Adjusted net assets of Weigao Blood Purification	威高血液淨化之經調整資產淨值	3,676,409	3,427,223
Proportion of the Group's ownership interest in Weigao Blood Purification	本集團於威高血液淨化之所有權權益比例	28.0871%	28.0871%
The Group's share of net assets of Weigao Blood Purification	本集團應佔威高血液淨化資產淨值	1,032,597	962,608
Goodwill	商譽	106,304	106,304
Carrying amount of the Group's interest in Weigao Blood Purification	本集團於威高血液淨化權益之賬面值	1,138,901	1,068,912

Note:

During the year ended 31 December 2020, Weigao Holding injected RMB1,300,000,000 to Weigao Blood Purification, which resulted in a dilution of the Group's interest in Weigao Blood Purification from 43.30% to 28.0871%.

威高血液淨化 (續)

上文概述之財務資料與於綜合財務報表確認的於聯營公司權益之賬面值的對賬：

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
Adjusted net assets of Weigao Blood Purification	威高血液淨化之經調整資產淨值	3,676,409	3,427,223
Proportion of the Group's ownership interest in Weigao Blood Purification	本集團於威高血液淨化之所有權權益比例	28.0871%	28.0871%
The Group's share of net assets of Weigao Blood Purification	本集團應佔威高血液淨化資產淨值	1,032,597	962,608
Goodwill	商譽	106,304	106,304
Carrying amount of the Group's interest in Weigao Blood Purification	本集團於威高血液淨化權益之賬面值	1,138,901	1,068,912

附註：

截至二零二零年十二月三十一日止年度，威高集團公司向威高血液淨化注資人民幣1,300,000,000元，導致本集團於威高血液淨化的權益由43.30%攤薄至28.0871%。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

21. INTERESTS IN JOINT VENTURES

21. 於合營企業的權益

		31/12/2021	31/12/2020
		RMB'000	RMB'000
			(restated)
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
			(經重列)
Cost of investment in joint ventures	投資合營企業的成本	182,730	182,730
Share of post-acquisition loss and other comprehensive income	應佔收購後虧損及其他全面收入	(531)	-
Exchange adjustments	匯兌調整	(1,442)	(803)
		180,757	181,927

Details of the Group's joint ventures at the end of the reporting period are as follow:

於報告期末，本集團的合營企業詳情如下：

Name of entity	Country of incorporation/ registration	Principal place of business	Proportion of ownership interest held by the Group		Proportion of voting rights held by the Group		Principal activity
			31/12/2021	31/12/2020	31/12/2021	31/12/2020	
實體名稱	註冊成立/ 註冊所在國家	主要營業地點	本集團所持 所有者權益比例		本集團所持 投票權比例		主營業務
			二零二一年 十二月 三十一日	二零二零年 十二月 三十一日	二零二一年 十二月 三十一日	二零二零年 十二月 三十一日	
Qingdao Songyuan First Phase Medical Investment Partnership (Limited Partnership) ("Qingdao Songyuan")	PRC	PRC	38.5%	38.5%	38.5%	38.5%	Investment in companies in medical industry
青島松源壹期醫療投資合夥企業(有限合夥) (「青島松源」)	中國	中國					投資於醫療行業公司
Weihai Shangyuan Fund	PRC	PRC	19.8%	19.8%	19.8%	19.8%	Venture capital business
威海尚元基金	中國	中國					創業投資

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

21. INTERESTS IN JOINT VENTURES (continued)

Note:

On 24 December 2020, the Group entered into a partnership agreement, together with other six parties to establish Qingdao Songyuan to invest in company running business in medical industry.

The total subscribed capital of Qingdao Songyuan is RMB2,000,000,000, of which RMB770,000,000 is subscribed by the Group. As at 31 December 2021, the Group invested RMB154,000,000 to Qingdao Songyuan, the remaining RMB616,000,000 is to be invested within 5 years after the establishment of the partnership.

On 12 October 2020, Wego Healthcare entered into a partnership agreement, together with other seven parties to establish Weihai Shangyuan Fund. The total subscribed capital of Weihai Shangyuan Fund is RMB303,000,000, of which RMB60,000,000 is subscribed by Wego Healthcare. As at 31 December 2021, Wego Healthcare invested USD4,280,000 (equivalent to RMB27,288,000) to Weihai Shangyuan Fund.

The Group invested in Qingdao Songyuan and Weihai Shangyuan Fund as limited partner. The director of the Company considered that the interests the Group held over Qingdao Songyuan and Weihai Shangyuan Fund carry rights that are substantively the same as the investee's ordinary shares and provides current access to the returns associated with its ownership interest in the investee, which is driven by the investee's financial performance.

The Group had joint arrangements with other parties whereby the parties that have joint control of the arrangement and have rights to the net assets of the joint arrangement, the Group accounted the investments in Qingdao Songyuan and Weihai Shangyuan Fund as interests in a joint venture using the equity method.

No significant business operation conducted by Qingdao Songyuan and Weihai Shangyuan Fund during the year ended 31 December 2021, and therefore, no additional summarised financial information is disclosed.

21. 於合營企業的權益 (續)

附註：

於二零二零年十二月二十四日，本集團與其他六方訂立合夥協議，成立青島松源，以投資於從事醫療行業的公司。

青島松源的總認繳資本為人民幣2,000,000,000元，其中人民幣770,000,000元由本集團認繳。於二零二一年十二月三十一日，本集團向青島松源投資人民幣154,000,000元，其餘人民幣616,000,000元將在合夥企業成立後5年內投資。

於二零二零年十月十二日，Wego Healthcare與其他七方訂立合夥協議，成立威海尚元基金。威海尚元基金的總認繳資本為人民幣303,000,000元，其中人民幣60,000,000元由Wego Healthcare認繳。於二零二一年十二月三十一日，Wego Healthcare向威海尚元基金投資4,280,000美元（相等於人民幣27,288,000元）。

本集團作為有限合夥人投資青島松源及威海尚元基金。本公司董事認為，本集團持有青島松源及威海尚元基金的權益與被投資方的普通股具有實質相同的權利，並提供當前獲取與其在被投資方的所有者權益相關的回報的途徑，此乃受被投資方的財務表現驅動。

本集團與其他方訂有合營安排，據此，各方對該安排具有共同控制權且對該合營安排的淨資產享有權利，本集團使用權益法將於青島松源及威海尚元基金的投資入賬列為於一間合營企業的權益。

截至二零二一年十二月三十一日止年度，青島松源及威海尚元基金並無重大業務營運，故概無披露額外的財務資料概要。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

22. FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS

22. 按公平值計入損益計量之金融工具

		31/12/2021	31/12/2020
		RMB'000	RMB'000
			(restated)
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
			(經重列)
Unlisted investments:	非上市投資：		
– Structured Cross Currency Swap (note a)	– 結構性交叉貨幣置換 (附註a)	(35,883)	(59,072)
– Currency option (note b)	– 貨幣期權 (附註b)	(20,811)	(21,031)
– Interest rate swap (note c)	– 利率互換 (附註c)	(199)	(5,775)
– Investment funds (note d)	– 投資基金 (附註d)	100,943	108,420
Structured deposit (note e)	結構性存款 (附註e)	10,000	–
		54,050	22,542
Analysed for reporting purposes as:	就呈報目的分析為：		
– Current liabilities	– 流動負債	(56,694)	(21,031)
– Non-current liabilities	– 非流動負債	(199)	(64,847)
– Current assets	– 流動資產	10,000	–
– Non-current assets	– 非流動資產	100,943	108,420
		54,050	22,542

Notes:

- (a) As at 31 December 2021 and 2020, the Group holds a Structured Cross Currency Swap which is issued by HSBC Bank (China) Company Limited to exchange periodic interest obligation and principal payments for stated period of time. During the year ended 31 December 2021, the Group partially disposed Structured Cross Currency Swap with payment of RMB10,955,000 to HSBC Bank (China) Company Limited.

附註：

- (a) 於二零二一年及二零二零年十二月三十一日，本集團持有HSBC Bank (China) Company Limited發行的結構性交叉貨幣置換，以於規定期間內交換定期利息責任及本金款項。截至二零二一年十二月三十一日止年度，本集團向HSBC Bank (China) Company Limited部分出售支付款項為人民幣10,955,000元的結構性交叉貨幣置換。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

22. FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS

(continued)

Notes: (continued)

- (b) As at 31 December 2021 the Group holds a currency option which was issued by HSBC Bank (China) Company Limited to fix exchange rate of USD against RMB at maturity date of 27 April 2022, with principal amount of USD40,000,000. On 28 June 2021, the Group terminated the currency option they held as of 31 December 2020, with payment of RMB27,320,000 to HSBC Bank (China) Company Limited.
- (c) As at 31 December 2021 and 2020, the Group held an interest rate swap which was issued by HSBC Bank (China) Company Limited to exchange floating interest rate with fixed interest rate, matured on 21 June 2024, with principal amount of RMB300,000,000.
- (d) As at 31 December 2021, the amount of RMB78,092,000 represents 11.76% (2020: RMB87,167,000 represents 11.76%) of the interest in a health science fund. The amount of RMB22,851,000 represents 4.47% (2020: RMB21,253,000 represents 4.47%) of the interest in an investment fund.
- (e) As at 31 December 2021, the structured deposit was issued by a bank in the PRC with expected rate of return (not guaranteed) which is linked to interest rates, currency, stock index and commodity price.

22. 按公平值計入損益計量之金融工具 (續)

附註：(續)

- (b) 於二零二一年十二月三十一日，本集團持有HSBC Bank (China) Company Limited發行的貨幣期權，以於二零二二年四月二十七日期滿日期將美元兌人民幣的匯率固定，本金額為40,000,000美元。於二零二一年六月二十八日，本集團終止其於二零二零年十二月三十一日持有的貨幣期權，向HSBC Bank (China) Company Limited支付人民幣27,320,000元。
- (c) 於二零二一年及二零二零年十二月三十一日，本集團持有HSBC Bank (China) Company Limited發行的於二零二四年六月二十一日到期的利率互換，以固定利率交換浮動利率，本金額為人民幣300,000,000元。
- (d) 於二零二一年十二月三十一日，金額人民幣78,092,000元(二零二零年：人民幣87,167,000元；11.76%)指健康科學基金之11.76%權益。金額人民幣22,851,000元(二零二零年：人民幣21,253,000元；4.47%)指一項投資基金之4.47%權益。
- (e) 於二零二一年十二月三十一日，結構性存款由中國一間銀行發行，預期收益率(非保證)與利率、貨幣、股票指數及商品價格掛鉤。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

23. DEFERRED TAXATION

For the purpose of presentation in the consolidated statement of financial position, certain deferred tax assets and liabilities have been offset. The following is the analysis of the deferred tax balances for financial reporting purpose.

23. 遞延稅項

為呈列綜合財務狀況表，遞延稅項資產及負債已被抵銷。就財務申報目的作出之遞延稅項結餘分析如下。

		31/12/2021 RMB'000	31/12/2020 RMB'000 (restated)
		二零二一年 十二月 三十一日 人民幣千元	二零二零年 十二月 三十一日 人民幣千元 (經重列)
Deferred tax assets	遞延稅項資產	156,462	140,058
Deferred tax liabilities	遞延稅項負債	(222,620)	(291,797)
		(66,158)	(151,739)

The followings are the major deferred tax assets and liabilities recognised and movements thereon during the current and prior reporting year:

於本報告年度及過往報告年度，已確認的主要遞延稅項資產及負債及其變動載列如下：

		Time difference of property plants and equipment	Time difference of intangible assets	Unrealised profit	Share-based payments reserve	Unpaid bonus and salary	US research and development expenses	Impairment of assets	Interest deduction limited	Deductible losses	Time changes in fair value	Contract liabilities	Provision	Others (note)	Total	
		RMB'000 (restated)	RMB'000 (restated)	RMB'000 (restated)	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000 (restated)	RMB'000 (restated)	
		物業、廠房及設備的時間差	無形資產的時間差	未變現溢利	以股份為基礎的付款儲備	未支付花紅及薪金	美國研發開支	資產減值	利息折扣限額	可抵扣虧損	公平值變動時間差	合約負債	撥備	其他 (附註)	總計	
		人民幣千元 (經重列)	人民幣千元 (經重列)	人民幣千元 (經重列)	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元 (經重列)	人民幣千元 (經重列)	
At 1 January 2020 (restated)	於二零二零年一月一日 (經重列)	6,346	(16,702)	(366,165)	24,542	19,623	11,647	(8,372)	42,033	66,781	5,078	(1,185)	-	-	11,275	(205,099)
Acquisition of a subsidiary (note 39)	收購一間附屬公司 (附註39)	-	-	(3,596)	-	-	-	-	-	-	-	-	-	-	-	(3,596)
Credit (charge) to profit or loss (restated)	計入 (扣除) 損益 (經重列)	3,453	1,619	38,046	2,822	4,994	(9,768)	(14,575)	6,887	(37,232)	(383)	14,067	7,083	-	20,483	37,496
Exchange adjustments (restated)	匯兌調整 (經重列)	-	1,810	20,991	(25)	(710)	-	1,471	(151)	(1,947)	(100)	-	-	-	(1,879)	19,460
At 31 December 2020	於二零二零年十二月三十一日	9,799	(13,273)	(310,724)	27,339	23,907	1,879	(21,476)	48,769	27,602	4,595	12,882	7,083	-	29,879	(151,739)
Credit (charge) to profit or loss	計入 (扣除) 損益	(20)	(6,710)	37,187	6,854	13,167	-	(7,624)	2,128	(7,891)	(3,256)	(1,620)	1,532	54,770	(8,582)	79,935
Exchange adjustments	匯兌調整	-	689	6,505	(8)	(312)	-	581	(54)	(538)	(30)	-	-	(644)	(543)	5,646
At 31 December 2021	於二零二一年十二月三十一日	9,779	(19,294)	(267,032)	34,185	36,762	1,879	(28,519)	50,843	19,173	1,309	11,262	8,615	54,126	20,754	(66,158)

Note: The others mainly comprised transaction cost, prepaid expense, inventory capitalisation adjustment etc., due to the time differences under U.S. income tax code.

附註：其他主要包括美國所得稅法項下時間差產生的交易成本、預付開支、存貨資本化調整等。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

23. DEFERRED TAXATION (continued)

At the end of reporting period, no deferred tax asset has been recognised in relation to the following deductible temporary difference as it is not probable that taxable profit will be available against which the deductible temporary differences can be utilised.

23. 遞延稅項 (續)

於報告期末，概無就以下可扣稅減暫時差異確認遞延稅項資產，因為應課稅溢利不可能用於抵銷可扣稅暫時差異。

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
Arising from impairment of assets	自資產減值產生	25,413	25,186
Arising from other temporary differences	自其他暫時差異產生	3,972	8,410
		29,385	33,596

As at 31 December 2021, the Group has estimated unused tax losses of approximately RMB144,438,000 (2020: RMB82,432,000) available for offset against future profits. No deferred tax asset has been recognised in respect of the tax losses due to the unpredictability of future profit streams. The above tax losses will be expired in the following years:

於二零二一年十二月三十一日，本集團擁有可供抵銷未來溢利的估計未使用稅項虧損約人民幣144,438,000元(二零二零年：人民幣82,432,000元)。由於未能預測未來的溢利來源，故並無就稅項虧損確認遞延稅項資產。上述稅項虧損將於下列年限到期：

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
2021	二零二一年	-	8,397
2022	二零二二年	5,590	6,903
2023	二零二三年	6,279	13,122
2024	二零二四年	15,267	16,351
2025	二零二五年	36,709	37,659
2026	二零二六年	80,593	-
		144,438	82,432

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

24. FINANCE LEASE RECEIVABLES

The Group entered into certain finance lease agreements as a lessor for equipment. The average terms of finance leases entered into usually range from one to three years. All interest rates inherent in the leases are fixed at the contract date over the leases terms.

24. 應收融資租賃款項

本集團(作為設備承租人)訂立若干融資租賃協議。融資租賃平均租期通常訂立為介乎一至三年。有關租賃之全部利率均根據租期於合約日期釐定。

		31/12/2021	31/12/2020
		RMB'000	RMB'000
			(restated)
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
			(經重列)
Analysed for reporting purposes as:	就呈報目的分析為:		
Current assets	流動資產	85,122	136,908
Non-current assets	非流動資產	40,959	85,160
		126,081	222,068

		Minimum lease receivables		Present value of minimum lease receivables	
		31/12/2021	31/12/2020	31/12/2021	31/12/2020
		RMB'000	RMB'000	RMB'000	RMB'000
			(restated)		(restated)
		應收最低租賃款項		應收最低租賃款項之現值	
		二零二一年	二零二零年	二零二一年	二零二零年
		十二月	十二月	十二月	十二月
		三十一日	三十一日	三十一日	三十一日
		人民幣千元	人民幣千元	人民幣千元	人民幣千元
			(經重列)		(經重列)
Finance lease receivables comprise	應收融資租賃款項包括				
Within one year	於一年內	100,865	151,499	94,792	144,726
In more than one year but not more than two years	超過一年但不超過兩年	38,532	60,064	34,462	53,655
In more than two years but not more than five years	超過兩年但不超過五年	9,443	39,578	8,053	32,556
Unguaranteed residual values	無擔保剩餘價值	148,840	251,141	137,307	230,937
Less: unearned finance income allowance for credit losses	減: 未賺取融資收益 信貸虧損撥備	(11,533)	(20,204)	-	-
		(11,226)	(8,869)	(11,226)	(8,869)
Present value of minimum lease payment receivables	應收最低租賃款項之現值	126,081	222,068	126,081	222,068

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

24. FINANCE LEASE RECEIVABLES (continued)

Effective interest rates implicit in the above finance leases range from 5.18% to 9.44% per annum (2020: 4.43% to 8.93%).

Finance lease receivables are secured over the machineries leased. The Group is not permitted to sell or re-pledge the collateral in the absence of default by the lessee.

As at 31 December 2021, the carrying amount of the finance lease receivables due from fellow subsidiaries is RMB53,571,000 (2020: RMB83,216,000).

As at 31 December 2021, the finance lease receivables which has been pledged as security for the borrowings is nil (2020: RMB18,091,000).

Details of impairment assessment of financial lease receivables are set out in note 42.

25. LOAN RECEIVABLES

Fixed-rate loan receivables (note a) 固定利率應收貸款 (附註a)
Variable-rate loan receivables (note b) 浮動利率應收貸款 (附註b)
Less: Allowance for credit losses 減：信貸虧損撥備

Analysed for reporting purposes as: 就呈報目的分析為：
Current assets 流動資產
Non-current assets 非流動資產

24. 應收融資租賃款項 (續)

上述融資租賃內含之實際年利率介乎5.18厘至9.44厘 (二零二零年：4.43厘至8.93厘)。

應收融資租賃款項以所租機器作抵押。本集團不允許在承租人未違約情況下出售或再抵押抵押品。

於二零二一年十二月三十一日，應收融資租賃款項的賬面值包括應收同系附屬公司款項人民幣53,571,000元 (二零二零年：人民幣83,216,000元)。

於二零二一年十二月三十一日，已抵押為借款的抵押品的應收融資租賃款項為零 (二零二零年：人民幣18,091,000元)。

應收融資租賃款項減值評估詳情載於附註42。

25. 應收貸款

	31/12/2021	31/12/2020
	RMB'000	RMB'000
	二零二一年	二零二零年
	十二月	十二月
	三十一日	三十一日
	人民幣千元	人民幣千元
Fixed-rate loan receivables (note a)	707,845	398,412
Variable-rate loan receivables (note b)	64,945	65,410
Less: Allowance for credit losses	(25,465)	(17,848)
	747,325	445,974
Analysed for reporting purposes as:		
Current assets	428,514	232,873
Non-current assets	318,811	213,101
	747,325	445,974

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

25. LOAN RECEIVABLES (continued)

Notes:

- (a) As at 31 December 2021, the carrying amount of RMB340,713,000 represents the loan provided to third parties are secured by various equipment, carrying the effective interest rates range from 5.22% to 14%. (2020: RMB366,659,000, the effective interest rates range from 6.1% to 9.44%). As at 31 December 2021, the carrying amount of RMB367,132,000 loan receivables due from fellow subsidiaries, carrying the effective interest rates range from 6.35% to 8.00% (2020: RMB31,753,000, with the effective interest rates range from 6.1% to 7.4%).
- (b) As at 31 December 2021, one of the subsidiary of the Company provided loan with principal amount of RMB29,692,000 to the eligible employees of Weigao Orthopaedic to partially fund the subscription of share award scheme granted to them, with a period of five years (2020: RMB29,700,000), bearing the benchmark lending rate that published by the People's Bank of China. As at 31 December 2021, the accrued interest of the loan included in the balance of loan receivable was RMB1,604,000 (2020: RMB804,000). Detail of the share award scheme of Weigao Orthopaedic are set out in note 38 (c).

During the year ended 31 December 2021 and 2020, RMB17,027,000 loan was provided by the subsidiary of the Company to an employee of Weigao Orthopaedic with a period of five years. The loans are unsecured, bearing the benchmark lending rate that published by the People's Bank of China. As at 31 December 2021, the accrued interest of the loan included in the balance of loan receivable was RMB1,122,000 (2020: RMB379,000).

Details of impairment assessment of loan receivables are set out in note 42.

25. 應收貸款 (續)

附註：

- (a) 於二零二一年十二月三十一日，賬面值人民幣340,713,000元指提供予第三方之貸款（二零二零年：人民幣366,659,000元，實際年利率範圍介乎6.1厘至9.44厘），並以各設備作擔保，實際年利率範圍介乎5.22厘至14厘。於二零二一年十二月三十一日，應收貸款賬面值包括應收同系附屬公司款項人民幣367,132,000元，實際年利率範圍介乎6.35厘至8.00厘（二零二零年：人民幣31,753,000元，實際年利率範圍介乎6.1厘至7.4厘）。
- (b) 於二零二一年十二月三十一日，本公司一間附屬公司向威高骨科之合資格僱員提供本金額人民幣29,692,000元之貸款，以部分撥付授予彼等股份激勵計劃的認購，為期五年（二零二零年：人民幣29,700,000元），及按中國人民銀行公佈的基準貸款利率計息。於二零二一年十二月三十一日，計入應收貸款結餘之應計貸款利息為人民幣1,604,000元（二零二零年：人民幣804,000元）。威高骨科股份激勵計劃的詳情載於附註38(c)。

截至二零二一年及二零二零年十二月三十一日止年度，本公司附屬公司向威高骨科一名僱員提供人民幣17,027,000元之貸款，為期五年。該等貸款為無抵押，及按中國人民銀行公佈的基準貸款利率計息。於二零二一年十二月三十一日，計入應收貸款結餘之應計貸款利息為人民幣1,122,000元（二零二零年：人民幣379,000元）。

應收貸款減值評估詳情載於附註42。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

26. INVENTORIES

26. 存貨

		31/12/2021	31/12/2020
		RMB'000	RMB'000
			(restated)
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
			(經重列)
Raw materials	原料	344,151	287,843
Finished goods	製成品	1,390,406	1,275,010
		1,734,557	1,562,853

As at 31 December 2021, total net book value of inventories served as collateral for the Group's borrowing amounted to RMB212,104,000 (2020: RMB221,224,000).

於二零二一年十二月三十一日，用作本集團借款抵押品的存貨總賬面淨值為人民幣212,104,000元（二零二零年：人民幣221,224,000元）。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

27. TRADE AND OTHER RECEIVABLES

27. 應收貿易賬款及其他應收款項

		31/12/2021	31/12/2020
		RMB'000	RMB'000
			(restated)
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
			(經重列)
Trade receivables	應收貿易賬款	5,280,407	4,879,427
Less: Allowance for credit losses	減：信貸虧損撥備	(253,899)	(242,124)
		5,026,508	4,637,303
Receivables from factoring business	來自保理業務之應收款項	74,936	329,968
Less: Allowance for credit losses	減：信貸虧損撥備	(844)	(1,226)
		74,092	328,742
Other receivables	其他應收款項	515,698	638,817
Less: Allowance for credit losses	減：信貸虧損撥備	(2,161)	(2,110)
		513,537	636,707
Prepayments	預付款項	510,795	443,897
		6,124,932	6,046,649
Analysed for reporting purposes as:	就呈報目的分析為：		
Current assets	流動資產	6,045,579	5,958,479
Non-current assets	非流動資產	79,353	88,170
		6,124,932	6,046,649

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

27. TRADE AND OTHER RECEIVABLES

(continued)

As at 31 December 2021, trade receivables from contracts with customers amounted to RMB5,280,407,000 (2020: RMB4,879,427,000).

Included in trade receivables are an amount due from fellow subsidiaries of RMB2,057,959,000 (2020: RMB1,097,918,000), an amount due from a holding company of RMB2,341,000 (2020: RMB110,000), and an amount due from an associate of RMB46,087,000 (2020: RMB152,712,000), an amount due from associates of a holding company of RMB861,000 (2020: nil).

Included in receivables from factoring business are an amount due from fellow subsidiaries of RMB6,000,000 (2020: RMB322,990,000). The amounts are due in one year with effective interest rates 8% per annum (2020: 4.99% to 8.00% per annum).

Included in other receivables are an amount due from fellow subsidiaries of RMB87,611,000 (2020: RMB53,465,000), an amount due from a holding company of RMB349,028,000 (2020: RMB435,554,000), an amount due from an associate of nil (2020: RMB7,416,000), an amount due from associates of a holding company of RMB18,000 (2020: nil). The amounts are unsecured and repayable on demand.

Included in prepayments are an amount paid to fellow subsidiaries of RMB77,610,000 (2020: RMB27,891,000), an amount paid to a holding company of RMB908,000 (2020: nil), and an amount paid to an associate of RMB402,000 (2020: RMB971,000).

27. 應收貿易賬款及其他應收款項 (續)

於二零二一年十二月三十一日，來自客戶合約的應收貿易賬款為人民幣5,280,407,000元(二零二零年：人民幣4,879,427,000元)。

應收貿易賬款包括應收同系附屬公司款項人民幣2,057,959,000元(二零二零年：人民幣1,097,918,000元)、應收一間控股公司款項人民幣2,341,000元(二零二零年：人民幣110,000元)及應收一間聯營公司款項人民幣46,087,000元(二零二零年：人民幣152,712,000元)及應收一間控股公司的聯營公司款項人民幣861,000元(二零二零年：零)。

來自保理業務之應收款項包括應收同系附屬公司款項人民幣6,000,000元(二零二零年：人民幣322,990,000元)。該等款項於一年內到期，實際年利率為8厘(二零二零年：每年4.99厘至8.00厘)。

其他應收款項包括應收同系附屬公司款項人民幣87,611,000元(二零二零年：人民幣53,465,000元)、應收一間控股公司款項人民幣349,028,000元(二零二零年：人民幣435,554,000元)、應收一間聯營公司款項零(二零二零年：人民幣7,416,000元)及應收一間控股公司的聯營公司款項人民幣18,000元(二零二零年：零)。該等款項為無抵押及須於要求時償還。

預付款項包括已付同系附屬公司款項人民幣77,610,000元(二零二零年：人民幣27,891,000元)、已付一間控股公司款項人民幣908,000元(二零二零年：零)及已付一間聯營公司款項人民幣402,000元(二零二零年：人民幣971,000元)。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

27. TRADE AND OTHER RECEIVABLES

(continued)

The following is an aged analysis of trade receivables net of allowance for credit losses presented based on the invoice date at the end of the reporting period.

0 to 90 days	0至90天
91 to 180 days	91至180天
181 to 365 days	181至365天
Over 365 days	365天以上

Trade receivables

應收貿易賬款

As at 31 December 2021, included in the Group's trade receivables balance are debtors with aggregate carrying amount of RMB1,348,288,000 which are past due (2020: RMB1,302,478,000).

As at 31 December 2021, total net book value of trade and other receivables served as collateral for the Group's borrowing amounted to RMB180,649,000 (2020: RMB167,839,000).

Details of impairment assessment of trade and other receivables are set out in note 42.

27. 應收貿易賬款及其他應收款項 (續)

於報告期末，按發票日呈列的應收貿易賬款（經扣減信貸虧損撥備）之賬齡分析如下。

31/12/2021	31/12/2020
RMB'000	RMB'000
二零二一年	二零二零年
十二月	十二月
三十一日	三十一日
人民幣千元	人民幣千元
	(經重列)
2,568,131	2,377,901
1,147,653	997,902
993,716	773,449
317,008	488,051
5,026,508	4,637,303

於二零二一年十二月三十一日，本集團的應收貿易賬款結餘已包括賬面總值為人民幣1,348,288,000元（二零二零年：人民幣1,302,478,000元）已逾期的應收賬款。

於二零二一年十二月三十一日，作為本集團借款抵押品的應收貿易賬款及其他應收款項的賬面淨值總額為人民幣180,649,000元（二零二零年：人民幣167,839,000元）。

應收貿易賬款及其他應收款項的減值評估詳情載於附註42。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

28. DEBT INSTRUMENTS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

28. 按公平值計入其他全面收益計量之債務工具

	31/12/2021	31/12/2020
	RMB'000	RMB'000
		(restated)
	二零二一年	二零二零年
	十二月	十二月
	三十一日	三十一日
	人民幣千元	人民幣千元
		(經重列)
Unlisted investments:		
– Bills receivable	419,752	469,610
非上市投資：		
– 應收票據		

As at 31 December 2021, the Group endorsed bills receivable of RMB449,848,000 (2020: RMB292,547,000) for the settlement of trade and other payables. In the opinion of the directors of the Company, the Group has transferred the significant risks and rewards relating to these bills receivable, and the Group's obligations to the corresponding counterparties were discharged in accordance with the commercial practice in the PRC and the risk of the default in payment of the endorsed bills receivable is low because all endorsed bills receivable are issued and guaranteed by the reputable PRC banks. As a result, the relevant assets and liabilities were derecognised. The maximum exposure to the Group that may result from the default of these endorsed bills receivable are RMB449,848,000 (2020: RMB292,547,000). All bills received by the Group are with a maturity period of less than one year.

As at 31 December 2021, the Group has pledged bills receivable of RMB54,188,000 (2020: RMB128,188,000) to secure the letter of credit.

於二零二一年十二月三十一日，本集團已背書應收票據人民幣449,848,000元(二零二零年：人民幣292,547,000元)以支付應付貿易賬款及其他應付款項。本公司董事認為，本集團已轉移有關該等應收票據的重大風險及回報，而本集團對相對應手的責任已根據中國商業慣例獲解除。鑒於所有已背書應收票據均由聲譽良好的中國銀行發出及擔保，故已背書應收票據出現拖欠付款的風險低。因此，相關資產及負債已取消確認。本集團可能因該等已背書應收票據出現拖欠付款所蒙受的最大風險為人民幣449,848,000元(二零二零年：人民幣292,547,000元)。本集團收到的所有票據均於一年內到期。

於二零二一年十二月三十一日，本集團已抵押應收票據人民幣54,188,000元(二零二零年：人民幣128,188,000元)用於取得信用證。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

29. PLEDGED BANK DEPOSITS

As at 31 December 2021, pledged bank balances represent deposits pledged to banks to secure trade facilities such as bills payable and letter of credit and short-term borrowing amounting to RMB760,895,000 (2020: RMB340,129,000).

The pledged bank balances carry fixed interest rates which range from 0.01% to 2.25% per annum as at 31 December 2021 (2020: 0.3% to 2.10% per annum).

30. BANK BALANCES AND CASH

Bank balances carry interest at market rates which range from nil to 4.125% per annum as at 31 December 2021 (2020: nil to 4.125% per annum).

As at 31 December 2021, bank balances included deposits of RMB180,168,000 (2020: RMB194,942,000), carrying interest rates which range from 1.495% to 4.125% per annum (2020: 1.495% to 4.125% per annum), in an associate of a holding company.

As at 31 December 2021, bank balances and cash served as collateral for the Group's borrowing amounted to RMB266,646,000 (2020: RMB274,431,000).

29. 已抵押銀行存款

於二零二一年十二月三十一日，已抵押銀行結餘指抵押予銀行以擔保貿易融資（例如應付票據及信用證及短期借款）之存款金額人民幣760,895,000元（二零二零年：人民幣340,129,000元）。

於二零二一年十二月三十一日，已抵押銀行結餘按固定利率介乎每年0.01厘至2.25厘（二零二零年：每年0.3厘至2.10厘）計息。

30. 銀行結餘及現金

於二零二一年十二月三十一日，銀行結餘按介乎於每年0至4.125厘之間的市場利率（二零二零年：每年0至4.125厘）計息。

於二零二一年十二月三十一日，銀行結餘包括一間控股公司之一間聯營公司之按金人民幣180,168,000元（二零二零年：人民幣194,942,000元），按每年1.495厘至4.125厘的利率（二零二零年：每年1.495厘至4.125厘）計息。

於二零二一年十二月三十一日，用作本集團借款抵押品的銀行結餘及現金為人民幣266,646,000元（二零二零年：人民幣274,431,000元）。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

31. TRADE AND OTHER PAYABLES

The following is an aged analysis of trade payables presented based on the invoice date at the end of the reporting period:

31. 應付貿易賬款及其他應付款項

於報告期末，按發票日期呈列的應付貿易賬款的賬齡分析如下：

		31/12/2021	31/12/2020
		RMB'000	RMB'000
			(restated)
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
			(經重列)
0 to 90 days	0至90天	876,043	1,033,086
91 to 180 days	91至180天	257,150	240,787
181 to 365 days	181至365天	113,021	103,766
Over 365 days	365天以上	90,572	38,679
Trade payables	應付貿易賬款	1,336,786	1,416,318
Bills payable	應付票據	332,164	341,349
Other tax payables	其他應付稅項	116,185	134,908
Construction cost and retention payables	建築成本及應付保留金	64,490	90,430
Selling expense payables	應付銷售開支	889,433	818,530
Other payables	其他應付款項	1,212,986	1,048,044
		3,952,044	3,849,579
Analysed for reporting purposes as:	就呈報目的分析為：		
Current liabilities	流動負債	3,952,044	3,812,454
Non-current liabilities	非流動負債	-	37,125
		3,952,044	3,849,579

The normal credit period taken for trade purchases is 30 days to 180 days. All the bills payable will mature within six months.

貿易採購的正常信貸期為30天至180天。所有應付票據均將於六個月內到期。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

31. TRADE AND OTHER PAYABLES (continued)

Included in trade payables are an amount due to fellow subsidiaries of RMB409,852,000 (2020: RMB440,395,000), an amount due to an associate of RMB45,102,000 (2020: RMB83,218,000), an amount due to a holding company of RMB3,000 (2020: RMB1,221,000), and an amount due to associates of a holding company of RMB660,000 (2020: nil). The amounts are unsecured, interest-free and repayable within credit period.

Included in other payables are an amount due to fellow subsidiaries of RMB8,534,000 (2020: RMB23,696,000), an amount due to an associate of RMB571,000 (2020: nil), an amount due to a holding company of RMB20,099,000 (2020: RMB27,803,000), and an amount due to an associate of a holding company of RMB690,000 (2020: nil). The amounts are unsecured, interest-free and repayable on demand.

32. CONTRACT LIABILITIES

31. 應付貿易賬款及其他應付款項 (續)

應付貿易賬款包括應付同系附屬公司款項人民幣409,852,000元(二零二零年: 人民幣440,395,000元)、應付一間聯營公司款項人民幣45,102,000元(二零二零年: 人民幣83,218,000元)、應付一間控股公司款項人民幣3,000元(二零二零年: 人民幣1,221,000元)及應付一間控股公司的聯營公司款項人民幣660,000元(二零二零年: 零)。該等款項為無抵押、免息及按要求於信貸期內償還。

其他應付款項包括應付同系附屬公司款項人民幣8,534,000元(二零二零年: 人民幣23,696,000元)、應付一間聯營公司款項人民幣571,000元(二零二零年: 零)、應付一間控股公司款項人民幣20,099,000元(二零二零年: 人民幣27,803,000元)及應付一間控股公司的一間聯營公司款項人民幣690,000元(二零二零年: 零)。該等款項為無抵押、免息及於要求時償還。

32. 合約負債

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
			(經重列)
Sales of goods	銷售商品	314,171	315,164
Current	流動	310,866	313,373
Non-Current	非流動	3,305	1,791
		314,171	315,164

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

32. CONTRACT LIABILITIES (continued)

The revenue recognised in the current year relates to carried-forward contract liabilities amounted to RMB313,373,000. RMB310,866,000 contract liabilities will be recognised as revenue during the year ended 31 December 2022.

Included in contract liabilities are an amount received from fellow subsidiaries of RMB35,507,000 (2020: RMB44,159,000), and amount received from ultimate holding company of RMB11,000 (2020: nil).

32. 合約負債 (續)

本年度確認的與結轉合約負債相關的收入為人民幣313,373,000元。於截至二零二一年十二月三十一日止年度，合約負債人民幣310,866,000元將確認為收入。

合約負債包括已收同系附屬公司款項人民幣35,507,000元(二零二零年：人民幣44,159,000元)及已收最總控股公司款項人民幣11,000元(二零二零年：零)。

33. BORROWINGS

33. 借款

		31/12/2021 RMB'000 二零二一年 十二月 三十一日 人民幣千元	31/12/2020 RMB'000 二零二零年 十二月 三十一日 人民幣千元
Bank borrowings at variable-rate (note a)	按浮動利率計息的銀行借款(附註a)	2,264,020	2,725,759
Bank borrowings at fixed-rate (note b)	按固定利率計息的銀行借款(附註b)	799,996	573,420
		3,064,016	3,299,179
Secured (note c)	有抵押(附註c)	2,991,845	3,023,329
Unsecured	無抵押	72,171	275,850

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

33. BORROWINGS (continued)

33. 借款 (續)

The borrowings are repayable as follows:

借款須於下列期間償還：

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
Within one year	於一年內	601,328	297,890
More than one year but not exceeding two years	於一年以上但不超過兩年	214,092	377,790
More than two years but not exceeding five years	於兩年以上但不超過五年	2,248,596	2,623,499
		3,064,016	3,299,179
Less: Amount due within one year shown under current liabilities	減：列為流動負債而於一年以內到期的款項	(601,328)	(297,890)
Amount due after one year shown under non-current liabilities	列為非流動負債而於一年後到期的款項	2,462,688	3,001,289

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

33. BORROWINGS (continued)

Notes:

- (a) As at 31 December 2021, the variable-rate borrowings carry interest rates ranged from 1.35% to 5.3% per annum (2020: 1.84% to 4.99% per annum).
- (b) As at 31 December 2021, the fixed-rate borrowings carry interest rates ranged from 3.08% to 9.48% per annum (2020: 1.99% to 5.03% per annum).
- (c) On 31 March 2020, the Company entered into a loan agreement with International Finance Corporation, in the aggregate principal amount of RMB500,000,000, bearing fixed interest rate of 3.43% per annum. The borrowing are secured by equity interests of Jierui, Weigao Purui, Shandong Weigao Financial Leasing Co.,Ltd, Shanghai Weigao Financing Lease Co.,Ltd that owned by the Company.

As at 31 December 2021, the balance included loans of nil (2020: RMB18,091,000) secured by pledge of certain of the Group's finance lease receivables of nil (2020: RMB18,091,000)

On 12 September 2019, Argon entered into Tranche A Credit Agreement ("Tranche A"), with principal amount of USD325,000,000 (equivalent to RMB2,267,265,000), bearing variable interest at GBP London Interbank Offered Rate ("LIBOR") plus 2.125% and includes a revolving credit facility bearing interest at the same rate; WW Medical and Healthcare Holdings Corporation ("WW Holding") entered into Tranche B Facility Agreement ("Tranche B") with principal amount of USD75,000,000 (equivalent to RMB523,215,000), bearing variable interest at LIBOR plus 2.4%. As at 31 December 2021, the principal of Tranche A and Tranche B outstanding amounted to USD336,406,000 (equivalent to RMB2,144,825,000).

33. 借款 (續)

附註：

- (a) 於二零二一年十二月三十一日，浮動利率借款按介於每年1.35厘至5.3厘之間的利率(二零二零年：每年1.84厘至4.99厘)計息。
- (b) 於二零二一年十二月三十一日，固定利率借款按介乎每年3.08厘至9.48厘的利率(二零二零年：每年1.99厘至5.03厘)計息。
- (c) 於二零二零年三月三十一日，本公司與國際金融公司訂立本金總額為人民幣500,000,000元的貸款協議，固定年利率為3.43厘。該借款以本公司擁有的潔瑞、威高普瑞、山東威高融資租賃有限公司及上海威高融資租賃有限公司的股權提供擔保。

於二零二一年十二月三十一日，結餘包括貸款零(二零二零年：人民幣18,091,000元)，通過抵押本集團零(二零二零年：人民幣18,091,000元)之若干應收融資租賃款項提供擔保。

於二零一九年九月十二日，愛琅訂立本金額為325,000,000美元(相等於人民幣2,267,265,000元)的Tranche A信貸協議(「Tranche A」)，浮動利率為英鎊倫敦銀行同業拆放利率(「LIBOR」)加2.125厘，及包括以相同利率計息的循環信貸融資；WW Medical and Healthcare Holdings Corporation(「WW Holding」)訂立本金額為75,000,000美元(相等於人民幣523,215,000元)的Tranche B融資協議(「Tranche B」)，浮動利率為LIBOR加2.4厘。於二零二一年十二月三十一日，Tranche A及Tranche B的未償還本金為336,406,000美元(相等於人民幣2,144,825,000元)。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

33. BORROWINGS (continued)

33. 借款 (續)

Outstanding debt as of 31 December 2021 excluding debt discount, matures as follows:

於二零二一年十二月三十一日，除債務貼現外的未償債務期限如下：

		31/12/2021 RMB'000 二零二一年 十二月 三十一日 人民幣千元
Within one year	於一年內	168,358
More than one year but not exceeding two years	於一年以上但不超過兩年	220,161
More than two years but not exceeding five years	於兩年以上但不超過五年	1,756,306
		2,144,825

The Company guaranteed the borrowings under Tranche A and Tranche B. Certain of Argon's assets serve as collateral for borrowings under Tranche A and Tranche B.

本公司為Tranche A及Tranche B的借款提供擔保。愛琅若干資產作為Tranche A及Tranche B項下借款的抵押品。

On 31 December 2021, the details are as follow:

於二零二一年十二月三十一日，詳情如下：

		31/12/2021 RMB'000 二零二一年 十二月 三十一日 人民幣千元
Property, plant and equipment	物業、廠房及設備	44,915
Intangible assets	無形資產	1,558,472
Inventories	存貨	212,104
Trade and other receivables	應收貿易賬款及其他應收款項	180,649
Bank balances and cash	銀行結餘及現金	266,646

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

34. BONDS PAYABLE

34. 應付債券

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
Green Bonds	綠色債券	992,549	991,121

The bonds are repayable as follows:

債券須於下列期間償還：

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
More than five years	五年以上	992,549	991,121

On 31 March 2020, International Finance Corporation agreed to subscribe the senior secured green bonds (the "Green Bonds") issued by the Company in the aggregate principal amount of RMB1,000,000,000 with maturity in seven years. The Green Bonds bear fixed interest rate of 3.59% per annum, payable semi-annually. The effective interest rate of the Green Bonds is 3.73% per annum. The Green Bonds, are secured by equity interests of Jierui, Weigao Purui, Shandong Weigao Financial Leasing Co.,Ltd, Shanghai Weigao Financing Lease Co.,Ltd that owned by the Company.

於二零二零年三月三十一日，國際金融公司同意認購本公司發行的本金總額為人民幣1,000,000,000元的優先有擔保綠色債券（「綠色債券」），期限為7年。綠色債券的固定年利率為3.59%，每半年支付一次。綠色債券的實際年利率為3.73%。綠色債券以本公司擁有的捷瑞、威高普瑞、山東威高融資租賃有限公司及上海威高融資租賃有限公司的股權提供擔保。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

35. DEFERRED INCOME

35. 遞延收入

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
Arising from government grants	來自政府補助	93,581	78,759
Analysed for reporting purposes as:	就呈報目的分析為：		
Current liabilities	流動負債	8,816	7,861
Non-current liabilities	非流動負債	84,765	70,898
		93,581	78,759

During the year ended 31 December 2021, the Group received new government grants from the government authorities amounting to in aggregate RMB33,361,000 (2020: RMB34,175,000) to subsidy the Group's certain capital expenditures. The Group has complied with the conditions attached to the grants as at the end of 31 December 2021, and will transfer the grants to profit or loss over the useful lives of the related assets. During the year, the Group recognised these government grants to other income amounting to RMB18,539,000 (2020: RMB7,680,000).

截至二零二一年十二月三十一日止年度，本集團收到政府部門合共人民幣33,361,000元（二零二零年：人民幣34,175,000元）之新政府補助，以為本集團的若干資本開支提供補助。截至二零二一年十二月三十一日，本集團已遵守補助的附帶條件，並按有關資產之可使用年期內轉撥該等補助至損益。年內，本集團確認該等政府補助至其他收入人民幣18,539,000元（二零二零年：人民幣7,680,000元）。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

36. LEASE LIABILITIES

36. 租賃負債

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
Lease liabilities payable:	應付租賃負債：		
Within one year	於一年內	22,988	8,583
Within a period of more than one year but not more than two years	於一年以上但不超過兩年期間內	20,606	6,978
Within a period of more than two years but not more than five years	於兩年以上但不超過五年期間內	35,620	9,100
Within a period of more than five years	超過五年期間內	1,631	6,037
		80,845	30,698
Less: Amount due for settlement with 12 months shown under current liabilities	減：列為流動負債而於12個月以內到期結算的款項	22,988	8,583
Amount due for settlement after 12 months shown under non-current liabilities	列為非流動負債而於12個月以後到期結算的款項	57,857	22,115

The weighted average incremental borrowing rates applied to lease liabilities range from 4.75% to 8.69% (2020: from 4.75% to 8.69%).

租賃負債應用的加權平均增量借款利率介乎4.75厘至8.69厘之間（二零二零年：介乎4.75厘至8.69厘）。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

37. SHARE CAPITAL

37. 股本

		Nominal value of each share RMB 每股 股份面值 人民幣	Number of non-listed H shares 非上市 H股數目	Number of H shares H股數目	Total number of shares 股份總數	Value RMB'000 價值 人民幣千元
Registered: At 31 December 2020	註冊： 於二零二零年十二月三十一日	0.1	-	4,522,332,324	4,522,332,324	452,233
At 31 December 2021	於二零二一年十二月三十一日	0.1	48,300,000	4,522,332,324	4,570,632,324	457,063
Issued and fully paid: At 31 December 2020	已發行及繳足： 於二零二零年十二月三十一日	0.1	-	4,522,332,324	4,522,332,324	452,233
Ordinary shares issued (note)	已發行普通股 (附註)	0.1	48,300,000	-	48,300,000	4,830
At 31 December 2021	於二零二一年十二月三十一日	0.1	48,300,000	4,522,332,324	4,570,632,324	457,063

Note:

The Company issued ordinary shares of 48,300,000 non-listed H shares with consideration of RMB172,914,000 in 2021 for the purpose of share award scheme (note 38 (a)).

附註：

本公司於二零二一年發行48,300,000股非上市H股普通股，代價為人民幣172,914,000元以用於股份激勵計劃 (附註 38(a))。

38. SHARE-BASED PAYMENTS**(a) Share Award Scheme of the Company**

On 17 November 2014, the Company's share award scheme (the "Incentive Share Scheme") was adopted by the extraordinary general meeting. The maximum number of non-listed Shares which may be issued under the share award scheme would be 223,818,616, which represent 5% of the existing issued share capital of the Company or approximately 4.76% of the issued share capital of the Company as enlarged by the issue of the 223,818,616 non-listed shares, respectively, as incentive shares to key personnel of the Group, and other persons as approved by the Remuneration Committee (the "Selected Employee"), in batches in subsequent years. The life of the Incentive Share Scheme is for 10 years starting from 17 November 2014. Details of the Incentive Share Scheme are set out in the Company's announcement dated 15 August 2014.

According to the Incentive Share Scheme, the incentive shares will be granted to the Selected Employee, subject to non-market performance vesting conditions.

According to the Incentive Share Scheme, for Selected Employee with a domestic identity, the trustee will administer the incentive shares, which may be organised in forms of companies owned by the employees, limited partnership, or qualified trust companies in the PRC, or for Selected Employee with a foreign identity, the trustee will hold the incentive shares outside the PRC.

On 11 December 2015, the Company granted first 45,960,000 incentive shares to 111 Selected Employees. On 4 January 2016, the trustees subscribed the 45,960,000 shares with the consideration of RMB101,112,000 at the issue price of RMB2.20 per share.

38. 以股份為基礎付款**(a) 本公司股份激勵計劃**

於二零一四年十一月十七日，本公司通過股東特別大會採納股份激勵計劃（「激勵股份計劃」）。根據股份激勵計劃可發行非上市股份之最多數目將為223,818,616股，分別相當於本公司現有已發行股本5%或經發行223,818,616股非上市股份擴大後本公司已發行股本約4.76%，於隨後年度向本集團主要人員及薪酬委員會批准的其他人（「受益人」）分批發行作為激勵股份。激勵股份計劃之年期為自二零一四年十一月十七日起計十年。激勵股份計劃之詳情載於本公司日期為二零一四年八月十五日之公佈內。

根據激勵股份計劃，激勵股份將在非市場業績歸屬條件的規限下授予受益人。

根據激勵股份計劃，就持有境內身份的受益人而言，受託人將管理激勵股份，其可能以僱員擁有的公司、於中國的有限合夥公司或合資格信託公司的方式作出，或就持有境外身份的受益人而言，受託人將在中國境外持有激勵股份。

於二零一五年十二月十一日，本公司首次授出45,960,000股激勵股份予111名受益人。於二零一六年一月四日，受託人以每股股份人民幣2.20元之發行價認購45,960,000股股份，代價為人民幣101,112,000元。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

38. SHARE-BASED PAYMENTS (continued)

(a) Share Award Scheme of the Company (continued)

The fair value of the incentive shares as at grant date amounted to RMB104,121,000 which determined by market price of listing shares of the Company.

For grants of shares that are satisfying specified vesting conditions, the difference between the fair value and the issue price of the vested shares is expensed on a straight-line basis over the periods in which services are expected to be rendered by the relevant employees. The Group recognised the incentive share expenses of approximately RMB3,572,000 (2020: RMB7,903,000) into the profit or loss during the current year.

Three limited partnerships (named Weihai Chang Hong Enterprise Management Consulting Centre (Limited Partnership) (威海長弘企業管理諮詢中心(有限合夥)), Weihai Yang Fan Enterprise Management Consulting Centre (Limited Partnership) (威海揚帆企業管理諮詢中心(有限合夥)) and Weihai Hong Tu Enterprise Management Consulting Centre (Limited Partnership) (威海宏圖企業管理諮詢中心(有限合夥)), respectively) were set up for the purpose of administering the Incentive Share Scheme and holding the shares, and hereby regarded as trustees of the Company and consolidated to the Group accordingly.

38. 以股份為基礎付款 (續)

(a) 本公司股份激勵計劃 (續)

於授予日期之激勵股份之公平值人民幣104,121,000元乃經參考本公司上市股份之市價而釐定。

就授出須符合指定歸屬條件的股份而言，公平值與已歸屬股份發行價之間的差額於預期將由有關僱員提供服務的歸屬期內以直線法確認為開支。於本年度，本集團於損益確認激勵股份開支約人民幣3,572,000元(二零二零年：人民幣7,903,000元)。

就管理激勵股份計劃及持有股份設立之三間有限合夥公司(即分別為威海長弘企業管理諮詢中心(有限合夥)、威海揚帆企業管理諮詢中心(有限合夥)及威海宏圖企業管理諮詢中心(有限合夥))，據此被視為本公司之受託人及因此於本集團綜合入賬。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

38. SHARE-BASED PAYMENTS (continued)

(a) Share Award Scheme of the Company (continued)

Details of specific categories of share award are as follows:

Batch 1
第1批

Note: The granted shares are vested in five tranches with the vesting date on 31 December of each year from 2015 to 2019, the vested shares are exercisable after two years lock up period following vested.

As of 31 December 2021, the outstanding incentive shares under the Incentive Share Scheme were 16,904,000 (2020: 23,564,000), included 9,922,000 exercisable shares (2020: 9,570,000).

During the year ended 31 December 2021, the trustees repurchased 9,108,000 shares (2020: 9,064,000), which would be taken up by the Selected Employees with the net consideration of RMB20,293,000 (2020: RMB52,571,000) at the price of RMB4.43 per share (2020: RMB8.00). The repurchased shares are held by the trustees for the benefit of the Share Award Scheme, to grant to other selected employees or to sell for the repayment of the loan provided by the controlling shareholder.

During the year ended 31 December 2021, the trustees sold 6,660,000 repurchased shares for a total consideration of RMB94,170,000 (2020: 22,396,000 repurchase shares for a total consideration of RMB259,745,000, certain of which were used to settle the loan provided by the controlling shareholder and the interest thereon).

38. 以股份為基礎付款 (續)

(a) 本公司股份激勵計劃 (續)

具體股份激勵類別的詳情如下：

Date of grant 授出日期	Vesting period 歸屬期	Issue Price 發行價
11/12/2015 二零一五年 十二月十一日	5 years 5年	RMB2.2 人民幣2.2元

附註：授出的股份將分5批予以歸屬，歸屬日期為二零一五年至二零一九年各年之十二月三十一日，已歸屬股份可於歸屬後兩年鎖定期屆滿後予以行使。

截至二零二一年十二月三十一日，激勵股份計劃項下之尚未行使激勵股份為16,904,000股（二零二零年：23,564,000股），包括9,922,000股可行使股份（二零二零年：9,570,000股）。

截至二零二一年十二月三十一日止年度，受託人以每股人民幣4.43元（二零二零年：人民幣8.00元）的價格回購擬由受益人所接納的9,108,000股股份（二零二零年：9,064,000股），代價淨額為人民幣20,293,000元（二零二零年：人民幣52,571,000元）。回購股份由受託人為股份激勵計劃的利益持有，以向其他受益人授出或出售以償還控股股東提供的貸款。

截至二零二一年十二月三十一日止年度，受託人以人民幣94,170,000元的總代價出售6,660,000股回購股份（二零二零年：以人民幣259,745,000元的總代價出售22,396,000股回購股份，部分回購股份用於清償控股股東提供的貸款及其利息）。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

38. SHARE-BASED PAYMENTS (continued)

(a) Share Award Scheme of the Company (continued)

On 21 October 2021, the trustees subscribed the newly issued 48,300,000 non-listed domestic shares with the total consideration of RMB172,914,000 at the issue price of RMB3.58 per share. On 24 December 2021, the Company granted 48,300,000 incentive shares to 83 Selected Employees.

Based on the Share Award Scheme of the Company, the Company will repurchase the shares granted to the Selected Employees when the Selected Employees are not satisfying specified vesting conditions. The total consideration paid by the Selected Employees are recognised as liabilities, and will only be reversed by portion to other reserve when the shares are vested each year.

The fair value of the incentive shares as at grant date amounted to RMB197,490,000 which determined by market price of listing shares of the Company.

For grants of shares that are satisfying specified vesting conditions, the difference between the fair value and the issue price of the vested shares is expensed on a straight-line basis over the periods in which services are expected to be rendered by the relevant employees. The Group recognised the incentive share expenses of approximately RMB41,275,000 (2020: nil) into the profit or loss during the current year.

Nine limited partnerships were set up for the purpose of administering the Incentive Share Scheme and holding the shares, and hereby regarded as trustees of the Company and consolidated to the Group accordingly.

38. 以股份為基礎付款 (續)

(a) 本公司股份激勵計劃 (續)

於二零二一年十月二十一日，受託人以每股股份人民幣3.58元之發行價認購新發行的48,300,000股非上市內資股，總代價為人民幣172,914,000元。於二零二一年十二月二十四日，本公司授出48,300,000股激勵股份予83名受益人。

根據本公司的股份激勵計劃，本公司會在受益人未達到指定歸屬條件時回購已授予受益人的股份。受益人所支付的總代價確認為負債，並僅將於每年股份歸屬時撥回部分至其他儲備。

於授予日期之激勵股份之公平值人民幣197,490,000元乃經參考本公司上市股份之市價而釐定。

就授出須符合指定歸屬條件的股份而言，公平值與已歸屬股份發行價之間的差額於預期將由有關僱員提供服務的歸屬期內以直線法確認為開支。於本年度，本集團於損益確認激勵股份開支約人民幣41,275,000元（二零二零年：無）。

就管理激勵股份計劃及持有股份設立之九間有限合夥公司，據此被視為本公司之受託人及因此於本集團綜合入賬。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

38. SHARE-BASED PAYMENTS (continued)

(a) Share Award Scheme of the Company (continued)

Details of specific categories of share award are as follows:

	Date of grant 授出日期	Vesting period 歸屬期	Issue Price 發行價
Batch 2 第2批	24/12/2021 二零二一年 十二月二十四日	5 years 5年	RMB3.58 人民幣3.58元

(b) Share Option Scheme by WW Cayman

On 26 July 2018, WW Cayman, a subsidiary of the Company, adopted a non-qualified share option plan (the "Share Option Scheme") for the primary purpose of providing incentives to directors and eligible employees of WW Cayman and its subsidiaries, which shall be valid and effective for a period of 10 years commencing from the adoption date. Under the Share Option Scheme, a committee designated by the board of directors of the WW Cayman may from time to time in its sole discretion grant options to the eligible employees.

The total number of shares in respect of which options may be granted under the Share Option Scheme is not permitted to exceed 8% of the shares of WW Cayman in issue at closing date. Unless approved by the shareholders of the Company, the total number of shares issued and to be issued upon exercise of the options granted to each participant (including both exercised and outstanding options) in any 12-month period must not exceed 1% of WW Cayman's shares in issue.

38. 以股份為基礎付款 (續)

(a) 本公司股份激勵計劃 (續)

具體股份激勵類別的詳情如下：

(b) WW Cayman 的購股權計劃

於二零一八年七月二十六日，本公司附屬公司WW Cayman採納非限定購股權計劃（「購股權計劃」），其主要目的是為WW Cayman及其附屬公司的董事及合資格僱員提供激勵，自採用日期起10年內有效。根據購股權計劃，WW Cayman董事會指定的委員會可不時全權酌情向合資格僱員授出購股權。

根據購股權計劃可授出購股權的相關股份總數不得超過交割日期已發行的WW Cayman股份的8%。除非獲本公司股東批准，授予各參與者的購股權（包括已行使和未行使的購股權）獲行使而於任何12個月期間內已發行及將予發行的股份總數不得超過WW Cayman已發行股份的1%。

38. SHARE-BASED PAYMENTS (continued)**(b) Share Option Scheme by WW Cayman**
(continued)

As at 31 December 2021, the number of shares in respect of which options had been granted and remained outstanding under the Scheme was 2,654,859, representing 7% (2020: 2,166,213, representing 7%) of the shares at that date.

No consideration is payable on the grant of an option. Options may be exercised at any time after vesting and will be cancelled if not exercised before the 10th anniversary of the date of grant.

The exercise price of each batch of option is determined with reference to the total cash consideration paid by the Company in the formation of WW Cayman for the acquisition of Argon, taking into account the relevant costs and expenses involved, but in no event shall be less than the fair market value of a share of stock in WW Cayman on the date of grant.

38. 以股份為基礎付款 (續)**(b) WW Cayman 的購股權計劃**
(續)

於二零二一年十二月三十一日，計劃項下已授出及仍發行在外購股權的相關股份數目為2,654,859股，佔於該日期股份總數的7% (二零二零年：2,166,213股，佔7%)。

授出購股權無需支付代價。購股權可於歸屬後的任何時間行使，且倘未於授出日期起滿10年之前獲行使，則將被註銷。

每批購股權的行使價乃經參考本公司成立WW Cayman以收購愛琅所支付的現金代價總額，計及涉及的相關成本及開支釐定，惟無論如何不得低於授出日期WW Cayman股票的公平市場價值。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

38. SHARE-BASED PAYMENTS (continued)

(b) Share Option Scheme by WW Cayman (continued)

Details of specific categories of options are as follows:

38. 以股份為基礎付款 (續)

(b) WW Cayman 的購股權計劃 (續)

具體購股權類別詳情如下：

	Date of grant 授出日期	Vesting period 歸屬期	Exercise Price 行使價
Time-based options 時間基準購股權	26/07/2018 二零一八年 七月二十六日	4 years 4年	USD10.00 10.00美元
Time-based options 時間基準購股權	30/10/2019 二零一九年 十月三十日	4 years 4年	USD10.00 10.00美元
Time-based options 時間基準購股權	13/03/2020 二零二零年 三月十三日	4 years 4年	USD10.00 10.00美元
Time-based options 時間基準購股權	30/07/2021 二零二一年 七月三十日	4 years 4年	USD10.00 10.00美元
Performance-based options 表現基準購股權	26/07/2018 二零一八年 七月二十六日	4 years 4年	USD10.00 10.00美元
Performance-based options 表現基準購股權	30/10/2019 二零一九年 十月三十日	4 years 4年	USD10.00 10.00美元
Performance-based options 表現基準購股權	13/03/2020 二零二零年 三月十三日	4 years 4年	USD10.00 10.00美元
Performance-based options 表現基準購股權	30/07/2021 二零二一年 七月三十日	4 years 4年	USD10.00 10.00美元

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

38. SHARE-BASED PAYMENTS (continued)

38. 以股份為基礎付款 (續)

(b) Share Option Scheme by WW Cayman
(continued)

(b) WW Cayman 的購股權計劃
(續)

The following table discloses movements of the share options held by employees during the year:

下表披露年內僱員所持購股權的變動情況：

Option type		Outstanding at 1/1/2021 於二零二一年 一月一日 尚未行使	Granted during year 年內授出	Forfeited during year 年內沒收	Outstanding at 31/12/2021 於二零二一年 十二月三十一日 尚未行使
Time-based options	時間基準購股權	1,446,725	180,000	(29,075)	1,597,650
Performance-based options	表現基準購股權	719,488	337,721	-	1,057,209
		2,166,213	517,721	(29,075)	2,654,859

During the year ended 31 December 2021, options were granted on 30 July 2021. The estimated fair value of the time-based options granted on that date is USD4.64. The estimated fair value of the performance-based options on that date is USD4.64.

於截至二零二一年十二月三十一日止年度，購股權於二零二一年七月三十日獲授出。於該日期授出的時間基準購股權的估計公平值為4.64美元。於該日期的表現基準購股權的估計公平值為4.64美元。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

38. SHARE-BASED PAYMENTS (continued)

(b) Share Option Scheme by WW Cayman (continued)

The fair value of the options was calculated using the Black-Scholes pricing model. The inputs into the model were as follows:

	2021 二零二一年	2020 二零二零年
Weighted average share price 加權平均股價	10.00	10.00
Exercise price 行使價	10.00	10.00
Expected volatility 預期波動率	40%	40%
Expected life 預期年期	7 years年	7 years年
Risk-free rate 無風險利率	2.95%	2.95%

Expected volatility was determined by using the historical volatility of the comparable companies over the previous 7 years (2020: 7 years). The expected life used in the model has been adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations.

The Group recognised the total expense of USD4,108,000 (equivalent to RMB26,506,000) for the year ended 31 December 2021 (2020: USD2,267,000, equivalent to RMB15,801,000) in relation to share options granted under the Share Option Scheme by WW Cayman.

38. 以股份為基礎付款 (續)

(b) WW Cayman 的購股權計劃 (續)

購股權之公平值採用布萊克-斯庫爾斯定價模型計算。模型的輸入數據如下：

	2021 二零二一年	2020 二零二零年
Weighted average share price 加權平均股價	10.00	10.00
Exercise price 行使價	10.00	10.00
Expected volatility 預期波動率	40%	40%
Expected life 預期年期	7 years年	7 years年
Risk-free rate 無風險利率	2.95%	2.95%

預期波動率乃通過使用過去7年(二零二零年：7年)可資比較公司的歷史波動率確定。基於管理層的最佳估計，模型中使用的預期年期已根據不可轉移性、行使限制及行為考慮因素的影響作出調整。

本集團就根據WW Cayman的購股權計劃授出的購股權確認截至二零二一年十二月三十一日止年度總開支為4,108,000美元(相等於人民幣26,506,000元)(二零二零年：2,267,000美元，相等於人民幣15,801,000元)。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

38. SHARE-BASED PAYMENTS (continued)

38. 以股份為基礎付款 (續)

(c) Share Award Scheme by Weigao Orthopaedic

On 9 May 2020, a share award scheme was adopted by the extraordinary general meeting of Weigao Orthopaedic (the "Weigao Orthopaedic Share Award Scheme"). A total number of 3,300,000 shares of Weigao Orthopaedic were awarded to the eligible senior management and employees (the "Eligible Employees"), which representing 0.92% shareholding of Weigao Orthopaedic.

The issue price of Weigao Orthopaedic Share Award Scheme is RMB15 per share, the total consideration amounted to RMB49,500,000. 60% of consideration was covered by the loan provided by Weihai Hongyangrui to the Eligible Employees, and the remaining 40% was funded by themselves.

Details of the shares awarded are as follows:

Performance-based awards
表現基準獎勵

Based on the Weigao Orthopaedic Share Award Scheme, as the subsidiary of the Company will repurchase the shares granted to the Eligible Employees when the Eligible Employees are not satisfying specified vesting conditions, the total consideration paid by the Eligible Employees are recognised as liabilities, and will only be reversed by portion to other reserve when the shares are vested each year.

The estimated fair value of the performance-based awards on the grant date is RMB19.8 per share. The difference between the fair value and the issue price of the vested shares is expensed on a straight-line basis over the periods in which services are expected to be rendered by the Eligible Employees. During the year ended 31 December 2021, Weigao Orthopaedic recognised a share awards expense of approximately RMB5,139,000 into the profit or loss (2020: RMB6,958,000).

(c) 威高骨科的股份激勵計劃

於二零二零年五月九日，威高骨科股東特別大會採納股份激勵計劃（「威高骨科股份激勵計劃」）。合共3,300,000股威高骨科股份授予合資格高級管理層及僱員（「合資格僱員」），佔威高骨科股權的0.92%。

威高骨科股份激勵計劃的發行價為每股人民幣15元，總代價為人民幣49,500,000元，其中60%的代價由威海弘陽瑞向合資格僱員提供的貸款支付，其餘40%由其自身出資。

獲獎勵股份詳情如下：

Date of grant 授出日期	Vesting period 歸屬期
9/05/2020 二零二零年 五月九日	4 years 4年

根據威高骨科股份激勵計劃，由於本公司附屬公司會在合資格僱員未達到指定歸屬條件時回購已授予合資格僱員的股份，故合資格僱員所支付的總代價確認為負債，並僅將於每年股份歸屬時撥回部分至其他儲備。

表現基準獎勵於授出日期的估計公平值為每股人民幣19.8元。已歸屬股份的公平值與發行價之間的差額於合資格僱員預計提供服務的期間內按直線法支銷。於截至二零二一年十二月三十一日止年度，威高骨科將股份獎勵費用約人民幣5,139,000元（二零二零年：人民幣6,958,000元）計入損益。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

39. ACQUISITION OF SUBSIDIARIES

39. 收購附屬公司

(a) For the year ended 31 December 2021

On 10 December 2021, the Group's subsidiary Argon acquired 100% of the issued share capital of Matrex Mould & Tool Inc ("Matrex") for consideration of USD2,115,000 (equivalent to RMB13,472,000), including USD500,000 (equivalent to RMB3,185,000) of deferred consideration. Matrex is manufacturer of the custom moulds and tools.

(a) 截至二零二一年十二月三十一日止年度

於二零二一年十二月十日，本集團附屬公司愛琅收購Matrex Mould & Tool Inc (「Matrex」) 全部已發行股本，代價為2,115,000美元(相當於人民幣13,472,000元)，包括遞延代價500,000美元(相當於人民幣3,185,000元)。Matrex 為訂製模具及工具的製造商。

Consideration transferred	已轉移代價	RMB'000 人民幣千元
Cash	現金	10,287
Deferred consideration	遞延代價	3,185
Total	總計	13,472

The fair value of the net identifiable assets acquired at the date of acquisition are as follows:

於收購日期已收購的可識別淨資產的公平值如下：

		RMB'000 人民幣千元
Property, plant and equipment	物業、廠房及設備	8,762
Inventories	存貨	388
Trade and other payables	應付貿易賬款及其他應付款項	(3,315)
		5,835

Goodwill arising on acquisition:

收購所產生的商譽：

		RMB'000 人民幣千元
Consideration transferred	已轉移代價	13,472
Less: net assets acquired	減：所收購淨資產	5,835
Goodwill arising on acquisition	收購所產生的商譽	7,637

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

39. ACQUISITION OF SUBSIDIARIES (continued)

39. 收購附屬公司 (續)

(a) For the year ended 31 December 2021 (continued)

(a) 截至二零二一年十二月 三十一日止年度 (續)

Goodwill arose in the acquisition of Matrex due to the benefit of expected synergies, revenue growth, and future market development of Matrex. These benefits are not recognised separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets.

收購Matrex產生商譽，因為Matrex的預期協同效應、收入增長及未來市場發展所帶來的利益。該等利益並無與商譽分開確認，乃由於該等利益並不符合可識別無形資產的確認標準。

The goodwill arising on the acquisition is not expected to be deductible for tax purposes.

預期就稅項而言收購產生的商譽不可扣減。

Net cash outflow on the acquisition

收購所產生的現金流出淨額

	RMB'000 人民幣千元
Acquisition consideration in cash and cash equivalents	10,287
Less: Cash and cash equivalents of the acquired subsidiary	—
Net outflow of cash and cash equivalents paid upon acquisition of subsidiary	10,287

Had the acquisition been completed on 1 January 2021, the Group's revenue for the year ended 31 December 2021 would have been RMB13,170,353,000, and profit for the year ended 31 December 2021 would have been RMB2,433,869,000. The pro forma information is for illustrative purposes only and is not necessarily an indication of revenue and results of operations of the Group that actually would have been achieved had the acquisition been completed on 1 January 2021, nor is it intended to be a projection of future results.

倘收購於二零二一年一月一日完成，則本集團截至二零二一年十二月三十一日止年度收入將為人民幣13,170,353,000元，及截至二零二一年十二月三十一日止年度的溢利將為人民幣2,433,869,000元。備考資料只作說明之用，並非必然表示倘收購於二零二一年一月一日完成，則本集團將實際達到的收入及營運業績，亦無意作為對未來業績的預測。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

39. ACQUISITION OF SUBSIDIARIES (continued)

39 收購附屬公司 (續)

(b) For the year ended 31 December 2020

On 13 March 2020, the Group acquired 51% of share capital of GHC Healthcare, Inc. by capital injection into GHC Healthcare, Inc. of USD3,000,000 (equivalent to RMB21,010,000) in form of cash. This acquisition has been accounted for using the purchase method. GHC Healthcare, Inc. is a distributor of medical devices and was acquired to more closely control the distribution of medical device products in United States and South America.

(b) 截至二零二零年十二月三十一日止年度

於二零二零年三月十三日，本集團以現金形式向GHC Healthcare, Inc.注資3,000,000美元(相等於人民幣21,010,000元)，收購GHC Healthcare, Inc.股本的51%。該收購事項採用購買方法入賬。GHC Healthcare, Inc.為一家醫療器械經銷商，並已收購以更緊密地控制醫療器械產品在美國和南美的分銷。

Consideration transferred	已轉移代價	RMB'000 人民幣千元
Cash	現金	21,010

The fair value of the net identifiable assets acquired at the date of acquisition are as follows:

於收購日期已收購的可識別淨資產的公平值如下：

		RMB'000 人民幣千元
Property, plant and equipment	物業、廠房及設備	971
Right-of-use assets	使用權資產	5,014
Intangible assets	無形資產	14,007
Other non-current assets	其他非流動資產	7,382
Inventories	存貨	25,016
Trade and other receivables	應收貿易賬款及其他應收款項	51,294
Other current assets	其他流動資產	1,931
Bank balances and cash	銀行結餘及現金	465
Trade and other payables	應付貿易賬款及其他應付款項	(26,049)
Income tax payable	應付所得稅	(2,105)
Lease liabilities	租賃負債	(5,014)
Borrowings	借款	(33,083)
Other non-current liabilities	其他非流動負債	(1,471)
Deferred tax liabilities	遞延稅項負債	(3,596)
		<u>34,762</u>

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

39. ACQUISITION OF SUBSIDIARIES (continued)

39 收購附屬公司 (續)

(b) For the year ended 31 December 2020 (continued)

Goodwill arising on acquisition:

		RMB'000 人民幣千元
Consideration transferred	已轉移代價	21,010
Plus: non-controlling interests	加：非控股權益	17,033
Less: net assets acquired	減：所收購淨資產	<u>34,762</u>
Goodwill arising on acquisition	收購所產生的商譽	<u>3,281</u>

Goodwill arose in the acquisition of GHC Healthcare, Inc. due to the benefit of expected synergies, revenue growth, and future market development of GHC Healthcare, Inc. These benefits are not recognised separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets.

The goodwill arising on the acquisition is not expected to be deductible for tax purposes.

Net cash outflow on the acquisition

		RMB'000 人民幣千元
Cash and cash equivalents balances acquired	所收購的現金及現金等價物結餘	<u>465</u>

Included in the profit for the year ended 31 December 2020 is RMB19,705,000 attributable to the additional business generated by GHC Healthcare, Inc. Revenue for the year ended 31 December 2020 includes RMB146,055,000 generated from GHC Healthcare after the acquisition.

(b) 截至二零二零年十二月三十一日止年度 (續)

收購所產生的商譽：

		RMB'000 人民幣千元
Consideration transferred	已轉移代價	21,010
Plus: non-controlling interests	加：非控股權益	17,033
Less: net assets acquired	減：所收購淨資產	<u>34,762</u>
Goodwill arising on acquisition	收購所產生的商譽	<u>3,281</u>

收購GHC Healthcare, Inc.產生商譽，因為GHC Healthcare, Inc.的預期協同效應、收入增長及未來市場發展所帶來的利益。該等利益並無與商譽分開確認，乃由於該等利益並不符合可識別無形資產的確認標準。

預期就稅項而言收購產生的商譽不可扣減。

收購所產生的現金流出淨額

		RMB'000 人民幣千元
Cash and cash equivalents balances acquired	所收購的現金及現金等價物結餘	<u>465</u>

截至二零二零年十二月三十一日止年度，溢利包括人民幣19,705,000元，歸屬於GHC Healthcare, Inc.產生的其他業務。截至二零二零年十二月三十一日止年度，收入包括GHC Healthcare於收購後產生的人民幣146,055,000元。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

40. CAPITAL COMMITMENTS

As at 31 December 2021, the Group had commitments which were contracted for but not provided in the consolidated financial statements:

Commitments to Qingdao Songyuan (note 21)	對青島松源的承擔 (附註21)
Acquisition of property, plant and equipment	收購物業、廠房及設備
Incorporation of a joint venture	註冊成立一間合營企業

40. 資本承擔

於二零二一年十二月三十一日，本集團於綜合財務報表中擁有已訂約但未撥備的承擔：

31/12/2021
RMB'000
二零二一年
十二月
三十一日
人民幣千元

616,000
347,104
150,000

41. CAPITAL RISK MANAGEMENT

The Group manages its capital to ensure that entities in the Group will be able to continue as a going concern while maximising the return to shareholders through the optimisation of the debt and equity balance. The Group's overall strategy remains unchanged from prior year.

The capital structure of the Group consists of net debt (which includes borrowings net of cash and cash equivalents) and equity attributable to owners of the Company (comprising issued share capital, share premium, reserves and retained profits).

The directors of the Company review the capital structure on a semi-annual basis. As part of this review, the directors consider the cost of capital and the risks associates with each class of capital. Based on recommendations of the directors, the Group will balance its overall capital structure through the payment of dividends and issue of new shares as well as the issue of new debt or the repayment of existing debt.

41. 資本風險管理

本集團其管理資本乃為確保本集團內各實體將可以持續方式經營，同時透過適當優化債務與權益結餘為股東帶來最大回報。本集團的整體策略與以往年度保持不變。

本集團的資本結構包括債務淨額（包括扣除現金及現金等價物後之借款）以及本公司擁有人應佔權益（包括已發行股本、股份溢價、儲備及保留溢利）。

本公司董事按半年基準對資本結構進行檢討。作為是次檢討的一環，董事會考慮資本成本及與各類資本有關的風險。根據董事建議，本集團將透過派付股息、發行新股份及發行新債務或償還現有債務平衡其整體資本結構。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS

42. 金融工具

Categories of financial instruments

金融工具類別

		31/12/2021	31/12/2020
		RMB'000	RMB'000
			(restated)
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
			(經重列)
Financial assets	金融資產		
Financial assets at FVTPL	按公平值計入損益計量之 金融資產	110,943	108,420
Amortised cost	攤銷成本	13,751,284	12,054,511
Debt instruments at FVTOCI	按公平值計入其他全面收益 計量之債務工具	419,752	469,610
Financial liabilities	金融負債		
Amortised cost	攤銷成本	7,496,584	7,609,926
Financial liabilities at FVTPL	按公平值計入損益計量之 金融負債	56,893	85,878

Financial risk management objectives and policies

財務風險管理目標及政策

The Group's major financial instruments include receivables from factoring business, loan receivables, Financial assets at FVTPL, debt instruments at FVTOCI, trade and other receivables, pledged bank deposits, bank balances and cash, Financial liabilities at FVTPL, trade and other payables, borrowings and bonds payable. Details of these financial instruments are disclosed in the respective notes. The risks associated with these financial instruments include market risk (currency risk and interest rate risk), credit risk and liquidity risk. The policies on how to mitigate these risks are set out below. The management manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner.

本集團的主要金融工具包括來自保理業務之應收款項、應收貸款、按公平值計入損益計量之金融資產、按公平值計入其他全面收益計量之債務工具、應收貿易賬款及其他應收款項、已抵押銀行存款、銀行結餘及現金、按公平值計入損益計量之金融負債、應付貿易賬款及其他應付款項、借款及應付債券。該等金融工具詳情於各附註披露。與該等金融工具有關的風險包括市場風險（貨幣風險及利率風險）、信貸風險及流動資金風險。下文載列如何降低該等風險的政策。管理層管理及監控該等風險，以確保及時有效地採取適當的措施。

42. FINANCIAL INSTRUMENTS (continued)**Financial risk management objectives and policies** (continued)**Market risk***Currency risk*

Some subsidiaries of the Group undertakes certain operating transactions in foreign currencies other than functional currencies, which expose the Group to foreign currency risk. During the year ended 31 December 2021, as disclosed in note 22, the Group entered into currency option agreement to fix exchange rate of USD against RMB at maturity date of 27 April 2022, with principle amount of USD40,000,000.

During the year ended 31 December 2021, the Group hold a Structured Cross Currency Swap to exchange USD floating rate liability into CNY fixed rate debt with aggregate principal amount of USD122,500,000 (2020: USD175,000,000).

The Group did not applied hedge accounting in the measurement of currency option and Structured Cross Currency Swap. The management manages its currency risk by closely monitoring the movement of the foreign currency rates and considering hedging significant foreign currency exposure should such need arise.

42. 金融工具 (續)**財務風險管理目標及政策** (續)**市場風險***貨幣風險*

本集團若干附屬公司以功能貨幣以外的其他外幣進行若干經營交易，令本集團面臨外匯風險。截至二零二一年十二月三十一日止年度，誠如附註22所披露，本集團訂立貨幣期權協議，以於二零二二年四月二十七日屆滿日期將美元兌人民幣的匯率固定，本金額為40,000,000美元。

截至二零二一年十二月三十一日止年度，本集團持有結構性交叉貨幣互換合約，將美元浮動利率負債轉換為本金總額為122,500,000美元（二零二零年：175,000,000美元）的人民幣固定利率債務。

本集團於計量貨幣期權及結構性交叉貨幣互換時並無應用對沖會計處理。管理層通過密切監控外幣匯率變動來管理其貨幣風險，並考慮在有需要時對沖重大外幣風險。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Financial risk management objectives and policies (continued)

財務風險管理目標及政策 (續)

Market risk (continued)

市場風險 (續)

Currency risk (continued)

貨幣風險 (續)

The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities at the end of the reporting period are as follows.

於報告期末，本集團以外幣列值之貨幣資產及貨幣負債之賬面值如下。

		Liabilities		Assets	
		31/12/2021	31/12/2020	31/12/2021	31/12/2020
		RMB'000	RMB'000	RMB'000	RMB'000
		負債		資產	
		二零二一年 十二月 三十一日 人民幣千元	二零二零年 十二月 三十一日 人民幣千元	二零二一年 十二月 三十一日 人民幣千元	二零二零年 十二月 三十一日 人民幣千元
Group entities in PRC	本集團於中國的實體				
Currency of SGD	新加坡元	-	-	6,498	6,792
Currency of EUR	歐元	2,663	-	36,461	41,104
Currency of HKD	港元	-	-	2,576	2,277
Currency of USD	美元	81,101	53,107	1,305,252	759,076
Currency of CHF	瑞士法郎	-	-	333,328	-
Currency of JPY	日圓	501	-	363	5,381
Group entities in U.S.	本集團於美國的實體				
Currency of EUR	歐元	650	446	4,455	6,039
Currency of SGD	新加坡元	128	99	892	34
Currency of NOK	挪威克朗	5	-	3,219	6,995
Currency of CHF	瑞士法郎	513	151	555	498
Currency of DKK	丹麥克朗	27	14	2,829	4,168
Currency of SEK	瑞典克朗	66	-	3,098	6,543
Currency of GBP	英鎊	471	375	9,137	7,806
Currency of CLP	智利披索	2,114	984	11,227	11,660
Currency of COP	哥倫比亞披索	1,380	888	11,919	12,850

The Group's foreign currency risk is concentrated on the fluctuation of RMB and USD against foreign currency.

本集團的外匯風險主要集中在人民幣及美元兌外幣的波動。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

Financial risk management objectives and policies (continued)

Market risk (continued)

Currency risk (continued)

The following table details the Group's sensitivity to a 5% (2020:5%) increase and decrease in the RMB and USD against the relevant foreign currencies. 5% represents management's assessment of the reasonably possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end for a 5% change in foreign currency rates. A positive number below indicates an increase in post-tax profit for the year where RMB and USD weakens 5% against the relevant currency. For a 5% strengthening of RMB and USD against the relevant currency, there would be an opposite impact on the post-tax profit for the year.

		2021 RMB'000 二零二一年 人民幣千元	2020 RMB'000 二零二零年 人民幣千元
Profit for the year	本年度溢利		
– Group entities in PRC	– 本集團於中國的實體	68,009	32,365
– Group entities in U.S.	– 本集團於美國的實體	1,658	2,119

Interest rate risk

The Group is exposed to fair value interest rate risk in relation to loan receivables, pledged bank deposits, borrowings, bonds payable and lease liabilities with fixed interest rate (notes 25, 29, 33, 34 and 36).

42. 金融工具 (續)

財務風險管理目標及政策 (續)

市場風險 (續)

貨幣風險 (續)

下表詳列本集團對人民幣及美元兌相關外幣之匯率上升及下跌5% (二零二零年:5%) 之敏感度。5%為管理層對外匯匯率合理可能變動之評估。敏感度分析僅包括未結付之以外幣列值之貨幣項目，並於期末按5%之外匯匯率變動調整彼等之換算。以下正數表示當人民幣及美元兌相關外幣貶值5%時之本年度稅後溢利之升幅。倘人民幣及美元兌相關外幣升值5%，則會對本年度稅後溢利有相反影響。

利率風險

本集團面臨有關應收貸款、已抵押銀行存款、借款、應付債券及定息租賃負債的公平值利率風險 (附註25、29、33、34及36)。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

Financial risk management objectives and policies (continued)

Market risk (continued)

Interest rate risk (continued)

A fundamental reform of major interest rate benchmarks is being undertaken globally, including the replacement of some interbank offered rates (“IBORs”) with alternative nearly risk-free rates. Details of the impacts on the Group’s risk management strategy arising from the interest rate benchmark reform and the progress towards implementation of alternative benchmark interest rates are set out under “interest rate benchmark reform” in this note.

The Group is also exposed to cash flow interest rate risk in relation to loan receivables, bank balances and borrowings with variable interest rate (notes 25, 30 and 33). The Group’s cash flow interest rate risk is mainly concentrated on the fluctuation of saving/lending rate promulgated by the People’s Bank of China and LIBOR.

The Group manages its interest rate exposure based on the interest rate level and outlook as well as potential impact on the Group’s financial position arising from volatility of the interest rate.

During the year ended 31 December 2021, as disclosed in note 22, the Group hold an interest rate swap to keep variable interests (3 months SHIBOR) of principal amount of RMB300,000,000 as fixed 3.5%.

During the year ended 31 December 2021, the Group hold a Structured Cross Currency Swap to keep the variable interests (LIBOR plus 1.50%) as fixed 4.5% with principal amount of USD122,500,000 (2020: USD175,000,000). The Group had a loss on Structured Cross Currency Swap amounted to RMB22,453,000 (2020: RMB16,322,000). The Group did not applied hedge accounting in the measurement of Structured Cross Currency Swap.

42. 金融工具 (續)

財務風險管理目標及政策 (續)

市場風險 (續)

利率風險 (續)

全球正就主要利率基準進行根本性改革，包括以接近無風險的替代利率取代部分銀行同業拆息（「銀行同業拆息」）。有關利率基準改革對本集團風險管理策略的影響及替代基準利率的實施進度的詳情，載於本附註「利率基準改革」。

本集團亦面臨有關應收貸款、銀行結餘及浮息借款的現金流量利率風險（附註25、30及33）。本集團的現金流量利率風險主要集中於中國人民銀行頒佈的存款／貸款利率及LIBOR波動。

本集團基於利率水平及展望以及因利率波動對本集團財政狀況的潛在影響管理其利率風險。

截至二零二一年十二月三十一日止年度，誠如附註22所披露，本集團持有利率互換合約，以維持本金額為人民幣300,000,000元的浮動利率（3個月SHIBOR）固定為3.5%。

截至二零二一年十二月三十一日止年度，本集團持有本金額為122,500,000美元（二零二零年：175,000,000美元）的結構性交叉貨幣互換合約，以維持浮動利率（LIBOR加1.50%）固定為4.5%。本集團的結構性交叉貨幣互換虧損為人民幣22,453,000元（二零二零年：人民幣16,322,000元）。本集團於計量結構性交叉貨幣互換時並無應用對沖會計處理。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

Financial risk management objectives and policies (continued)

Market risk (continued)

Interest rate risk (continued)

Total interest income from financial assets that are measured at amortised cost are as follows:

Interest income	利息收入		
Financial assets at amortised cost	按攤銷成本計量之金融資產	143,943	114,979

Interest expense on financial liabilities not measured at FVTPL:

Financial liabilities at amortised cost	按攤銷成本計量之金融資產		
		136,728	177,232

42. 金融工具 (續)

財務風險管理目標及政策 (續)

市場風險 (續)

利率風險 (續)

以攤銷成本計量的金融資產的利息收入總額如下：

Year ended 31/12/2021 RMB'000	Year ended 31/12/2020 RMB'000 (restated)
截至 二零二一年 十二月 三十一日 止年度 人民幣千元	截至 二零二零年 十二月 三十一日 止年度 人民幣千元 (經重列)

未按公平值計入損益計量之金融負債的利息開支：

Year ended 31/12/2021 RMB'000	Year ended 31/12/2020 RMB'000
截至 二零二一年 十二月 三十一日 止年度 人民幣千元	截至 二零二零年 十二月 三十一日 止年度 人民幣千元

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Financial risk management objectives and policies (continued)

財務風險管理目標及政策 (續)

Market risk (continued)

市場風險 (續)

Sensitivity analysis

敏感度分析

The sensitivity analysis below has been determined based on the exposure to interest rates for loan receivables, bank balances and borrowings with variable interest rate at the end of the reporting period. The analysis is prepared assuming the variable-rate loan receivables, bank balances and variable-rate borrowings at the end of the reporting period were outstanding for the whole year. A 25 basis points (2020: 25 basis points) increase or decrease represents management's assessment of the reasonably possible change in interest rates.

下文的敏感度分析已按於報告期末應收貸款、銀行結餘及浮息借款承受的利率風險釐定。分析經假設於報告期末的浮息應收貸款、銀行結餘及浮息借款於全年均屬未償還而編製。25個基本點子(二零二零年：25個基本點子)增加或減少代表管理層對利率的合理可能變動作出的評估。

If interest rates on variable-rate loan receivables, bank balances and variable-rate borrowings had been 25 basis points (2020: 25 basis points) higher/lower and all other variables were held constant, the Group's post-tax profit for the year ended 31 December 2021 would have decreased/increased by RMB8,072,000 (2020: decreased/increased by RMB4,758,000(restated)).

倘浮息應收貸款、銀行結餘及浮息借款利率升高/降低25個基本點子(二零二零年：25個基本點子)，所有其他變動維持不變，則本集團於截至二零二一年十二月三十一日止年度的稅後溢利將減少/增加人民幣8,072,000元(二零二零年：減少/增加人民幣4,758,000元(經重列))。

Credit risk and impairment assessment

信貸風險及減值評估

Credit risk refers to the risk that the Group's counterparties default on their contractual obligations resulting in financial losses to the Group. The Group's credit risk exposures are primarily attributable to trade receivables, receivables from factoring business, other receivables, pledged bank deposits, bank balances and cash, loan receivables, debt instruments at FVTOCI, finance lease receivables. The Group does not hold any collateral or other credit enhancements to cover its credit risks associated with its financial assets, except that the credit risks associated with loan receivables and finance lease receivables are mitigated because they are secured over various equipment and machineries.

信貸風險指本集團對手違約其合同義務而給本集團造成財務虧損的風險。本集團信貸風險主要來自應收貿易賬款、來自保理業務之應收款項、其他應收款項、已抵押銀行存款、銀行結餘及現金、應收貸款、按公平值計入其他全面收益計量的債務工具及應收融資租賃款項。本集團並無持有任何抵押品或其他信用增級以抵銷與其金融資產相關的信貸風險，惟與應收貸款及應收融資租賃款項相關的信貸風險得以緩解，因其為通過各種設備及機器做擔保。

42. FINANCIAL INSTRUMENTS (continued)**Financial risk management objectives and policies** (continued)**Credit risk and impairment assessment**
(continued)

In order to minimise the credit risk, the management of the Group has delegated a team responsible for determination of credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debtors. For finance lease business and factoring business, the Group also has delegated a team responsible for (i) designing and implementation of overall risk management internal control policies and procedures and establishing appropriate risk appetite; (ii) designing and execution of due diligence procedures; (iii) reviewing the creditworthiness of customers. In addition, the Group performs impairment assessment under ECL model in accordance with HKFRS 9 on receivable balances individually or based on provision matrix.

The Group's debt instruments at FVTOCI only comprise bills receivable that are issued and guaranteed by the reputable PRC banks and therefore are considered to be low credit risk.

The Group has concentration of credit risk on liquid funds which are deposited with several banks. However, the credit risk on pledged bank deposits and bank balances and cash is limited because the majority of the counterparties are banks with good reputation.

The Group has concentration of credit risk as 39% of the total trade receivables was due from fellow subsidiaries (2020: 23%), and 68% of the total other receivables was due from a holding company (2020: 68%).

42. 金融工具 (續)**財務風險管理目標及政策** (續)**信貸風險及減值評估** (續)

為盡量降低信貸風險，本集團管理層已委派一組人員負責釐定信貸限額、信貸審批及其他監控措施，以確保採取跟進措施收回逾期債項。就融資租賃業務及保理業務而言，本集團亦組建團隊負責(i)設計及實施全面風險管理的內部控制政策及程序，並設定適當的風險承受能力；(ii)設計及執行盡職調查程序；(iii)審查客戶的信貸情況。此外，本集團根據香港財務報告準則第9號按預期信貸虧損模式單獨或根據撥備矩陣對應收結餘進行減值評估。

鑒於本集團的按公平值計入其他全面收益計量之債務工具僅包括由聲譽良好的中國銀行發出及擔保的應收票據，因此被視為低信貸風險。

本集團之信貸風險集中於存置於若干銀行之流動資金。然而，已抵押銀行存款及銀行結餘之信貸風險有限，原因為大部分對手方為信譽良好之銀行。

由於應收貿易賬款總額的39% (二零二零年：23%) 為應收同系附屬公司款項及應收貿易賬款總額的68% (二零二零年：68%) 為應收一間控股公司款項，因此本集團有信貸風險集中情況。

42. FINANCIAL INSTRUMENTS (continued)**42. 金融工具** (續)**Financial risk management objectives and policies** (continued)**財務風險管理目標及政策** (續)**Credit risk and impairment assessment**
(continued)**信貸風險及減值評估** (續)

For trade receivables, the Group has applied the simplified approach of HKFRS 9 to measure the loss allowance at lifetime ECL. Except for debtors with significant outstanding balances or credit-impaired, the Group determines the ECL on these items by using a provision matrix grouped by risk portfolio, which is estimated based on the financial quality of the debtors, historical credit loss experience and the past due status of the debtors, general economic conditions of the industry in which the debtors operate and assessment of both the current as well as the forward-looking information that available without undue cost or effort at the reporting date.

就應收貿易賬款而言，本集團已採用香港財務報告準則第9號中的簡化方法按全期預期信貸虧損計量虧損撥備。除具有重大未償還餘額或信貸減值的債務外，本集團通過使用按風險組合分組的撥備矩陣釐定該等項目的預期信貸虧損，此乃根據債務人的財務質素、基於債務人逾期狀況的歷史信貸虧損經驗、債務人經營所在行業的一般經濟狀況以及報告日期無須耗費龐大人力物力而取得的前瞻性信息現有及前瞻性信息進行估計。

The following table provides information about the exposure to credit risk for trade receivables which are assessed based on provision matrix as at 31 December 2021 within lifetime ECL (not credit impaired). Debtors with significant outstanding balances or credit-impaired with gross carrying amounts of RMB1,621,211,000 and RMB36,923,000 respectively as at 31 December 2021 were assessed individually (2020: RMB1,208,302,000 and RMB34,266,000 respectively).

下表載列有關貿易應收款項信貸風險敞口的資料，該等應收貿易賬款在全期預期信貸虧損（無信貸減值）內基於二零二一年十二月三十一日的撥備矩陣評估。於二零二一年十二月三十一日具有重大未償還結餘或信貸減值，賬面總值分別為人民幣1,621,211,000元及人民幣36,923,000元（二零二零年：分別為人民幣1,208,302,000元及人民幣34,266,000元）的債務人獲單獨評估。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Financial risk management objectives and policies (continued)

財務風險管理目標及政策 (續)

Credit risk and impairment assessment (continued)

信貸風險及減值評估 (續)

		Average loss rate	31/12/2021 Trade receivables – Gross carrying amount RMB'000 二零二一年十二月三十一日 應收貿易賬款 一賬面總值 人民幣千元
Low risk type customer	低風險型客戶	3.66%	1,925,500
Normal risk type customer	正常風險型客戶	5.04%	1,696,773
Total	總計		3,622,273
		Average loss rate	31/12/2020 Trade receivables – Gross carrying amount RMB'000 (restated) 二零二零年十二月三十一日 應收貿易賬款 一賬面總值 人民幣千元 (經重列)
Low risk type customer	低風險型客戶	3.54%	2,267,107
Normal risk type customer	正常風險型客戶	8.05%	1,369,752
Total	總計		3,636,859

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

Financial risk management objectives and policies (continued)

Credit risk and impairment assessment
(continued)

The following table shows the movement in lifetime ECL that has been recognised for trade receivables under the simplified approach.

42. 金融工具 (續)

財務風險管理目標及政策 (續)

信貸風險及減值評估 (續)

下表顯示採用簡化方法就應收貿易賬款確認的全期預期信貸虧損變動。

		Lifetime ECL (not credit -impaired) RMB'000 全期預期 信貸虧損 (無信貸減值) 人民幣千元	Lifetime ECL (credit -impaired) RMB'000 全期預期 信貸虧損 (信貸減值) 人民幣千元	Total RMB'000 總計 人民幣千元
As at 1 January 2020 (restated)	於二零二零年一月一日 (經重列)	200,649	8,881	209,530
Transfer to credit-impaired	轉至信貸減值	(25,385)	25,385	-
Impairment losses recognised	已確認減值虧損	35,063	-	35,063
Impairment losses reversed	已撥回減值虧損	(2,301)	-	(2,301)
Exchange adjustments	匯兌調整	(121)	-	(121)
Write-off	撇銷	(47)	-	(47)
As at 31 December 2020	於二零二零年十二月三十一日	207,858	34,266	242,124
Transfer to credit-impaired	轉至信貸減值	(2,657)	2,657	-
Impairment losses recognised	已確認減值虧損	19,446	-	19,446
Impairment losses reversed	已撥回減值虧損	(2,156)	-	(2,156)
Exchange adjustments	匯兌調整	(135)	-	(135)
Write-off	撇銷	(5,380)	-	(5,380)
As at 31 December 2021	於二零二一年十二月三十一日	216,976	36,923	253,899

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

Financial risk management objectives and policies (continued)

Credit risk and impairment assessment (continued)

The Group writes off a trade receivable when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery, e.g. when the debtor has been placed under liquidation or has entered into bankruptcy proceedings. None of the trade receivables that have been written off is subject to enforcement activities.

For finance lease receivables, the Group has applied the simplified approach in HKFRS 9 to measure the loss allowance at lifetime ECL.

The following tables show reconciliation of loss allowances that has been recognised for finance lease receivables.

42. 金融工具 (續)

財務風險管理目標及政策 (續)

信貸風險及減值評估 (續)

倘有資料顯示債務人面對嚴重財務困難且收回款項的機率不大(如債務人遭清盤或啟動破產程序)，本集團將撇銷應收貿易賬款。概無應收貿易賬款因執法行動而撇銷。

就應收融資租賃款項而言，本集團已採用香港財務報告準則第9號中的簡化方法按全期預期信貸虧損計量虧損撥備。

下表載列就應收融資租賃款項確認的虧損撥備對賬。

		Lifetime ECL (not credit -impaired) RMB'000 全期預期 信貸虧損 (無信貸減值) 人民幣千元	Lifetime ECL (credit -impaired) RMB'000 全期預期 信貸虧損 (信貸減值) 人民幣千元	Total RMB'000 總計 人民幣千元
As at 1 January 2020	於二零二零年一月一日	4,135	2,923	7,058
Impairment losses recognised	已確認減值虧損	1,811	-	1,811
As at 31 December 2020	於二零二零年十二月三十一日	5,946	2,923	8,869
Impairment losses recognised	已確認減值虧損	2,357	-	2,357
As at 31 December 2021	於二零二一年十二月三十一日	8,303	2,923	11,226

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Financial risk management objectives and policies (continued)

財務風險管理目標及政策 (續)

Credit risk and impairment assessment (continued)

信貸風險及減值評估 (續)

The following tables show reconciliation of loss allowances that has been recognised for receivables from factoring business.

下表載列就來自保理業務之應收款項確認的虧損撥備對賬。

		12 m ECL RMB'000	Lifetime ECL (not credit -impaired) RMB'000	Lifetime ECL (credit -impaired) RMB'000	Total RMB'000
		12個月 預期信貸虧損 人民幣千元	全期預期 信貸虧損 (無信貸減值) 人民幣千元	全期預期 信貸虧損 (信貸減值) 人民幣千元	總計 人民幣千元
As at 1 January 2020	於二零二零年一月一日	1,099	550	-	1,649
Impairment losses recognised	已確認減值虧損	122	-	-	122
Impairment losses reversed	已撥回減值虧損	(545)	-	-	(545)
At 31 December 2020	於二零二零年十二月三十一日	676	550	-	1,226
Impairment losses recognised	已確認減值虧損	640	-	-	640
Impairment losses reversed	已撥回減值虧損	(472)	(550)	-	(1,022)
At 31 December 2021	於二零二一年十二月三十一日	844	-	-	844

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

Financial risk management objectives and policies (continued)

Credit risk and impairment assessment (continued)

The following tables show reconciliation of loss allowances that has been recognised for other receivables.

42. 金融工具 (續)

財務風險管理目標及政策 (續)

信貸風險及減值評估 (續)

下表載列就其他應收款項確認的虧損撥備對賬。

		12 m ECL RMB'000	Lifetime ECL (not credit -impaired) RMB'000	Lifetime ECL (credit -impaired) RMB'000	Total RMB'000
		12個月 預期信貸虧損 人民幣千元	全期預期 信貸虧損 (無信貸減值) 人民幣千元	全期預期 信貸虧損 (信貸減值) 人民幣千元	總計 人民幣千元
As at 1 January 2020	於二零二零年一月一日	4,776	346	5,000	10,122
Impairment losses recognised	已確認減值虧損	6,959	-	-	6,959
Impairment losses reversed	已撥回減值虧損	(10,097)	-	(5,000)	(15,097)
Exchange adjustments	匯兌調整	126	-	-	126
At 31 December 2020	於二零二零年十二月三十一日	1,764	346	-	2,110
Impairment losses recognised	已確認減值虧損	11	-	-	11
Impairment losses reversed	已撥回減值虧損	(15)	-	-	(15)
Exchange adjustments	匯兌調整	55	-	-	55
At 31 December 2021	於二零二一年十二月三十一日	1,815	346	-	2,161

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Financial risk management objectives and policies (continued)

財務風險管理目標及政策 (續)

Credit risk and impairment assessment
(continued)

信貸風險及減值評估 (續)

The following tables show reconciliation of loss allowances that has been recognised for loan receivables.

下表載列就應收貸款確認的虧損撥備對賬。

		12 m ECL RMB'000	Lifetime ECL (not credit -impaired) RMB'000	Lifetime ECL (credit -impaired) RMB'000	Total RMB'000
		12個月 預期信貸虧損 人民幣千元	全期預期 信貸虧損 (無信貸減值) 人民幣千元	全期預期 信貸虧損 (信貸減值) 人民幣千元	總計 人民幣千元
As at 1 January 2020	於二零二零年一月一日	8,616	-	-	8,616
Transfer to credit-impaired	轉至信貸減值	(1,425)	-	1,425	-
Impairment losses recognised	已確認減值虧損	9,475	-	-	9,475
Impairment losses reversed	已撥回減值虧損	(243)	-	-	(243)
At 31 December 2020	於二零二零年十二月三十一日	16,423	-	1,425	17,848
Transfer to credit-impaired	轉至信貸減值	(6,075)	-	6,075	-
Impairment losses recognised	已確認減值虧損	7,826	-	-	7,826
Impairment losses reversed	已撥回減值虧損	(105)	-	-	(105)
Write-off	撇銷	(104)	-	-	(104)
At 31 December 2021	於二零二一年十二月三十一日	17,965	-	7,500	25,465

42. FINANCIAL INSTRUMENTS (continued)

Financial risk management objectives and policies (continued)

Liquidity risk

In the management of the liquidity risk, the Group monitors and maintains a level of cash and cash equivalents deemed adequate by the management to finance the Group's operations and mitigate the effects of fluctuations in cash flows. The management monitors the utilisation of borrowings and ensures compliance with loan covenants.

The amounts included below for variable interest rate instruments for non-derivative financial liabilities are subject to change if changes in variable interest rates different to those estimates of interest rates determined at the end of the reporting period.

The following table details the Group's remaining contractual maturity for its non-derivative financial liabilities based on the agreed repayment terms. The table has been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Group can be required to pay. The table includes both interest and principal cash flows. To the extent that interest flows are floating rate, the undiscounted amount is derived from the interest rate at the end of the reporting period.

42. 金融工具 (續)

財務風險管理目標及政策 (續)

流動資金風險

在管理流動資金風險時，本集團監察及維持管理層視為足夠水平的現金及現金等價物，以為本集團營運提供資金並減輕現金流量波動所帶來的影響。管理層監察借款的使用情況並確保符合貸款契約。

倘可變利率變動有別於報告期末所釐定之利率估計，則以下就非衍生金融負債之可變利率工具納入之數額會出現變動。

下表根據協定償還期限詳細載列本集團非衍生金融負債的剩餘合約到期日。該表乃根據要求本集團償還金融負債的最早日期的金融負債的未貼現現金流量而編製。該表包括利息及本金現金流量。因利息流為浮動利率，於報告期末之未貼現款項源自於利率。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Financial risk management objectives and policies (continued)

財務風險管理目標及政策 (續)

Liquidity risk (continued)

流動資金風險

Liquidity tables

流動資金表

		Weighted average effective interest rate	On demand or less than 1 year	1-2 years	2-5 years	Over 5 years	Total undiscounted cash flows	Carrying amount at 31/12/2021
		%	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		加權平均實際利率	按要求或少於1年	1至2年	2至5年	超過5年	未貼現現金流量總額	於二零二一年十二月三十一日的賬面值
		%	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
2021	二零二一年							
Non-derivative financial liabilities	非衍生金融負債							
Trade payables	應付貿易賬款		1,336,786	-	-	-	1,336,786	1,336,786
Construction cost and retention payables	建築成本及應付保留金		64,490	-	-	-	64,490	64,490
Bills payable	應付票據		332,164	-	-	-	332,164	332,164
Other payables	其他應付款項	8	1,723,382	-	-	-	1,723,382	1,706,579
Lease liabilities	租賃負債	3.59	25,485	22,304	37,332	1,758	86,879	80,845
Bonds payable	應付債券	3.73	35,900	35,900	107,700	1,010,471	1,189,971	992,549
Borrowings	借款							
- fixed rate	- 固定利率	3.3	330,347	17,150	622,051	-	969,548	799,996
- variable rate	- 浮動利率	4.39	353,242	263,072	1,785,075	-	2,401,389	2,264,020
			4,201,796	338,426	2,552,158	1,012,229	8,104,609	7,577,429
Derivatives - net settlement	衍生工具-結算淨額							
Structured Cross Currency Swap	結構性交叉貨幣互換		35,883	-	-	-	35,883	35,883
Currency Option	貨幣期權		20,811	-	-	-	20,811	20,811
Interest rate swap	利率互換		-	-	199	-	199	199
			56,694	-	199	-	56,893	56,893

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Financial risk management objectives and policies (continued)

財務風險管理目標及政策 (續)

Liquidity risk (continued)

流動資金風險 (續)

Liquidity tables (continued)

流動資金表 (續)

	Weighted average effective interest rate	On demand or less than 1 year	1-2 years	2-5 years	Over 5 years	Total undiscounted cash flows	Carrying amount at 31/12/2020
	%	RMB'000 (restated)	RMB'000	RMB'000	RMB'000	RMB'000 (restated)	RMB'000 (restated)
	加權平均實際利率	按要求或少於1年	1至2年	2至5年	超過5年	未貼現現金流量總額	於二零二零年十二月三十一日的賬面值
	%	人民幣千元 (經重列)	人民幣千元	人民幣千元	人民幣千元	人民幣千元 (經重列)	人民幣千元 (經重列)
2020		二零二零年					
Non-derivative financial liabilities		非衍生金融負債					
Trade payables		應付貿易賬款	1,416,318	-	-	1,416,318	1,416,318
Construction cost and retention payables		建築成本及應付保留金	90,430	-	-	90,430	90,430
Bills payable		應付票據	341,349	-	-	341,349	341,349
Other payables		其他應付款項	1,437,799	12,375	24,750	1,474,924	1,474,924
Lease liabilities	8	租賃負債	8,842	7,060	9,101	31,041	30,698
Bonds payable	3.73	應付債券	35,900	35,900	107,700	1,225,871	991,121
Borrowings		借款					
- fixed rate	3.26	- 固定利率	76,518	-	-	648,539	573,420
- variable rate	4.31	- 浮動利率	342,094	507,934	2,756,859	3,606,887	2,725,759
			3,749,250	563,269	2,898,410	8,835,359	7,644,019
Derivatives - net settlement		衍生工具-結算淨額					
Structured Cross Currency Swap		結構性交叉貨幣互換	-	59,072	-	59,072	59,072
Currency Option		貨幣期權	21,031	-	-	21,031	21,031
Interest rate swap		利率互換	-	-	5,775	5,775	5,775
			21,031	59,072	5,775	85,878	85,878

42. FINANCIAL INSTRUMENTS (continued)**42. 金融工具** (續)**Financial risk management objectives and policies** (continued)**財務風險管理目標及政策** (續)**Interest rate benchmark reform****利率基準改革**

Several of the Group's borrowings and financial liabilities will be subject to the interest rate benchmark reform. As at 1 January 2021, the Group has borrowings bear the interests of which are indexed to LIBOR with amounts of RMB2,707,668,000, the Structured Cross Currency Swap in a financial liability position which are indexed to LIBOR with amounts of RMB35,859,000, interest rate swap in a financial liability position indexed to Shanghai Interbank Offered Rate ("SHIBOR") with amounts of RMB5,775,000. None of the relevant contracts has been transitioned to the relevant replacement rates during the year. The Group is closely monitoring the market and managing the transition to new benchmark interest rates, including announcements made by the relevant IBOR regulators.

本集團的若干借款及金融負債將受到利率基準改革的影響。於二零二一年一月一日，本集團有按與LIBOR掛鈎的利率計息的借款人民幣2,707,668,000元，按與LIBOR掛鈎的利率計息的屬於金融負債狀況的結構性交叉貨幣掉期人民幣35,859,000元，按與上海銀行同業拆息（「SHIBOR」）掛鈎的利率計息的屬於金融負債狀況的利率掉期人民幣5,775,000元。本年度並無任何相關合約過渡至相關的替代率。本集團正密切監察市況並管理向新基準利率過渡的資訊，包括有關同業拆息監管機構作出的公告。

*LIBOR**LIBOR*

The Financial Conduct Authority has confirmed all LIBOR settings will either cease to be provided by any administrator or no longer be representative:

英國金融市場行為監管局已確認，以下時間後任何管理者立即終止提供所有LIBOR設定，且不再具代表性：

- immediately after 31 December 2021, in the case of all sterling, euro, Swiss franc and Japanese yen settings, and the 1-week and 2-month US dollar settings; and
- immediately after 30 June 2023, in the case of the remaining US dollar settings.

- 就所有英鎊、歐元、瑞士法郎及日圓設定，以及一個星期及二個月美元設定而言，乃於二零二一年十二月三十一日後；及
- 其餘美元設定則於二零二三年六月三十日後。

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Financial risk management objectives and policies (continued)

財務風險管理目標及政策 (續)

Interest rate benchmark reform (continued)

利率基準改革 (續)

(i) *Risks arising from the interest rate benchmark reform*

(i) *利率基準改革引致的風險*

The following are the key risks for the Group arising from the transition:

以下為過渡時給本集團帶來的主要風險：

Interest rate related risks

利率相關風險

For contracts which have not been transitioned to the relevant alternative benchmark rates and without detailed fallback clauses, if the bilateral negotiations with the Group's counterparties are not successfully concluded before the cessation of LIBORs, there are significant uncertainties with regard to the interest rate that would apply. This gives rise to additional interest rate risk that was not anticipated when the contracts were entered into.

對於未過渡至有關替代基準利率且無詳盡後備條款的合約而言，倘與本集團交易對手方的雙邊磋商未能在LIBORs終止發佈前達成共識，則適用利率有重大不確定性，會引致合約訂立時未預計到的額外利率風險。

There are fundamental differences between IBORs and the various alternative benchmark rates. IBORs are forward looking term rates published for a period (e.g. 3 months) at the beginning of that period and include an inter-bank credit spread, whereas alternative benchmark rates are typically risk-free overnight rates published at the end of the overnight period with no embedded credit spread. These differences will result in additional uncertainty regarding floating rate interest payments.

同業拆息與多項替代基準利率之間存在基本差異。同業拆息乃就一個期間(如三個月)在期初時發佈的遠期利率，包括銀行間信貸息差，而替代基準利率通常為無風險隔夜利率，在隔夜期末發佈，且無嵌入信貸息差。該等差異可導致有關浮息利率付款的額外不確定性。

42. FINANCIAL INSTRUMENTS (continued)**42. 金融工具** (續)**Financial risk management objectives and policies** (continued)**財務風險管理目標及政策** (續)**Interest rate benchmark reform** (continued)**利率基準改革** (續)*(i) Risks arising from the interest rate benchmark reform* (continued)*(i) 利率基準改革引致的風險* (續)

Liquidity risk

流動資金風險

The additional uncertainty on various alternative rates which are typically published on overnight basis will require additional liquidity management.

對於通過在隔夜發佈的各項替代利率的額外不確定性將需作出額外的流動資金管理。

Litigation risk

訴訟風險

If no agreement is reached to implement the interest rate benchmark reform on contracts which have not been transitioned to the relevant alternative benchmark rates (e.g. arising from differing interpretation of existing fallback terms), there is a risk of prolonged disputes with counterparties which could give rise to additional legal and other costs. The Group is working closely with all counterparties to avoid this from occurring.

倘對於尚未過渡至有關替代利率的合約無法達成實施利率基準改革的共識（如對現行後備條款的詮釋不同所引致），或存在與交易對手方長期糾紛的風險，而可能增加額外的法律及其他成本。本集團正與交易對手方緊密合作，以避免發生有關情況。

Interest rate basis risk

利率基準風險

Interest rate basis risk may arise if a non-derivative instrument and the derivative instrument held to manage the interest risk on the non-derivative instrument transition to alternative benchmark rates at different times. This risk may also arise where back-to-back derivatives transition at different times.

倘持作管理非衍生金融工具利率風險的非衍生工具及衍生工具於不同時間點過渡至替代基準利率，或會產生利率基準風險。背對背衍生工具於不同的時間點過渡時亦會產生該項風險。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Fair value measurement of financial instruments

金融工具的公平值計量

Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis

本集團以經常性基準按公平值計量的金融資產及金融負債的公平值

Some of the Group's financial assets are measured at fair value at the end of each reporting period. The following table gives information about how the fair values of these financial assets are determined (in particular, the valuation technique(s) and inputs used).

本集團部分金融資產於各報告期末按公平值計量。下表載列有關如何釐定該等金融資產及金融負債公平值之資料(尤其是,所用估值方法及輸入數據)。

Financial assets	Fair value as at (RMB'000)		Fair value hierarchy	Valuation technique(s) and key input(s)
	31/12/2021	31/12/2020 (restated)		
金融資產	於以下日期的公平值 (人民幣千元)		公平值等級	估值方法及關鍵輸入數據
	二零二一年 十二月 三十一日	二零二零年 十二月 三十一日 (經重列)		
FVTPL – Structured Cross Currency Swap	(35,883)	(59,072)	Level 2	The Cross current swap is a structured product constructed by interest rate swap and range forward. The interest rate swap is valued by discounting floating and fixed leg cash flows at appropriate discount rate. The range forward creates a range of exercise prices through two derivative market positions (long call and short put) that is valued by Black Scholes Pricing model.
按公平值計入損益計量 — 結構性交叉貨幣互換			第二級	交叉流動互換為一種通過利率互換及範圍性遠期構建的結構性產品。利率互換通過以適當的折現率對浮動及固定支票現金流量進行折現來評估。透過布萊克-斯克爾斯定價模型評估的兩個衍生市場頭寸(多頭及空頭),遠期範圍創造了一系列行權價。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Fair value measurement of financial instruments (continued)

金融工具的公平值計量 (續)

Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis (continued)

本集團以經常性基準按公平值計量的金融資產及金融負債的公平值 (續)

Financial assets	Fair value as at (RMB'000)		Fair value hierarchy	Valuation technique(s) and key input(s)
	31/12/2021	31/12/2020 (restated)		
金融資產	於以下日期的公平值 (人民幣千元)		公平值等級	估值方法及關鍵輸入數據
	二零二一年 十二月 三十一日	二零二零年 十二月 三十一日 (經重列)		
FVTPL – Currency option	(20,811)	(21,031)	Level 2	The Currency Option comprised of Seagull Option and Collar Option. A seagull option is a three-legged European option trading strategy which implemented using two puts and a call or vice versa. The Seagull option entered by the Group involves two call options and one put option to minimum risk. The collar position limits the return of the portfolio to a specified range and can hedge a position against potential volatility of the underlying asset. It is created through the usage of a protective put and covered call option. The key parameters applied are CNY/USD Spot Rate, discount rate, volatility, option fee.
按公平值計入損益計量 — 貨幣期權			第二級	貨幣期權由海鷗期權和領子期權組成。海鷗期權是一種三足鼎立的歐式期權交易策略，使用兩個看跌期權和一個看漲期權或反之。本集團的海鷗期權涉及兩個認購期權及一個認沽期權，以減低風險。領口頭寸將投資組合的回報限制在特定範圍內，並可針對相關資產的潛在波動對沖頭寸。其乃通過使用保護性看跌期權及覆蓋性看漲期權建立。應用的關鍵參數是人民幣／美元即期匯率、貼現率、波動率、期權費用。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Fair value measurement of financial instruments (continued)

金融工具的公平值計量 (續)

Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis (continued)

本集團以經常性基準按公平值計量的金融資產及金融負債的公平值 (續)

Financial assets	Fair value as at (RMB'000)		Fair value hierarchy	Valuation technique(s) and key input(s)
	31/12/2021	31/12/2020 (restated)		
金融資產	於以下日期的公平值 (人民幣千元)		公平值等級	估值方法及關鍵輸入數據
	二零二一年 十二月 三十一日	二零二零年 十二月 三十一日 (經重列)		
FVTPL – Interest rate swap	(199)	(5,775)	Level 2	Interest rate swap are forward contracts where one stream of future interest payments is exchanged for another based on a specified principal amount. The key parameters applied are Forward Rate Curve and Discount Rate Curve. The Forward Rate Curve is 3 – month SHIBOR and the forward reset rates are projected using Bloomberg SWPM function, 3 – month SHIBOR Curve is applied as discount curve for both fixed and floating leg valuation and is extracted from Bloomberg.
按公平值計入損益計量 – 利率互換			第二級	利率互換為遠期合約，即根據約定的本金額，將未來的利息支付流交換為另一種。應用的主要參數是遠期利率曲線和貼現率曲線。遠期利率曲線為三個月SHIBOR，而遠期重設利率則使用彭博SWPM功能進行預測。三個月SHIBOR曲線用作固定及浮動部分估值的貼現曲線，並從彭博提取。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Fair value measurement of financial instruments (continued)

金融工具的公平值計量 (續)

Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis (continued)

本集團以經常性基準按公平值計量的金融資產及金融負債的公平值 (續)

Financial assets	Fair value as at (RMB'000)		Fair value hierarchy	Valuation technique(s) and key input(s)
	31/12/2021	31/12/2020 (restated)		
金融資產	於以下日期的公平值 (人民幣千元)		公平值等級	估值方法及關鍵輸入數據
	二零二一年 十二月 三十一日	二零二零年 十二月 三十一日 (經重列)		
FVTOCI – Debt instruments at FVTOCI	419,752	469,610	Level 2	Discounted cash flow – future cash flows discounted at a rate that reflects the credit risk of various counterparties.
按公平值計入其他全面收益計量—按公平值計入其他全面收益計量之債務工具	419,752	469,610	第二級	貼現現金流量—以反映各交易對手信貸風險的貼現率貼現的未來現金流量。
FVTPL – Structured deposit	10,000	–	Level 2	Discounted cash flow – Future cash flows are estimated based on estimated return (from observable interest rates, currency, stock index and commodity price)
按公平值計入損益計量—結構性存款	10,000	–	第二級	貼現現金流量—根據估計回報(根據可觀察利率、貨幣、股票指數及商品價格)估計未來現金流量
FVTPL – Investment funds and equity security	100,943	108,420	Level 3	Income approach – in this approach, the discounted cash flow method was used to capture the present value of the expected future economic benefits to be derived from the ownership of this investee, based on an appropriate discount rate.
按公平值計入損益計量—基金投資和權益抵押	100,943	108,420	第三級	收入法—此方法中,使用貼現現金流量法獲得將自該等投資對象的擁有權取得的預期未來經濟利益的現值(按適用貼現率計量)。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

42. FINANCIAL INSTRUMENTS (continued)

42. 金融工具 (續)

Fair value measurement of financial instruments (continued)

金融工具的公平值計量 (續)

Reconciliation of Level 3 fair value measurements

第三級公平值計量的對賬

31 December 2021	二零二一年十二月三十一日	Financial assets at FVTPL RMB'000 按公平值計入損益計量之金融資產 人民幣千元
Balance at 1 January 2020	於二零二零年一月一日之結餘	402,426
Total gains in profit or loss	於損益之收益總額	39,223
Disposal	出售	(307,999)
Exchange adjustments	匯兌調整	(25,230)
Balance at 31 December 2020	於二零二零年十二月三十一日之結餘	108,420
Total gains in profit or loss	於損益之收益總額	(7,477)
Balance at 31 December 2021	於二零二一年十二月三十一日之結餘	100,943
Fair value of financial instruments that are recorded at amortized cost	按攤銷成本入賬的金融工具的公平值	
The Directors consider that the carrying amounts of financial assets and financial liabilities recorded at amortised cost in these consolidated financial statements approximate their fair values.	董事認為，該等綜合財務報表中按攤銷成本入賬的金融資產及金融負債的賬面值與其公平值相若。	

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

43. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES

The table below details changes in the Group's liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flow were, or future cash flows will be classified in the Group's consolidated statement of cash flows from financing activities.

43. 融資活動產生的負債之對賬

下表詳述本集團融資活動所產生的負債變動(包括現金及非現金變動)。融資活動所產生的負債已經或將會於來自融資活動之本集團綜合現金流量報表內分類。

		Borrowings	Bonds	Loans from a holding company	Dividend payable	Lease liabilities	Total
		RMB'000 (note 33)	RMB'000 (note 34)	RMB'000	RMB'000 (note 13)	RMB'000 (note 36)	RMB'000 (restated)
		借款	債券	來自 控股公司 的貸款	應付股息	租賃負債	合計
		人民幣千元 (附註33)	人民幣千元 (附註34)	人民幣千元	人民幣千元 (附註13)	人民幣千元 (附註36)	人民幣千元 (經重列)
At 1 January 2020	於二零二零年一月一日	5,349,231	-	143,982	144,800	25,711	5,663,724
Dividend declared	已宣派股息	-	-	-	556,549	-	556,549
Interest accrued	應計利息	153,046	21,230	2,956	-	1,703	178,935
Exchange adjustments	匯兌調整	(187,175)	-	-	-	890	(186,285)
Acquisition of a subsidiary	收購一間附屬公司	33,083	-	-	-	5,014	38,097
New lease	新租賃	-	-	-	-	10,629	10,629
Financing cash flows	融資現金流量	(2,049,006)	969,891	(146,938)	(701,349)	(13,249)	(1,940,651)
At 31 December 2020	於二零二零年十二月三十一日	3,299,179	991,121	-	-	30,698	4,320,998
Dividend declared	已宣派股息	-	-	-	653,288	-	653,288
Interest accrued	應計利息	97,261	39,467	-	-	3,668	140,396
Exchange adjustments	匯兌調整	(55,762)	-	-	-	419	(55,343)
New lease	新租賃	-	-	-	-	71,897	71,897
Financing cash flows	融資現金流量	(276,662)	(38,039)	-	(653,288)	(25,837)	(993,826)
At 31 December 2021	於二零二一年十二月三十一日	3,064,016	992,549	-	-	80,845	4,137,410

44. MAJOR NON-CASH TRANSACTIONS

During the year ended 31 December 2021, the Group endorsed bill receivables of RMB1,304,354,000 (2020: RMB975,155,000) to settle the trade and other payables.

44. 主要非現金交易

截至二零二一年十二月三十一日止年度，本集團就結算應付貿易賬款及其他應付款項背書應收票據人民幣1,304,354,000元(二零二零年：人民幣975,155,000元)。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

45. RELATED PARTY TRANSACTIONS

45. 關連人士交易

(a) The Group had the following related party transactions during the two years ended 31 December 2021 and 2020:

(a) 於截至二零二一年及二零二零年十二月三十一日止兩個年度內，本集團有下列關連人士交易：

		2021 RMB'000 二零二一年 人民幣千元	2020 RMB'000 (restated) 二零二零年 人民幣千元 (經重列)
Sales to fellow subsidiaries	銷售予同系附屬公司	394,988	397,872
Sales to a holding company	銷售予一間控股公司	2,793	326
Sales to an associate	銷售予一間聯營公司	39,136	26,379
Sales to associates of a holding company	銷售予一間控股公司的聯營公司	610	-
Distribution made through fellow subsidiaries	通過同系附屬公司作出分銷	2,226,169	1,128,233
Logistic support services received from fellow subsidiaries	自同系附屬公司接獲之物流支持服務	70,107	-
Purchases from fellow subsidiaries	向同系附屬公司採購	866,738	866,688
Purchases from a holding company	向一間控股公司採購	297	16,472
Purchases from an associate	向一間聯營公司採購	164,776	158,281
Operating lease income from fellow subsidiaries	來自同系附屬公司之經營租賃收入	6,693	12,369
Operating lease income from an associate	來自一間聯營公司之經營租賃收入	1,968	-
Operating lease income from an associate of a holding company	來自一間控股公司的一間聯營公司之經營租賃收入	742	-
Finance lease income from fellow subsidiaries	來自同系附屬公司之融資租賃收入	9,055	7,292
Interest income from factoring business from fellow subsidiaries	來自同系附屬公司保理業務之利息收入	19,554	14,890
Service received from fellow subsidiaries	自同系附屬公司接獲之服務	13,117	17,685
Service received from a holding company	自一間控股公司接獲之服務	527	5,253
Service received from an associate of a holding company	自一間控股公司的一間聯營公司接獲之服務	2,561	-
Service provided to fellow subsidiaries	向同系附屬公司提供之服務	9,488	21,426
Service provided to an associate of a holding company	向一間控股公司的一間聯營公司提供之服務	236	-
Service provided to an associate	向一間聯營公司提供之服務	3,663	9,936
Interest income from an associate	來自一間聯營公司之利息收入	-	8,399
Interest income from an associate of a holding company	來自一間控股公司的一間聯營公司之利息收入	7,013	4,922
Interest expense arising from a holding company	一間控股公司產生之利息支出	-	2,956

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

45. RELATED PARTY TRANSACTIONS

(continued)

(a) (continued)

Details of amounts due from/to related parties are set out in notes 24, 25, 27, 30, 31, and 32.

During the year ended 31 December 2021, the principal of the finance lease business provided to fellow subsidiaries by the Group amounted to RMB366,275,000 (2020: RMB29,814,000).

During the year ended 31 December 2021, the principal of the factoring business provided to fellow subsidiaries by the Group amounted to RMB133,010,000 (2020: RMB465,870,000).

As at 31 December 2021, a holding company provided guarantees of RMB58,000,000 (2020: RMB47,000,000) to one of the subsidiary of the Company related to its short-term bank borrowings.

During the year ended 31 December 2021, the subsidiary of the Company acquired interests in a Wego Healthcare from Weigao Holding. Detail of the related party transactions are set out in note 3 merger accounting and restatements.

During the year ended 31 December 2021, the Company participated the Asset Backed Securitization issued by Weigao Holding with the carrying amount of RMB232,687,000 account receivables, the Company has transferred all risks and rewards of those account receivables to Weigao Holding, and therefore derecognised the account receivables.

45. 關連人士交易 (續)

(a) (續)

應收／付關連人士款項的詳情載於附註24、25、27、30、31及32。

截至二零二一年十二月三十一日止年度，本集團向同系附屬公司提供之融資租賃業務本金額為人民幣366,275,000元(二零二零年：人民幣29,814,000元)。

截至二零二一年十二月三十一日止年度，本集團向同系附屬公司提供之保理業務本金額為人民幣133,010,000元(二零二零年：人民幣465,870,000元)。

於二零二一年十二月三十一日，一間控股公司就其短期銀行借款向本公司其中一間附屬公司提供人民幣58,000,000元(二零二零年：人民幣47,000,000元)之擔保。

截至二零二一年十二月三十一日止年度，本公司附屬公司向威高集團公司收購Wego Healthcare權益。相關關聯方交易之詳情載於附註3合併會計與重列。

截至二零二一年十二月三十一日止年度，本公司參與威高集團公司發行的賬面值為人民幣232,687,000元的應收賬款的資產證券化，本公司已將與該等應收賬款相關的一切風險及回報轉讓予威高集團公司，及因此終止確認應收賬款。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

45. RELATED PARTY TRANSACTIONS

(continued)

(a) (continued)

During the year ended 31 December 2020, the Group early repaid the long-term bank borrowings amounting to RMB1,220,835,000, and the guarantees related to this borrowing provided by a holding company were early released.

During the year ended 31 December 2020, the subsidiary of the Company exchanged assets with Weigao Holding. Details are set out in the consolidated statement of changes in equity.

During the year ended 31 December 2020, the subsidiary of the Company acquired interests in a company from Weigao International. Details are set out in note 3 merger accounting and prior year restatements.

During the year ended 31 December 2020, the subsidiary of the Company, Weihai Weigao Xingda Enterprise Management Consulting Services Co., Ltd acquired 28.57% interests of Weihai Hongyangrui from the executive director of the Company in year of 2020, Mr. Gong Jianbo. Detail of the acquisition are set out in the consolidated statement of changes in equity.

During the year ended 31 December 2020, the Group disposed the investment of secured convertible promissory notes issued by NeuroVasc Technologies Inc to Weigao Holding with an amount of USD46,944,000 (equivalent to RMB307,249,000).

During the year ended 31 December 2020, the Company sold Contracts to Weigao Holding with a consideration of USD17,921,000 (equivalent to RMB117,292,000). Details are set out in note 7 (d).

During the year ended 31 December 2020, the Group repaid the loan of RMB24,500,000 from a holding company with interest rate at 4.785% per annum.

45. 關連人士交易 (續)

(a) (續)

截至二零二零年十二月三十一日止年度，本集團提前償還金額為人民幣1,220,835,000元的長期銀行借款，及控股公司就該借款提供的相關擔保已提前解除。

截至二零二零年十二月三十一日止年度，本公司附屬公司與威高集團公司進行資產交換。詳情載於綜合權益變動表。

截至二零二零年十二月三十一日止年度，本公司附屬公司向威高國際收購公司權益。詳情載於附註3合併會計與上一年度重列。

截至二零二零年十二月三十一日止年度，本公司附屬公司威海威高信達企業管理諮詢服務有限公司於二零二零年自本公司執行董事弓劍波先生收購威海弘陽瑞28.57%權益。收購詳情載於綜合權益變動表。

截至二零二零年十二月三十一日止年度，本集團出售對NeuroVasc Technologies Inc發行予威高集團公司的抵押可轉換承兌票據之投資，金額為46,944,000美元（相當於人民幣307,249,000元）。

截至二零二零年十二月三十一日止年度，本公司向威高集團公司出售合約，代價為17,921,000美元（相當於人民幣117,292,000元）。詳情載於附註7 (d)。

截至二零二零年十二月三十一日止年度，本集團償還來自一間控股公司的貸款人民幣24,500,000元，年利率為4.785%。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

45. RELATED PARTY TRANSACTIONS

(continued)

(b) Compensation of key management personnel

The remuneration of directors and other members of key management during the year was as follows:

		2021 RMB'000 二零二一年 人民幣千元	2020 RMB'000 二零二零年 人民幣千元
Short-term employee benefits	短期僱員福利	10,155	20,759
Post-employment benefits	離職後福利	164	152
Share-based payments	以股份為基礎付款	8,273	665
		18,592	21,576

The remuneration of directors and key executives is determined by the remuneration committee having regard to the performance of individuals and market trends.

45. 關連人士交易 (續)

(b) 主要管理人員的報酬

於年內，董事及主要管理層的其他成員的薪酬如下：

		2021 RMB'000 二零二一年 人民幣千元	2020 RMB'000 二零二零年 人民幣千元
Short-term employee benefits	短期僱員福利	10,155	20,759
Post-employment benefits	離職後福利	164	152
Share-based payments	以股份為基礎付款	8,273	665
		18,592	21,576

董事及主要行政人員的薪酬乃由薪酬委員會就個別人士的表現及市場趨勢而釐定。

46. RETIREMENT BENEFITS SCHEMES

The Group participates in a Mandatory Provident Fund Scheme established under the Mandatory Provident Fund Ordinance in December 2000. The assets of the schemes are held separately from those of the Group, in funds under the control of trustees. All Hong Kong employees joining the Group are required to join the Mandatory Provident Fund Scheme.

No forfeited contribution under the scheme is available to reduce the Group's future contribution.

The employees of the Group's subsidiaries in the PRC are members of a state-managed retirement benefit scheme operated by the government of mainland. These subsidiaries are required to contribute 16% for the year ended 31 December 2021.(2020:16%) of payroll costs to the retirement benefit scheme to fund the benefits. The only obligation of the Group with respect to the retirement benefit scheme is to make the specified contributions.

46. 退休福利計劃

本集團於二零零零年十二月參與根據強制性公積金計劃條例而設立之強制性公積金計劃。該等計劃之資產乃由受託人監管之基金，與本集團之資產分開持有。所有加盟本集團之香港僱員均須參與強制性公積金計劃。

根據該計劃並無沒收供款可用作減少本集團之將來供款。

本集團之中國附屬公司之僱員均為大陸政府經營之國家管理退休福利計劃之成員。於截至二零二一年十二月三十一日止年度，該等附屬公司須按薪金成本之16% (二零二零年：16%) 向退休福利計劃供款以作為福利所需資金。本集團對退休福利計劃之唯一責任為作出指定之供款。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

46. RETIREMENT BENEFITS SCHEMES

(continued)

Argon sponsors a 401(k) retirement savings plan for all Argon employees. This plan includes both employee contributions as well as employer matching contributions.

Other subsidiaries in jurisdictions outside of the PRC contribute to statutory retirement plans on behalf of their employees which in many cases are managed by the government in those territories. Those subsidiaries make periodic contributions to the statutory retirement plans as required and contributions are generally determined as a percentage of employees' basic salaries or a fixed amount per employee per calendar year depending on the jurisdiction.

The contributions paid and payable to the schemes by the Group are disclosed in note 11.

47 CONTINGENT LIABILITIES

As disclosed in note 7(e), a subsidiary of the Group was defendant in a product liability claim. The Group recorded a pre-tax charge of RMB522,650,000 for losses related to product liability litigation. The Group regularly monitors and evaluates the status of product liability, and may, from time-to-time, engages in settlement and mediation discussions, taking into consideration of developments in the matters and the inherent risks and uncertainties surrounding the litigation.

46. 退休福利計劃 (續)

愛琅為所有愛琅僱員提供401(k)退休儲蓄計劃。該計劃包括僱員供款以及僱主匹配供款。

中國以外司法權區的其他附屬公司代表其僱員參與法定退休計劃，而在許多情況下，該等計劃由該等地區的政府管理。該等附屬公司按要求定期向法定退休計劃供款，且供款通常按僱員基本工資的百分比或根據司法權區每個日曆年度每名僱員的固定金額釐定。

本集團就該等計劃已付及應付的供款於附註11作出披露。

47 或有負債

誠如附註7(e)所披露，本集團一間附屬公司乃一宗產品責任索賠的被告。本集團就產品責任訴訟的相關損失錄得稅前費用人民幣522,650,000元。本集團定期監察及評估產品責任的狀況，並可能不時參與和解及調解討論（經考慮事件的發展以及圍繞訴訟的固有風險及不確定性）。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

48. 本公司主要附屬公司詳情

Particulars of the Company's subsidiaries as at 31 December 2021 and 2020 are as follows:

於二零二一年及二零二零年十二月三十一日，本公司附屬公司的詳情如下：

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權		於十二月三十一日 本集團應佔之實際股權		
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Weigao Orthopaedic * (山東威高骨科材料股份有限公司) (note a)	PRC	RMB358,585,800	50.63	56.47	21.55	24.04	Manufacturing of orthopaedic medical device products
山東威高骨科材料股份有限公司 (附註a)	中國	人民幣358,585,800元					製造骨科醫療設備產品
Beijing Weigao Yahua Artificial Joints Development Company Limited* (北京威高亞華人工關節開發有限公司) (note a)	PRC	RMB70,000,000	-	-	72.18	80.51	Research, services and sales of medical devices
北京威高亞華人工關節開發有限公司 (附註a)	中國	人民幣70,000,000元					醫療設備的研發、服務及銷售
Changzhou Jianli Bangde Medical Devices Co., Ltd* (常州健力邦德醫療器械有限公司) (note a)	PRC	RMB65,000,000	-	-	72.18	80.51	Manufacturing of orthopaedic devices, implantation materials and artificial organs
常州健力邦德醫療器械有限公司 (附註a)	中國	人民幣65,000,000元					製造骨科設備、移植材料及人造器官
Weihai Weigao Management Asset Management Co., Ltd* (威海威高資產管理有限公司) (note a)	PRC	RMB10,000,000	-	-	72.18	80.51	Asset management and enterprise consulting service
威海威高資產管理有限公司 (附註a)	中國	人民幣10,000,000元					資產管理及企業顧問服務

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情 (續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權				
			% (直接)	% (間接)			
			二零二一年	二零二零年	二零二一年	二零二零年	
Weigao Group (Weihai) Medical Products Marketing Co., Ltd* (威高集團(威海)醫用製品營銷有限公司)	PRC	RMB950,000,000	25	25	75	75	Wholesale of Type I medical devices, surgical devices and other disposal medical products
威高集團(威海)醫用製品營銷有限公司	中國	人民幣950,000,000元					批發第一類醫療設備、手術設備及其他一次性醫療產品
Weigao Group (Weihai) Medical Products Material Supply Co., Ltd* (威高集團(威海)醫用製品材料供應有限公司)	PRC	RMB1,309,070,000	19.21	21.95	80.79	78.05	Wholesale of Type I medical devices, surgical devices and other disposal medical products
威高集團(威海)醫用製品材料供應有限公司	中國	人民幣1,309,070,000元					批發第一類醫療設備、手術設備及其他一次性醫療產品
Weihai Jierui Medical Products Company Limited* (威海潔瑞醫用製品有限公司)	PRC	RMB114,030,000	87.70	53.2	12.30	46.7	Manufacturing of medical PVC granules, plastic packing bags and carton boxes
威海潔瑞醫用製品有限公司	中國	人民幣114,030,000元					製造醫用PVC粒料、塑料包裝袋及紙箱
Shandong Weigao Automatic Equipment Company Limited* (山東威高自動化設備有限公司)	PRC	RMB5,000,000	-	-	100	100	Manufacturing of industrial automatic equipment and parts
山東威高自動化設備有限公司	中國	人民幣5,000,000元					製造工業自動化設備及配件
Shandong Weigao Group Logistic Company Limited* (山東威高集團物流有限公司)	PRC	RMB20,000,000	100	100	-	-	Provision of logistics and storage services
山東威高集團物流有限公司	中國	人民幣20,000,000元					提供物流及儲存服務

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情
(續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權				
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Weihai Weigao Group Mould Company Limited* (威海威高集團模具有限公司)	PRC	RMB8,000,000	90	90	10	10	Manufacturing of moulds
威海威高集團模具有限公司	中國	人民幣8,000,000元					製造模具
Sichuan Jierui Weigao Medical Device Company Limited* (四川潔瑞威高醫療器械有限公司)	PRC	RMB2,000,000	100	100	-	-	Trading of medical products
四川潔瑞威高醫療器械有限公司	中國	人民幣2,000,000元					買賣醫療產品
Weihai Weigao Jiasheng Medical Devices Co., Ltd.* (威海威高潔盛醫療器材有限公司)	PRC	RMB20,000,000	-	-	95.9	95.9	Trading of medical products
威海威高潔盛醫療器材有限公司	中國	人民幣20,000,000元					買賣醫療產品
Weihai Weigao Medical International Trading Co., Ltd.* (威海威高醫療國際貿易有限公司)	PRC	RMB5,000,000	80	80	20	20	Sales of medical devices, imports and exports of registered products
威海威高醫療國際貿易有限公司	中國	人民幣5,000,000元					銷售醫療設備、進出口登 記產品
Weigao International Medical Co., Ltd. (威高國際醫療有限公司)	Hong Kong	HKD207,699,690	100	100	-	-	Investment holding and trading
威高國際醫療有限公司	香港	207,699,690港元					投資控股及貿易

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情 (續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities	
			% (direct)		% (indirect)			
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務	
			於十二月三十一日 本集團應佔之實際股權					
			% (直接)		% (間接)			
			二零二一年	二零二零年	二零二一年	二零二零年		
Wellford Capital Limited	British Virgin Islands ("BVI")	USD50,000	-	-	100	100	Investment holding	
Wellford Capital Limited	英屬處女群島 (「英屬處女群島」)	50,000美元					投資控股	
Shandong Weigao Financial Leasing Co., Ltd.* (山東威高融資租賃有限公司)	PRC	RMB500,000,000	-	-	100	100	Engaged in various financial leasing business of medical equipment	
山東威高融資租賃有限公司	中國	人民幣500,000,000元					從事醫療設備的各類融資租賃服務	
Wego Medical Holding Company Limited (威高醫療控股有限公司)	Hong Kong	HKD1,000,000	-	-	100	100	Investment holding	
威高醫療控股有限公司	香港	1,000,000港元					投資控股	
Weihai Weigao Medical Device Sales Co., Ltd.* (威海威高醫療器械銷售有限公司)		RMB150,000,000/ RMB200,000,000	-	-	75	75	Manufacturing and sales of hemo-dialysis equipment	
威海威高醫療器械銷售有限公司		人民幣150,000,000元/ 人民幣200,000,000元					血液透析設備的製造及出售	
Shanghai Weigao Financing Lease Co., Limited* (上海威高融資租賃有限公司)	PRC	USD45,000,000/ USD50,000,000	-	-	100	100	Engaged in various financial leasing business	
上海威高融資租賃有限公司	中國	45,000,000美元/ 50,000,000美元					從事各類融資租賃業務	

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情
(續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
			2021	2020	2021	2020	
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	於十二月三十一日 本集團應佔之實際股權				主要業務
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Champion Falcon limited (翔冠有限公司) 翔冠有限公司	Hong Kong 香港	HKD1 1港元	-	-	100	100	Investment holding 投資控股
Brilliant Grace limited (耀恩有限公司) 耀恩有限公司	BVI 英屬處女群島	USD1 1美元	-	-	100	100	Investment holding 投資控股
Fuzhou Fanshun Medical Device Technology Company Limited* (福州帆順醫療器械技術有限公司) 福州帆順醫療器械技術有限公司	PRC 中國	RMB500,000 人民幣500,000元	95	95	-	-	Wholesale, sales and purchases of disposable sterile medical devices 一次性無菌醫療設備的批 發、銷售及採購
Taian Weixin Medical Products Co., Ltd. * (泰安市威新醫用製品有限公司) 泰安市威新醫用製品有限公司	PRC 中國	RMB800,000/ RMB30,000,000 人民幣800,000元/人民幣 30,000,000元	1	1	99	99	Trading of medical products 買賣醫療產品
Weihai Chang Hong Enterprise Management Consulting Centre (Limited Partnership)* (威海長弘企業管理諮詢中心 (有限合夥)) 威海長弘企業管理諮詢中心(有限合夥)	PRC 中國	RMB50 人民幣50元	-	-	-	-	Enterprise management advisory services 企業管理顧問服務

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情 (續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權				
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Weihai Yang Fan Enterprise Management Consulting Centre (Limited Partnership) * (威海揚帆企業管理諮詢中心(有限合夥))	PRC	RMB50	-	-	-	-	Enterprise management advisory services
威海揚帆企業管理諮詢中心(有限合夥)	中國	人民幣50元					企業管理顧問服務
Weihai Hong Tu Enterprise Management Consulting Centre (Limited Partnership) * (威海宏圖企業管理諮詢中心(有限合夥))	PRC	nil/ RMB41	-	-	-	-	Enterprise management advisory services
威海宏圖企業管理諮詢中心(有限合夥)	中國	無/人民幣41元					企業管理顧問服務
Anhui Weigao Orthopaedic Medical Device Co., Ltd. * (安徽威高骨科醫療器械有限公司) (note a)	PRC	RMB40,920,595.50/ RMB150,000,000	-	-	72.18	80.51	Sales of Type I, Type II and Type III medical device; Enterprise management advisory services
安徽威高骨科醫療器械有限公司(附註a)	中國	人民幣40,920,595.50元/ 人民幣150,000,000元					銷售第一類、第二類及第三類醫療設備；企業管理顧問服務
Weihai Hai Xing Medical Devices Co., Ltd.* (威海海星醫療器械有限公司)(note a)	PRC	RMB70,000,000	-	-	72.18	80.51	Production and sales of Type III medical implant material and artificial organ (6846); production and sales of Type I medical devices.
威海海星醫療器械有限公司(附註a)	中國	人民幣70,000,000元					生產及銷售第三類醫療植入物材料及人造器官(6846)；生產及銷售第一類醫療設備。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情

(續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權				
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Sichuan Weigao Tianfu Medical Technology Co. Ltd. * (四川威高天府醫藥科技有限公司)	PRC 中國	nil/ RMB20,000,000	90	90	10	10	Research, sales of medicines and medical devices 醫藥及醫療設備的研發、銷售
Jilin Weigao Bao Ren Medical Products Co., Ltd. * (吉林省威高寶仁醫用製品有限公司)	PRC 中國	RMB20,116,810/ RMB50,000,000	65	65	-	-	Wholesale and retail of medical products and medical devices 批發及零售醫療產品及醫療設備
Weihai Weigao Yi Kang Medical Device Sales Co., Ltd. * (威海威高億康醫療器械銷售有限公司)	PRC 中國	RMB30,000,000	10	10	90	90	Sales of medical devices 銷售醫療設備
WW Medical and Healthcare Company Limited	Cayman Islands 開曼群島	USD50,000	-	-	89.81	89.81	Investment holding 投資控股
WW Medical and Healthcare Holdings Corporation	U.S. 美國	USD1,000	-	-	89.81	89.81	Investment holding 投資控股
Argon Medical Devices Holding, Inc.	U.S. 美國	USD1/ USD2,000,000	-	-	89.81	89.81	Investment holding 投資控股

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情 (續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權				
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Weihai Weigao Medical Products Co., Ltd. * (威海威高醫用製品有限公司)	PRC	nil/ RMB10,000,000	90	90	10	10	Sales of medical devices
威海威高醫用製品有限公司	中國	無/人民幣10,000,000元					銷售醫療設備
Shandong Weigao Jiahe Pharmaceutical Technology Co., Ltd. * (山東威高佳禾醫藥科技有限公司)	PRC	RMB5,000,000	67	67	-	-	Sales of Type I, Type II and Type III medical device; Biotechnology Extension Service
山東威高佳禾醫藥科技有限公司	中國	人民幣5,000,000元					銷售第一類、第二類及第三類醫療設備；生物技術推廣服務
Argon Medical Devices (Hong Kong) Co., Ltd. (愛琅醫療器械(香港)有限公司)	Hong Kong	HKD1	-	-	89.81	89.81	Investment holding
愛琅醫療器械(香港)有限公司	香港	1港元					投資控股
Argon Medical Devices (Shanghai) Co., Ltd. * (愛琅(上海)醫療器械有限公司)	PRC	nil/ RMB1,000,000	-	-	89.81	89.81	Sales of Type II and Type III medical device; technical services and technology transfer.
愛琅(上海)醫療器械有限公司	中國	無/人民幣1,000,000元					銷售第二類及第三類醫療設備；技術服務及技術轉讓。
Alang (Weihai) Medical Instrument Co., Ltd. * (愛琅(威海)醫療器械有限公司)	PRC	USD1,400,000	-	-	89.81	-	Production and sales of Type II and Type III. Sales of Type I. Information consulting service.
愛琅(威海)醫療器械有限公司	中國	1,400,000美元					生產及銷售第二類及第三類。銷售第一類。信息諮詢服務。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情 (續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
			2021	2020	2021	2020	
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	於十二月三十一日 本集團應佔之實際股權				主要業務
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Shandong Weigao Puri Pharmaceutical Packaging Co., Ltd. * (山東威高普瑞醫藥包裝有限公司)	PRC	RMB100,169,817/ RMB104,275,000	95.9	95.9	-	-	Production and marketing of medical polymer materials and products, injection puncture instruments
山東威高普瑞醫藥包裝有限公司	中國	人民幣100,169,817元/ 人民幣104,275,000元					生產及銷售醫用高分子材料及產品、注射穿刺器械
Shandong Mingde Biomedical Engineering Co., Ltd. * (山東明德生物醫學工程有限公司) (note a)	PRC	RMB18,703,417/ RMB20,000,000	-	-	57.74	64.41	Production and marketing of medical polymer materials and products, injection puncture instruments
山東明德生物醫學工程有限公司 (附註a)	中國	人民幣18,703,417元/ 人民幣20,000,000元					生產及銷售醫用高分子材料及產品、注射穿刺器械
Yunnan Weigao Orthopaedic Medical Devices Co., Ltd. * (雲南威高骨科醫療器械有限責任公司) (note a)	PRC	RMB50,000/ RMB50,000,000	-	-	36.81	41.06	Sales of medical devices
雲南威高骨科醫療器械有限責任公司 (附註a)	中國	人民幣50,000元/ 人民幣50,000,000元					銷售醫療設備
Shandong Weikang Medical Technology Co., Ltd. * (山東威康醫療科技有限公司)	PRC	RMB2,000,000/ RMB10,000,000	100	100	-	-	Research and sales of medical devices
山東威康醫療科技有限公司	中國	人民幣2,000,000元/ 人民幣10,000,000元					研發及銷售醫療設備
Shandong Weigao Orthopaedic Devices Sales Co., Ltd. * (山東威高骨科醫療器械銷售有限公司) (note a)	PRC	RMB10,000,000/ RMB50,000,000	-	-	72.18	80.51	Sales of medical devices
山東威高骨科醫療器械銷售有限公司 (附註a)	中國	人民幣10,000,000元/ 人民幣50,000,000元					銷售醫療設備

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情 (續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities	
			% (direct)		% (indirect)			
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務	
			於十二月三十一日 本集團應佔之實際股權					
			% (直接)		% (間接)			
			二零二一年	二零二零年	二零二一年	二零二零年		
Hunan Weigao Orthopaedic Devices Co., Ltd. * (湖南威高骨科醫療器械有限公司) (note a)	PRC	RMB13,750,000/ RMB50,000,000	-	-	54.86	61.19	Sales of medical devices	
湖南威高骨科醫療器械有限公司 (附註a)	中國	人民幣13,750,000元/ 人民幣50,000,000元					銷售醫療設備	
Sichuan Weigao Orthopaedic Devices Co., Ltd. * (四川威高骨科醫療器械有限公司) (note a)	PRC	RMB5,000,000/ RMB50,000,000	-	-	72.18	80.51	Sales of medical devices	
四川威高骨科醫療器械有限公司 (附註a)	中國	人民幣5,000,000元/ 人民幣50,000,000元					銷售醫療設備	
Fenwei Healthcare Technology and Development (Shanghai) Co., Ltd. * (威高奮威健康科技發展(上海) 有限公司)	PRC	RMB10,000,000/ RMB50,000,000	100	100	-	-	Research, services and consulting	
威高奮威健康科技發展(上海) 有限公司	中國	人民幣10,000,000元/ 人民幣50,000,000元					研發、服務及諮詢	
Weigao Medical Korea Co. Ltd. (威高醫療韓國有限公司)	Korea	KRW 173,180,000/ KRW 168,000,000	100	100	-	-	Sales of medical devices	
威高醫療韓國有限公司	韓國	173,180,000韓元 /168,000,000韓元					銷售醫療設備	
Shandong Weigao Blood Technology Limited* (山東威高血液技術有限公司)	PRC	nil/ USD55,000,000	-	-	100	100	Research, services and sales	
山東威高血液技術有限公司	中國	無/55,000,000美元					研發、服務及銷售	

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情
(續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權				
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Shandong Weigao Pharmaceutical Packaging Products Co., Ltd. * (山東威高醫藥包裝製品有限公司)	PRC	nil/ RMB45,000,000	-	-	95.9	95.9	Production and Sales
山東威高醫藥包裝製品有限公司	中國	無/人民幣45,000,000元					生產及銷售
Weihai Weigao Xinda Enterprise Management Consulting Service Co., Ltd. * (威海威高信達企業管理諮詢服務有限公司)	PRC	nil/ RMB100,000	90	90	10	10	Consulting
威海威高信達企業管理諮詢服務有限公司	中國	無/人民幣100,000元					諮詢
Weihai Hongyangrui Information Technology Center (Limited Partnership) * (威海弘陽瑞資訊技術中心(有限合夥))	PRC	nil/ RMB217,777,770	-	-	80.15	80.15	Computer technical services and sale of electronic products.
威海弘陽瑞資訊技術中心(有限合夥)	中國	無/人民幣217,777,770元					計算機技術服務及電子產品銷售。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情 (續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
			2021	2020	2021	2020	
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	於十二月三十一日 本集團應佔之實際股權				主要業務
			% (直接)	% (間接)			
			二零二一年	二零二零年	二零二一年	二零二零年	
Shandong Weigao Weinasi Medical Technology Co., Ltd. * (山東威高威納思醫療科技有限公司)	PRC	nil/ RMB20,000,000	90	90	10	10	Development, services and sales of medical technology development.
山東威高威納思醫療科技有限公司	中國	無/人民幣20,000,000元					醫療技術的開發、服務及銷售。
Weigao (Beijing) Medical Technology Co., Ltd. * (威高(北京)醫療科技有限公司)	PRC	nil/ RMB50,000,000	100	100	-	-	Research, sales of medicines
威高(北京)醫療科技有限公司	中國	無/人民幣50,000,000元					藥品研發、銷售
Shandong Weiteng Medical Products Co., Ltd. * (山東威藤醫用製品有限公司)	PRC	nil/ RMB50,000,000	1	1	99	99	Sales of medical devices
山東威藤醫用製品有限公司	中國	無/人民幣50,000,000元					銷售醫療設備
Global Healthcare, Inc.	USA	USD3,791,097/ USD10,000,000	-	-	51	51	Distribution of medical devices
Global Healthcare, Inc.	美國	3,791,097美元 /10,000,000美元					醫療設備的分銷
Henan Weigao Orthopaedic Medical Technology Co., Ltd. * (河南威高骨科醫療科技有限公司) (note a)	PRC	RMB50,000/ RMB10,000,000	-	-	72.18	80.51	Technology development of medical devices, technology consulting and service.
河南威高骨科醫療科技有限公司(附註 a)	中國	人民幣50,000元/人民幣10,000,000元					Sales of Type I, Type II and Type III medical device 醫療設備的技術開發、技術諮詢及服務。 銷售第一類、第二類及第三類醫療設備

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情
(續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權				
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Shandong Weigao Yahua Orthopaedic Device Sales Co., Ltd. * (山東威高亞華醫療器械銷售有限公司) (note a)	PRC	RMB10,000,000/ RMB10,000,000	-	-	72.18	80.51	Sales of Type I and Type II medical device
山東威高亞華醫療器械銷售有限公司 (附註a)	中國	人民幣10,000,000元/ 人民幣10,000,000元					銷售第一類及第二類醫療設備
Weigao (Jinan) Orthopaedic Device Co., Ltd. * (威高(濟南)骨科材料有限公司) (note a)	PRC	nil/ RMB10,000,000	-	-	50.53	56.36	Sales of Type I, Type II and Type III medical device;
威高(濟南)骨科材料有限公司 (附註a)	中國	無/人民幣10,000,000元					銷售第一類、第二類及第三類醫療設備；
Weigao (Shanghai) Orthopaedic Device Co., Ltd. * (威高(上海)骨科材料有限公司) (note a)	PRC	nil/ RMB60,000,000	-	-	72.18	80.51	Sales of Type I, Type II and Type III medical device;
威高(上海)骨科材料有限公司 (附註a)	中國	無/人民幣60,000,000元					銷售第一類、第二類及第三類醫療設備；
Shandong Gaowo Medical Device Co., Ltd. * (山東高沃醫療器械有限公司) (note a)	PRC	nil/ RMB10,000,000	-	-	64.96	72.46	Sales of Type I, Type II and Type III medical device;
山東高沃醫療器械有限公司 (附註a)	中國	無/人民幣10,000,000元					銷售第一類、第二類及第三類醫療設備；
Wego Healthcare Fund Holding Corporation (威高醫療健康基金控股公司)	USA	USD10	-	-	100	100	Investment holding
威高醫療健康基金控股公司	美國	10美元					投資控股

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情 (續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權				
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Rad Source Technologies, Inc. (拉德索斯科技有限公司)	USA	USD10,634	-	-	100	100	Manufacturing and sales of X-ray based irradiation machines;
拉德索斯科技有限公司	美國	10,634美元					X射線輻照儀的製造及銷售；
Rad Source Medical Technology Co., Ltd. (拉德索斯(中國)醫療科技有限公司)	PRC	USD 1,000,000	-	-	100	100	Manufacturing and sales of X-ray based irradiation machines;
拉德索斯(中國)醫療科技有限公司	中國	1,000,000美元					X射線輻照儀的製造及銷售；
Shanghai Weigao Pharmaceutical Technology Co., Ltd.* (上海威高醫藥科技有限公司)	PRC	RMB20,000,000	100	100	-	-	Sales of medical device;
上海威高醫藥科技有限公司	中國	人民幣20,000,000元					銷售醫療設備；
Shanghai Weigao Gaojingchuang Medical Technology Co., Ltd.* (上海威高精創醫療科技有限公司)	PRC	RMB20,000,000	-	-	72.18	-	Production and sales of Type I, Type II and Type III medical devices.
(note a) 上海威高精創醫療科技有限公司	中國	人民幣20,000,000元					生產及銷售第一類、第二類及第三類醫療設備。
(附註a)							
Zhejiang Weigao Medical Products Co., Ltd.* (浙江威高醫用製品有限公司)	PRC	RMB50,000,000	1	1	99	99	Production and sales of Type I, Type II and Type III medical devices.
浙江威高醫用製品有限公司	中國	人民幣50,000,000元					生產及銷售第一類、第二類及第三類醫療設備。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情
(續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權				
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Mianyang Weigao Pharmaceutical Technology Co., Ltd.* (綿陽威高醫藥科技有限公司)	PRC	RMB20,000,000	-	-	100	-	Sales of Type I, Type II and Type III medical device;
綿陽威高醫藥科技有限公司	中國	人民幣20,000,000元					銷售第一類、第二類及第三類醫療設備；
Shandong Weigao Hainasi Medical Technology Co., Ltd.* (山東威海納思醫療科技有限公司)	PRC	RMB11,377,200	-	-	66.60	-	Development, services and sales of medical technology development.
山東威海納思醫療科技有限公司	中國	人民幣11,377,200元					醫療技術的開發、服務及銷售。
Shanghai Shuruikang Medical Technology Development Co., Ltd.* (上海舒瑞康醫療科技發展有限公司)	PRC	RMB20,000,000	100	-	-	-	Production and sales of Type I, Type II and Type III medical devices.
上海舒瑞康醫療科技發展有限公司	中國	人民幣20,000,000元					Sales of Type II and Type III ray devices. 生產及銷售第一類、第二類及第三類醫療設備。 銷售第二類及第三類放射設備。
Shandong Weigao Blood Transfusion Technology Equipment Co., Ltd.* (山東威高輸血技術裝備有限公司)	PRC	RMB50,000,000	100	-	-	-	Production and sales of Type I, Type II and Type III medical devices.
山東威高輸血技術裝備有限公司	中國	人民幣50,000,000元					Sales of Type II and Type III ray devices. 生產及銷售第一類、第二類及第三類醫療設備。 銷售第二類及第三類放射設備。

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情 (續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities	
			% (direct)		% (indirect)			
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務	
			於十二月三十一日 本集團應佔之實際股權					
			% (直接)		% (間接)			
			二零二一年	二零二零年	二零二一年	二零二零年		
Weigao(Suzhou) Medical Technology Co., Ltd.* (威高(蘇州)醫療科技有限公司)	PRC	RMB10,000,000	90	-	10	-	Production and sales of Type I, Type II and Type III medical devices. Sales of Type II and Type III ray devices.	
威高(蘇州)醫療科技有限公司	中國	人民幣10,000,000元					生產及銷售第一類、第二類及第三類醫療設備。 銷售第二類及第三類放射設備。	
Shandong Weigao Furui Medical Products Co., Ltd.* (山東威高福瑞醫用製品有限公司)	PRC	RMB8,000,000	-	-	100	-	Production and sales of Type I, Type II and Type III medical devices.	
山東威高福瑞醫用製品有限公司	中國	人民幣8,000,000元					生產及銷售第一類、第二類及第三類醫療設備。	
Shanghai electron Microscope Medical Technology Co., Ltd.* (上海電鏡醫療科技有限公司)	PRC	RMB10,000,000	100	-	-	-	Production and sales of Type I, Type II and Type III medical devices. Leasing of Type II, Type III medical devices.	
上海電鏡醫療科技有限公司	中國	人民幣10,000,000元					生產及銷售第一類、第二類及第三類醫療設備。 租賃第二類、第三類醫療設備。	
Tianjin Yangfan No. 1 Enterprise Management Consulting Partnership (Limited Partnership)* (天津揚帆一號企業管理諮詢合夥企業(有限合夥))	PRC	RMB746	-	-	-	-	Enterprise management advisory services	
天津揚帆一號企業管理諮詢合夥企業(有限合夥)	中國	人民幣746元					企業管理顧問服務	

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL
SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情
(續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權				
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Tianjin Yangfan No. 2 Enterprise Management Consulting Partnership (Limited Partnership)* (天津揚帆二號企業管理諮詢合夥企業 (有限合夥))	PRC	RMB481	-	-	-	-	Enterprise management advisory services
天津揚帆二號企業管理諮詢合夥企業 (有限合夥)	中國	人民幣481元					企業管理顧問服務
Tianjin Yangfan No. 3 Enterprise Management Consulting Partnership (Limited Partnership)* (天津揚帆三號企業管理諮詢合夥企業 (有限合夥))	PRC	RMB501	-	-	-	-	Enterprise management advisory services
天津揚帆三號企業管理諮詢合夥企業 (有限合夥)	中國	人民幣501元					企業管理顧問服務
Tianjin Yangfan No. 4 Enterprise Management Consulting Partnership (Limited Partnership)* (天津揚帆四號企業管理諮詢合夥企業 (有限合夥))	PRC	RMB506	-	-	-	-	Enterprise management advisory services
天津揚帆四號企業管理諮詢合夥企業 (有限合夥)	中國	人民幣506元					企業管理顧問服務
Tianjin Yangfan No. 5 Enterprise Management Consulting Partnership (Limited Partnership)* (天津揚帆五號企業管理諮詢合夥企業 (有限合夥))	PRC	RMB571	-	-	-	-	Enterprise management advisory services
天津揚帆五號企業管理諮詢合夥企業 (有限合夥)	中國	人民幣571元					企業管理顧問服務

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

48. 本公司主要附屬公司詳情 (續)

Name of subsidiary	Place of registration	Paid up issued/ registered capital	Effective equity interest attributable to the Group as at 31 December				Principal activities
			% (direct)		% (indirect)		
附屬公司名稱	註冊地點	已發行實繳/ 註冊資本	2021	2020	2021	2020	主要業務
			於十二月三十一日 本集團應佔之實際股權				
			% (直接)		% (間接)		
			二零二一年	二零二零年	二零二一年	二零二零年	
Tianjin Yangfan No. 6 Enterprise Management Consulting Partnership (Limited Partnership)* (天津揚帆六號企業管理諮詢合夥企業 (有限合夥))	PRC	RMB17,000,000	-	-	-	-	Enterprise management advisory services
天津揚帆六號企業管理諮詢合夥企業 (有限合夥)	中國	人民幣17,000,000元					企業管理顧問服務
Tianjin Yangfan No. 7 Enterprise Management Consulting Partnership (Limited Partnership)* (天津揚帆七號企業管理諮詢合夥企業 (有限合夥))	PRC	RMB17,540,000	-	-	-	-	Enterprise management advisory services
天津揚帆七號企業管理諮詢合夥企業 (有限合夥)	中國	人民幣17,540,000元					企業管理顧問服務
Tianjin Yangfan No. 8 Enterprise Management Consulting Partnership (Limited Partnership)* (天津揚帆八號企業管理諮詢合夥企業 (有限合夥))	PRC	RMB119,153,000	-	-	-	-	Enterprise management advisory services
天津揚帆八號企業管理諮詢合夥企業 (有限合夥)	中國	人民幣119,153,000元					企業管理顧問服務
Tianjin Yangfan No. 9 Enterprise Management Consulting Partnership (Limited Partnership)* (天津揚帆九號企業管理諮詢合夥企業 (有限合夥))	PRC	RMB18,974,001	-	-	-	-	Enterprise management advisory services
天津揚帆九號企業管理諮詢合夥企業 (有限合夥)	中國	人民幣18,974,001元					企業管理顧問服務

* For identification purposes only

* 僅供識別

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

48. PARTICULARS OF PRINCIPAL SUBSIDIARIES OF THE COMPANY

(continued)

Note:

- (a) As disclosed in consolidated statement of changes in equity, Weigao Orthopaedic listed separately on Science and Technology Innovation Board of the Shanghai Stock Exchange, resulting in an deemed disposal of the Group's interest in Weigao Orthopaedic and the subsidiaries of Weigao Orthopaedic.

None of the subsidiaries had issued any debt securities at the end of the year.

In the opinion of the directors of the Company, there is no subsidiary that has non-controlling interests which is material to the Group.

48. 本公司主要附屬公司詳情

(續)

附註：

- (a) 誠如綜合權益變動表所披露，威高骨科在上海證券交易所科創板單獨上市，導致視作出售本集團於威高骨科及其附屬公司的權益。

概無附屬公司於年末發行任何債務證券。

本公司董事認為，概無擁有對本集團有重大影響之非控股權益之附屬公司。

49. COMPANY'S STATEMENT OF FINANCIAL POSITION

49. 本公司之財務狀況表

		31/12/2021	31/12/2020
		RMB'000	RMB'000
		二零二一年	二零二零年
		十二月	十二月
		三十一日	三十一日
		人民幣千元	人民幣千元
Non-current assets	非流動資產		
Property, plant and equipment	物業、廠房及設備	2,986,064	3,290,839
Investment properties	投資物業	292,450	305,276
Right-of-use assets	使用權資產	243,187	225,584
Investments in subsidiaries	於附屬公司的投資	1,271,556	1,239,184
Interests in an associate	於一間聯營公司的權益	1,004,362	924,633
Interests in a joint venture	於一間合營企業的權益	153,624	154,000
Deferred tax asset	遞延稅項資產	68,840	60,501
Deposit paid for acquiring property, plant and equipment	就收購物業、廠房及設備已付之按金	106,515	60,151
Prepayments	預付款項	79,353	88,170
		6,205,951	6,348,338

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

49. COMPANY'S STATEMENT OF FINANCIAL POSITION (continued)

49. 本公司之財務狀況表 (續)

		31/12/2021 RMB'000 二零二一年 十二月 三十一日 人民幣千元	31/12/2020 RMB'000 二零二零年 十二月 三十一日 人民幣千元
Current assets	流動資產		
Inventories	存貨	633,363	570,263
Trade and other receivables	應收貿易賬款及 其他應收款項	3,319,135	3,305,201
Debt instruments at fair value through other comprehensive income	按公平值計入其他全面 收益計量之債務工具	196,101	241,935
Amount due from subsidiaries	應收附屬公司款項	8,427,651	5,605,314
Pledged bank deposits	已抵押銀行存款	222,425	273,558
Bank balances and cash	銀行結餘及現金	1,252,851	2,196,497
		14,051,526	12,192,768
Current liabilities	流動負債		
Financial liabilities at fair value through profit or loss	按公平值計入損益計量 之金融負債	56,694	21,031
Trade and other payables	應付貿易賬款及 其他應付款項	1,509,056	2,015,542
Contract liabilities	合約負債	272,816	144,826
Borrowings	借款	300,000	-
Amount due to subsidiaries	應付附屬公司款項	4,536,093	3,978,185
Lease liabilities	租賃負債	8,045	1,428
Tax payable	應付稅項	-	25,595
Financial guarantee contracts	財務擔保合約	7,296	7,196
		6,690,000	6,193,803
Net current assets	流動資產淨額	7,361,526	5,998,965
Total Assets less Current Liabilities	總資產減流動負債	13,567,477	12,347,303
Capital and reserves	資本及儲備		
Share capital	股本	457,063	452,233
Reserves	儲備	11,549,270	10,284,188
Total equity	權益總額	12,006,333	10,736,421
Non-current liabilities	非流動負債		
Financial liabilities at fair value through profit or loss	按公平值計入損益計量之 金融負債	199	64,847
Borrowings	借款	496,497	495,498
Bonds payable	應付債券	992,549	991,121
Financial guarantee contracts	財務擔保合約	15,028	22,243
Deferred income	遞延收入	37,810	35,073
Lease liabilities	租賃負債	19,061	2,100
		1,561,144	1,610,882
Total equity and non-current liabilities	權益及非流動負債總額	13,567,477	12,347,303

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

For the year ended 31 December 2021 截至二零二一年十二月三十一日止年度

49. COMPANY'S STATEMENT OF FINANCIAL POSITION (continued)

49. 本公司之財務狀況表 (續)

Information about the movements in reserves of the Company at the end of the reporting period includes:

有關本公司於報告期末之儲備變動之資料包括：

		Share premium RMB'000	Other reserves RMB'000	Statutory surplus reserve RMB'000 法定盈餘 儲備	Retained profits RMB'000	Total RMB'000
		股份溢價 人民幣千元	其他儲備 人民幣千元	人民幣千元	保留溢利 人民幣千元	總計 人民幣千元
At 1 January 2020	於二零二零年一月一日	2,575,060	307,078	226,117	4,836,523	7,944,778
Profit for the year	本年度溢利	-	-	-	2,887,754	2,887,754
Share-based payments (note 38(a))	以股份為基礎付款 (附註38(a))	-	7,903	-	-	7,903
Dividends recognised as distribution	確認為分派的股息	-	-	-	(556,247)	(556,247)
At 31 December 2020	於二零二零年十二月三十一日	2,575,060	314,981	226,117	7,168,030	10,284,188
Profit for the year	本年度溢利	-	-	-	1,707,890	1,707,890
Adoption of share award scheme	採納股份激勵計劃	168,084	-	-	-	168,084
Share-based payments (note 38(a))	以股份為基礎付款 (附註38(a))	-	44,847	-	-	44,847
Dividends recognised as distribution	確認為分派的股息	-	-	-	(655,739)	(655,739)
At 31 December 2021	於二零二一年十二月三十一日	2,743,144	359,828	226,117	8,220,181	11,549,270

FINANCIAL SUMMARY

財務概要

		For the year ended 31 December				
		2021	2020	2019	2018	2017
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
			(restated)	(restated)	(restated)	(restated)
		截至十二月三十一日止年度				
		二零二一年	二零二零年	二零一九年	二零一八年	二零一七年
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
			(經重列)	(經重列)	(經重列)	(經重列)
RESULTS	業績					
Revenue	收入	13,151,719	11,622,337	10,594,855	8,843,807	7,719,229
Profit before taxation	除稅前溢利	2,841,721	2,565,459	2,294,423	1,777,575	2,084,902
Taxation	稅項	(415,093)	(358,422)	(335,056)	(258,431)	(258,686)
Profit for the year	本年度溢利	2,426,628	2,207,037	1,959,367	1,519,144	1,826,216
Profit for the year attributable to:	年內下列各項應佔溢利：					
Owners of the Company	本公司擁有人	2,244,778	2,086,783	1,884,070	1,475,198	1,729,507
Non-controlling interests	非控股權益	181,850	120,254	75,297	43,946	96,709
		2,426,628	2,207,037	1,959,367	1,519,144	1,826,216
		As at 31 December				
		2021	2020	2019	2018	2017
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
			(restated)	(restated)	(restated)	(restated)
		於十二月三十一日				
		二零二一年	二零二零年	二零一九年	二零一八年	二零一七年
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
			(經重列)	(經重列)	(經重列)	(經重列)
ASSETS AND LIABILITIES	資產及負債					
Total assets	總資產	30,367,058	27,957,716	26,934,976	24,021,030	16,812,491
Total liabilities	總負債	(9,459,608)	(9,079,028)	(9,478,608)	(8,840,273)	(3,186,544)
Non-controlling interests	非控股權益	(1,640,359)	(845,108)	(811,436)	(678,219)	(305,934)
Equity attributable to owners of the Company	本公司擁有人應佔權益	19,267,091	18,033,580	16,644,932	14,502,538	13,320,013

WEGO 威高